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Abstract 
Research into effective treatments for menopausal symptoms faces several challenges.  
Interpretation of the existing literature is hampered by a lack of consistency in terminology 
relating to the different phases of menopause.  In addition, neither the endocrinology of 
menopause nor the mechanisms underlying hot flushes have as yet been fully elucidated.  
Further, there is lack of consensus regarding which symptoms are due to endocrinological 
changes at menopause, as distinct from the psychosocial circumstances women experience 
at this stage of life.  Mood changes, for example, are attributed in psychosocial theory to the 
age-related factors such as changes in a woman’s role, and the awareness of ageing.  In 
practical terms, endocrinological events and psycho-social factors are likely to interact.  It is 
well established that anxiety exacerbates the physiological symptoms of hot flushes, for 
example.  Thus hormonal and psychological approaches to treatment are both relevant.   
In terms of phytotherapeutic treatment, while traditional use supports a range of herbs for 
the symptoms of menopause, evidence supporting their use from rigorous scientific trials is 
limited.  Moreover, in most cases, their mechanisms of action are still largely unknown.  
Nonetheless, use of phytotherapy for menopausal symptoms has become very popular.  
Interest in alternatives to hormone therapy (HT), including non-estrogenic treatments that 
have shown varying degrees of efficacy, has increased due to the serious health risks that 
have been associated with HT, despite its incontrovertible effectiveness.  In terms of 
phytotherapeutic options, the limited research has largely focussed on the phytoestrogenic 
plants.  However, there have been some safety concerns expressed over their long-term 
use.  In the practice of phytotherapy according to the Anglo-American and European 
traditions, non-oestrogenic herbs are also employed.  Two such herbs were the focus of the 
principal study to be reported herein, namely Hypericum perforatum and Vitex agnus-castus.   
Both study herbs are also used in, and have been trialled for, the alleviation of symptoms of 
premenstrual syndrome (PMS), which is reported to be more severe in the perimenopausal 
years.  Many of the so-called menopausal symptoms could be viewed as an exacerbation of 
PMS in the perimenopause.   
Research on vasomotor symptoms during menopause is prone to a substantial response in 
the placebo arm, due in part to the natural history of the symptoms.  There has been much 
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interest in increasing our understanding of the placebo response with a view to controlling it 
in clinical research and harnessing it in clinical practice.   
The hypotheses to be tested were 
1.  that the combination of two herbs, Hypericum perforatum and Vitex-agnus-castus, 
known to have central nervous system (CNS) effects and/or efficacy in PMS or 
depression, would alleviate the physiological flushing symptoms and psychological 
symptoms of menopause and improve quality of life in late peri-menopausal and early 
post-menopausal women 
2.  that the PMS-like symptoms in the perimenopausal sub-group would be relieved by 
the intervention 
3. that the placebo would have significant impact on menopausal and PMS-like 
symptoms and would be predicted by psychological factors.   
The main aim of the study was to examine a specific herbal combination with CNS activity 
and established efficacy in PMS and/or depression in the late perimenopause and early 
post-menopause on 
 i) the physiological symptoms of flushing and sweating; 
ii)  the psychological symptoms of depression and anxiety; and 
iii)  quality of life. 
Secondary aims were   
i) to study the effect of this combination in PMS-like symptoms in perimenopausal 
women; and 
ii) to examine predictors of the placebo response, and to compare these with 
predictors of the response to active treatment.  
A double-blind, randomised controlled trial (RCT), with a 16-week treatment phase, was 
conducted on 100 women in the late-perimenopause and early postmenopause.  For this 
study, the herbal combination (Hypericum perforatum and Vitex agnus-castus) was not 
found to be superior to placebo for any of the endpoints - daily weighted flushing scores, 
scores on the Greene Climacteric scale and the Hamilton Depression Inventory. However, 
significant improvements across the treatment phase were observed in both the placebo and 
active treatment groups on all of these outcome measures. No significant change was found 
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for either group on the Utian quality of life scale.  The herbal combination was well-tolerated 
with no significant adverse events noted over the 16-week treatment phase.  
The effects of the combination of Hypericum perforatum and Vitex agnus-castus were 
examined on PMS-like symptoms in the small sub-population of late-perimenopausal 
women.  The intervention was found to be superior to placebo for total PMS-like symptoms 
and the sub-clusters, PMS-D (depression) and PMS-C (cravings).  The active treatment 
group also showed significant improvements on PMS-A (anxiety) and PMS-H (hydration), 
although this effect was not superior to placebo.  Results of a trend analyses revealed 
significant quadratic trends for four of the five measures in the treatment group: PMS-Total, 
PMS-A, PMS-C, and PMS-D, but no significant trends in the placebo group.  
Predictors of the placebo response were found to include anxiety at study entry for the 
outcome measures of flushing, depression and overall menopausal symptoms (measured 
on the Greene Climacteric scale), and improvement during non-treatment run-in for 
depression and overall symptoms. Because no difference had been found between active 
and placebo groups in the RCT (above), it was hypothesised that the same predictors would 
similarly predict the response in the active treatment group. However, low anxiety was 
significantly associated with improvement in the active treatment group.  None of the other 
variables found to predict the placebo response was relevant to the treatment arm.  This 
finding is discussed with reference to the possibility that ‘drug’ effects and placebo effects 
are not necessarily additive, and that the same magnitude of effect in both arms might not 
necessarily imply activity via the same pathways. 
Randomised controlled trials of complementary and alternative medicine (CAM) are often 
criticised as not reflecting actual clinical practice, which involves individualised prescribing 
rather than the ‘one-size fits all’ approach.  An alternative experimental design has been 
proposed and trialled for use in CAM studies by Bensoussan to overcome this problem.  
However this design was not used in the present study as the sample size required for 
obtaining sufficient power would have been impractical. 
Substantial placebo effects are a nuisance in RCTs.  Studies of CAM may be subject to 
enhanced placebo effects.  In addition, the assumption of additivity of treatment and placebo 
effects, which underlies the practice of placebo-controlled trials, has recently been 
challenged.  Alternative paradigms are discussed. 
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Chapter One 
  
 
 
A Brief History  
of the Treatment of Menopausal Symptoms 
 
 
 
  
 
 
 
1.0  Introduction 
 
The first chapter of the Literature Review examines the historical treatments of menopausal 
symptoms in the context of both the recognition of menopause as a syndrome, and the 
origins of the current practice of phytotherapy in the Anglo-American tradition.  The Anglo-
American tradition of phytotherapy arose from Samuel Thompson in North America and the 
interaction of his followers with herbalists in the UK in the nineteenth century.  It is a specific 
form of Western herbal medicine practised in the English-speaking world, and differs from 
other forms of Western herbalism as practised in Europe. 
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1.1  A Modern Presentation? 
 
Menopause, the cessation of menstruation, marks the end of the reproductive phase of a 
woman’s life.  Although a natural event, the transition from regular cycling to the final 
menstrual period (FMP) and beyond into postmenopause, is commonly accompanied by 
physiological and/or psychological symptoms.  In addition, the incidence of certain disorders 
such as breast cancer, noted by Burns in 1814, has long been observed to increase in 
postmenopausal women.1 
 
While not a condition of the modern age, the ‘climacteric’ or menopause transition had 
received relatively little attention in the published literature until the 1890’s.  Factors 
contributing to this include the shorter life expectancy in earlier times, which meant that 
many women did not reach menopause.  At the beginning of the nineteenth century, 
average life expectancy was 36.5 years for a female,2 increasing to 49 for an American 
female by the early 1900’s.3  Other reasons for menopausal women presenting less 
frequently to medical practitioners may well have included the cost of healthcare and social 
taboos regarding discussing such an intimate topic with male doctors. 
1.2 Early references to Menopause 
 
Nonetheless, references to menopause or the climacteric appeared in the literature as far 
back as Aristotle’s times (384-322BC) when menstruation was observed to cease at the age 
of 40.2,4  In the sixth century, Aetios of Amida wrote that “Menstruation does not cease 
before the thirty-fifth year, nor does it (usually) continue after the fiftieth year. Meanwhile, 
menstruation may in the rarest cases last as late as the sixtieth year.  Fat women lose their 
periods very early”(p18).5   
 
1.2.1 References to Associated symptoms 
 
It was not until 1816, with the coining of the term la Ménespausie by the French physician 
CPL De Garndanne, that climacteric complaints were recognised as a syndrome with a 
common cause.6  However, the association of the cessation of menstruation with other 
organic and emotional problems had been made in 1777 by Leake in a chapter entitled 
Cessation of the Periodical Discharge in the decline of life, and the disorders arising from 
that critical change of constitution.  He observed that some women at this critical time of life 
(one meaning of term ‘climacteric’) were “subject to pain and giddiness of the head, hysteric 
6 
disorders, colic pains, and female weakness… The rheumatism,.. pains in the limbs and 
eruptions on the skin at this time frequently appear (and); also...cancerous tumors of the 
breast or womb.  Women are likewise sometimes affected by low spirits and 
melancholy.”(p90)7  
 
A reference to flushings and night sweats is also made in this chapter: “Where the patient is 
delicate and subject to female weakness, night sweats or habitual looseness, with flushings 
in the face and hectic fever..”(p96).7  
 
Flushes and perspiration also appear in the 1857 writings of Edward Tilt,8 (pp4,70-1,175-9) 
the British physician who wrote one of the first full-length books on the ‘Change of life’, in 
which he lists a wide range of “morbid liabilities at the change of life” (pp70-2) as well as 
their treatments.  He also describes the disorders most likely to be experienced by the 
different temperaments, with “..women of nervous temperament suffer(ing) ..more than all, 
particularly during the dodging time” (perimenopause) (p74) whereas “women with a marked 
biliary temperament are likely to suffer much from …..the various forms of insanity, if the 
nervous be associated with the bilious temperament..”(p74).  Tilt’s recommended treatment 
for reducing sweating was to “Diminish the mass of blood by taking 2 or 3 ounces from the 
arm at successive months”… since “The relative superabundance of blood is often the 
cause of the superabundant heat, and therefore of the perspirations….” (p179).8  To relieve 
the “irritability of the nervous system… sedative preparations” were recommended (p179).8 
1.3 Historical Treatments  
 
At this time, menstruation was seen as a form of detoxification of poisons from the woman’s 
blood9 and the menopause as an accumulation of unexpelled toxins that could lead to the 
development of diseases such as cancer, gout and rheumatism and other mental and 
physiological symptoms.  Treatment was aimed at either encouraging menstruation by the 
use of herbal emmenagogues, or removing these unexpelled toxins by other purification 
methods such as blood-letting, purging, applying leeches to the genitalia or cervix, setons 
(threads of horsehair or strips of linen inserted beneath the skin to provide drainage)  or 
induction of sweating.10  
 
Treatments recommended by Leake in 1777 for curing specific diseases or alleviating 
psychological symptoms that were associated with the menopause likewise included blood-
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letting and purgatives, but also reduced intake of animal food, “a spare and simple diet 
consisting chiefly of vegetables, fish and spoon meats, and increased exercise”.  For the 
delicate patient with flushings and night-sweats, ass’s milk, jellies, raw eggs and cooling 
fruits were recommended with “at meals…half a pint of old clear London Porter or a glass of 
rhenish wine”(p96).7 
1.4 The Dawn of Hormone Replacement Therapy (HRT) 
 
The ancient form of organotherapy, or glandular therapy, became popularised in the late 19th 
century with injections of ‘testicular juice’ being used for rejuvenation of men and to combat 
feminine debility.  Ovarian therapy, the administration of crude ovaries, powdered ovaries 
and powdered ovarian tablets, was used for physiological and surgical menopause and, in 
1896, clinical trials conducted in Germany recommended substitution with ovarian therapy 
as a means of alleviating menopausal symptoms.11  
 
The first scientific evidence of the existence of hormones was provided in 1902, and the 
term ‘hormone’ adopted in 1905 (p391).12  This replaced the earlier term ‘internal secretion’ 
coined by the French professor, Claude Bernard, although the notion of internal secretions 
by cells dates back to 1775 with the French physician De Bordeau.12 (pp390-1) It was not 
until 1926 that oestrogenic hormones were detected by the chemists Loewe and Lange in 
human urine and the name ‘estrin’ was given by Parkes and Bellerby to the hormone 
extracted from the ovary.13  Oestrone was isolated from the urine of pregnant women in 
1929 by Butenandt and oestriol discovered in human pregnancy urine in 1930.1  The most 
potent form of oestrogen in the female body, oestradiol, was isolated from sow’s ovaries in 
1930 by Marrian, although it was not until 1940 that β-oestradiol was demonstrated in 
human pregnancy urine and the placenta.13  In a comprehensive article on the history of 
HRT, Davis13 outlines the development, promotion and challenges of hormone therapy. 
 
Progesterone was first isolated in 1934 from corpus luteum extracts injected into rabbits.  
This ‘corpus luteum hormone’ was called ‘progesterone’ because it maintained gestation.  In 
1943 it was synthesised by Marker and colleagues from the precursor saponin, diosgenin, 
from Mexican wild yams (Dioscorea composita), that could be converted into synthetic 
progestin quite easily with a few chemical steps.14  Diosgenin  had previously been isolated 
from the rhizomes of D. villosa (wild yam) in 1940,15 but because of the relatively low yield 
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from this species, the richer sources, tubers of D. composita and D. floribunda from Mexico 
and Central America came to be used by the pharmaceutical industry.16 
 
The first commercially available oestrogen, ‘Progynon’ was developed in 1928 from animal 
placentas and subsequently from the urine of pregnant women.17 A substance resembling 
estrin was manufactured from the urine of pregnant women and launched in the US in 1933 
but faced the problem that limited raw material for production could not meet market 
demand.13 The discovery of oestrogens in pregnant mare’s urine in the 1930s led to the 
creation of Premarin (conjugated oestrogens from Pregnant mare’s urine) and its launch 
onto the market in North America in 1941-2 as the first orally active oestrogen.3  By 1975 it 
had become the most-dispensed drug in the United States, reportedly taken by 6 million 
women.13  The preference for the combination of oestrogen with cyclic progestin therapy 
arose from the discovery in the 1970s of the link between unopposed oestrogen and 
endometrial cancers.2 Progestins had been reported to protect against this adverse effect by 
counteracting the proliferative effects of oestrogens.18 
 
By the 1960s, menopause had come to be viewed as a deficiency disease, a term used by 
the New York gynaecologist, Wilson, in his book Feminine Forever19 (financed by Ayerst 
Laboratories). This, according to Davis and colleagues, further contributed to the success of 
hormone replacement by promoting its virtues in alleviating the symptoms of menopause as 
well as helping to maintain youth and sexuality.13  
1.5 Plant therapies for Menopausal Symptoms 
 
Specific references to the climacteric period do not appear in herbal texts until the mid 
1800’s.  However, as mentioned above, treatments were historically aimed at re-instating 
menstruation using, among other means, herbal emmenagogues.  It seems likely, therefore, 
that treatment of menopausal symptoms employed herbs indicated for amenorrhoea, or 
whose virtues included “provoking women’s courses”, such as Leonurus cardiaca 
(Motherwort) listed in the 17th century Culpeper’s Complete Herbal (p239).20   Its other 
virtues included treatment of “trembling of the heart, fainting and swooning”, a possible 
reference to the symptoms of dizziness, heart palpitations and feeling faint that are currently 
associated with menopause, and “making mothers joyful” (p239).20 Motherwort remains 
listed in the British Herbal Pharmacopoeia (BHP) of 1983 as indicated for amenorrhoea 
(p130).21 
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In 1853, Pereira refers to herbal treatment of symptoms associated with the climacteric 
period with Lolium temulentum  (Bearded Darnell)  which had been successfully used by 
Fantoni “in the case of a widow who, at the climacteric period, was affected with giddiness, 
headache, and epistaxis, which had resisted various other remedies.”(p81)22  
 
Senecio aureus (Life root) is another herb for amenorrhoea and menorrhagia referred to in a 
19th century text that retains an indication for menopause-related symptoms in the current 
BHP (p195).21  In 1870, Scudder’s Specific medication and Specific medicines lists it as a 
“uterine tonic (for) amenorrhoea, dysmenorrhoea (and) menorrhagia”(p217);23 in 1931, Mrs 
Grieve refers to its emmenagogue action(p379);24 the 1983 BHP includes “menopausal 
neurosis” as one of its indications, and specific indications as “emotional and vascular 
instability, including the hot flush, associated with the menopause”(p195). It “may be used 
with Hypericum (also indicated for “menopausal neurosis” p115), Avena (for ‘”menopausal 
neurasthenia” p37), Viburnum prunifolium and Pulsatilla in menopausal 
disturbances”(p195).21  
 
Cimicifuga racemosa, synonymous with Actaea racemosa, (Black cohosh), now widely 
employed for the treatment of hot flushes, made its way into the Eclectic Dispensary in 1852 
as a highly regarded treatment for amenorrhoea,25 having been adopted by the European 
colonists from the native Americans; the Cherokee and Iroquois people used it for 
“gynecopathy (diseases peculiar to women) ..and rheumatism”.26 
 
Other 19th century references to the ‘climacteric’ include herbs for uterine haemorrhage 
attending the menopause such as Viburnum prunifolium (Black haw)(p2061)27 and  
Hydrastis canadensis (Golden seal)27,28  for “climacteric haemorrhage”(p1028) in the 1898 
King's American Dispensatory.  Herbs in the same work that were recommended for other 
physiological and emotional symptoms attending the climacteric/menopause include  
• Cypripedum pubscens (Lady’s slipper) whose specific indications include “insomnia, 
nervous irritiability, menstrual irregularities, with despondency; tendency to dementia 
at climacteric”(p644) 
• Viburnum prunifolium (Black haw) recommended by Professor Howe for the debility 
of the second climacteric (p2061) 
• Passiflora incarnata (Passion flower) for various forms of “neuralgia, many reflex 
painful conditions incident to ..the menopause” (p1440) 
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• Ignatia amara (Ignatia) for “nervous atony,  where the patient is cold, and especially 
when coldness of the extremities is one of the distressing features of the 
menopause” (p1043)  
• Cannabis indica (Indian cannabis) for “migraine, nervous headache, facial, and other 
neuralgias, … attending the menopause, as well as those depending upon fatigue, 
(which) are relieved when nervous depression is the most marked symptom” (p425-6).27  
 
Winterburn in 1882-3 listed Sanguinaria canadensis (Blood root) for “congestion to the head 
and lungs, especially at the climacteric”(p394);29 in 1902, Potter recommended  Valeriana 
officinalis (Valerian) for “hypochondriasis, especially at the climacteric period” (p147). 
 
1.5.1 Plant remedies specifically for hot flushes 
 
References to plant remedies for hot flushes appear in Kings Dispensatory of 1898:  
Aconitum napellus (Aconite) is recommended for “Disorders of the menopause, with 
alternate chills and flushes of heat,  with rush of blood to the head, cardiac palpitation, 
dyspnoea, gastric fullness, sense of distension in the bladder, with frequent attempts to pass 
urine (Locke)” (p105).27  
 
They can also be found in early 20th century herbal texts. For example, the Lloyd brothers’ 
drug pamphlets of 1908 refer to Cactus grandiflorus (Cactus) for the flushes as well as 
emotional conditions:  “Dr Lydia Ross has made extended and satisfactory observations 
concerning the influence of Cactus in the disorders of women.  She especially advises it 
where there are hot flashes during the climacteric”, sometimes given in conjunction or 
alternation with Helleborus niger.  “The melancholia, irritability of temper, nervousness, 
neuralgia, hypersensitiveness, vague fears and fantasies present during the menopause are 
influenced by Cactus and Pulsatilla, alone or in conjunction or in alternation.(p11)”30   This 
indication is echoed in 1919 by Ellingwood, who lists Cactus for “the hot flashes which are 
so disagreeable during the climacteric.  The dose of specific cactus varies from a half minim 
to two or three minims”*(p396).31  
 
In Ellingwood’s Therapeutist of 1908, it is reported that gelsiminine from Gelsemium 
sempervirens (Yellow jasmine) “will check the hot flashes that occur during or after the 
                                                 
* 1 mL= 15 minims (BHP); 1 minim = 1 drop (German Commission E) 
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menopause in nervous, plethoric or relaxed women.. (at a dose of).. 1/250 grain”,32 and 
elsewhere a single dose of “ten drops of specific gelsemium, (if necessary followed up by ) 3 
drop doses every hour (is) excellent for the hot flashes that are apt to occur during the 
menopause”.33 
 
Many of the above-mentioned remedies are no longer commonly used in phytotherapeutic 
practice that follows the Anglo-American tradition.  Some have simply fallen out of popularity 
in favour of different herbs/plants based on greater physiological understanding, while others 
such as Ignatia, Gelsemium, Aconitum, Cactus and Sanguinaria  are now used preferentially 
in homeopathic potencies, in some cases their use in material doses having been 
scheduled. Current phytotherapeutic treatment of menopausal symptoms additionally 
involves herbs with a tradition of less than 3 generations of use,** such as Dioscorea villosa 
(Wild yam), Cimicifuga racemosa (Black cohosh), Helonias/Chamaelirium luteum (False 
Unicorn root) and Vitex agnus-castus (Chaste-tree/berry). 
 
1.5.2 More recent introductions  
 
The earliest references to the treatment of menopausal complaints with Dioscorea villosa 
(Wild yam) appear after the discovery of yams as a prized source of the precursor saponin, 
diosgenin, for the synthesis of progestins34 and other sex hormones.35  The results of rodent 
studies published in 1992 supported diosgenin’s oestrogenic activity and augmentation of 
oestrogenic acitivity.36 
  
Chamaelirium luteum (also known as Helonias dioica, Helonias lutea, Veratrum luteum;  
common name False Unicorn root) is referred to by Cook in his 1869 The Physiomedical  
Dispensatory, for menorrhagia with laxity and depression, as well as restoring the menstrual  
flow, possible allusions to menopausal symptoms: 
 
 “But its most prominent and valuable action is upon the uterine organs; where it 
scarcely has an equal in ….. menorrhagia, and similar enfeebled conditions. …(I)ts 
tonic influence is peculiarly efficacious in arresting too excessive menstruation and 
lochia, when associated with laxity and depression; That these influences over the 
                                                 
** 3 generations of use is the minimum requirement for the label ‘traditional use’ according to the 
Therapeutic Goods Administration (TGA) in Australia. 
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uterine function are due to the pure tonic action of the agent, is at once seen in the 
fact that it is a valuable article to restore the menstrual flow when this is absent from 
sheer inability of the generative organs.   It is a valuable ingredient in the compounds 
called ‘Woman's Friend (and) Female Restorative’.”(p467-8)37  
 
However, its role in the treatment of menopausal symptoms does not appear until the 
twentieth century.  In 1950, Costello and Lynn reported that oestrogenic effects of Helonias 
dioica were found in animal studies.38  
 
References to the  use of Vitex agnus-castus as a sitz bath for “diseases of the uterus” can 
be found as far back as Hippocrates in 4th century BC and Dioscorides in AD77(p87).39  
One of the great Renaissance herbalists, Gerard, recommended it for inflammation of the 
uterus and as an emmenagogue.(p6)40  Modern interest in Vitex has been attributed to the 
scientific research on its effects on the female reproductive system conducted by Dr 
Gerhard Madaus in Germany in 1930.  The benefits of Vitex for menopausal complaints 
were reported in 1972 in a collective report on the clinical experience of five practitioners 
with Agnolyt® (a patent medicine extracted from dried Vitex berries) by Attelmann and 
colleagues in Germany.41 
 
In Madaus’ 1938 text, he wrote that Cimicifuga/Actaea racemosa, (Black cohosh) was 
recommended for climacteric symptoms, at a higher dose for somatic symptoms and a lower 
dose for the neurological symtpoms.42  Remifemin®,, an extract of Cimicifuga  has been used 
in Germany for the relief of menopausal symptoms since the mid-1950s.43  Positive results 
of uncontrolled studies with Remifemin® in menopausal women  were first published in the 
German literature in 1957 and 1958.44,45 Reports from clinical trials of  its effectiveness in 
specifically relieving hot flushes are found from 1982 onwards.46   
 
Hypericum perforatum (St John’s wort) is recommended for “menorrhagia, hysteria, nervous 
affections with depression” in Kings’ Dispensatory of 1898 (p1038)27, and subsequently in 
the 1918 Dispensatory of the United States of America for “hysteria, mania,…, 
hemorrhages..  It formerly enjoyed great reputation for the cure of demoniacs.”(p36)47  In 
1938, Dr Gerhard Madaus states that “in the area of the gynecology Hypericum (also) 
makes a substantial contribution….  For menopausal bleeding, it is indicated with Viscum 
album” (p1592).42  The 1983 British Herbal Pharmacopoeia lists it as specific for 
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“menopausal neurosis” (p115)21  and a study published in 1986 reported it to be of 
comparable efficacy to diazepam for climacteric depression.48  Reference to its potential 
benefit in hot flushes appears in the published research literature in the 1990s.49 
1.6 Summary 
 
While references to menopause, its associated symptoms and treatments have appeared 
throughout history, it was only recognised as a syndrome with a common cause in 1816, 
when the term ‘la menespausie’  was first coined.  It was not until the 1890’s that it began to 
receive more attention in the published literature, possibly due to the increasing life 
expectancy which meant that more women reached menopausal age.  Herbal remedies 
specifically for hot flushes also appear in the late nineteenth century texts.  However, it is 
possible that menopause-related symptoms were not differentiated from the same 
symptoms occurring at any other stage of reproductive life, and were treated accordingly 
with emmenagogues for amenorrhoea or herbs for menorrhagia, depression and hysteria 
that are listed in earlier works.  As these symptoms have increasingly become the focus of 
published research, another difficulty has been highlighted, namely that of the inconsistency 
in terminology for the different menopausal phases.  This remains a current issue when 
comparing research findings. 
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Chapter Two 
  
 
 
Definitions of Menopause  
and its Phases  
 
 
  
 
 
 
 
2.0  Introduction 
 
The second chapter of the Literature Review addresses the issue of the inconsistent 
definitions used in the literature to describe the various phases of menopause, and defines 
the terms used in this thesis.  
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2.1 Lack of Consensus regarding Terminology 
Reproductive ageing in women is a dynamic process occurring over a period of time 
culminating in the menopause, which is a normal “physiological event that occurs universally 
to all women who reach midlife”.50  Menopause, the permanent cessation of menstruation ,  
is said to have occurred after twelve consecutive months of amenorrhoea not due to 
pathological or other physiological cause.51  
While the final menstrual period (FMP) is a single event, it is preceded by a series of clinical 
changes occurring over period of time that follow recognisable stages, although not all 
women progress through the stages in a linear fashion and some skip a stage altogether.52   
Lack of consistency in the use of terminology relating to these menopausal stages, such as 
pre-menopause, perimenopause, menopause and postmenopause,  has dogged the 
literature, rendering comparisons between studies difficult.  To address this problem, a 
scientific group for the World Health Organisation (WHO) in 1996 recommended the 
following definitions: 
2.2 WHO Definitions 
Natural menopause: the permanent cessation of menstruation resulting from loss of 
ovarian follicular activity. It is recognised as having occurred after 12 consecutive 
months of amenorrhoea for which there is no other obvious pathological or 
physiological cause.  Menopause occurs with the FMP which is known with certainty 
only in retrospect a year or more after the event.  An adequate biological marker for 
the event does not exist. 
The perimenopause (or Climacteric): the period immediately prior to menopause 
(when the endocrinological, biological and clinical features of approaching 
menopause commence) and at least the first year after the menopause.  The term 
climacteric should be abandoned to avoid confusion. 
Menopausal transition: that period of time before the FMP when variability in the 
menstrual cycle is usually increased. 
Pre-menopause:  the entire reproductive period up to the FMP. 
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Induced menopause:  the cessation of menstruation following either surgical removal 
of both ovaries (with or without hysterectomy) or iatrogenic ablation of ovarian 
function (for example, by chemotherapy or radiation). 
Simple hysterectomy:  where at least one ovary is conserved, defines a distinct group 
of women in whom ovarian function may persist for a variable period after surgery. 
The postmenopause: dates from the FMP, regardless of whether the menopause 
was induced or spontaneous. 
Premature menopause:   should be defined as menopause that occurs at an age 
less than two standard deviations below the mean estimated for the reference 
population.  In practice, the age of 40 years is frequently used as an arbitrary cut-off 
point, below which menopause is said to be premature.53 
2.3 Refinements to definitions  
 
Further refinements to these definitions have subsequently been suggested. 
 
2.3.1 The Menopausal Transition 
  
The menopausal transition, from regular cycling to complete cessation, is the part of the 
perimenopause that ends with the FMP.54   
 
2.3.2 Pre-menopause 
 
Pre-menopause is used in differently by different authors and must therefore be clarified on 
an individual basis.  It has been used to refer to  
i) the one or two years immediately prior to the FMP,  
ii) the whole of the reproductive life preceding menopause or 
iii) the part of the reproductive life prior to the onset of changes to the menstrual 
cycle pattern.53,54  
 
2.3.3 The Perimenopause   
 
The perimenopause is further divided into early and late-perimenopause although there is 
no consensus as to the definitions of these two phases.    
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2.3.4 Early perimenopause 
 
Entry to the menopause transition, or early perimenopause, is often taken as the 
commencement of cycle irregularity53,55-58 which precedes the FMP by an average of 3.8 years.59  
It has variously been defined by self-reported changes to the frequency and/or flow, 
although the reliability of self-reports is questionable given that subjective reports of irregular 
cycles do not necessarily track with diary entries.60 
 
Examples of the variation in definitions are given below:   Self-reports of  
• change in cycle frequency but experiencing menses in the preceding 3 months 54 
• changes in frequency or frequency and flow (but not changes in flow alone) over the 
preceding  year 61,62 
• 3 – 12 months’ amenorrhoea 63   
• changes in flow, flow duration or cycle length. 64  
 
The Stages of Reproductive Aging Workshop [STRAW], which attempted to develop a 
standardised staging system, defined early menopause [Stage  –2, where the FMP is the 
‘anchor’] as regular menstrual cycles, but a variation in length of more than 7 days different 
from normal.  However, elsewhere it defines entry into early menopause as “variation in 
menstrual cycle length in a woman who has a monotropic follicle stimulating hormone (FSH) 
rise”. 52 
 
Others have noted that women’s self-rated menopausal status based on their symptoms 
may more reliably reflect endocrine changes than definitions based on menstrual cycle 
characteristics.62,65,66  For clinical purposes, women’s self-report may therefore be 
considered a pragmatic way of determining entry into the menopause transition62 whilst for 
research purposes, Burger suggests that entry to the early perimenopause (MT1 = 
menopause transition 1) be defined as the first of 3+ cycles, in any consecutive series of 10, 
that are outside the normal cycle range of 23–35 days observed in reproductive-aged 
women (29± 6). 54,60, 67 
 
2.3.5 Late perimenopause 
 
For most women experiencing a natural menopause, the time immediately preceding the 
FMP is characterised by cycles of increasingly variable length.60 Definitions of late 
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perimenopause appear to be less diverse, with either a 60-day or 90-day inter-menstrual 
interval predominantly used as the hallmark. 
 
An inter-menstrual interval of 60 days was associated with ovulatory failure 68 and was found 
to be a more consistent predictor than any other menstrual criteria of the FMP69 within 2 
years in women over the age of 45 years.70  This is consistent with the STRAW definition of 
“2 or more skipped cycles and at least one inter-menstrual interval of 60 days or more”. 52 
 
Menses within the preceding 12 months but not the preceding 3 months has commonly been 
used to determine late perimenopause.51,64,71 This is  consistent with findings from a 
longitudinal study of 250 Australian-born women over four years, that 3 –11 months of 
amenorrhoea had a high specificity for predicting the FMP within the next 4 years (99%).61  
 
As pointed out by Burger and colleagues,54 however, a single period of 60 or 90 days of 
amenorrhoea is not confined to the perimenopause and can occur during other periods of 
reproductive life and thus, in determining the late-perimenopause in an individual woman, 
previous menstrual irregularity and the existence of symptoms should also be taken into 
account. 
 
2.3.6 Menopause 
 
Menopause is generally agreed to have occurred 12 months after the FMP, which can only 
be determined retrospectively.  This convention has arisen because in 90% of Caucasian 
women, the permanent cessation of menstruation is preceded by amenorrhoea for 12 
months.53  Nonetheless some researchers use 3 months72 or 6 months of amenorrhoea to 
denote menopause.73-77   
 
2.3.7 Postmenopause 
 
Postmenopause:  STRAW52 suggested the division of postmenopause into two stages, 
namely early and late.   
The early postmenopause was defined as 5 years since the FMP, during which time 
further dampening of ovarian hormone function continued to a permanent level, as well as 
accelerated bone loss. Early postmenopause was further divided into segment a, the first 12 
months after the FMP, and segment b, the next 4 years.   
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 Late postmenopause was defined as beginning 5 years after the FMP and ending 
with death.60   
Subsequent to these recommendations, however, it is still possible to find studies on early 
postmenopause defining this as between five to ten years after natural menopause.78  
 
2.3.8 Premature menopause  
 
Ovarian failure can occur before the age of 40, resulting in premature menopause. 
 
2.3.9 Artificial menopause 
 
Artificial or iatrogenic menopause can follow medical or surgical interventions (See Induced 
under WHO definitions).    
2.4 Definitions used in this thesis 
 
In this thesis, the following definitions are used 
• pre-menopause   prior to the onset of changes to the menstrual  
cycle pattern53,54  
• early perimenopause   change in cycle frequency but experiencing  
menses in the preceding 3 months 54 
• late perimenopause   after a 90-day inter-menstrual interval until the   
menopause  
• menopause   12 months after the FMP 
• postmenopause   from the FMP, which is only known  
 retrospectively 
• menopause transition   the perimenopause up to the FMP54   
• climacteric   this term will not be used other than to quote   
from other sources, but is taken to be synonymous with 
the perimenopause. 
 
As mentioned above, clarity and consistency in terminology is essential to permit 
comparisons between studies.  Women recruited to the RCT to be reported herein were in 
the late perimenopause or postmenopause according to the above definitions, and aged 
between 40 – 60 years. 
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Chapter Three 
  
 
 
Epidemiology  
 
 
 
  
 
 
 
3.0  Introduction 
 
 
The third chapter of the Literature Review examines the prevalence of menopause and 
associated morbidity. 
21 
3.1 Age at Menopause 
 
Menopause does not occur at a specific chronological age.  However, natural menopause 
generally occurs in women between the ages of 40 and 60 years, and predominantly 
between 45-55 years.79 80 The mean age for women of European origin is said to be 50 
years 9 months 81  with median onset of the perimenopause between 45.5 and 47.5 years81 
and average duration of 3.8-5 years.57,59,64   Most of the data on age at menopause has 
been derived from Caucasian women in western countries.  Limited data exists for women of 
other racial origins (Appendix 1).   
 
Knowledge of the age at menopause informs clinical practice as well as inclusion criteria for 
clinical studies.    As mentioned previously, in the early 1900’s the average life expectancy 
for an American female was 49 years.3  As life expectancy has increased, women are not 
only are reaching menopause in greater numbers, but are living a greater proportion of their 
lives postmenopausally.  Thus the incidence of menopause-related symptoms and 
postmenopausal health conditions has increased exponentially, necessitating research to 
establish appropriate treatments according to the needs of the different user groups. 
3.2 Prevalence 
 
According to the WHO population projections, the number of women aged 50 years and 
over is expected to reach 1,200 million by the year 2030, with 47 million new entrants each 
year.82  In 1990, 25 million women worldwide reached menopause: this number is expected 
to double by the late 2020s.53   
 
In Australia, at 30 June 2006, there were 2,771,063 women between the ages of 40 and 60 
years, constituting 27% of the total female population (or 13.96% of the total population).  In 
the 50-59 age range, there were 1,285,953 Australian women, with almost 1.5 million of the 
current Australian female population due to reach menopause within the next decade, using 
age 50 as a proxy for menopause.83  
 
Statistics from the North American Menopause Society (NAMS) indicate that most American 
women can expect to live a third of their lives beyond menopause, given that “a woman who 
reaches 54 can expect to reach 84.3” years of age.84 
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3.3 Symptom Prevalence 
 
Estimates of menopause-related symptom prevalence are widely divergent.  This may be 
due to a number of methodological factors as well as cross-cultural differences in symptoms 
experience or symptom reporting.  These include53,85  
• lack of consistency in the symptoms included and instruments used 
• differing definitions of menopausal stages  
• lack of distinction between natural menopause and surgically-induced menopause 
• different sampling methods – from the general community or menopause clinics 
• inclusion criteria of age rather than menstrual characteristics as an indicator of 
menopausal status 
• different symptoms, or symptom expression, in different cultural populations 
• lack of objective measures to determine whether symptoms are related to 
menopause or other pathology/life event 
• lack of distinction between symptom experience and experience of the symptom as 
problematic. 
 
The lack of consensus regarding which symptoms can truly be regarded as part of the 
menopausal syndrome underlies much of the disparity in reports of their prevalence.  Hot 
flushes and night sweats are among the symptoms that are unequivocally linked to 
endocrine changes associated with menopause, along with breast tenderness and vaginal 
dryness,71  while the other symptoms may be accounted for by psychosocial stresses 
associated with the mid-life years, and the ageing process.59   
 
A UK-based cross-sectional survey of 45-54 year old women from the general population 
reported that 84% had experienced at least one of fifteen menopause-related symptoms 
listed, with 40% to 45% rating their symptom(s) as problematic.86  Findings from the USA 
and Australia of women who reported five or more core symptoms were respectively 35% 
and 22% for perimenopausal women and 32% and 36% for naturally postmenopausal 
women, although an underestimation of symptom prevalence in the Australian study may 
have resulted from the attrition rate related to women who commenced HRT due to 
bothersome symptoms.71,87  Fewer than 12% of women reported having none of the 
symptoms in the preceding two weeks.62,88 (Details of large cohort studies investigating 
menopausal symptoms are included in Appendix  2 ). 
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Symptom experience varies according to the individual and the stage of the transition.89  
Perimenopausal women have been found to experience the most symptoms, especially 
somatic symptoms,62 while vasomotor symptoms of hot flushes and night sweats increase 
throughout the transition, becoming most prevalent in the late perimenopause and 
postmenopause.90,91  The prevalence of individual symptoms is included below with a 
discussion of their aetiology.  This will be prefaced by a general overview of the 
endocrinological changes associated with menopause and the menopause transition. 
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Chapter Four 
  
 
 
Endocrine Characteristics  
of the Menopause Transition and Menopause 
 
 
  
 
 
 
4.0  Introduction 
 
The fourth chapter of the Literature Review examines the endocrinological changes at 
menopause.  This provides the background for the discussion of symptoms that follows, and 
for potentially appropriate actions of targeted therapies for these symptoms.  
25 
4.1 The Normal Reproductive Cycle  
 
During the reproductive years, normal cyclic ovarian function depends on the coordinated 
activity of a feedback system involving the hypothalamic-pituitary-ovarian axis (referred to as 
the HPO axis) with associated structural and functional changes in the target tissues, the 
ovaries and uterus.92 The interaction between gonadal steroids and 
neurotransmitters/neuropeptides modulates ovulatory function  via the synthesis and release 
of gonadotropin-releasing hormone (GnRH) at the hypothalamus.93  
 
The endocrinological changes occurring throughout the perimenopause must be viewed in 
the context of the regulation of the normal menstrual cycle.  A detailed outline of this has 
been provided in Appendix 3.  In summary, episodic secretion of  GnRH by the 
hypothalamus regulates the anterior pituitary which produces the gonadotrophins, follicle 
stimulating hormone (FSH) and luteinising hormone (LH), in a pulsatile manner.  These, in 
turn, regulate ovarian function.  The pulsatile frequency and amplitude are dictated by 
opioidergic signals and predominantly negative feedback by the ovarian steroids, oestradiol 
(E2) and progesterone,94 and the FSH regulatory peptides, the inhibins (INHs).95 
4.2 Changes at the Menopause 
4.2.1 Onset of Menopause  
Although recently challenged by Johnson and co-workers96, the classical view is a woman is 
born with a finite primordial follicle pool.  It is estimated that, at birth, the female has around 
a million oocytes (immature ova) that are arrested in prophase I of meiosis.52  These are 
gradually lost throughout her reproductive life through ovulation or atresia, with an 
exponential acceleration of follicle loss after the age of 40.94  At the time of menopause 
itself, few if any follicles remain within the ovary.51   When follicle numbers reach a critical 
level of between 100 and 1000,95 menstrual cycles change from regular to irregular; the 
changes in ovarian follicle numbers and function are also believed to be responsible for the 
endocrinological changes of the menopausal transition and menopause.51  
Although exhaustion of the reservoir of ovarian follicles was once thought to be solely 
responsible for menopause, current evidence suggests that the age-related neuroendocrine 
alterations in the brain may be ultimately responsible, as the feedback system of the HPO-
pacemakers becomes dysfunctional.97,98 Changes in GnRH release and reduced 
responsiveness to it by cells in the anterior pituitary gland that secrete LH and/or FSH are 
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additionally thought to contribute to the onset of menopause.99,100 Reduced hypothalamic–
pituitary sensitivity to the effects of oestrogens on gonadotropins may also contribute to 
perimenopausal endocrine physiology.101,102  
 
The timing of the final menstrual period (FMP) may be determined by an endometrial rather 
than a hormonal event,54,103 as no single endocrinological event has been identified that 
coincides with the FMP; endocrinologically the late perimenopause and early 
postmenopause are indistinguishable. 
 
4.2.2 Cycle Changes  
 
Entry to the menopause transition is marked by menstrual irregularities, including changes 
to the flow, frequency and duration, which are estimated to precede the FMP by an average 
of 4-5 years.89,104 Initially, in the late reproductive years, as the length of the follicular phase 
becomes shorter with the decline in ovarian function, cycle lengths also become 
shorter.105,106 After entry to the menopause transition, however, with the onset of irregular 
cycles, anovulatory cycles begin to occur 54 and both long and short cycles become more 
common.  As the menopause transition progresses, elongated ovulatory and anovulatory 
cycles become more common and normal cycles occur less frequently.95  With the approach 
of the FMP, there is a tendency towards less frequent menses.53  However, waning fertility is 
said to begin about 10 years prior to menopause,107 and may be at least partly due to 
dysregulation of folliculogenesis, as progress of follicle growth is found to be slower in older 
reproductive-aged women.108 
 
4.2.3 Endocrinological changes 
   
Overall, the major endocrine changes associated with the menopausal transition are 
declining inhibin-B (INH-B) in the follicular phase of the cycle in conjunction with a rise in 
serum FSH,109,110followed later by declining oestradiol. There is also a decline in luteal 
phase progesterone levels.111 112  Comparing postmenopausal women with women of 
reproductive age, using the early follicular phase as a reference point, in postmenopausal 
women, FSH levels are 10-15 fold higher, (reaching their maximum 3-4 years after the 
FMP),53 LH approximately 4 fold higher, oestradiol levels 90% lower and Inhibin A & B more 
than 90% lower.66  
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However, the menopausal transition from regular cycling to final cessation of menstruation is 
characterised by marked fluctuations in hormone levels.113 The endocrinology of menopause 
has not yet been fully elucidated and is complicated by the irregular cycles that characterise 
the menopause transition; these vacillate between normal length ovulatory and anovulatory 
cycles, and elongated ovulatory cycles.114 Conflicting findings from studies could reflect the 
different types of cycles and cycle lengths, which makes it difficult to determine the stage of 
the cycle and its ovulatory status. 
The Individual Hormones  
Follicle-Stimulating Hormone 
Elevated early follicular phase FSH* has long been accepted as a hallmark of menopause107 
and a necessary feature of entry to the menopausal transition according to the STRAW 
definition.52 Serum FSH levels are somewhat higher in early perimenopause compared with 
pre-menopause but rise markedly in the late perimenopause and postmenopause.51   
 
The rise in early follicular phase FSH has been shown to be associated with a decrease in 
follicular phase length and menstrual cycle length in regularly cycling, late-reproductive-aged 
women, which may be due to earlier recruitment of follicles.115,116,117 However, once irregular 
cycling has commenced, according to findings from the FREEDOM study,116 FSH levels vary 
according to whether cycles are normal or the delayed-response type.  Single 
measurements of FSH levels during the menopause transition will therefore vary according 
to cycle length and ovulatory status,54 which may account for the marked variability of 
circulating FSH and oestradiol reported during the menopause transition by cross-sectional 
and longitudinal studies.66,103,113,118,119  In elongated/delayed response cycles and 
anovulatory cycles, increased levels of FSH are found.  With ovarian ‘quiescence’, when 
oestradiol is low, FSH levels peak .116 
 
FSH is under the dual feedback control of the inhibins as well as the sex steroids, 
particularly oestradiol.  It was previously thought that the rise in FSH throughout the 
menopausal transition was due to the fall in oestradiol with advancing age and the resultant 
                                                 
* Typical FSH reference ranges 
Follicular phase  2.5 – 10.00 
Midcycle peak  3.0 – 33.0 
Luteal phase  1.5 – 9.0 
Postmenopausal       > 23.0 
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removal of its suppression on FSH secretion. However, more recent studies have shown 
that oestradiol levels can remain unchanged or even increase throughout the menopausal 
transition,66,103,120-128 116 with elevated levels having been found in regularly cycling women 
up to the age of 55.123 Hence another mechanism was implied for the early follicular phase 
rise in FSH. 
The Inhibins 
As mentioned previously, FSH is also inhibited by INH-B, which is central to the 
endocrinological changes at menopause.  The inhibins are dimeric protein hormones made 
up of a common α- subunit, linked to 1 of 2 β-subunits-, βA  or βb to give inhibins A and B 
respectively. There is substantial evidence to suggest that INH-A and INH-B are under 
differential control.128  
 
Inhibin B is a product of the antral follicles and is involved in a closed loop feedback system 
whereby FSH stimulates secretion of oestrogens and INH-B, which together exert negative 
feedback on FSH.  The system is maintained in a continual state of balance in the normal 
menstrual cycle of normal reproductive-aged women.  As ovarian follicle numbers fall and/or 
the granulosa cells lose their ability to secrete INH-B, there is a resulting decline in INH-B 
levels, without any initial fall in oestradiol, and an ensuing rise in FSH levels.  A clear inverse 
relationship has been shown between INH-B and FSH in women over the age of 40.128  The 
marked fall in INH-B levels in the first half of the cycle has been found to occur in the early 
perimenopause, defined by self-reported changes in menstrual cycle regularity.  At this time, 
oestradiol and INH-A levels are no different from pre-menopausal women.129 This further 
supports the hypothesis that the major fall in INH-B is responsible for allowing FSH to rise 
while maintaining early follicular-phase oestradiol levels relatively intact.  Burger and 
colleagues concluded that the declining concentration of INH-B levels in the first half of the 
cycle129 was the earliest endocrine change marking entry into the menopausal transition.128 
Oestrogens 
The hypothesis that the fall in inhibin levels (especially INH-B) leads to the maintenance of 
oestrogen levels until just prior to the FMP is in contradistinction to the previously-held belief 
that the perimenopause is characterised by a gradual decline in oestrogen levels with rising 
FSH. 94 However, there is mounting evidence from studies to show that oestradiol levels  
29 
either increase or are well maintained, even in irregularly cycling women,66,103,120-128 until 
about 2 years prior to the FMP,130 although circulating FSH levels begin to rise significantly a 
year or two prior to the FMP.127,131  Miro115,116 proposed that the elevated levels of oestradiol 
may be due to the higher concentrations of FSH and resultant increased driving of the 
dominant follicle, which may  lead to accelerated follicle development and occasions of 
multiple follicles developing at once.  This suggests that, in some cycles at least, the ovary 
responds to the increased FSH levels by increasing oestradiol secretion.  
 
Some studies have demonstrated marked variability with periods of hyperestrogenism 
consistent with erratic follicular development and multiple follicles developing at once, with 
elevated FSH.103,111  Periods of unopposed oestrogen are consistent with the high incidence of 
dysfunctional uterine bleeding occurring during perimenopause, generally in anovulatory cycles.54  
 
However conflicting results have been obtained from different studies observing oestradiol 
levels during the menopausal transition, including elevated levels, decreased levels or no 
change.  In a subset of women with regular, normal length ovulatory cycles, there were no 
changes found in ovulatory oestradiol or progesterone levels during the entire 4–9 year 
period prior to the FMP.114  It has been proposed that these conflicting findings may reflect 
data derived from different types of cycles or pooling of data from different types of cycles 
(normal length ovulatory cycles, delayed ovulatory and anovulatory cycles).95    
 
Lower than normal levels of oestradiol have been found in late-perimenopausal women who 
had experienced 3 months’ amenorrhoea131 and in late-perimenopausal women during 
anovulatory cycles,132 and in cycles with an elongated ‘lag period’ between the menstrual 
phase and onset of follicular phase.115  As pointed out previously, these types of cycles 
become more common with the progression of the menopause transition.   Weiss and co-
workers observed 3 distinct hormonal patterns associated with anovulatory cycles: i) normal 
oestrogen increase with subsequent LH surge but no appreciable progesterone production, 
suggesting disruption to corpus luteum dysfunction; ii) oestrogen increase but not LH surge, 
implying failed CNS response to the oestrogen; and iii) tonically elevated LH and FSH but no 
increase in osteogen, which resembles the postmenopausal pattern.102 
 
Ovarian refractoriness to FSH underlies elongated menstrual cycles115 and is thought to be 
due to the drop to a critical number of follicles, fewer gonadotrophin receptors in the ovary 
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and a reduced ability to respond.  This leads to the changes in menstrual flow and frequency 
of menstrual cycles115 such as prolonged ovulatory cycles, resulting from delayed oestradiol 
secretion. In this type of cycle, dominant follicle development can lead to higher than normal 
levels of oestradiol but lower luteal phase levels of progesterone.115,133  Miro and colleagues 
found a strong parallelism between oestrogen take-off, defined as day 1 of the sustained 
rise in oestradiol, and cycle length variability,115 consistent with refractoriness of the ovary to 
FSH stimulation.  
 
Oestradiol is the major secreted ovarian oestrogen in reproductive aged women.  However, 
after menopause ovarian oestrogen secretion ceases largely or entirely and oestrone 
derived from peripheral conversion of androstenedione is the major form of oestrogen.134  
Progesterone 
Progesterone levels ultimately decline as the FMP approaches.  Lower luteal phase 
progesterone levels would be expected to occur in the absence of the development of a 
corpus luteum.111  With the onset of irregular cycles, decreased progesterone levels135 and, 
in a randomly collected sample, fewer concentrations indicative of the normal post-ovulatory 
state have been observed.130,136  Lower concentrations were especially noted in the delayed-
response (D-type) cycles.116  Some studies have found reduced excretion of progesterone’s 
major urinary metabolite, pregnanediol glucuronide* (PdG),103,111,119,127  although this has not 
been reported consistently.114,121,137  Low progesterone is clearly associated with failure of 
the secretory phase; continued proliferation of the endometrium in anovulatory cycles leads 
to menorrhagia (heavy periods).95  
Androgens 
The major circulating androgen in women is testosterone and the major pre-androgen, 
dehydroepiandrosterone sulphate (DHEAS); these are produced by the ovaries and 
adrenals.  Menopause does not appear to significantly affect the rate of decline in 
testosterone or DHEAS levels.110,138 Testosterone levels in women fall by approximately 
50% between the ages of 25 and 45, while DHEAS levels fall progressively with age.  In the 
                                                 
*Cycles are classified as ovulatory or anovulatory according to blood progesterone or urinary PdG. 
Blood parameters: ≥16-20 nmol per cycle = ovulatory 
5-16 = luteal insufficiency 
<5 = anovulatory  
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postmenopausal woman, the stroma of ovaries and the adrenal glands continue to produce 
androstenedione, which is used in peripheral aromatisation to oestrone in adipose tissue. 
Adrenal production of testosterone also continues,139 and it has recently been shown that 
the postmenopausal ovary also makes testosterone, and continues to do so for as long as 
10 years beyond the menopause.140 
Luteinising Hormone 
LH levels have been found to increase progressively with the increased frequency of 
delayed-response (elongated) cycles during the menopausal transition, but not to differ in 
normal cycles throughout the transition from those seen in regularly cycling women.116 It 
appears that LH is entirely GnRH dependent.94  LH pulses, which correspond to the pulsatile 
secretion of GnRH, occur approximately every 60 minutes postmenopause in the absence of 
negative feedback.   
Anti-Müllerian hormone 
Anti-Müllerian hormone (AMH), also called Müllerian inhibiting factor , Müllerian inhibiting 
hormone , and Müllerian inhibiting substance, has recently received attention as an indicator 
of reproductive ageing.  AMH is a dimeric glycoprotein expressed by granulosa cells of the 
ovary during the reproductive years that controls the formation of primary follicles by 
inhibiting excessive follicular recruitment by FSH. It therefore has a role  in 
folliculogenesis.141  AMH is not influenced by the gonadotropic status and reflects only the 
follicle population.142   Recent studies have found that AMH levels are related to onset of 
menopause,143 with reductions in AMH and INH-B significantly associated with cycle 
irregularity, and supporting its role as a predictor of the menopausal transition, alone or in 
combination with INH-B.144   
4.3 Diagnosing Menopausal stage 
Endocrinologically, the late perimenopause and the early postmenopause are 
indistinguishable.  Oestradiol levels have fallen by approximately 50% compared with earlier 
follicular phase levels at the time of the FMP, and FSH levels have risen to about 50% of the 
ultimate peak they will reach postmenopausally.131 
 
As mentioned above, FSH measurements are dependent on cycle phase, cycle length and 
ovulatory status.  As the menopause transition progresses there is an increased incidence of 
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elongated ovulatory cycles and anovulatory cycles while ‘normal’ cycles occur less 
often.114,116  In view of the inconsistency between women and from cycle to cycle during the 
menopause transition, as well as the difficulty of determining early follicular phase in 
amenorrhoeic or irregularly cycling women, “single-time FSH measurements have a limited 
capacity to reliably predict reproductive status”.66 
 
The Melbourne Women’s Midlife Health Project (MWMHP) found that experiencing 
symptoms tracks closely with hormone profiles and cycle features,90 suggesting that 
symptom diaries are therefore more useful than isolated endocrine profiles in ascertaining 
the stage of the menopause transition.94  
4.4 Summary  
The commencement of irregular cycling marks entry to the menopause transition, after 
which anovulatory cycles become progressively more common.  The declining antral follicle 
count underlies the endocrinological changes associated with reproductive ageing.145  There 
is also evidence of reduced hypothalamic–pituitary sensitivity to oestrogen feedback in 
perimenopausal women. It is hypothesised that the fall in inhibin levels (mainly INH B), 
resulting from the declining antral follicle count, allows the rise in FSH, which leads to 
accelerated follicle development and occasions of multiple follicles developing.  This causes 
the fluctuating or increased oestradiol secretion in perimenopausal women, until the late 
transition, when oestradiol levels fall markedly. After menopause, the major oestrogen is 
oestrone derived from peripheral conversion of androstenedione secreted by the adrenals. 
Progesterone levels decline with the increasing frequency of anovulatory cycles; the decline 
in androgen levels is associated with age but not menopause per se.  The endocrine 
changes appear to vary between and within individuals, and substantial changes have been 
observed from one cycle to the next.  In addition, the high degree of overlap with FSH levels 
in regularly cycling women makes single FSH measurements unreliable indictors of 
reproductive status;146 this may be more reliably ascertained through symptom diaries.  
 
The above has methodological implications for the study to be described in this thesis.  It is 
also of relevance to the ensuing discussion of symptoms and their aetiology, as well as to 
the phytotherapeutic approach to the treatment of menopausal symptoms which will be 
elaborated in a later section. 
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Chapter Five 
  
 
 
Menopausal Symptoms in General 
 
 
  
 
 
 
5.0  Introduction 
 
The fifth chapter of the Literature Review explores the symptoms commonly associated with 
menopause, their prevalence and underlying aetiology.  This has relevance to the 
hypothesised effects of the phytomedicines tested in the RCT described in this thesis.  
Factors that could potentially impact on symptom experience that may be of relevance to the 
design and interpretation of data from the RCT are also examined.  
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5.1 Symptom Experience 
 
The majority of women in the age group 45-54 years experience menopausal symptoms, although 
not all experience these as troublesome.86   While endocrine changes are permanent, 
menopausal symptoms such as hot flushes and mood changes usually spontaneously resolve 
with time.147,148 However, some symptoms, such as genital atrophy, may remain the same or 
worsen.81  Quantification of menopausal symptoms is rendered difficult by their subjective nature.  
The high degree of overlap between the physical and psychological symptoms of menopausal 
oestrogen withdrawal and other common midlife conditions, such as hypothyroidism and  
major depression, means that symptom presentation alone is not diagnostic.149   
 
Symptoms typically associated with the menopausal transition can be categorised as 
follows, according to standard medical texts (Table 5.1).150,151 
TABLE 5.1   MENOPAUSE-RELATED SYMPTOMS  
Symptom cluster Typical symptoms 
Vasomotor symptoms hot flushes, night sweats, cold sweats/perspiration, dizziness, migraine, palpitations 
Psychological and emotional 
symptoms 
irritability, memory and concentration difficulties, depression, anxiety and nervousness, 
mood swings,  fatigue, sleep disturbances, tearfulness, unloved feelings, loss of self-
confidence, decreased libido   
Changes to the reproductive 
cycle 
menorrhagia, dysfunctional uterine bleeding, shorter and longer cycle lengths, breast 
tenderness,  worsening premenstrual syndrome  
Urogenital symptoms atrophic vaginitis , vaginal dryness, dyspareunia, urinary (stress) incontinence,  dysuria, 
urinary tract infections (UTIs) or other bladder dysfunction 
Musculoskeletal arthralgia, myalgia (diffuse muscle and joint pains) 
Skin and other tissue 
changes 
Mucosal thinning and drying that leads to cyclic acne, pruritis, dry eyes, sinusitis,149 
formication, dry skin, breast glandular tissue atrophy, new facial hair 
Other somatic symptoms weakness/fatigue, paraesthenia, headaches, worsening allergies149 
weight gain152   
 
Menopause-rating scales such as the Kupperman Index (KI) and the Greene Climacteric 
Scale contain different sub-divisions such as psychological, somatic, vasomotor and sexual.153 
5.2 Cross cultural data 
It has long been observed that symptomatology varies markedly among ethnic groups, 
cultures, socioeconomic groups, geographic locations and climates. 52,154 The Study of 
Women’s Health Across the Nation (SWAN) found that symptom prevalence was lower in 
the Japanese and Chinese populations in the US than in Caucasians, especially for the 
symptoms of hot flushes, vaginal dryness, sleep difficulty and urine leakage.155  In Japanese 
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women, the most prevalent symptoms associated with the climacteric (‘konenki') have been 
found to be shoulder stiffness, memory loss, and stress.156 
5.3 Evidence for Symptom Specificity 
There is lack of consensus regarding which of the observed symptoms experienced by 
middle-aged women can be attributed to declining hormone levels at menopause as distinct 
from the process of ageing, as “the symptoms do not track closely with the menstrual cycle 
or endocrine changes during the menopausal transition.”52   As mentioned previously, some 
research suggests only  the flushing and night sweats, breast tenderness and vaginal 
dryness are definitely related to the endocrine changes of menopause.157 71  There is some 
evidence that the other complaints  are equally common in men aged between 45 and 54 
years,158 although Dennerstein and co-workers62 found that two groups of symptoms were 
significantly related to changes in menstrual status: vasomotor symptoms which increased 
through the menopause transition; and general somatic symptoms which were more 
frequent in the perimenopause.   The principal way of establishing a relationship of 
symptoms to hypoestrogenemia is observation of any amelioration that occurs after 
oestrogen-based hormonal replacement.  However, it has been suggested that  the 
beneficial effect on oestrogen on many of the menopause-related symptoms found to 
improve in conjunction with hot flushes may be attributable to a ‘domino effect’ that is 
initiated by the primary relief of the hot flushes.159  
5.4 Causes of systemic effects  
Oestrogen, progesterone and androgen receptors are found in tissues throughout the body, 
including the brain.160  Oestrogen receptors are found in uterus, liver, kidneys and heart (ERα), 
ovaries, lungs, gastrointestinal tract, bladder, hematopoetic and CNS (ERβ), with both types 
expressed in the breast, thyroid, adrenal, bone and some parts of the brain.161  Additionally 
they occur in skin tissue, the vagina, uterus,160 cervix, urethra, joints,  muscles of the pelvic 
floor162 and many other tissues, which may account for the distribution of systemic symptoms. 
 
In the brain, oestrogen receptors are very dense in regions of the limbic system and 
hypothalamus, which serves as a bridge between the nervous system and endocrine systems. 
Oestrogens modify synthesis, release and metabolism of many neurotransmitters   
such as noradrenaline, dopamine, acetylcholine, serotonin and melatonin, and neuropeptides 
including  β-endorphin, which modulate the activity of hypothalamic centres and the limbic 
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system.93 The decline in sex steroids, particularly oestrogen, results in altered function of the 
hypothalamus and limbic system, with associated changes in thermoregulation, 
satiety/appetite, metabolic rate, sleep patterns, vasomotor stability,163  blood pressure, 
sexuality, locomotor activity, immune response, memory and cognitive function164 and, via the 
limbic system, the regulation of mood tone and psychological well-being165,166  
 
Age-related decreases are observed in melatonin levels, as well as the time during which 
melatonin remains elevated at night.167  Studies in women during the perimenopause reveal 
that the decline in melatonin precedes the FSH increase, with a decline of 41% in the age 
group 40 to 44 years and a further decline of 35% between ages 50-54 years and 55 to 59 
years.168  Whether this decline in melatonin secretion contributes to the development of 
menopause or its symptoms has not been established.169  An association between the quality 
of sleep and the amount of melatonin secreted has been noted, especially in the elderly.170   
 
Age-related declines are also found to occur in concentrations of noradrenaline in the 
hypothalamus171 (which influences the secretion of LH, growth hormone (GH) and thyroid-
stimulating hormone172), total brain serotonin levels,173  β-endorphin neurones in the 
arcuate nucleus,174 and  γ-aminobutyric acid (GABA).175 Age related decreases in the 
dopamine receptor D-2 subtype,176 and increases in brain monamine oxidase (MAO)-B also 
occur.177  In women, levels of prolactin, a precursor of noradrenaline, begin to fall around 
menopause.178  This will be referred to in the subsequent sections on the specific 
symptoms under investigation in the studies to be described herein. 
5.5 Symptoms according to Stage of the Transition 
Symptom experience varies according to the individual, the stage of the transition and 
whether menopause is natural or surgically-induced.  Hysterectomised women suffer more 
severe symptoms overall than women who reach menopause naturally.50  It is during the 
perimenopause that most symptoms are reported.62,90 These symptoms can be due to 
oestrogen excess (breast tenderness, menorrhagia, migraine, nausea, shorter cycle 
length)101,111,179 or deficiency (vasomotor symptoms)79,90 and often fluctuate, reflecting the 
underlying hormonal instability during these years.179  Dysfunctional uterine bleeding is 
maximal during the menopausal transition due to persistent unopposed oestrogen.128,180  
Rates of psychological distress are reported to be highest during the perimenopause.88,181-185  
There is also a marked increase in disturbances of sexuality.62,186  The other most frequently 
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occurring symptoms during this phase include forgetfulness, lack of energy, irritability, and 
weight gain, while those causing most distress include weight gain, heavy bleeding, poor 
concentration, leaking of urine, and feeling as though life were not worth living.152   The 
incidence of hot flushes increases throughout the transition62 with a peak generally at the 
time of the menopause88  and in postmenopausal women.187  The most common symptoms 
reported around the time of the menopause are musculoskeletal aches and pains, 
vasomotor symptoms, sleeping difficulties and fatigue, forgetfulness and nervous 
tension/irritability.62,86,155,188  The incidence of symptoms in the late-perimenopause  is similar 
to that in early postmenopausal women.62,89 
 
The most prevalent symptoms are not necessarily regarded as the most problematic.  A 
cross-sectional survey of 8,000, aged 45-54 women in Scotland found Irritability to be 
reported by the highest percentage, followed by sleeping problems, concentration/memory 
difficulties, anxiety, hot flushes, night sweats and depression.  However, in terms of being 
the most problematic, sleep problems were rated highest, followed by concentration/memory 
difficulties, anxiety,  irritability, night sweats, and depression.86  Findings from this and other 
studies are also included in Table 5.2 below.147  
TABLE 5.2   SYMPTOM  PREVALENCE IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN 
(VASOMOTOR AND PSYCHOLOGICAL SYMPTOMS) 
The Study of Women’s 
Health Across the Cross-
sectional Survey of 
women in US aged 40-55 
years 
Prevalence of Symptoms 
in previous 2 weeks. 
Late-peri-/ 
postmenopausal155 
Scottish Cross-sectional 
Survey 
Prevalence of Symptoms 
in preceding 6 months 
In women aged 45-54 
(% Perceiving symptom 
as  Problematic)86 
Melbourne Cross-
sectional Survey 
Prevalence of Symptoms 
in previous 2 weeks in 
Peri-/postmenopausal 
women62 
US (Californian) Recall 
Study 
Postmenopausal women 
(aged 50-89 years)147 
 irritability   72% (25%)  irritability 25% 
difficult sleep 
43.9%40.4% 
sleep problems 66% 
(33%) 
sleeping difficulties 
35.35% /41.41% 
insomnia 28% 
forgetfulness 
44.8%/42.0% 
memory /concentration 
problems  64% (30%) 
concentration difficulties 
27.5% /18.31% 
 
 anxiety  58% (26%) nervous tension  40.62% 
/40% 
anxiety about looking 
older 11% 
hot flushes 56.8%/48.8% hot flushes  56% (22%) hot flushes  
31.51%/39.44% 
hot flushes 70% 
 night sweats 55%(24%)  night sweats 35% 
 depression  51% (22%) feeling down or sad-
hearted 32.97%/28.73% 
depression 20% 
stiff/sore 
54.8%/58.4% 
aching/painful joints 67% 
(29%) 
aches or stiff joints 
51.55%/50.42% 
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A brief outline of the symptom clusters and their aetiology will be given here.  The symptoms 
of interest in the clinical trial reported on in this thesis, namely vasomotor and psychological 
symptoms will be dealt with in greater detail in the following sections. 
5.6 Aetiology of Individual Symptoms/Symptom Clusters 
5.6.1 Vasomotor Symptoms 
 
 Collectively, hot flushes (known as flashes in the US) and nights sweats are termed 
‘vasomotor symptoms’ because they occur secondary to vasomotor instability.189   However 
the term ‘vasomotor symptoms’ is sometimes used more broadly to include light-
headedness/dizziness, migraine and  palpitations.190    The term ‘hot flushes’ will be used in 
this thesis to refer to hot flushes and night sweats, the latter being hot flushes with 
perspiration that occur during sleep.191   The impact of hot flushes on a woman’s sense of  
well-being and quality of life can be significant,188 sometimes causing extreme anxiety and 
leading to social isolation.152  Night sweats are thought to be at least partly responsible for 
disrupted sleep patterns associated with menopause192,193 which can in turn contribute to 
other associated symptoms such as mood changes,194,195 concentration difficulties and 
fatigue.195   
 
An association between the experience of hot flushes and the overall decline of oestrogens 
is undisputed, and is supported by the efficacy of oestrogen administration in eliminating 
them.196    However, oestrogen reduction also occurs in asymptomatic women.   A complex 
interaction between oestrogens, progesterone and neurotransmitters may underlie the 
thermoregulatory changes involved in hot flushes.197,198 This is described in more detail in 
the following chapter.   
5.6.2 Sleep Disturbances 
 
The factors that influence sleep disturbances have not yet been fully elucidated.  While  a 
causal connection between nocturnal  hot flushes (night sweats) and sleep disturbances is 
not universally supported, data do exist  from studies using both subjective and objective 
sleep assessment techniques showing an association between vasomotor symptoms and  
poor sleep quality, reduced sleep efficiency, longer rapid eye movement latencies and  mid-
sleep waking episodes and arousals.199-202  However, not all of the waking episodes are 
associated with flushing,199,201 suggesting this may not be the only factor responsible.  
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Conversely, not all of the nocturnal flushes are found to be associated with waking episodes 
or arousals.   Freedman and Roehrs202   found that in the first half of the night, hot flushes 
were associated with more arousals and awakenings than in the second half of the night.  
They attributed this to the predominance of rapid eye movement (REM) sleep in the second 
half of the night, suppressing thermoregulation and possibly thereby suppressing the 
disruptive effects of hot flushes on sleep. This may account for the finding of one study that 
acute sleep problems were associated with reported, but not with physiologically monitored 
sleep hot flushes.203  Waking has been observed to precede nocturnal flushes and occur 
prior to any change in skin temperature, implying a possible central phenomenon.200   
However Freedman and Roehrs, in another study, observed arousals and awakenings to 
precede or follow hot flushes at approximately the same rate.204 
 
An association between sleep disruption in perimenopausal women and altered mood has 
also been observed, with positive correlations between frequent sleep disruptions and 
anxiety; time spent active and negative mood; and frequency and duration of arousals with 
confusion.195  This is supported by the observed age-related decrease in total brain 
serotonin, one of the main regulators of circadian sleep-wake cycles. 205   Deficiency of 
serotonin is associated with many psychological disorders as well as sleep disorders.205   It  
has been suggested that anxiety and depression may be important mediators of 
menopausal sleep disturbances,206 which can impact adversely on quality of life.  As pointed 
out by Utian, inadequate and unrefreshing sleep can eventually lead to chronic sleep 
deficits, significantly impaired alertness and mental acuity, forgetfulness, and decreased 
work productivity. In the case of drenching night sweats that necessitate a change of clothes 
and/or bedding, the disturbance to the bed partner’s sleep can also affect familial 
relationships.207 
 
Other proposed causes of sleep disturbances in the menopause transition are nocturia,208 
hormonal changes, age-related decrease in slow-wave sleep and GH secretion,209,210 
depression,211 stress, nocturnal myoclonus,212 respiratory abnormalities such as sleep 
apnoea and hypopnoea, which are reported to increase during this time.202,213   
5.6.3 Psychological and Emotional Symptoms 
 
Psychological and emotional symptoms associated with menopause include irritability, 
inability to concentrate, depression, anxiety and nervousness, mood swings, poor short-term 
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memory, fatigue, tearfulness, unloved feelings, loss of self-confidence and sometimes sleep 
disturbances. 150,151  Controversies exist regarding whether there is an actual rise of mood 
symptoms during the menopause transition compared with the premenopause, as well as 
their aetiology.  The oestrogen-withdrawal perspective holds that symptoms such as 
depressed mood are triggered by endocrine changes, in contrast to social circumstances 
frequently encountered by women aged 40 – 60 years.  A biopsychosocial aetiological 
model has been proposed which suggests that “underlying endocrinological changes trigger 
emotional complaints in women who are vulnerable by virtue of developmental factors, 
personality, psychiatric history, known vulnerability to hormonally triggered mood changes, 
or current social problems.”214 
 
While rates of psychological distress are commonly reported to be highest during 
perimenopausal years,88,181-185 some studies report that its prevalence does not  differ 
significantly from males of the same age.215   Methodological differences that render 
comparison between studies difficult include the criteria for determining reproductive status 
as well as mood disorders, scales for detecting and measuring depression and anxiety, and 
the failure to distinguish between mood symptoms and mood syndromes.  The inconsistency 
between studies regarding inclusion of current HT users is an additional limitation.  This will 
be discussed further in the section on psychological symptoms. 
 
5.6.4 Memory and concentration 
 
Forgetfulness was reported by 44.8% of late-perimenopausal and 42% of postmenopausal 
women in the SWAN, compared with 31% of premenopausal women.  A relationship 
between cognitive impairment and the endocrine changes of menopause is disputed,216,217   
with evidence for the connection being mainly derived from observations following 
oophorectomy, where there is an abrupt decline in oestrogen levels.218  However, 
spontaneous menopause appears to cause little change,219 and it is suggested that any 
cognitive decline may be more related to ageing.220   Administration of oestrogens with or 
without progesterone (conjugated equine oestrogens with or without medroxyprogesterone 
acetate) in The Women's Health Initiative Memory Study (WHIMS), did not protect against 
dementia or cognitive decline, but substantially increased the risk.217  However, this finding 
may be explained by the characteristics of the study sample, which included 
postmenopausal women aged 65 years and older, who performed poorly at baseline, 
whereas the best evidence for a favourable effect on cognitive function is from studies on 
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women under 65 years of age.221  Recent evidence from human and animal models 
suggests a critical time for the initiation of oestrogen in the context of memory preservation, 
namely at the time of menopause, or soon after ovariectomy;218 administration a 
considerable time after ovariectomy had little or no beneficial effect on cognition.222,223    
 
5.6.5 Changes to the Reproductive cycle 
 
During the menopause transition changes to the menstrual flow, frequency and duration 
often occur, but these changes are highly variable.52,89  One study found that 10% of women 
stop menstruating abruptly, while the majority experience months or years of irregular 
bleeding and variable cycle length before menses cease. 89   In the early perimenopause, 
both long and short cycles become more common, but as women approach the FMP, there 
is a tendency towards less frequent menses.53  However, waning fertility is said to begin 
about 10 years prior to menopause.160  
 
Menorrhagia can occur during ovulatory cycles due to increased oestrogen levels during the 
follicular and luteal phases.95  
 
Although there is a peak of premenstrual syndrome (PMS) in women in their late 30’s, 
anecdotal reports suggest that perimenopausal women also experience an aggravation of 
PMS-like symptoms, or at least appear to tolerate them less well.224  It has even been 
proposed that mood symptoms and breast discomfort during the menopause-transition are 
more likely to be related to menstrual cycles than menopause, given that they improve after 
cessation of menstruation.225   
 
5.6.6 Urogenital/Vulvovaginal symptoms  
 
After the menopause, the vaginal mucosa atrophies, vaginal flora changes and the vaginal 
pH becomes less acidic.226 227  Vaginal atrophy can be asymptomatic or associated with 
pain, burning, dryness, discharge, dyspareunia and/or vaginal bleeding.228  Changes to the 
thickness and secretions of the vagina are accepted as being due to declining oestrogen 
levels,229-231 and can be improved by oestrogen administration.232 However, findings are 
conflicting regarding incontinence and recurrent cystitis.233,234   The beneficial effects of 
oestrogen in UTIs may be due to decreasing colonisation of bacterial pathogens. 232  
Symptoms of incontinence, while temporally associated with menopause, may be related 
more to ageing and obstetric history than directly  to menopause or hypo-oestrogenism.162 
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Estimates of the prevalence of vaginal dryness range from 4% to 47% depending on the 
stage of the transition and study population.71,155,235,236  In perimenopause and 
postmenopause, data from the UK and Australian studies range between 21% to 47%.86,71   
Among sexually active postmenopausal 40 to 65 year-olds in the USA, the prevalence of 
vulvovaginal atrophy (vaginal dryness, itching, irritation; pain on urination; or pain or 
bleeding on intercourse) was 57% and female sexual dysfunction 55%.237    
 
Female sexual dysfunction (the decline in sexual interest, arousal, capacity for orgasm and 
frequency of sexual activity) has been associated with the natural menopause transition,50 
although it is more problematic in surgical menopause with removal of the ovaries.238  This 
decline may be partly attributable to ageing.239,240 However, depression and vaginal dryness 
were found to be reliable predictors of low sexual desire,241 and an association with 
menopausal status and oestrogen, but not testosterone levels, has been observed in some 
studies. 238,242  Androgen administration, in conjunction with oestrogens and progestins, or 
tibolone® (which has oestrogenic, progestogenic and androgenic effects) can significantly 
improve sexual performance, including sexual desire, sexual arousal and satisfaction243,244 
Hormonal determinants, however, have been found to be less important than psychosocial 
factors238  such as previous sexual function, loss or gain of a sexual partner and feelings 
towards the partner.245  Other factors affecting wellbeing such as lifestyle factors, stress, 
daily hassles, vasomotor symptoms, sleep, self-rated health241 and neuroticism246 also 
contribute.   However, not all women experiencing low sexual function are distressed about 
it, and this distress declines with age.238  
 
5.6.7 Musculoskeletal symptoms 
 
Osteoarthritis and joint pain increase in prevalence from premenopausal  to postmenopausal 
women with hormonal change implicated in their aetiology.247,248,249 Aches and stiff joints 
were the most frequently reported symptom in studies of mid-life (51.7%)62, perimenopausal 
(55%) and postmenopausal (58%) women.155  Fibromyalgia commonly develops or worsens 
markedly during the perimenopausal period.250,251   The experience of stiff or aching joints is 
not necessarily indicative of radiological osteoarthritis,252 although this is more prevalent, 
severe and generalised in women than in men after the age of 50,253 and may be linked with 
menopausal changes.254  (Oestrogens may have a role in  triggering the initial changes in 
proteoglycan in cartilage, either directly or indirectly via cytokines;255,256 lower endogenous 
oestradiol levels impact on arachidonic acid metabolism, altered receptor binding and 
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structural proteins, such as collagens.257)  Although HT reduces the disease progression and 
may prevent incident disease, evidence from RCTs is lacking.  
 
The role of declining oestrogen production in musculoskeletal pain during the menopause 
transition is supported by the existence of an arthralgia syndrome both in patients taking 
aromatase inhibitors,258 and at HT discontinuation,253 as well as experimental evidence that 
acute aromatase inhibition affects nociception.259   Several studies support a link between 
pain and oestrogens260 and have examined their influence on cytokine production,261 
increased nitric oxide production by endothelial cells262 and central effects via enkephalins 
that inhibit neurons involved in nociception.263 
  
5.6.8 Skin and other tissue changes 
 
Dry skin complaints are common among menopausal women and in severe cases  can lead 
to intense pruritis, compromised barrier function, and secondary microbial invasion or 
inflammation264  Atrophy of the dermis after the menopause is due to a decrease in the 
dermal skin collagen content,265 which occurs much more rapidly in the initial 
postmenopausal years than in the later years with 30% of skin collagen being lost in the first 
5 years after menopause.266  HT can help to increase collagen content, dermal thickness 
and elasticity,  possibly improve cutaneous injury repair,267 dampen the pace of development 
of fine wrinkles, increase skin strength and perhaps prevent skin breakdown in elderly 
postmenopausal women.264  A summary of findings relating to the effect of HT on dry skin 
can be found in the review by Katz and Prystowsky.264 
 
High collagen content, together with hydrophilic glycosaminoglycans,  is also present in 
intervertebral discs.265 Changes in the collagen content occur with the ageing process and 
may have significant effects on the shape and biomechanics of the intervertebral disc, which 
could impact on vertebral body deformity and fracture.  Studies on intervertebral disc height 
have found that hormone treated postmenopausal women have significantly greater disc 
heights than untreated counterparts.265,268 
 
5.6.9 Weight changes and Fat Distribution 
 
Weight gain, which can be quite marked in midlife women, has been found to be associated 
with ageing, rather than menopause.269 However body fat redistribution to the abdominal 
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region, which occurs in association with menopause, may be attributable to the effects of 
oestrogen deficiency on adipocyte metabolism and fat partitioning,270 which refers to the 
distribution of adipose tissue between the central and peripheral regions.  Studies have 
found oestrogen to prevent this menopause-related increase in central fat deposition271 and 
HT to be associated with less central (but not total) body fat. 272   
5.7 Predictors of Symptoms 
The Melbourne Women’s Midlife Health Project (MWMHP) found that  predictors of 
experiencing fewer symptoms were increasing years of education, better self-rated health, 
the use of fewer non-prescription medications, the absence of chronic health conditions , a 
low level of interpersonal stress, the absence of premenstrual complaints, not currently 
smoking, exercise at least once a week, and positive attitudes to ageing and menopause,62 
consistent with an earlier study relating symptom experience with a negative attitude 
towards menopause.273   
5.8 Prevalence of Morbidity in Postmenopausal Women 
Rates of cardiovascular disease and stroke are four times greater in postmenopausal 
women compared to premenopausal women, diabetes risk and the rates of osteoporosis, 
immune disorders and Alzheimer’s disease also increase dramatically after menopause.149  
Despite the temporal association with postmenopause, however, the relative contributions of 
ageing and menopause-related endocrine changes to this increased morbidity have yet to be 
determined.   For a more detailed outline of post menopausal morbidity, refer to Appendix 4.  
 
The symptoms constituting the main outcomes in the studies reported herein will now be 
considered in more depth.  These are the vasomotor symptoms of hot flushes and night 
sweats, the mood symptoms and PMS-like symptoms. 
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Hot Flushes/Flashes and Night Sweats 
 
 
  
 
 
 
6.0  Introduction 
 
This chapter of the Literature Review explores the aetiology of the vasomotor symptoms of hot 
flushes and nights sweats, symptoms under investigation in the RCT described within this 
thesis. 
 
Hot flushes (referring to both hot flushes and night sweats) are considered to be the 
hallmark of menopause.  Also referred to as ‘hot flashes’, they are defined as recurrent, 
transient episodes of a sensation of intense heat that may be accompanied by 
perspiration.274  Of the symptoms typically associated with menopause, hot flushes are the 
most common reason cited for seeking treatment.275  
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6.1 Prevalence of Hot Flushes  
  
The prevalence of hot flushes in women who are spontaneously menopausal varies 
according to country and ethnic origin.   Worldwide, it is estimated that they are experienced 
by 50%-85% of women over 45 years.276  In Australia, they are experienced by 83% of 
women experiencing the menopause transition,90 62% of postmenopausal women277 and 
75% overall278 compared with  55% in UK women279 and 68%-88% in perimenopausal 
women in the USA.280,281  However, in Mayan women the prevalence is reported to be 
0%282,283 and in Chinese women, 10%.284  A comprehensive review of international hot flush 
prevalence has been conducted by Freeman and Sherif.154 
 
In ovariectomised women, the incidence is 90-92%.281,285 Tamoxifen® use following breast 
cancer is associated with more severe hot flushes and night sweats, occurring in an 
estimated 80% and 72% respectively.286 
6.2 Cultural differences  
 
Lower rates of hot flush reporting occur among women from non-Western countries 
compared with those in Western societies287 and women in rural areas compared with urban 
women, particularly in non-western countries, although the reasons for this are unknown.154   
The Study of Women’s Health Across the Nation (SWAN), the largest evaluation of 
menopausal symptoms ever carried out, found that significantly more Afro-American and 
Hispanic women, and significantly fewer Chinese and Japanese women living in the USA,288 
experienced vasomotor symptoms than their Caucasian counterparts.   
 
Japanese women are generally reported to have a low rate of hot flushes,87  in the range of  
3.0% to 22.1%,289  although a recent study reported 40% incidence in the general 
population, and 70% in a menopause clinic sample.290  The lower prevalence also applies to 
Japanese-American women living in Hawaii.291 Chilliness, which also constitutes an 
important vasomotor symptom, has been suggested to be a more important vasomotor 
symptom than hot flushes and sweats in Japanese women292 and was reported by 29.3% of 
participants in one study.292  Proposed explanations for the reduced incidence of hot flushes 
in Japanese women include the higher phytoestrogen intake by these women, from dietary 
soy beans and soy products.293,294 
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Results of soy studies have been variable; in Japanese-American women, the higher intake 
of soy was not associated with fewer vasomotor symptoms,291 while in other studies, soy or 
fermented soy product  intake has been significantly negatively correlated with hot flush 
severity.294,295,296  Evidence suggests that in studies reporting a statistically significant 
decrease in hot flush symptoms, soy products containing higher levels of genistein were 
used, providing more than 15 mg (calculated as aglycone equivalents) per treatment. 297  
 
The lack of menopausal symptoms among the Mayan women may be attributable to high 
yam consumption; it is not attributable to a difference in endocrinology.282,283  Studies have 
provided basic evidence for the beneficial effect of yam for menopausal women.298,299 One 
study found that a 30 day period of yams as the staple food improved the status of sex 
hormones in postmenopausal women, with significant increases serum concentrations of 
oestrone (26%), sex hormone binding globulin (SHBG) (9.5%), and near significant increase 
in oestradiol (27%)299.   In another, ethyl acetate extracts of varieties of yam were found to 
activate human alpha and beta oestrogen receptors to various extents.298   
6.3 Timing, Frequency and Duration 
 
Hot flushes are generally found to be most prevalent in women in the late perimenopause 
and postmenopause, and to decrease with age.90,91  Findings from SWAN suggest that hot 
flushes are more frequently reported by women in late perimenopause155 whereas previous 
studies had found them to be most severe 6 months to 2 years after menopause.188   
In more than 80% of women, they continue to occur for more than one year; in 25-50% the 
duration is more than 5 years107,189,281 and in 10%. more than 10 years 281  They may even 
continue for several decades.300   
 
The frequency of hot flushes varies from hourly to monthly.191,300  An actual flushing episode 
typically lasts from one to five minutes300  but can last up to one hour.274  A circadian rhythm 
has been demonstrated with an increased frequency of hot flushes during the late afternoon 
and early evening.301 
6.4 Experience of the Hot Flush  
 
The hot flush is experienced as a sensation of internal heat in the upper body301 and is 
described as a feeling of heat or burning, usually beginning at the head and neck area that 
may then pass, often in waves, over the entire body.  It may be followed by an immediate 
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outbreak of sweating, most often in the face, head, neck an chest, and is frequently followed 
by chills.274  Concomitant symptoms can include visible reddening of the skin, dizziness, 
headaches, clamminess, anxiety300 or even panic,302  irritability and palpitations.303 
 
An aura precedes the actual flush by several seconds, which may be described as an uneasy or 
queasy feeling, with increased heart rate and finger blood-flow that  correlate with flush intensity, 
reaching peak levels of 10-20 beats/min (mean of 16) and 30-fold respectively.274  
 
6.4.1 Intensity 
 
Flushing episodes can be of differing intensities, variously defined as mild, moderate or 
severe.  While no standardised scales have been developed to measure them, typical 
categorisation is as follows: 
 
Mild flush without perspiration or clamminess OR sensation of heat 
Moderate hot flush associated with perspiration or 
clamminess 
OR sensation of heat accompanied by 
sweating 
Severe hot flush associated with intense 
perspiration that requires changing of 
clothing304 
OR sensation of heat accompanied by 
sweating, with consequences affecting 
daily activities305 
 
6.4.2 Triggers 
 
Triggers of individual episodes of flushing are suggested to include thermally hot food, spicy 
food, confined spaces, caffeine and alcohol,300 although evidence from studies examining 
this relationship is limited.  The Melbourne Women's Midlife Health Project (MMWHP)  found 
no significant association between alcohol intake and hot flush rates.277  Other triggers 
include stress,306 higher ambient temperatures,307 peripheral heating308  and possibly 
conditions of fasting/low blood glucose.309   
6.5 Risk Factors for Hot Flushes 
 
As mentioned previously, not all women experience hot flushes.  Risk factors found to be 
associated with experiencing these symptoms include high BMI, ethnic origin,155 maternal 
history,310 anxiety,91 premenstrual symptoms during reproductive years,181,277 longer 
perimenopause,  lower education, more negative attitude toward menopause,311 lack of 
exercise,90 daily alcohol consumption (hot flushes and bothersome night sweats)312 and 
smoking,241,310 which was found in one study to increase the risk of bothersome hot flushes, 
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but not bothersome night sweats. 312  Higher education and a self-rating of excellent health 
were associated with decreased risk of night sweats, but not hot flushes.241,312 
 
Low levels of circulating oestrogens277 as well as high level of LH,  and FSH prior to the 
menopause transition313 have been associated with the occurrence of hot flushes, although data 
regarding FSH is inconsistent.277  High levels of thyroid-stimulating hormone (TSH) were found 
to be related to hot flushes during the menopause transition, while postmenopausally, high 
levels of testosterone and DHEAS seem to protect against vasomotor symptoms.313   
6.6 Differential Diagnoses 
 
Hot flushes are not exclusive to menopausal women.  They are reported to occur in 10% of 
women before the menopausal transition,89 and also in men88 and may indicate other 
disease processes that need to be excluded (Table 6.1). 
TABLE 6.1  DIFFERENTIAL DIAGNOSIS OF HOT FLUSHES276,314 
 Hot Flushes Associated with Systemic Diseases 
Carcinoid syndrome 
Mastocytosis315 
Pheochromocytoma 
Medullary thyroid carcinoma    
Pancreatic islet-cell tumors 
Renal cell carcinoma 
Anaphylaxis315 
Neurological Flushing 
Spinal cord injury 
Migraine 
Parkinson's disease       
Brain tumors 
Emotional flushing and somatic stress-related 
disorders (e.g., anxiety) 
Hot Flushes Associated with Drugs/Vitamins , Alcohol (and associated tyramine or histamine) or an 
endogenous vasoactive mediator 
Vasodilators 
Calcium channel blockers 
Nicotinic acid 
Morphine and other opiates 
Amyl nitrate and butyl nitrate 
Selective serotonin reuptake inhibitors (SSRIs) 
Cholinergic drugs 
Bromocriptine 
Thyrotropin-releasing hormone 
Tamoxifen 
Cyproterone acetate 
Oral triamcinolone used in psoriatic arthritis 
Cyclosporine 
Anti-oestrogens (Selective estrogen receptor 
modulators--SERMs) 
Luteinising hormone-releasing hormone agonists 
or antagonists 
Aromatase inhibitors316 
Hot Flushes Associated with Eating and Food Additives 
Nitrites or sulfites 
Spicy foods, red pepper or capsaicin 
Hot beverages 
 
Auriculotemporal flushing after cheese, chocolate, 
lemon or highly spiced food 
Dumping syndrome 
Gustatory flushing 
50 
6.7 Physiological signs 
 
Thermoregulatory and cardiovascular changes have been observed to precede and 
accompany hot flushes. In the 60 seconds prior to the actual flush, increases have been 
observed to occur in mean skin temperature,317 finger blood-flow and heart rate.318   Skin 
temperature increases result from cutaneous vasodilation, and precede the small but 
significant elevations in core body temperature (Tc)  of approximately 0.1oC that occur before 
most hot flushes.301,317  
 
Concomitant with the hot flush, finger temperature continues to increase by an average of 3.9o 
C (range 0.3o – 6.6o)274  due to peripheral vasodilation.  Sweating and skin conductance 
responses, an index of perspiration, also increase, 198 resulting in a drop in oesophageal 
temperature of 0.2-0.6 degrees C.274   in some women, a significant reduction in blood 
pressure can also accompany hot flushes, although this is not associated with changes in 
cutaneous vascular conductance.319 Hot flushes are also accompanied by abrupt increases in 
plasma epinephrine (of about 150%) and concomitant decreases in noradrenaline (of about 
40%), consistent with the observed cardiovascular changes such as increased pulse/heart 
rate.274 
6.8 Aetiology of Hot Flushes  
 
The pathogenesis of flushing associated with menopause has not been fully elucidated.  
Current evidence centres around the dysfunction of central thermoregulatory mechanisms in 
the hypothalamus.198,274 Thermoregulation, or temperature homeostasis, requires co-
ordination between core body temperature, the CNS (neurotransmitter activity impinging on 
the hypothalamus) and peripheral vasculature, and involves neuroendocrine, autonomic and 
somatomotor responses.305 
 
Much work in the area of hot flush physiology and endocrinology has been conducted by 
Freedman and co-workers and is reviewed below.   
 
6.8.1 The Role of Oestrogens 
 
The role of oestrogens in the genesis of hot flushes is incontrovertible, since hot flushes 
accompany the decline of oestrogens in the vast majority of menopausal women198 and 
oestrogen administration in HT virtually eliminates hot flushes.196    Moreover, oestrogen 
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withdrawal  rather than low levels of oestrogens, is associated with hot flushes,320 as abrupt 
decline of endogenous plasma concentrations with oophorectomy  in premenopausal 
women triggers the rapid onset of hot flushes while women with gonadal dysgenesis with 
low levels of circulating oestrogens do not experience hot flushes, unless exposed to 
oestrogen which is then withdrawn. 321   Hot flushes are also more likely to occur with 
withdrawal of oestrogen therapy.322 
 
However declining oestrogen levels occur in symptomatic and asymptomatic women alike, 
and thus cannot fully account for the symptoms.198  Furthermore, the levels of oestrogens in 
plasma, urine and the vagina were not found to correlate with the presence or absence of 
hot flushes.323-325  
 
6.8.2 Luteinising Hormone 
  
Similarly, no relationship between hot flushes and circulating levels of LH has been 
observed.  Although most hot flushes coincide with the onset of LH pulses, with increased 
LH associated with most hot flushes,274 not every increase in LH is associated with a hot 
flush326 and flushing still occurs in women who have pituitary failure and thus do not secrete 
LH.189  In addition, suppression of LH release with GnRH-agonists does not eliminate hot 
flushes,327nor does GnRH-stimulated LH-release cause hot flushes.328  This suggest an 
association, but not a casual relationship, between hot flushes and LH-pulses. 
 
6.8.3 Hypothalamic or Pituitary Thermoregulation? 
 
Because removal of the anterior pituitary does not eliminate hot flushes, hypothalamic, 
rather than pituitary, thermoregulatory centres appear to be the site of thermoregulatory 
dysfunction.321 
 
6.8.4 Thermoregulation 
 
A hot flush is essentially a heat-dissipation response.  The medial preoptic area of the 
hypothalamus is involved in thermoregulation, or the maintenance of core body temperature.  
When exposed to temperature changes, mechanisms of heat loss such as perspiration and 
vasodilation are activated to maintain core body temperature. 
 
Core body temperature is regulated between upper thresholds for sweating and cutaneous 
vasodilation, and lower thresholds for shivering and vasoconstriction.  Between these 
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thresholds is a thermoneutral zone or ‘null’ zone (or thermoregulatory inter-thresholds zone) 
within which major thermoregulatory adjustments do not occur.  Freedman and co-workers 
measured the thermoneutral zone and found it to be 0.40C in asymptomatic women and 
zero in symptomatic women, suggesting that narrowing of the thermoneutral zone in 
symptomatic women may be involved in triggering hot flushes.198  In a subsequent study, 
they found that symptomatic  postmenopausal women had significantly lower sweating 
thresholds and higher maximum sweat rates compared with all other women.329 
 
It is thought that this narrowed thermoregulatory zone is at least partly a result of elevated 
brain noradrenaline (norepinephrine/NA) levels, as this has been shown to narrow the 
thermoneutral zone in animal studies.330   Increased levels of brain NA have been found in 
symptomatic women.   In addition, the main metabolite of brain noradrenaline, 3-methoxy-4-
hydroxy-phenylglycol [MHPG], further increases significantly between preflush and postflush 
measurements.331 Considerable evidence has supported  the role of  α2-adrenergic 
receptors in temperature regulation.330 Central NA activity is, in turn, modulated by ovarian 
steroids.332 
 
6.8.5 Elevations in Core Body Temperature  
 
Within the reduced thermoneutral zone, small elevations in core body temperatures (Tc) that 
precede most hot flushes are thought to constitute the triggering mechanism.198  Evidence of 
increased Tc  preceding hot flushes was obtained by Freedman and co-workers using an 
ingested telemetry pill to measure Tc  and a separate device measuring skin conductance 
level to record hot flushes.301,317 This phenomenon is consistent with the aggravating effect 
of  factors such as peripheral warming333 and higher ambient  temperature that raise Tc.307,334 
The Tc changes occur 15 minutes before hot flushes in up to 60% of episodes. The 
existence of a circadian thermodynamic rhythm is supported by the frequency of hot flushes 
and Tc elevations during the late afternoon to early evening. 301 
 
Freedman’s theory of a central noradrenergic mechanism is supported by findings that 
• skin temperature increases precede elevations in Tc and skin conductance 
responses, showing that peripheral vasoconstriction is not responsible for either 
event, suggesting a central event driving skin temperature increases, Tc elevations 
and metabolic rate.331  
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• the main metabolite of brain noradrenaline, MHPG, increases significantly between 
preflush and postflush measurements.331 (However this represents whole-body 
sympathetic activation as the majority of MHPG is derived from skeletal muscle 
rather than brain.)335 
• clonidine, an α2 adrenergic agonist, reduces levels of brain noradrenaline and 
plasma MHPG, raises the sweating threshold and ameliorates hot flushes.318   
• yohimbine, an α2 adrenergic antagonist that increases brain noradrenaline, can 
trigger hot flushes.331  
• oestradiol (1 mg/d 17beta-estradiol) was found to ameliorate hot flushes by widening 
the thermoneutral zone and thereby raising the sweating threshold.336  
• some behavioural relaxation procedures ameliorate hot flushes, suggesting a decline 
in sympathetic activation may impact on the narrowing of the thermoneutral zone.  
As outlined above, this narrowing may be due to elevated sympathetic activity.334  
 
However, this theory cannot fully account for menopausal hot flushes since increased brain 
noradrenaline also occurs in asymptomatic women of the same age.198   
 
6.8.6 Other Postulated Mechanisms: Endogenous Opioids 
 
It has been hypothesised that central noradrenergic instability associated with menopausal 
hot flushes could be due to the reduction of endogenous opioid activity.  There is a 
remarkable similarity between many symptoms associated with menopause and opiate 
withdrawal.337,338  The alteration in skin temperature, heart rate and LH secretion during 
precipitated morphine withdrawal in the rat are similar in magnitude, duration and temporal 
relationship to those observed during the hot flush.338 
 
Furthermore, because oestrogen and testosterone can stimulate natural endorphin 
production, declining oestrogen levels at the time of menopause, as well as age-related  
androgen decline, result in reduced endogenous opioid peptide activity.  Hypothalamic 
opioidergic activity normally has an inhibitory effect on noradrenergic neurons in the 
brainstem. Oestrogen withdrawal is linked with noradrenergic hyperactivity and its 
inappropriate activation of the medial preoptic area where thermoregulation and GnRH 
secretion are stimulated.339,340 It has been suggested that in addition to triggering peripheral 
vasodilation, this also accounts for pulsatile LH release.  Casper and Yen320  proposed that 
successful therapies for hot flushes may exert their effects by increasing endogenous opioid 
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peptide activity with consequent inhibition of noradrenergic activity below the threshold 
needed to activate heat loss (Figure 6.1). 
 
 
FIGURE 6.1   A PROPOSED ROLE FOR ENDOGENOUS OPIOIDS IN FLUSHING 
From Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush 
mechanism. Clin Endocrinol (Oxf) 1985;22(3):293-312.  Reproduced with permission from Blackwell 
Publishing.320 
 
The evidence regarding the involvement of an opioidergic system in flushing has been 
inconsistent. A small study in 6 postmenopausal women reported that the opioid antagonist, 
naloxone, acutely blocked subjective hot flushes. 341 This seems paradoxical as naloxone 
increases the magnitude and frequency of LH pulses in premenopausal women.  However, it 
was not borne out by a subsequent study that found naloxone did not change the rate of 
objectively measured hot flashes, mean serum LH or FSH levels, or the frequencies or 
amplitudes of gonadotropin pulses.342 Genazzani and co-workers343 reported an increase in 
proopiomelanocortin-related peptides (adrenocorticotropic hormone, beta-endorphin, and 
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beta-lipotropin) during subjective menopausal flushes, and Tepper344 found levels of plasma 
beta-endorphin levels to drop with the onset of hot flushes and then rise significantly 5 - 15 
minutes post-flush.  However, no casual connection between β-endorphin plasma 
concentrations and hot flushes has been conclusively established. 
 
6.8.7 Dopamine  
 
Recent evidence suggests that dopamine is an important thermoregulatory neurotransmitter, 
with D2 receptors involved principally with the maintenance of body temperature in 
euthermia.345 Earlier research had observed the dopamine agonist bromocriptine to increase 
the activity of the endogenous opioid system on the thermoregulation mechanisms that 
regulate body temperature in postmenopausal women346 and to be effective in alleviating hot 
flushes.347  Interestingly, antidopaminergic agents were also effective, leading researchers to 
propose a direct dopaminergic action is in the case of bromocriptine but indirect 
mechanisms for antidopaminergic drugs such as stimulation of the opioid systems.347 
 
6.8.9 Serotonin 
 
The neurotransmitter, serotonin, has also been implicated in the generation of hot flushes, 
through its interaction with oestrogens.  Oestrogen withdrawal in menopausal women results 
in dramatically lowered blood serotonin levels348,349 while treatment with oestrogen has been 
shown to augment the serotonergic activity.350  Low blood oestrogen levels are correlated 
with upregulation of certain serotonin receptors (5-HT2A) in the hypothalamus351 that are 
believed to be involved in thermogenesis. Stimulation of this receptor may change the set-
point temperature and thereby activate some autonomic functions to cool down the body, 
such as increased skin temperature and sweating, which supports an involvement of these 
receptors in the aetiology of hot flushes.  Internal and external stimuli, including anxiety, 
consumption of alcohol, coffee and spicy food,306 high ambient temperature and even 
dreams may activate these receptors to trigger a hot flush.197  
 
The potential role of serotonin in the genesis of hot flushes has been comprehensively 
reviewed by Berensden, who proposed a model outlining the interaction between 
oestrogens, the serotonergic system and environmental and psychological stimuli.197 
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6.8.10 An Integrated Model  
 
The following model adapted from Shanafelt321,352 and Berensden197 integrates the theories 
of several key researchers (Figure 6.2):301,320,339,340,353  
 
GnRH = gonadotrophin-releasing hormone.   LH = luteinising hormone 5-HT= serotonin 
 
FIGURE 6.2  AN INTEGRATED MODEL OF PHYSIOLOGICAL AND PSYCHOLOGICAL FACTORS 
PROPOSED TO TRIGGER HOT FLUSHES  Adapted from Berensden 2000197 and Shanafelt321,352 with 
permission. 
 
Declining oestrogen levels are associated with noradrenergic hyperactivity, possibly 
mediated by decreased endogenous opioid peptide activity, 339,340 decreased blood serotonin 
levels and upregulation of 5-HT2A receptors in the hypothalamus.351  Activation or 
upregulation of this receptor as a consequence of stressors197 or decreased plasma 
serotonin levels348,349 may lower the thermoregulatory set point, and elevated NA may 
narrow the thermoregulatory zone, allowing subtle increases in core body temperature to 
trigger heat loss mechanisms.164 
Stressors:  
psychogenic: 
anxiety, dreams, 
close physical 
contact; ambient 
temperature;  
caffeine, spicy food, 
alcohol 
Acute oestrogen withdrawal 
Age-related  
↓ in androgens 
↑ release of 
serotonin in 
hippocampus, 
hypothalamus & 
cortex 
↓ serotonin blood levels
↓ endorphins
↑ release of 
hypothalamic 
noradrenaline
Up-regulation and activation of 5-HT2A 
receptors in the hypothalamus 
(disturbance of thermoregulatory system) 
Heat loss mechanisms; 
vasodilatation, increased 
skin temperature,  
perspiration 
Subtle increase in core 
body temperature 
GnRH release 
LH release 
Hot Flush 
Psychological and Physiological triggers of hot flushes acting via the hypothalamus 
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6.9 Summary 
 
In summary, a multi-factorial aetiology has been proposed for hot flushes, including a role 
for known environmental and psychological triggers via their effects on neurotransmitters, 
specifically noradrenaline and serotonin, which interact with gonadal hormones.  In terms of 
the mechanisms of action of the herbs trialled in this study, the potential effects of dopamine 
and endogenous opioids are also of interest. 
58 
 
 
 
 
 
 
Chapter Seven 
  
 
 
Psychological Symptoms  
 
 
 
  
 
 
 
7.0  Introduction 
 
This chapter of the Literature Review examines the aetiology of the psychological symptoms 
commonly associated with the menopause transition, a secondary endpoint of the principal 
study to be described herein. As mentioned above, controversies currently exist regarding  i) 
an increased prevalence of emotional symptoms associated with menopause, ii) an 
association between affective symptoms and the endocrinological changes that occur with 
menopause, and iii) effective treatment of such symptoms. 
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7.1 Association between mood disorders and menopause 
 
The perimenopause has long been recognised as a time of increased susceptibility to 
depressive symptoms354 with terms such as ‘menopausal neurosis’21,354 and ‘involutional 
melancholia’, (dropped from the Diagnostic and Statistical Manual (DSM) in 1980), 
previously used to describe the depressed mood, anxiety, irritability, nervous tension and 
loss of confidence commonly reported at this time.   However, data from epidemiological and 
therapeutic studies do not consistently report an increased prevalence of mood symptoms 
associated with this period.  Some epidemiologic studies have reported depressive or mood 
symptoms in up to 51% of  women at this time.62,86,88,355  This compares with a lifetime 
prevalence of depressive disorders of 15-25% in the US356,357 and 6.8% for Australian 
females in a 30-day period.358  Other studies, however, have failed to find any evidence of 
an increase in depressive symptoms associated with menopause.89,359,360  
 
The discrepancy in these findings has been attributed, at least in part, to methodological 
differences such as the criteria used for defining reproductive status and depression, which 
covers psychological distress to  minor or major depression,* as well as instruments of 
detection and measurement. Many studies investigating mood have employed instruments 
such as the Beck Depression Inventory (BDI)361 or the Centre for Epidemiological Studies-
Depression scale (CES-D)59,355,362,363  that measure clinically meaningful minor or major 
depressive disorders whereas others have relied on psychological subscales of menopause 
rating scales that are more sensitive to less severe psychological distress.  In addition, some 
have attempted to extrapolate these findings from depression scales to mood, despite the 
important distinctions between mood variability and major depression.207   As pointed out by 
Klein, the diversity of emotional changes occurring at different stages of the perimenopause 
include both the agitated and vegetative forms of depression, general anxiety disorders, 
panic attacks, phobias and obsessive-compulsive disorders, possibly related to the different 
gonadal hormone alterations.364 Other factors that may impact on findings regarding 
                                                 
* The American Psychiatric Association’s Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) 
specifies five selected core symptoms for major depression and 3 for minor depression which must 
persist for at least a 2-week period and be associated with clinically significant distress or impairment 
in social or occupational functioning, and not be caused by medications, a medical condition such as 
thyroid disorders, or bereavement.  [See Appendix 4 for symptoms of major depressive disorder 
(MDD), minor depression, dysthymic disorder (DD) and generalised anxiety disorder (GAD).] 
60 
symptom prevalence are cultural differences and the inclusion/exclusion of current HT-
users.363 
 
With regard to major depressive disorder (MDD), evidence suggests that the transition to 
menopause is not associated with increased risk, particularly for women who with no past 
history of depression. A co-morbidity survey reported no gender-related differences in 
prevalence of major depressive episodes at midlife (45 to 55 years).365 However, non-major 
depressive disorders are reported to be two to three times more common in older women 
than in their male counterparts.366  It has been suggested that the terms ‘subthreshold 
depression’, ’subsyndromal depression’ or ‘dysphoria’ are more appropriate for the minor 
psychological morbidity associated with the perimenopause, due to the lack of adequate 
symptoms or symptom severity associated with clinical depression.80   
 
The Harvard Study of Moods and Cycles, a longitudinal, prospective cohort study that 
followed 460 premenopausal women as they entered perimenopause found that women with 
no lifetime history of major depression who entered the perimenopause were twice as likely 
to develop significant depressive symptoms as women who remained premenopausal.367  
This is consistent with previous findings that 35% of first episodes of depression in women in 
the UK occur during the perimenopause,183 and 40% in the US between the ages of 40 and 
60 years.59    
 
This association between transition to menopause and new onset depression was found to 
be independent of factors such as negative attitudes, stressful events, past history of 
depression or severe premenstrual syndrome (PMS) or poor sleep in the SWAN, a 
longitudinal cohort study that enrolled 16,065 women 40 to 55 years old185,355 and the 
Pennsylvania Ovarian Aging Study, an 8-year longitudinal study to identify risk factors of 
depressed mood during the menopausal transition.181,368   
 
A number of studies have found the incidence of psychiatric symptoms during menopause to 
be higher in women with a history of depression or other psychiatric disorders.362,183,367 A 
significant risk for first onset depression has been associated with surgical 
menopause71,194,362,363 and among those who enter the transition earlier.367,369  Current or 
prior PMS, or premenstrual dysphoria (PMD) have been found to predict as well as 
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accompany perimenopausal depression in some women in both retrospective and 
prospective studies.62,362,369-371,372   
7.2 Psychological symptoms and Stage of transition  
 
Menopause-clinic-based studies22 and cross-sectional surveys62,279 have supported the 
findings that it is commonly during the perimenopause, as distinct from pre- or 
postmenopause, that vulnerability for depression and ‘psychological distress’ is increased.  
The SWAN longitudinal study found a significant association between depressed mood and 
the late transition stage.373 However, both the late perimenopause and the early 
postmenopause were found to be associated with an increased rate of onset of depression 
in  a recent prospective study of 29 asymptomatic premenopausal women who were 
followed until 6 to 12 months after their FMP;  a 14-fold increase was observed in the 24 
months surrounding the FMP.374   
 
In contrast, the Melbourne Women's Midlife Health project (MWMHP), a large-scale, 
longitudinal study recently reported that the prevalence of mood symptoms peaked before 
the expected age of natural menopause, between 35 to 40 years, and decreased with age 
from the middle- reproductive years.375   
 
Symptoms of anxiety have similarly been found to be more prevalent in perimenopausal 
women and to remain that way into postmenopause, according to a population-based 
survey.184 The prevalence of anxiety disorders in Australian women in the 45-54 year age-
group was 15.9% in 1997358 compared with 8.0% for males in the same age bracket and 
12.1% for females in the total population over a 30-day period.  Surveys of women in this 
same age range report 38% experienced symptoms of anxiety in the previous 2 weeks 
compared with 40.62% in peri-menopausal women62 and 58% in the preceding 6 months.86    
7.3 Aetiology: Endocrinopathy or Psychosocial? 
Oestrogen deficiency has been suggested as a cause of the increased prevalence of non-
major depressive disorders in midlife women but the relationship remains to be 
established.354 Psychosocial theory suggests that socio-cultural and personal circumstances 
are more important than changing menopause status in the aetiology of psychological 
morbidity, 376,377 which may be caused by the vicissitudes of life.186,378 Data from community-
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based cross-sectional and longitudinal studies support the relationship of depression in this 
demographic to factors shown in Table 7.1 below. 
  
TABLE 7.1   FACTORS ASSOCIATED WITH DEPRESSION IN MIDLIFE OR MENOPAUSAL WOMEN 
Study design  
 
Cross-sectional Longitudinal/ 
Cohort 
surgical menopause X59  X376 
longer duration of perimenopause  X362  
Reproductive 
events 
current or prior PMS or PMD X369,370  X362,371,372 
health status problems  X59,62  X376,379 
trait anxiety  X380 
Health 
hypochondria/disease phobia  X381 
current stress, (especially chronic)  X373,379,380 
pessimism, with chronic stress  X380 
interpersonal stress /relationship 
dissatisfaction, especially marital problems or 
relationships with children 
 
X382 
 
X376,379 
Stress 
multiple roles including paid work, adolescent 
children, ailing husbands, aging parents or 
parents-in-law  
 
X59  
 
recent bereavement X382  
major life events  X383 
Loss 
role loss X59   
negative attitudes towards ageing or to 
menopause 
X59,62 X273 381 Negative 
attitude/ 
experience a history of negative life events  X367  
no partner/marital status X369 X379,383 
nulliparity X369  
lower socio-economic status X384   
ethnic origin X384,385  
Demographic 
factors 
lack of employment outside the home X386  
work dissatisfaction  X383 
smoking, current X369 X379,385 
exercise, low  X379,381 
Diet and 
Lifestyle 
factors 
high BMI  X373 
 
A variety of different rating scales were used in the above studies, with several using the 
CES-D.59,273,362,367,370,376,384 The Beck Depression Inventory (BDI) was used in the study on 
pessimism, trait anxiety and life stress,380 and the Hamilton Depression Rating Scale 
(HAMD/HDRS) in one study of the Harvard Study of Moods and Cycles.385 
 
Findings regarding predictors of perimenopausal depression are not always consistent, 
however.  This is possibly a product of differences in study design.  Cross-sectional studies 
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have certain limitations inasmuch as they may not control for prior episodes of affective 
disorders, nor characterise the temporal sequence of events occurring with transition 
through menopause.362 Thus, a causal connection cannot be inferred from the coexistence 
of these factors with depressive symptoms.   
 
Schmidt and colleagues,374 in a longitudinal study, found no association with the number of 
exit events (bereavement/divorce/family members leaving home) or personal losses, nor any 
other variable previously associated with the onset of perimenopausal or midlife depression.  
The MWMHP,387 a 9-year annual prospective study of 438 women, failed to provide 
evidence for the ‘empty nest’ syndrome as a predictor. In fact, it found that for the majority of 
women, the departure of the last child from the household led to positive changes in 
women's mood state.  
 
As pointed out by Rubinow,354the main predictors for depression in the menopause are the 
same as for other stages of life, namely prior depressive episodes148  and poor current or 
past health status.,362,379,50,35  Stressful life events, history of smoking, sleep disturbances and 
PMD or PDD also frequently accompany depression at other stages of life.354  
 
Because vasomotor symptoms and sleep disruption can co-exist with mood changes at 
menopause, 71,181,211,362,373,379,381,388380,387 it has been suggested that depression may be a 
secondary reaction to these bothersome physical symptoms.  Hot flushes are hypothesised 
to affect sleep and thereby  emotional stability and quality of life,389 consistent with the 
domino theory.159 However findings from recent studies, both longitudinal181,368 and a 
community sample of 16,065 women,185 suggest that perimenopausal depression is not an 
epiphenomenon to hot flushes but an independent risk factor181,185,368 as  the relationship 
between perimenopausal endocrine changes remained after adjusting for hot flushes.368  
 
7.3.1 Oestrogen and depression  
 
Evidence regarding an involvement of endocrine events and mood alterations is derived 
from  
i) the relationship between the incidence of affective symptoms and stage of the 
MP transition 
ii) studies attempting to correlate the serum levels of gonadal hormones with mood 
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iii) therapeutic studies investigating the effect of oestrogen administration on mood, 
depression and well-being in natural menopause, surgical menopause, clinically 
depressed and healthy women.   
The involvement of endocrine events is suggested by the finding that depression is 
associated with the stage of the transition or entry to a different phase.  The SWAN reported 
depressions most commonly appearing during the late-perimenopause,355 the phase most 
characterised by oestradiol ‘withdrawal’, as hypogonadism is more prolonged than in the 
early perimenopause.109,111   A large-scale cross-sectional study in Eindhoven of 8,098 
women reported a high increase of depressive symptoms as women passed from pre- to 
perimenopause and from peri- to postmenopause.390  
 
A relationship between perimenopause-related changes in oestrogen and depression 
remains to be established.  While some studies have found no direct association between 
oestrogen levels and depression,285,391,392 others report significant associations with 
hormone levels.87,285,368,393 Soares and colleagues found oestradiol and FSH levels to be 
associated with changes in the severity of depressive symptoms in perimenopausal 
women.393  Freeman and colleagues368 found increased variability of oestradiol, FSH and LH 
to be significantly associated with high CES-D scores.  A significantly increased incidence of 
depression as measured by the CES-D was found in the year following the last period, 
which coincided with a significant drop in oestradiol levels.87 In healthy non-depressed 
women treated with oestrogen, mood covaried with circulating oestradiol levels.394,395  
 
Attempts to study the effects of oestrogen therapy on mood have been hampered by the 
‘domino effect’ – the flow-on effects from concomitant relief of hot flushes to improvements 
in other symptoms.159  Nonetheless, findings from several studies of oestradiol therapy 
suggest its effects on depression are independent of its salutary effect on hot 
flushes.361,396,389,397   No association was found between the response of the vasomotor 
symptoms and depressive symptoms to treatment with Premarin.397  Similarly Schmidt and 
co-workers, when examining oestrogen treatment of depression in perimenopausal women 
with and without hot flushes, found that the presence of hot flushes did not modify the 
outcome.396  This was supported by findings from a small scale clinical trial of oestrogen in 
peri- and postmenopausal women that the antidepressant response was not associated with 
concomitant improvement in menopause-related symptoms.361   
 
65 
Studies have not consistently supported a salutary effect of ostreogen therapy (ET) in mood 
symptoms, however.   This may be attributable to the confounding factors and limitations 
that exist in these studies, namely, i) the intimate relationship between oestrogen-deficiency-
related vasomotor symptoms, poor sleep patterns and emotional stability,388 ii) the lack of 
standardised diagnostic criteria and measuring instruments for the depression syndrome, iii) 
the extrapolation from studies on perimenopausal depression to other menopause–related 
mood changes,398 iv) different preparations of HT in different doses, v) inclusion in some 
studies of women with concurrent psychiatric illness399 or malignant disease.285  
 
Nonetheless oestrogen preparations, with or without progesterone or testosterone,400 have 
been found to be effective over placebo in several studies. A 2001 review of the literature 
concerning the role of oestrogen in the treatment of mood disorders found growing evidence 
for oestrogen as a sole antidepressant in perimenopausal depression.350  This is consistent 
with a 1997 meta-analysis401 reporting that most studies showed HT to be effective in 
reducing depressed mood among menopausal women, with an overall effect size of 0.68.   
Findings of an RCT in major and minor depressions by Schmidt and co-workers396 found 
oestradiol to significantly decrease depression rating scale scores in 80% of subjects 
compared with 22% of the placebo group.  In an RCT of endocrinologically-confirmed 
perimenopausal women with major or minor depressive disorders, or dysthymic disorder, 
oestradiol was also reported to result in remission of symptoms regardless of type of 
disorder compared with placebo.402  
   
In contrast, studies of HT in mood in postmenopausal women, such as the Women's Health 
Initiative (WHI) studies with combined oestrogen/progesterone,403 have failed to find any 
improvement.  A study  of women who were 5-10 years postmenopausal  with major and 
minor depressions, found no clinically significant effect of oestradiol (40% improvement) 
over placebo (44%).404  The ineffectiveness of oestrogen in women with more severe 
depressive symptoms has also been reported,405, 406 while non-depressed women, or those 
with mild symptoms, improved in their sense of wellbeing.406   Acute mood-enhancing effects 
in asymptomatic women were also reported by Ditkoff and colleagues,407 suggesting a 
different mechanism of action to traditional antidepressants.  
 
It has been suggested that the rate of change of hormone secretion and levels may be as 
important as, or more important than, the absolute (low) hormone levels in provoking 
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affective symptoms.408-410,411  This view receives support from findings that perimenopausal 
women, but not postmenopausal women with prolonged oestrogen deficiency, may respond 
to ET.361,404  Additionally, mood-enhancing effects have been shown in women who have 
undergone surgical menopause, 395,405,412,413 where significant decrease in circulating sex 
hormones, with corresponding symptom experience, occurs abruptly. 
 
While many studies have investigated depressive symptoms, few have focussed on anxiety.  
Anxiety symptoms were lower in women treated with ET than untreated women in an 
uncontrolled study,414 and were shown to decrease in postmenopausal women during 
treatment with oestradiol, compared with placebo.415   
7.4 Neuroendocrinology of Mood  
 
7.4.1 Pathophysiology of Depression 
 
(Refer to appendix 5 for a brief description of the monoamine transport cycle). 
The underlying pathophysiology of depressive disorders is not yet fully understood.  It is 
complicated not only by the various neurobiological and neurochemical (or neurofunctional) 
components involved but also by the range of depressive subtypes, which may reflect 
different underlying neurochemical changes. Malhi and co-workers suggest that “non-
melancholic depression may be largely serotonergically driven, while melancholic and 
psychotic depressions have significant additional contributions from the noradrenergic and 
dopaminergic systems, respectively.”416  The generation and maintenance of anxiety 
disorders are also associated with noradrenaline and serotonergic dysfunction.416 
 
Research in the past 10 years on the aetiology of depression has gone beyond the 
monoamine-depletion hypothesis, which was based on the observation of acute depletion of 
the neurotransmitters serotonin or noradrenaline/dopamine in depressed subjects417,418 and 
supported by the observed activity of antidepressants that enhance the synaptic 
concentrations of one or more of these monoamines.  However, the significant delay 
between the neurochemical effects of these antidepressants (which may occur within hours) 
and the clinical response (which may take weeks)416 led to a shift in interest to alterations in 
neurotransmitter receptor levels or function, which have been observed post-mortem and in 
vivo.419,418 
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Dysfunction of the neurotransmitter regulation systems, especially serotonin, noradrenaline 
and dopamine, include a functional defect in the serotonin transporter,418 monoaminergic 
underactivity, particularly involving serotonin and noradrenaline  (for example, diminished 
noradrenergic activity in the prefrontal cortex and reduced activity of post-synaptic 
hypothalamic α2 adrenoceptors), receptor density changes, such as  diminished numbers of 
5HT1A and 5HT2A, changes in α1 and α2-adrenoceptors, (for example, increases in 
presynaptic α2 adrenoceptors),418 increased sensitivity of dopamine receptors, lower density 
of striatal dopamine transporters and mesolimbic dopaminergic dysfunction in anhedonia 
(lack of enjoyment of activities than normal give pleasure).420 
 
Abnormalities have also been observed in regional blood flow and metabolism in several 
brain regions relevant to mood regulation354 in post-mortem studies of patients with affective 
disorders.421  Studies have also demonstrated that stress and depression can lead to 
neuronal atrophy and cell loss in key limbic brain regions implicated in depression, including 
the amygdala, prefrontal cortex, and hippocampus.422  The synthesis of new cellular 
constituents such as neurotransmitter receptors and synthetic enzymes is necessary for 
remission of depressive symptoms416 and it is now thought that antidepressants may act by 
reversing neuronal atrophy and cell loss.422 (Enhancement of hippocampal neurogenesis by 
antidepressants may also explain their efficacy in hypercortisolaemia, which can cause 
neuronal cell death in some brain regions.423)  
 
Other observed changes in depressed patients, such as mechanisms involving the 
hypothalamic-pituitary-adrenal (HPA) axis, include:418 
• Hypersecretion of cortisol, reflecting failure of negative feedback mechanism   
• Increased activity of corticotrophin-releasing factor (CRF ); increased density of CRF 
neurons in paraventricular nucleus of; reduced density of CRF1 receptors in frontal 
cortex 
• Subclinical hypothyroidism; desensitised TRH receptors; defective transport of 
thyroid hormone 
• Increased pro-inflammatory cytokines (which induce hypercortisolaemia and 
neurotransmitter changes) and decreased anti-inflammatory cytokines 
• Neurodegenerative changes in the brain – atrophy of the hippocampus, amygdala 
and frontal cortex, associated with a rise in brain concentrations of glucocorticoid that 
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cause reduction in the synthesis of neurotrophic factors such as brain derived 
neurotrophic factors (BDNF), which is responsible for neuronal repair  
• Disturbance in circadian rhythm 
• Overactive glutamate pathways; higher cortical glutamate concentration 
• Reduced concentration of GABA in cerebrospinal fluid (CSF), plasma and 
hippocampus  
• Elevated concentrations of substance P in CSF. (Substance P modulates the stress 
response as well as reducing pain perception). 
 
A neurotrophic hypothesis for the pathogenesis of depression proposes that  stress 
decreases the expression of BDNF which, together with other factors such as down-
regulation of receptor sensitivity,  could contribute to the atrophy of certain limbic structures, 
including the hippocampus and prefrontal cortex, observed in depressed subjects.422,424 
 
7.4.2 Role of Hormonal Changes at Menopause 
 
Psychological well-being at the menopause may be affected by changes to oestrogen levels 
influencing neuropeptides and neurotransmitters in the brain93 and/or the effects of 
oestrogen withdrawal on oestrogen receptors in the limbic system and hypothalamus.214,425  
Oestrogen deficit has been linked with changes in the cholinergic, catecholaminergic and 
serotonergic systems.409 The action of oestrogen on the neurotransmitter receptors and 
synapses involved in all these systems is rapid.426   
 
Sensitivity to change in gonadal hormones 
 
A pre-existing sensitivity in some individuals to the change in the gonadal hormones and 
resultant decreases in neural transmitters, or reactions to the physiological changes 
associated with menopause has also been proposed.182   
CNS activity of oestrogen that may modulate mood via effects on serotonin, noradrenaline, 
dopamine and opioids, include the following. 
7.4.3 Neurotransmitters and Neuropeptides 
 
Serotonin 
  
? increasing synthesis of serotonin (5-hydroxytryptamine /5-HT)427,428  
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? increasing the  rate of free tryptophan (by displacing it from its binding sites on 
plasma albumin) to be metabolised to 5-HT 429,430 
? reducing breakdown of 5-HT427,431  
? modifying the concentration and availability of serotonin by stimulating degradation of 
monoamine oxidase (MAO, the enzyme that catabolises 5-HT)161,429,430  
? up-regulating expression of serotonin receptors432-434  
? increasing post-synaptic responsivity to 5-HT435,436 
? enhancing the effect of 5-HT by increasing the affinity of certain types of 5-HT 
receptors for this neurotransmitter332  
Overall oestrogen decline results in a decrease in 5-HT synthesis and activity, which is 
related to mood disorders.165  Decreased serotonin 1A receptors have been observed post-
mortem and in vivo in depressed subjects in radioligand imaging studies,419 and  5-HT1A 
receptor agonists have been shown to have anxiolytic and antidepressant properties.417  
Noradrenaline 
 
? increasing synthesis and  
? increasing available NA by reducing breakdown by degradative MAOs427,431  
? selectively increasing NA activity and turnover in the brain431  
? enhancing the effect of noradrenaline by increasing the affinity of certain types of 
noradrenergic receptors for these neurotransmitters332  
Noradrenaline has been suggested to play a significant role in mood and behaviour.165  
Decreased α-2 and β-adrenergic receptors have been identified post-mortem in depressed 
subjects.419  In the absence of oestrogen, a decrease in activity of both of these systems 
would be expected.  In addition, there is a dynamic interdependent relationship between the 
serotonergic and noradrenergic systems.  Serotonergic neurons project to noradrenergic 
neurons and vice versa, allowing ‘cross-talk’ between the neurotransmitter systems.  
Stimulation of serotonergic neurons leads to a net decrease of noradrenergic transmission, 
while conversely, noradrenergic firing causes a net increase in 5-HT transmission.  The 
stimulatory effects of NA on the serotonergic neurons may directly offset the loss of 
oestrogen’s stimulatory effects on the serotonergic system.   
 
Opioids 
 
? Potentiating the activity of opiate-containing neurons438 
? Increasing the synthesis and release of β-endorphin.  
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Change in β-endorphin synthesis and secretion is related to the pathogenesis of mood, 
behaviour and nocioceptive perception changes439  Declining oestrogen levels result in a 
decrease in endogenous opioid peptide activity and its normal inhibitory effect on 
noradrenergic neurons in the brainstem. Thus oestrogen withdrawal is linked with 
noradrenergic hyperactivity.320  
 
Dopamine  
 
? directly modulating dopaminergic activity99 
? increasing dopamine release in the hypothalamus99 
? increasing dopamine transmission and D2 receptors426 
? low concentrations of 17beta-oestradiol inhibit uptake via the dopamine transporter 
DAT440  
In the cerebral cortex, dopamine is involved in emotional responses. In postmenopausal 
women, the activity of the dopaminergic system was found to be significantly lower than in 
premenopausal women, but was significantly increased by HT administration, with a 
concomitant significant decrease in psychological symptoms.441 In contradistinction to the 
proposed delayed secondary effect of selective serotonin reuptake inhibitors (SSRIs), 
oestrogen’s effect on dopamine levels and receptors is very rapid.426  
7.4.4 Other Proposed Factors 
 
Progesterone and Androgens 
Because the menopause is often regarded as an oestrogen deficiency condition, the 
consequences of altered secretion of progesterone and other ovarian hormones have often 
been neglected.442,443  During the perimenopause, there may be periods of serum oestrogen 
excess relative to serum progesterone. While oestrogens have arousing, antidepressant and 
potentially anxiogenic effects in excess, progesterone/allopreganolone has a potent 
anxiolytic effect.444,445  Acute progesterone withdrawal can cause anxiety and seizures.446 
Although no clear patterns of testosterone and androstenedione changes have been shown 
in menopausal women, androgen administration appears to improve well-being, anxiety and 
depressive symptoms in naturally and surgically menopausal women being treated with 
exogenous oestrogen.  A discussion of testosterone studies in general can be found in the 
reviews by Alexander et al447 and Arlt et al.448  
 
71 
It has also been suggested that the rate of change of these hormones and their ratios may 
be as important as their absolute levels in determining their overall effect on emotional 
behaviour.364 
Dehydroepiandrosterone (DHEA)/Dehydroepiandrosterone sulphate (DHEAS) 
Although menopause does not appear to significantly affect the rate of decline in DHEAS 
levels,110 the drop in DHEA(S) synthesis occurring between the ages of 20 and 60 years has 
been associated with depressive symptoms, 449 poor subjective perception of health and life 
satisfaction, as well as reduced libido.450  In addition, the alpha-reduced metabolite of 
androstenedione (and indirectly DHEA) is lower in menopausal women with anxiety than 
asymptomatic menopausal women; its serum levels correlate inversely with anxiety 
scores.451  
Growth factors 
Oestrogen has been shown to have reciprocal interactions with CNS growth factors.  Recent 
reports that BDNF levels are decreased by stress and elevated by mood stabilisers and 
antidepressants  suggest that BDNF may be of potential importance in the aetiology and 
treatment of depression during the perimenopause.354 
Circadian Rhythms 
The effects of ovarian hormones on circadian rhythmicity could also contribute to the 
development of mood disorders in predisposed women, as hormone levels fluctuate during 
the menopause transition and circadian rhythms become destabilised.  Oestrogen treatment 
increases the amplitude of melatonin circadian rhythms, which lose their regularity and 
stability with ageing.452  
Maintaining functional homeostasis  
Another hypothesis put forward by Deecher and co-workers453 is that, in order to maintain 
functional homeostasis as ovarian hormone levels become fluctuating and unpredictable, 
increased flexibility in neuronal responsiveness is needed. An inability to rapidly establish a 
new baseline of neuronal function could lead to increased susceptibility to mood disorders 
and diminished brain-related functions in predisposed women.453  The lack of effectiveness 
of oestrogen therapy for postmenopausal depressed mood has been interpreted as 
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evidence that postmenopausal brain adaptation is less dependent on and/or vulnerable to 
modulation by ovarian hormones.   
Relationship between Premenstrual dysphoria and Perimenopausal depression 
It has also been suggested that in women  previously reporting a history of PMS, 
perimenopausal depression could represent the elimination of follicular phase-related 
symptom remissions, and the development of a more persistent pattern of dysphoria.372   
The overlapping symptoms of PMS and menopause is examined in the following section. 
7.5 Summary 
 
Whether or not the incidence of affective disorders increases during the perimenopause is 
unknown, but prevalence estimates suggest these symptoms are deserving of attention.  
While the exact aetiology is as yet unclear, current evidence supports interactions between 
steroid hormones, predominantly oestrogen, and neurotransmitters and neuropeptides as 
being of central importance.  Evidence for conventional HT in this context is inconsistent and 
its use controversial.  Understanding of the underlying pathophysiology of these symptoms, 
and of the mechanisms of phytotherapeutic interventions, assists in identifying potentially 
efficacious and acceptable treatments for this neglected group of women. 
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Chapter Eight 
  
 
 
Premenstrual Syndrome-like symptoms 
 
during the perimenopause  
 
 
 
  
 
 
 
8.0  Introduction 
 
This chapter of the Literature Review examines the aetiology of premenstrual (PMS)-like 
symptoms in perimenopausal women.  A sub-study of the RCT described in this thesis 
focused on the effects of the intervention on PMS-like symptoms in a late-perimenopausal 
subgroup.  While the peak of actual PMS is found to occur in the late reproductive 
(premenopausal) years,454 anecdotal reports suggest that women in the perimenopause are 
increasingly prone to PMS-like symptoms, or at least tolerate them less well.224   
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8.1 Co-existence of PMS and Perimenopausal Symptoms  
 
It has been suggested that some of the perimenopausal symptoms typically attributed to 
menopause (such as breast discomfort and the mood symptoms of irritability, excitability, 
depression and poor concentration) may be more related to menstrual cyclicity than 
menopause.225  Where these overlap, distinguishing PMS-symptoms from perimenopausal 
symptoms can be difficult.  The distinction is usually made on the basis of the cyclic 
symptom pattern of premenstrual worsening and post-menstrual abatement in PMS.454  
However, because menstrual periods become unpredictable, perimenopausal women may 
be less aware of the relationship of the symptoms to the menstrual cycle.455  Under-reporting 
of premenstrual dysphoria in perimenopausal women has been observed, with significant 
rates occurring in women who reported an absence of premenstrual symptoms.372   
 
When PMS co-exists with menopausal symptoms, management with hormone therapy (HT) 
is difficult as progestins are found to aggravate PMS symptoms and combined HT regimes 
frequently induce PMS-like symptoms in susceptible women.456  A significant need exists for 
effective treatments that are safe and well tolerated for these symptoms in perimenopausal 
women.  
8.2 Definition and diagnosis 
 
Premenstrual syndrome is defined as the repeated occurrence of behavioural and somatic 
symptoms severe enough to impair a woman’s social and work-related functioning during 
the luteal phase of the menstrual cycle.457   While definitions and inclusion criteria vary 
significantly among studies due to the lack of a universally accepted and implemented 
diagnostic tool for PMS, the key elements of a diagnosis of PMS are i) symptoms consistent 
with PMS; ii) occurring during the luteal phase of the menstrual cycle; iii) assessed 
prospectively; iv) resulting in identifiable dysfunction in social or economic performance; and 
v) not due to another diagnosis.  Disappearance of symptoms after menstruation is the key 
to diagnosis.  Typically women have the same set of symptoms from one cycle to the 
next.458   The current World Health Organisation's International Classification of Diseases 
(ICD-10) description of PMS has been criticised as “vague, fail(ing) to establish the degree 
of impairment, list(ing) only a few specific symptoms, and ..not require(ing) prospective 
confirmation of symptoms to make a diagnosis”.459  
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A definition developed for research purposes by the University of California requires at least 
1 of 6 behavioural symptoms (depression, angry outbursts, irritability, anxiety, confusion, 
social withdrawal) and 1 of 4 somatic symptoms (breast tenderness, abdominal bloating, 
headache, swelling of extremities).  The symptoms must resolve within 4 days of the onset 
of menses, without recurrence until at least cycle day 13.  They must occur in the absence 
of pharmacological therapy, hormone ingestion, drug or alcohol use and result in identifiable 
dysfunction in social or economic performance.  The diagnosis is confirmed by means of at 
least 2 cycles of prospective ratings.460  It has been suggested elsewhere that the definition 
must include the severity  of symptoms, which differentiates clinically significant pathological 
PMS from the physiological discomfort of normal menstrual cycle changes.461  
 
Whether all symptoms occurring in the premenstrual phase should be considered as parts of 
a single syndrome has been questioned, as there is no evidence that all symptoms share a 
common pathophysiologic basis.462  Abraham, for example, used the term ‘premenstrual 
tension syndrome (PMTS)’ in recognition that PMS represents a group of syndromes which 
may have different pathophysiologies,463,464 with the common occurrence of nervous tension.  
More recently, it has been proposed that future directions for clinically-relevant research 
should include identification of specific subgroups of menstrual-related syndromes.465 
 
Premenstrual dysphoric disorder (PMDD) is a more severe form of PMS with a 
predominance of mood symptoms, the diagnosis of which requires i) the presence of at least 
5 luteal phase symptoms, at least one of which must be a mood symptom (Appendix 6); ii) 2 
cycles of daily charting to confirm the timing of symptoms; and iii) evidence of functional 
impairment.  The symptoms must not represent the exacerbation of pre-existing depression, 
anxiety, or a personality disorder.466 
8.3 Aetiology of PMS 
 
The exact aetiology of PMS remains unknown, although several biological mechanisms 
have been proposed suggesting that disrupted homeostasis and deficient adaptation may be 
core underlying mechanisms,465 with some consideration also given to genetic propensity 
and environmental inputs.467  
 
Recent research suggests that symptoms of PMS occur only in predisposed women who 
have sensitivity to the normal hormonal fluctuations that occur in the late luteal phase of the 
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menstrual cycle.  This is supported by observations of a lack of difference in levels of 
gonadal steroids between women with and without PMS.468,469 
 
Ovulation, and the subsequent ovulation-related production of sex steroids by the corpus 
luteum,470,471 are considered a necessary pre-condition for the development of the 
symptoms of PMS, which disappear in anovulatory cycles when a corpus luteum is not 
formed,456,472,467and when hormonal cyclicity ends.462 
 
The enhanced responsiveness to normal fluctuations in hormone concentrations469 in PMS 
sufferers may be due to neurotransmitter dysfunction.473  Several neurotransmitters are 
influenced by ovarian steroids, or engage in reciprocal interactions with them. 
Serotonin  
The serotonergic system is involved in mood, sleep, sexual activity, appetite and cognitive 
ability.  Serotonin concentrations vary throughout the menstrual cycle, with periovulatory and 
premenstrual levels being higher than at the start of menstruation.474  The involvement of 
serotonin in the pathophysiology of PMS is supported by studies demonstrating altered 
serotonin metabolism in women with PMS,462 as well as altered postsynaptic serotonergic 
responsivity,472and serotonin deficiency, which may enhance sensitivity to progesterone in 
PMS-sufferers.475,476   Furthermore, SSRIs are efficacious in the treatment of somatic and 
mood symptoms of PMS/PMDD.462  It has been suggested that the role of serotonin may be 
modulating role rather than causal, as there is little evidence for luteal phase-specific 
serotonergic dysfunction, but there is evidence for dysregulation of serotonin control of the 
hypothalamic-pituitary-adrenal axis in women with PMS.477 
Noradrenaline 
In healthy women, plasma noradrenaline has a cycle with peaks at ovulation and early luteal 
phase. In women with PMS, lack of NA cyclicity was observed in one study, with symptoms 
such as abrupt mood swings, impatience, nervousness, tiredness, weakness, apathy, and 
headache associated with decreased noradrenergic activity at ovulation and the luteal 
phase, and low oestradiol levels during the late luteal phase.478  Treatment with 
antidepressants predominantly affecting NA transmission, however, are found to be less 
effective than SSRIs for PMS.479   
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Other neurotransmitters that may have relevance to PMS include GABA470 and dopamine.  
Dopamine 
Dopamine receptor agonists are possibly the most effective treatment for premenstrual 
mastalgia.480  It is interesting to note that  Vitex agnus-castus (Chaste tree), found to be 
effective for the treatment of premenstrual irritability, mood alteration, anger, headache, 
breast fullness, and other menstrual symptoms including bloating,481,482has dopaminergic 
activity.483 
Gamma (γ)-aminobutyric acid  
Low GABA activity has been reported in women with PMS and low late-luteal- phase plasma 
concentrations in PMDD.484 It has been postulated that GABA’s role in the pathophysiology 
of PMS may be due to the interaction between GABA-ergic and serotonergic neurons, 
consistent with the serotonin hypothesis.462  This theory gains support from the action of 
SSRIs of enhancing GABA function.485  
Progesterone 
The long-held view that PMS is due to a progesterone deficiency has been challenged by 
the lack of efficacy of progesterone treatment. In fact, progesterone administration has been 
reported to aggravate PMS in women after pre-treatment with a GnRH agonist for one 
month to abolish hormonal cyclicity.486  Progesterone added to HT regimens triggers PMS-
like symptoms,487 with a dose-dependent increase in depression, loss of energy, loss of 
libido and mastalgia.488  This led Smith and co-workers to conclude that PMS-sufferers are 
hypersensitive to normal endogenous post-ovulatory levels of progesterone.488  Other 
reported symptoms of progesterone intolerance are bloating, mood swings, fatigue, 
depression, irritability, skin disorders, weight gain and anxiety. 456 
Oestrogen 
An alternative hypothesis is that PMS symptoms are triggered by the pre-ovulatory peak in 
oestradiol or the postovulatory peak in progesterone, or both.  Although not consistent with 
the absence of PMS during the oestrogen-dominated follicular phase, it has been noted that 
luteal phase administration of oestrogen provokes or aggravates PMS-like complaints486,489 while 
an oestrogen-antagonist reduced PMS mastalgia.490  
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Other Factors  
Other factors potentially implicated in the aetiology of PMS include  
• thyroid indices, which were found to be more variable in women with PMS than in 
controls;491,492 
• changes in circadian rhythms, found to be similar to those occurring in anxiety and 
mood disorders, with aberrant timing of the secretion of melatonin, cortisol and 
prolactin.452  
8.4 Aetiology of PMS-like symptoms in Perimenopause   
 
According to its defining characteristics and aetiology, PMS requires the presence of 
ovulatory cycles, which become increasingly infrequent as the menopause transition 
progresses.  Such symptoms experienced by late-perimenopausal women may, therefore, 
be more appropriately termed ‘PMS-like’ symptoms.  The aetiology of PMS-like symptoms 
during this phase may differ from during the normal reproductive years.  However, it should 
also be noted that ovulatory cycles can occur in the absence of subsequent menstruation 
during the perimenopause,55 so that their relationship to cyclic hormonal fluctuations may 
not be apparent to the women themselves.  Increased sensitivity to normal fluctuations in 
ovarian hormones may continue to be responsible for the symptoms during the 
perimenopause, as evidence supports reduced hypothalamic–pituitary sensitivity to 
oestrogen feedback in perimenopausal women.101,102,372,462   Alternatively, oestrogen excess 
has been hypothesised to be a possible cause for these symptoms in late perimenopausal 
women.  This is supported by the recent observation of a premenstrual dysphoria (‘luteal-out-
of-phase’  or LOOP) phenomenon, common in the early and late menopause transitions, 
where it appears that in the mid-luteal phase of the cycle, a new follicle is recruited, which 
may go on to ovulate in the perimenstrual period at the beginning of the next cycle. This is 
associated with high estradiol levels peri-menstrually which could give rise to PMS-like 
symptoms.493   
 
The increased risk of developing perimenopausal depression in PMS-sufferers has led to 
the suggestion that these conditions represent expressions of the same underlying disorder, 
namely a vulnerability to changes in ovarian steroid concentrations.372,462 In women 
previously reporting a history of PMS, it has been suggested that perimenopausal 
depression could be due to the elimination of follicular phase symptom remissions of 
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premenstrual dysphoria, as a consequence of the shorter follicular phase, resulting in a 
more persistent pattern of dysphoria.372    
8.5 Complementary and Alternative Medicine use for PMS 
 
Complementary medicine use is high among PMS-sufferers.  It was found that 91% of 
women attending a specialist PMS clinic in the UK had used at least one form of 
complementary therapy for the management of their PMS symptoms, 494 with over 40% 
having used St John’s wort. 495  As mentioned above, the evidence for conventional therapy 
is inadequate and controversial495 for the treatment of PMS, particularly when these 
symptoms occur in conjunction with menopausal symptoms.  Conventional medical options 
for the treatment of menopausal symptoms will be discussed in the following section. 
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Chapter Nine 
  
 
 
Pharmacological Treatment Options 
 
 
  
 
 
 
9.0  Introduction 
 
This chapter of the Literature Review explores the pharmacological treatment options for 
menopausal symptoms, and concerns regarding their use.  As the pharmacological 
mechanisms of the non-oestrogenic agents may have relevance to the phytomedicines 
selected for the RCT conducted, these are also examined.
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9.1 Hormone Therapy  
Current pharmacological treatment for the relief of menopausal symptoms primarily involves 
hormone replacement therapy (HRT), now more commonly referred to as Hormone Therapy 
(HT), which aims to compensate for the declining levels of ovarian hormones, particularly 
oestrogen and progesterone.   
 
Despite the well-established benefits of HT, side-effects and long-term safety concerns deter 
many women.  Non-oestrogenic pharmacological treatments available for menopausal 
symptoms also carry their own limitations.   The efficacy of the various pharmaceutical 
agents for different menopausal symptoms helps to elucidate their pharmacological 
mechanisms in relation to these symptoms, and thereby informs the potential role of 
phytotherapeutic alternatives. 
9.1.1 HT Use in Australia 
By 1997, 60% of Australian women 55 years and over had used HT.  It has predominantly 
been used short-term for the relief of the vasomotor symptoms,496  as opposed to prevention 
of osteoporosis or cardiovascular disease, or post hysterectomy or oophorectomy.79  
However, due to its purported protection from chronic degenerative disease,  HT use for 
long-term indications increased throughout the 1990’s497 although this dramatically declined 
following publication of findings from large-scale studies, linking it with adverse events 
(chapter 10). 
9.1.2 Types of Hormone Therapy   
The main types of HT used include oestrogen monotherapy (also known as unopposed 
oestrogen therapy), cyclic progestin therapy alone, combined oestrogen-progesterone, or 
the low dose oral contraceptive pill.   More recently, testosterone has also been used and 
tibolone, which combines oestrogenic, progesterogenic and androgenic effects.79    
 
Conjugated equine oestrogen (CEE) prepared from pregnant mares’ urine (hence the name 
Premarin is also the most widely used oestrogen preparation worldwide. (See Appendix 7 
for other preparations available in Australia.) 
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9.1.3 Symptoms Effectively Treated with HT 
HT has well-established efficacy in providing relief from hot flushes and  night sweats, which 
are the most common of the menopausal symptoms for which women initiate treatment.275   
Its benefits in retardation of bone loss and reversal of urogenital atrophy498 are also well 
established.  CEE is the form of oestrogen used in the majority of studies, although it is 
generally considered that others forms, including oestradiol and oestriol, offer comparable 
benefits.  However, evidence for its use in other symptoms is inconsistent and even 
conflicting (Table 9.1). 
TABLE 9.1   SUMMARY OF FINDINGS FOR HT IN DIFFERENT MENOPAUSAL SYMPTOMS  
Symptom  Evidence 
Vasomotor 
symptoms 
77% decrease in hot flush frequency and 87% reduction in their severity with HT 
(Cochrane systematic review of RCTs).499   
Sleep ET effective192,193,500 via ‘domino effect’, and in  absence of vasomotor symptoms193 
Shorter mean sleep latency, longer period of REM sleep;501 Reduced rates of cyclic 
alternating patterns of sleep in conjunction with decreased  frequency of nocturnal 
arousals and improved sleep quality.192      
Urogenital  
symptoms 
ET: vaginal dryness, atrophy and dyspareunia502,503   
Systemic or local for recurrent cystitis and stress incontinence (Meta-analysis);233  
Systemic HT may aggravate urinary incontinence (observational study).234  
Loss of libido Androgens503 or tibolone, (Livial®) effective;  
Androgens conventionally given with progestogens as concerns that testosterone may 
induce endometrial hyperplasia. 504 
Depression Oestradiol (17β-oestradiol): Conflicting findings: effective in perimenopausal women 
(RCTs);396,402 oestrogen alone, with androgens, but less effective with progestins.401 
Oestradiol - no effect over  placebo in postmenopausal women;404 WHI: oestrogen-
progestin not effective.505   
Most marked effect in surgical menopause.506  
ET may augment response to SSRI’s.507 
Anxiety Tibolone Over 6-months, significant improvement (small study; not RCT).508   
Little influence of oestrogen-progestin regimens.196 
Musculoskeletal pain Oestrogen/Progestin improved Postmenopausal Interventions  (PEPI) trial,196 
Evidence inconsistent 
Other: tooth loss ET associated with a reduced risk.509   
          headaches Inconsistent findings: alleviation, aggravation or no change with HT.510 
Postmenopausal Health Benefits 
Fracture risk, long-
term 
 
HT reduces bone turnover, preserves bone mass and increases bone mineral density 
(BMD);511 reduces fracture risk with continuous use.505 (up to 35% in hip and vertebral 
fractures)511   
Continuous CEE-medroxyprogesterone acetate (MPA): 44% reduced risk of all 
fractures (WHI).505,512 
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Cardiovascular, 
Cerebrovascular 
disease and 
Cognition  
Oestrogens reduce risk of vascular disease:513 lower low-density lipoproteins (LDLs), 
increase high-density lipoproteins (HDLs); favourable effects on endothelial function.513   
Beneficial effects on cognition in symptomatic postmenopausal women,514 stroke risk, 
dementia and Alzheimer’s disease515 now called into question by findings of large-
scale studies.505,516,517 
No evidence of benefit in established vascular disease, or healthy women; may worsen 
outcomes in CVD and CHD.518  
9.1.4 Advantages and Limitations of HT 
Despite the incontrovertible efficacy of HT for the treatment of vasomotor symptoms of 
menopause,229,519,520 many women find it unacceptable because of contraindications, 
associated risks, side-effects, lack of effectiveness for other symptoms or because of a 
natural reticence to taking drug therapy for a ‘natural event’.521  Different benefits and side-
effects are associated with each form of HT and route of administration (Table 9.2).  Routes 
of administration are discussed in Appendix 8. 
 
9.1.5 Adverse Events Reported in Large-scale studies  
The relative benefits and risks of long-term HT use have become more controversial since 
the publication of the findings of three large-scale studies between 2002 and 2007, linking 
HT use to serious adverse events such as increased risk of female reproductive cancers,  
venous thromboembolism, cardiovascular disease (CVD) and stroke.  Cancer risks are said 
to increase with continued use of HT for 5 years or more.   However, the risk of venous 
thrombosis is relevant even with short-term use, as most events occur during the first two 
years of HRT use.496   
TABLE 9.2   ADVANTAGES AND LIMITATIONS OF DIFFERENT HORMONE THERAPY PREPARATIONS 
Preparation Advantages Limitations 
Oestrogen preparations 
 
Benefit for vasomotor 
symptoms, retardation of 
bone loss and reversal of 
urogenital atrophy.498 
Unopposed oestrogen increases risk of endometrial 
hyperplasia and endometrial cancer (so not usually 
prescribed for women with an intact uterus) 
Combined 
oestrogen/progestins 
 
Counteracts the 
proliferative effects of 
oestrogens on 
endometrial tissue. 497 
Short-term side-effects: withdrawal bleeding and 
breakthrough bleeding occur in 40-90% of users of 
sequential regimens. 522 
Progesterone 
 
Megesterol acetate,  safe 
in history of breast or 
uterine cancer with < 5 
years continuous use523; 
decreases hot flushes 
approx 80% 235,321   
Concerns about increased risk of breast cancer.524   
Continuous progestins -breakthrough vaginal 
bleeding,79 weight gain and bloating; may also lead 
to thromboembolitic events.525  (see also appendix 
9). 
Tibolone 
 
Relief of menopausal 
symptoms; improves 
libido. Improves BMD; 
May lower HDL cholesterol 
Androgens conventionally combined with 
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lower risk for breast 
cancer - blocks oestrogen 
metabolism in breast; 
does not increase 
mammo-graphic 
density.79,526-528   
progestogen as concerns that testosterone may 
induce endometrial hyperplasia. 504 
Cardiovascular and Cerebrovascular disease  
The  HERS, a secondary prevention trial with combined oestrogen and progesterone for 6.8 
years in women with established CVD, and an unblinded open-label follow-up (HERS II), 
found no benefit for either primary of secondary prevention of cardiovascular disease.235   In 
fact, they observed a small increase in the risk of CVD and cardiovascular accident (stroke), 
venous thromboembolism and gall bladder disease.529  Increased risks of CVD and strokes 
were also found in the Women’s Health Initiative (WHI), a chronic disease (primary) 
prevention trial in older postmenopausal women, for combined oestrogen- progesterone.512   
Oestrogen alone did not increase the risk of CVD although it did increase stroke risk 
similarly to combined oestrogen-progesterone.505 
Breast cancer 
Administration of oestrogen monotherapy has long been known to increase the risk of 
oestrogen-dependent cancers.  Combined oestrogen-progesterone was also found to 
increase breast cancer risk in the WHI, one arm of which was terminated prematurely due to 
risks of invasive breast cancer exceeding the stopping boundary after a mean of 5.2 years of 
follow-up.  The breast cancers were diagnosed at a more advanced stage compared with 
placebo use.  The percentage of women with abnormal mammograms was also 
substantially increased, suggesting not only that  combined oestrogen plus progestin may 
stimulate breast cancer growth,530,531 but also that it may  hinder breast cancer diagnosis.531   
 
This finding was subsequently borne out by the U.K. Million Women’s Study (MWS), a 
longitudinal observational study of 1,084,110 women aged 50-64 years.  The effect was 
observed for combined oestrogen-progesterone, oestrogen-only preparations (5 additional 
cancers per 1,000 users) and tibolone.530   This was translated to an estimated 20,000 extra 
breast cancers due in UK women aged 50-64 years  in the previous decade due to use of 
HT,  of which 15,000 were associated with oestrogen-progestogen.530   
Endometrial and Ovarian cancers 
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When increased oestrogen is accompanied by low progesterone, there is a potentially 
increased risk of endometrial hyperplasia and possibly endometrial cancer. The MWS also 
reported an increased risk of endometrial cancer with oestrogen and tibolone.  In oestrogen-
progesterone preparations, progestogens protected against the adverse effect of oestrogen 
on the endometrium, with a greater effect  observed with longer duration of use of 
progestogen.532   An  increased risk of breast and endometrial cancers had previously been 
established with oestrogen-monotherapy.533  
 
HT use was also associated with an increased ovarian cancer risk in the MWS, but not WHI, 
for both incident and fatal ovarian cancer. On the basis of this, it was estimated that in the 
UK between 1991 and 2001, there were 1,300 additional ovarian cancers and 1,000 
additional deaths from ovarian cancer as a result of HT use.534  A recent meta-analysis has 
confirmed the increased risk of ovarian cancers with HT use, finding a stronger association 
with ET than oestrogen-progestin regimens.535 
Cognitive function  
A sub-study within the WHI, the WHI memory study (WHIMS) demonstrated a lack of  
preventive effects for  mild cognitive impairment and increased the risk for dementia when 
HT (oestrogen and progesterone or oestrogen-monotherapy) is commenced in  
postmenopausal women aged 65 years or older.505,517,516 Greater adverse effects were noted 
for women with lower cognitive function at the start of treatment.516   
Limitations of these studies  
A major criticism made of the HERS and WHI, however, is that the women enrolled in these 
studies were not representative of the typical population in whom HT is commenced, in  
terms of age, reproductive status and pre-existing medical history. They were aged, on 
average, in their mid 60’s, without menopausal symptoms, and many years past the 
menopause.  Many had previous HT use. As such, these findings may not be applicable to 
symptomatic peri- or early postmenopausal women who use HT for short periods and at 
doses lower than those used in the trials.  In addition, the WHI was not truly a primary 
prevention study due to the age and pre-existing medical conditions of many of those 
enrolled: one-third were overweight and another third obese; 40% were past smokers, 
10.5% current smokers and about one-third were hypertensive.536   
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The issue of clinical significance versus statistical significance has also been raised in 
regards to the findings of the WHI, where the actual increase in breast cancer risk was 8 per 
10,000 woman years536  (Table 9.3). 
 
TABLE 9.3    ABSOLUTE EXCESS RISKS PER 10 000 PERSON-YEARS ATTRIBUTABLE TO 
OESTROGEN PLUS PROGESTIN IN WHI537 
Outcome Absolute excess risks  
per 10,000 person-years 
Coronary Heart Disease (CHD) 7 more 
Stroke 8 more 
Pulmonary embolisms 8 more 
Invasive breast cancer 8 more 
Colorectal cancer 6 fewer 
Endometrial cancer 1 fewer 
Hip fracture 5 fewer 
Vertebral fracture 6 fewer 
 
The MWS looked retrospectively at HT use and subsequent breast cancer, but not at types 
and regimens of HT used.  As an observational study, it was therefore subject to selection 
bias.  The large sample size would amplify any small error that occurred as a result of this 
bias.  However, a recent study of new breast cancer events following HT in breast cancer 
survivors found a clinically and statistically significant increased risk,538 consistent with findings 
from a meta-analysis of RCTs examining recurrence of breast cancers with HT use.539 
 
The results of these studies are important and have impacted greatly on subsequent HT use 
and prescribing.  Their impact on CAM use is discussed in the following section. 
 
9.1.6 Contraindications to HT 
Apart from unwillingness to risk or tolerate adverse events, a woman may not be eligible to 
use HT because of its contraindications (Table 9.4). 
 TABLE 9.4  CONTRAINDICATIONS TO HT504 
Absolute contraindications 
Previous oestrogen-dependent neoplasms: breast, endometrial or ovarian cancers  
Impaired liver function 
Ischaemic heart disease 
Relative contraindications 
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Diabetes 
Hypertension 
Risk factors for ischaemic heart disease 
Past history of thromboembolism 
Significant uterine fibroids 
 
9.2 Non-oestrogenic options 
 
The limitations of HT have stimulated increased interest in pharmacological alternatives, 
especially for breast cancer survivors who are more likely to experience hot flushes and 
vaginal dryness due to tamoxifen® use, premature menopause from chemotherapy and/or 
denial of HRT.540  
 
Oestrogen and progesterone strongly interact with a number of neurotransmitters. This has 
led to a range of non-oestrogenic treatments for hot flushes, including compounds that 
target various non-oestrogen components of the vasomotor response.  These include 
agents acting via the noradrenergic or dopaminergic systems, the most promising being the 
anti-depressant selective serotonin reuptake inhibitors (SSRIs)197 and serotonin and 
noradrenaline  reuptake inhibitors (SNRIs).  Other pharmacological non-oestrogenic agents 
include the antihypertensive, clonidine, and the anti-convulsant, gabapentin (Table 9).  
However, all of these, with the exception of melatonin, are associated with undesirable side-
effects or safety concerns (Table 9.5).  
9.3 Conclusion 
 
Current pharmaceutical treatments for menopause-associated vasomotor symptoms include 
HT, which has been the mainstay for the management of these symptoms for more than 50 
years, and prescription medications developed for other indications.  All of these are 
associated with undesirable side-effects or risk of serious adverse events.  The publicity 
surrounding findings from large-scale studies such as the WHI and the MWS substantially 
decreased the use of HT.   Because many women now seek to avoid hormone therapy, 
there is a significant unmet need for additional therapies that have been validated by results 
from controlled clinical trials, and are safe, efficacious and well- tolerated by symptomatic 
menopausal women. 
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TABLE 9.5   PHARMACOLOGICAL ALTERNATIVES TO HT: ASSOCIATED BENEFITS AND RISKS 
Substance & Definition Advantages Evidence Concerns/Limitations 
Selective oestrogen receptor 
modulators (SERMs) (act in a 
tissue-specific manner, as 
oestrogen receptor agonists in 
some tissues and as oestrogen- 
receptor antagonists in others) 
May dissociate favourable oestrogenic 
effects on the bone and cardiovascular 
system from unfavourable stimulatory 
effects on the breast and 
endometrium.541 
Raloxifene is safe for the endometrium 
and holds promise for breast cancer 
prevention; tamoxifen has been 
associated with fewer fatal myocardial 
events than placebo in clinical trials.542 
Raloxifene & tamoxifen induce hot 
flushes 
Bio-identical hormone 
therapy - derivatives of plant 
extracts chemically modified to 
be exact chemical molecular 
copies of endogenous 
hormones, (typically, oestriol, 
oestrone, oestradiol, 
testosterone, progesterone, and 
sometimes DHEA.543  
Compounded, often on the 
basis of saliva tests or blood 
sera, by compounding chemists 
according to individually 
customised prescriptions. 
Believed to provide the benefits of HT 
while attenuating the risks to blood 
lipids and  vasculature, breast cancer 
and blood clots.544   
Scientific evidence from well controlled 
studies to support these claims is 
lacking.   
Concerns about the ratios of bio-
identical oestrogens in many 
preparations543 and the safety of 
oestriol on cardiovascular health, 
especially at doses used.545  
Compounded preparations not 
produced according to federal Good 
Manufacturing Practice.546  
 
Non-oestrogenic Options 
Selective serotonin reuptake 
inhibitors (SSRIs) and 
Serotonin and noradrenaline  
reuptake inhibitors (SNRIs)  
(anti-depressant medication) 
The effects on hot flushes are seen 
within a few weeks of commencement, 
earlier than for psychiatric symptoms, 
and occur regardless of co-existing 
depression or anxiety, suggesting a 
separate mechanism.547   
Venlafaxine: dose-related effects at 
three doses (37.5, 75 and 115 mg/day) 
Paroxetine: reduced frequency x 
severity of 54-65% vs 19-38% for 
placebo.547,548   
The highest and most effective doses 
caused frequent side-effects of 
nausea, decreased appetite, dry mouth 
and constipation.540  SSRI’s commonly 
cause nausea, anxiety, insomnia, 
headache, restlessness and sexual 
dysfunction.189 
Clonidine  
(centrally-acting adrenergic 
agonist primarily used as an anti-
hypertensive- proposed 
mechanism for relief of hot 
flushes is reduction of peripheral 
vascular reactivity.549) 
Of modest benefit in controlling hot 
flushes (1 flush per day);549 
Used in tamoxifen users. 
Reduction in frequency  of hot flushes of 
24%-44% vs 14%-27% for placebo, or a 
reduction in the combined frequency x 
severity score of 29%-56% vs 16%-30% 
for placebo.550,551  Long-term efficacy (> 
8 weeks) not established.  Results of 
RCTs inconsistent. 
Side-effects: incidence of increases in 
the higher doses, -limits its practicality 
as a therapeutic agent -  drowsiness, 
dry mouth, sleep disturbances and 
gastrointestinal upsets.151  
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Gabapentin (λ-amino butyric 
acid analogue - anticonvulsant 
for seizures and neuropathic 
pain. (Not a GABA agonist, 
does not inhibit GABA uptake 
and acts independently of 
GABA receptors.321)  
May increase activity of 
neurotransmitters in hypothalamus as 
a consequence of up-regulation of the 
gabapentin binding site from oestrogen 
withdrawal552   
At 900mg/day, reductions in hot flush 
frequency were 44-45% vs 15-29% 
with placebo, no significant effect at 
300mg.552   
Side-effects: somnolence, fatigue, 
dizziness, rash, heart palpitations and 
peripheral oedema.549 
Supplemental 
Dehydroepiandrosterone  
(DHEA) 
(DHEA and its sulphate ester 
are androgen pro-hormones 
produced by the adrenal glands 
and ovaries.) 
Improved psychological well-being and 
the sleep pattern in clinical trials553,554   
In postmenopausal women 25mg/day 
long-term modified circulating levels of 
androgens and progestins via 
modulation of age-related changes in 
adrenal function.555 Sustained 
improvement in overall menopause-
related symptoms, vasomotor and 
psychological symptoms.556-558 
No improvement over placebo on 
mood, memory, cognition, well-being 
or libido in 60 perimenopausal women 
50mg/day. 559   
Undergoes significant first-pass 
metabolism, so need high doses, 
which increases risk of side–effects: 
hirsuitism, acne, increased sebum 
(short-term); dyslipidaemia, hepatic 
dysfunction (long-term).450   
Melatonin 
 
 
 
Significant improvement in mood and 
morning depression in 42-62 year-old 
women following evening 
administration.560 
3mg improved thyroid function, 
returned gonadotropins towards more 
juvenile levels, and had some 
antidepressant activity in 
perimenopausal and postmenopausal 
women.561   
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Chapter Ten 
  
 
 
Complementary/Alternative Medicine 
 
use for Menopausal symptoms 
 
 
  
 
 
 
10.0  Introduction 
 
This brief chapter outlines the impact of the publication of results from the large-scale 
studies on HT use, and the prevalence of CAM use among menopausal and midlife 
women.
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10.1 HT Avoidance  
A 1997 Swdish study reported a 20% discontinuation of oestrogen from fears of cancer 
(9%) or other side-effects (14%), while the most common reasons cited for refraining 
from HT use were minor climacteric symptoms (27%), fear of cancer (9%) or side-effects 
(15%) and the opinion that the menopause is a natural process (20%).  Some others 
gave lack of effectiveness as the reason for non-use.521 
In 2002, in the wake of the publication of results from the Womens’ Health Initiative 
(WHI) and the Million Women’s Study (MWS), a dramatic decline in HT use ensued.  The 
rates of discontinuation varied from country to country and for different user-groups.  In 
the Netherlands, the MWS had a bigger impact than the WHI (Table10.1). 
TABLE 10.1   HT DISCONTINUATION RATES FOLLOWING ADVERSE PUBLICITY FROM LARGE –
SCALE STUDIES 
Country 
(Study Authors) 
Years/Dates 
compared 
User-group Rate of Decline 
New Zealand (Lawton 
et al.)562 
2000-2002 
vs 6 months after 
publication of WHI 
HT users from general 
practices 
58% initially 
40% still discontinued 
at time of survey 
USA, Boston (Kelly et 
al.)563 
The first half of 2002 to 
the first half of 2004 
Women aged 50 years 
and over 
57% 
USA (Hersh et al.)564 January-June 2002 vs 
January-June 2003 
Combined 
oestrogen/progesterone  
users 
Oestrogen-only 
(Premarin) users 
66% 
 
 
33% 
Netherlands (Faber et 
al.)565 
2000 vs 2003 post 
MWS publication 
45-45 year-olds 
50-54 year olds 
55-59 year olds 
42% 
46% 
37% 
Italy (Parazzini et 
al.)566 
1997-8 vs 2002-3 All current HT users 35% 
Germany (Clanget et 
al.)567 
Prior to publication vs 
7 months following 
WHI and HERS II 
publication 
Combined HT users 
Overall HT users 
(Aged 45-65) 
41% 
16% 
 
 
It is unclear whether fears concerning HT use generated by publication of these large-
scale studies led to an increased use of CAM for menopausal symptoms.  According to 
the Boston study,563 there was no correspondingly significant increase in 
postmenopausal use of black cohosh (2.0%) or soy (2.0%) in 2004.  However, 
Schonberg and Wee568 found that 82% of women who stopped HT re-experienced some 
menopausal symptom, for which 48%  tried at least one CAM, most commonly soy or 
black cohosh.  Nonetheless, the rate of use of CAM is high among midlife and 
menopausal women. 
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10.2 Prevalence of Use of CAM in Midlife/Menopausal Women 
 
Surveys of CAM use by midlife women do not always specifically focus on their use for 
menopausal symptoms.  In a 2003-2004 Australian study investigating CAM use for the 
alleviation of menopausal symptoms in 45-65 year-old women, 53.8% were reported to 
have visited a CAM practitioner and/or used a CAM product during the previous year.569  
This was consistent with findings from the SWAN in 2003 that 52% of midlife women 
aged 48–52 used CAM, although not exclusively for menopause-related symptoms.570 
However, the prevalence of CAM use during menopausal years was found to be as high 
as 82.5% in women aged 47-67 years in South East Queensland in 2004.  Prior to the 
publication of the major studies that generated fears about HT use, reports of CAM use 
in English-speaking countries ranged from 45% to 79% in mid-life women, and 46% to 
76.1% for menopause symptoms (Table 10.2). 
TABLE 10.2   PREVALENCE OF USE OF CAM  IN  MIDLIFE/MENOPAUSAL WOMEN 
Source, Study 
year/s & Authors 
Demographic % CAM 
use 
Modality/Complementary Medicine 
Australia: Sydney, 
2003-2004 
Van der Sluijs et 
al.569 
Women aged 45 - 65 years 
Menopause symptoms: 
menopause & general practice 
clinics; government agencies 
53.8% Naturopathic practitioner visits  7.2% 
Acupuncturist-visits 4.8% 
Soy 25.4% 
Evening primrose oil 18.4% 
USA, 2003 
Gold et al. 570 
Women aged 48 - 52 years; 
cross-sectional analyses of 
midlife women in the longitudinal 
Study of Women's Health Across 
the Nation [SWAN] 
 
52.7% Black cohosh 6.4%  
DHEA 1.3%  
Dong quai 2.8%  
Flaxseed/flaxseed oil 10.6%  
Ginkgo biloba 6.8%  
Ginseng 5.8%  
Glucosamine 15.9%  
Mexican yam/progesterone cream 2.9%  
MSM 3.8%  
SAMe 1.1%  
Soy supplement 16.6%  
St John’s wort 2.2%  
Acupuncture 4.7%  
Energy healing 4.8%  
Tai chi 3.1%  
Yoga 12.8%  
Self-help group 5.4%  
USA Published 2003 
Mahady et al. 571 
Women aged 40-60; survey of 
outpatients at University of 
Illinois Chicago clinics using 
botanic dietary supplements 
(herbs) 
79% 
36.5% 
daily use 
Soy 42% 
Green tea 34.7% 
Chamomile 20.8% 
Ginkgo 20.5% 
Ginseng 18% 
Echinacea 15.4% 
St John’s wort 7.3% 
USA: Washington, 
2002 Newton et al. 
572 
Menopausal aged women and 
menopausal symptoms; 
randomly sampled through 
primary care providers 
 
76% of 
45-65 
year-old 
women 
22% for 
meno-
pausal 
symptoms 
Stress management 43.1% 
OTC CAM 37% 
Chiropractic 31.6% 
Massage therapy 29.5% 
Dietary soy 22.9% 
Acupuncture 10.4%  
Naturopathy or homeopathy 9.4%  
Herbalist 4.6% 
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TABLE 10  PREVALENCE OF USE OF CAM IN  MIDLIFE/MENOPAUSAL WOMEN CONT 
Source, Study 
year/s & Authors 
Demographic % CAM 
use 
Modalities 
USA, 2002 
Brett et al.  573 
Midlife women aged 45 -57 
years; obtained from the 2002 
National Health Interview Survey 
45% 
within 
previous 
12 months 
Biologics (e.g. herbs) or mind-body 
(e.g.biofeedback) 25%,  
Body work (e.g.. massage and 
chiropractic)  15%  
Herbs  26.4 
Relaxation 21.6 
Chiropractic 9.4 
Yoga/Tai chi/Qi gong  8.5 
Massage 7.6 
Vitamins 3.4 
Homeopathy 2.7 
Acupuncture 1.7 
Energy healing/ Reiki 1.2 
Naturopathy  0.4 
Australia: South east 
Queensland, 2001 
Gollschewski et al. 
574 
Women aged 47-67 years postal 
questionnaire on menopause 
experience – ever used and use 
in previous month 
82.5% 
(not 
specified 
ever-use 
or 
previous 
month) 
Nutrition 67%  
Phytoestrogens 56% 
Herbal therapies 41% 
Evening primrose oil 34% 
Vitamin E  29% 
Ginseng 13% 
Unspecified CAM  25% 
Therapeutic techniques 83% 
UK:  London,  
2001 Vashisht et 
al.575 
Women aged 49-59 years; 
prospective questionnaire; 
London menopause clinic – use 
for menopause symptoms 
 
66% 
regular 
users 
(68.5% 
ever used) 
 
Phytoestrogens 1% (6.5%) 
Chinese herbs 1% (10%) 
Wild yam 3% (9.5%) 
Dong quai  2.5% (9.5%) 
Ginkgo  7% (16.5%) 
Black cohosh  1.5% (5%) 
Homeopathy  5% (19.5%) 
Vitamins 32.5% (50%) 
Acupuncture 3.5% (16.5%) 
Hypnosis  0.5% (6%) 
Spiritual Healing 4.5% (11%) 
Massage 0.5% (1.5%) 
Reflexology  0.5% (1.5%) 
Natural progesterone cream 4% (11.5%)  
Evening Primrose oil 0.5% (1.5%) 
USA:  Florida, 
Minnesota & 
Tennessee, 1997-8 
Keenan et al. 576 
Women aged 45+; menopausal 
symptoms cross-sectional 
telephone survey 
46% 
regular 
use 
20.8% CAM only (includes chiropractic, 
homeopathy, naturopathy, herbalism, 
TCM, acupuncture, increased physical 
activity, dietary supplements, soy 
foods/beverages, mid-body techniques 
(e.g. biofeedback, yoga576) and self-help 
groups). 
25.2% CAM + conventional therapies 
 
These findings do not suggest that CAM use in this particular demographic has 
increased dramatically since the publications of results from WHI, the MWS and HERS II.    
 
However, one limitation of comparing studies of CAM use is the different modalities 
included across studies; for example, some include support groups, 570,576 educational 
interventions, exercise, prayers for healing and dietary modification.570  Another limitation 
is the different sampling methods: clinic samples of women presenting with bothersome 
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symptoms could be expected to generate higher figures than general population 
samples.  Comparison is also restricted by the differing inclusion criteria and instruments 
for measuring menopausal symptoms and their severity. 
 
Nonetheless, even the most conservative estimates suggest that close to half of 
menopausal and midlife women in Western countries use CAM.  If this trend continues, it 
will constitute an increasingly significant demand for CAM by this user-group, given that 
50 million women in the established market economies (Australia, Canada, Japan, New 
Zealand, USA and Western Europe) are expected to reach the menopausal age between 
2000 and 2030, according to projections of the world’s population by the World Bank’s 
1993 World Development Report (p7).53  This is without taking into consideration the 
demand by women in developing nations.   
 
Despite such widespread use, however, scientific knowledge from clinical trials regarding 
the effectiveness of CAM is still limited.  The following sections will review the current 
evidence for phytotherapeutic interventions used in the practice of Western herbal 
medicine.  
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Chapter Eleven 
  
 
 
Phytotherapeutic Interventions  
for Menopausal Symptoms  
 
 
 
  
 
 
 
11.0  Introduction 
 
This chapter contains a review of the literature relating to phytomedicines currently 
administered for menopause-related symptoms in the Anglo-American practice of 
phytotherapy. Despite the variety of phytomedicines used in the treatment of 
menopausal symptoms in the Western tradition, rigorous evidence from clinical trials in 
this context is still limited.   
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11.1  Phytoestrogens 
 
The phytoestrogen-containing plants have received the most attention in the scientific 
arena, with relatively little research conducted on other herbs for menopause.577  
However, concerns have now been raised over the safety of long-term use of some 
phytoestrogens and phyto-SERMs (defined below), specifically on breast and 
endometrial tissue proliferation.578,579  
 
 ‘Phytoestrogens’ have been defined as plant-derived diphenolic substances with a 
chemical structure similar to oestrogen that enables them to bind to both alpha (ERα) 
and beta (ERβ) oestrogen receptors.580  Phytoestrogens might act as anti-oestrogens 
(oestrogen antagonists) or oestrogen agonists, depending on the levels of endogenous 
oestrogens or other competitive receptor ligands.581 Thus, their oestrogen-like effects 
could be predominant in the oestrogen-depleted environment of postmenopause. 
 
11.1.1 Classes of phytoestrogens  
 
The main classes of phytoestrogens are isoflavones, coumestrol and lignans.  
Isoflavones such as daidzein and genistein are found in highest concentrations in 
soybeans and soy products.  In soybean itself and most soy products, genistein and its 
beta glycoside, genistin, constitute about 50-55% of total isoflavone content, compared 
with 40-45% for daidzein/daidzin and 5-10% for glycitein/glycitin.582  Isoflavones are also 
found in Trifolium pratense (red clover) along with coumestrol.  Coumestrol also occurs 
in alfalfa sprouts, clover sprouts, soy sprouts and split peas.287,583 Lignans such as 
secoisolariciresinol diglucosides are found in linseeds (flaxseed) and whole grains 
(Appendix 10, Table A10.1).287,583   
 
11.1.2 Mechanisms of Action 
 
There are several possible mechanisms by which phytoestrogens may exert their effects, 
including interaction with oestrogen receptors,584,585 displacement of oestrogens from sex 
hormone binding globulin,586-588 regulation of oestrogen metabolism589,590 and inhibition of 
aromatase (oestrogen synthetase).591   While the condition for phytoestrogen activity in 
the case of lignans is completely dependent on colonic bacteria that convert the 
precursor, secoisolariciresinol diglucoside, into enterodiol and enterolactone,592 
isoflavones are inherently oestrogenic and may become further activated by conversion 
to equol, a bacterial metabolite of daidzein in the gastrointestinal tract.593    
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11.1.3 Oestrogenic potency of phytoestrogens  
 
The oestrogenic potency of all the xenobiotic oestrogens, however, is very low compared 
with that of endogenous oestrogens.594,595,596 Genistein transactivates ERα and induces 
oestrogenic effects with approximately 103 – 104 less potency than oestradiol.595,596 
Similarly, for daidzein and two of its metabolites, equol and O-desmethylangolensin,  
binding affinity to ERα was found to be 103 – 104-fold lower than for the endogenous 
oestrogen oestradiol.597  [S-equol has an affinity for ERβ nearly as high as that of 
genistein.595]  Nonetheless, the oestrogenic potency of phytoestrogens is believed to be 
significant enough, especially for ERβ, that they may trigger many of the biological 
responses that are evoked by the physiological oestrogens.580  After a high soy meal, 
serum isoflavone concentrations can reach low micromolar levels,598,599 exceeding 
postmenopausal total oestrogen concentrations by approximately 103, although free 
serum genistein levels return to baseline after twenty-four hours.600  
11.2 PhytoSERMS 
 
Some phytoestrogens are believed to have selective oestrogen receptor modulator 
activity, and hence have been termed ‘phytoSERM’.  Like the selective oestrogen 
receptor modulator (SERM) drugs, they may have a selective pattern of oestrogen 
agonist-antagonist activity depending on the target tissue.  The soy isoflavone, genistein, 
preferentially binds to ERβ, with a 7-30 fold greater affinity for ERβ than for ERα.601   
11.3 Glycine max L. (Soybean, Family: Fabaceae) 
 
11.3.1 Research on Soy for Menopausal Symptoms/Hot flushes 
 
Evidence of benefit in hot flushes has been derived from clinical studies on soy, in the 
form of soy isoflavones,602 a standardised soy extract,603 soy protein,76,604,605 soy foods,606 
daidzein-rich isoflavone aglycones607 and genistein.608,609 Genistein also significantly 
improved Kupperman Index (KI) scores in an open RCT, compared with baseline and 
with placebo, p < 0.05, after 12 months.610  Another RCT with a soy isoflavone extract 
(total of 50 mg genistin and daidzin per day) showed a positive trend that did not reach 
statistical significance, p <= 0.08.611   However, findings from soy studies in this context 
have been conflicting, with other RCTs showing improvements for the control group as 
well as soy flour,612 isoflavone supplementation,613,614 soy protein,615,616 and soy beverage 
(Table 11.1).617,618  
98 
TABLE 11.1    RESULTS OF SOY TRIALS FOR MENOPAUSAL SYMPTOMS  
Authors N Intervention Comparator Study 
length 
Findings 
Han et al,602 
2002 
 
80 
100 mg soy 
isoflavones 
 
placebo 
4 
months 
KI scores significantly decreased from 
baseline p < 0.01, and between groups, p 
< 0.01. 
Faure et 
al,6042002 
75 soy IF extract 
(genistein/ daidzein 
70 mg/day) 
placebo 16 
weeks 
61% reduction in HFs versus 21% placebo 
; Responders 65.8% vs 34.2%, p < 0.005 
Scambia et 
al,603 2000 
39 standardised soy 
extract 
(SOYSELECT) 50 
mg/day IF 
placebo 6wks 
CEE added for 
next 6wks 
12 
weeks 
At 6 wks, soy decreased frequency of HFs, 
p < 0.01 compared to placebo, and 
severity on GCS, p < 0.001. 
Albertazzi, et 
al76 1998 
104 soy powder 60g (IF 
76 mg) 
casein powder 12 
weeks 
HF frequency improved with soy vs casein, 
p < 0/01).  31% reduction with soy vs 31% 
with casein. 
Washburn, et 
al605 1999 
51 soy protein, 20 g 
(POs 34 mg/day) 
placebo 6 weeks Improved severity of HFs with soy vs 
placebo, p < 0.001. 
Dalais, et al606 
1998 
52 soy or linseed diet wheat diet 24 
weeks 
Reduced rate of HFs with linseed diet 
451%), wheat diet (51%), but not soy. 
Khaodhiar, et 
al607  2008 
190 daidzein-rich IF, 40 
or 60 mg/ day  
placebo 12 
weeks 
At 12 weeks, HF frequency was reduced 
by 52% with 40-mg DRI, 51% with 60-mg 
DRI, and 39% with placebo, p = 0.07 and p 
= 0.09 vs placebo.  
Crisafulli, et 
al608 2004 
90 genistein (54 
mg/day).   
 
placebo and 
oestrogen/ 
progesterone 
(HT) 
12 
months 
HFs decreased with genistein vs placebo 
at 3, 6 months and 12 months (p < 0.01). 
Improvement with HT greater than 
genistein at all times, p < 0.05. 
D’Anna, et 
al609 2007 
247 genistein (54 mg/d) placebo 12  
months 
Genistein significantly outperformed 
placebo on HFs at all intervals from the 
first month, p < 0.001.  
Sammartino, 
et al610 2003 
70 genistein 36 mg/day placebo 12 
months 
Improved KI score with genistein vs 
placebo, p < 0.05. 
Upmalis, et 
al611 2000 
177 soy extract (50 
mg/day IF) 
placebo 12 
weeks 
Between-group differences in HFs at week 
6, p = 0.03, but not significant at week 12, 
p = 0.08. Significant reduction in severity of 
HFs with soy, p = 0.01 
Murkies, et 
al612 1995 
58 soy flour, 45 g/day wheat flour 45 
g/day 
14 
weeks 
No between group differences. Reduced 
HFs and general symptoms in both 
groups, p < 0.05.  
Secreto, et 
al613 2004 
262 80 mg of soy IF +/- 3 
mg of melatonin 
placebo 
melatonin 
12 
weeks 
No significant difference between groups. 
Median percent reductions on GCS of 39% 
for IF + MEL, 38% for IF alone, 26% for MEL 
and 38% for placebo. 
Knight, et al614 
2001 
24 soy IF powder 
beverage 60 g/day (IF 
134 mg/day) 
casein powder 12 
weeks 
No between-group differences. Improved 
flushing frequency in both groups. 
Burke, et al615 
2003 
241 soy drink, IF, 42 
mg/day or 58 mg/day 
Soy drink with 
IF removed 
96 
weeks 
No between-group differences. Improved 
HF frequency and severity in all groups. 
Van Patten, et 
al617 2002 
157 soy beverage, IF 90 
mg/day 
placebo 12 
weeks 
No between-group differences. Improved 
HF frequency in both groups.  
St Germain, 
et al616 2001 
69 soy protein IF 80 
mg/day or 44 mg/day 
placebo (whey 
powder) 
24 
weeks 
No between-group differences. Significant 
decline in HF frequency (p = 0.0003) and 
night sweat (p = 0.0007) in all groups.  
Kotsopoulos,et 
al618 2000 
94 soy supplements 
118 mg IF  
casein placebo 3 
months 
No significant between-group differences 
on menopausal symptoms. 
IF = isoflavones   DRI = Daidzein-rich isoflavones   HF = hot flushes 
MEL = melatonin   GCS= Greene Climacteric Scale KI = Kupperman Index 
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11.3.2 Possible reasons for conflicting findings regarding hot flushes 
 
It has been suggested that these contradictory findings may reflect the diverse 
supplement regimens studied,601 the range of exposure measures used (urinary or serum 
isoflavone levels versus intake of soy products/foods/isoflavones), and/or the differing 
amounts of products consumed or dosages administered.582  In addition, variations in the 
bioavailability of genistin may be at least partially responsible for conflicting findings.  
Processing has been shown to reduce the isoflavone content of some soy proteins by as 
much as 80%,619 thereby affecting the oestrogenicity620 as well as circulating (and 
probably also target tissue) concentrations of genistein aglycone (the biologically active 
form).621  It is therefore possible that some of the isoflavone regimens tested have failed 
to achieve adequate free genistein concentrations in some subjects.601  There is also 
considerable inter-individual variation in gut metabolism of genistein and daidzein,593 and 
it has been suggested that “bacterio-typing" individuals according to their capacity to 
form equol may hold the clue to the effectiveness of soy protein diets in the treatment or 
prevention of hormone-dependent conditions.593  As suggested by the recent study on 
daidzein-rich isoflavone aglycones,607 the type of isoflavone may be the determining 
factor in the effectiveness of soy supplementation for alleviating hot flushes.  High 
genistein-containing isoflavone supplements (providing more than 15 mg genistein, 
calculated as aglycone equivalents, per treatment) were also found to consistently report 
a statistically significant decrease in hot flush symptoms according to a review of 11 
studies.297 Additionally, the failure of some studies to reach significance over 
placebo/control, may reflect the modest benefit of soy isoflavones that is expected in 
relation to hot flushes.601  
 
11.3.3 Other benefits of Soy in post-menopause 
 
In addition to potential benefits on menopausal symptoms, soy has been shown to 
favourably affect cardiovascular risk markers such as total cholesterol, low-density 
lipoprotein (LDL) cholesterol,605,622,623 diastolic blood pressure,605 high density lipoprotein 
(HDL) cholesterol and triglycerides624 and vascular endothelium.625  Studies have also 
shown benefits on bone metabolism,581,626,627 with some additional support from 
epidemiological studies from China and Japan for a positive relationship between bone 
density and soy intake.626,628 The preventive effects of isoflavones on bone loss in early 
postmenopausal women were shown in a 1-year RCT to depend on an individual's 
equol-producing capacity.629 Thus, dietary or supplemental soy may confer additional 
advantages for the postmenopausal woman at greater risk than her premenopausal 
counterpart of CVD and osteoporosis. 
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11.3.4 Soy Safety Concerns 
 
However, because of the oestrogen-like effects exerted by isoflavones under some 
conditions, concerns have arisen that they may potentially promote breast and 
endometrial cancers.578,579 This is discussed further below.  Uterotrophic effects were 
shown in rats fed genistein at doses of 750 mg/kg.630,631 In an RCT with 376 healthy 
postmenopausal women with an intact uterus, long-term treatment (up to 5 years) with 
soy phytoestrogens (150 mg of isoflavones per day) was associated with a significantly 
higher occurrence of endometrial hyperplasia than with placebo (3.37% vs. 0%), 
although no cases of malignancy were detected by endometrial histology from biopsies.  
However, no impact has been shown of soy isoflavones on endometrial proliferation in 
other clinical studies.609,610,632,633  Also of some concern is the potential anti-
thyroid/goitrogenic effect of soy, especially in an iodine-deficient environment,634,635 and 
possible exacerbation of autoimmune thyroid disease with high soy intake.636  However, 
this appears unlikely given the high dietary levels required. 
 
11.3.5 Soy consumption/supplementation and breast cancer  
 
Soy was initially investigated for its potential to reduce cancer risk, particularly breast 
cancer.637   This is supported by epidemiological evidence showing that among Asian 
women, higher soy intake is associated with a lower breast cancer risk,638-642 (nearly a 
one-third reduction).639 The findings that soy isoflavones exert anti-oestrogenic effects, 
and may thereby be chemopreventative;643 and a protective effect of soy against 
carcinogen-induced breast cancer in rodent studies644 also add weight to this 
consideration. 
 
Concerns that subsequently arose regarding a potential adverse impact on breast cancer 
risk and the growth of existing oestrogen-dependent tumours were predominantly 
triggered by findings from in vitro research, as well as rodent studies showing that 
isoflavones bind to and transactivate oestrogen receptors (ERs),595,596 and  induce 
proliferation and oestrogenic markers in MCF-7 cells (an ER positive breast cancer cell 
line).578,597,645  In ovariectomised athymic mice, dietary genistein and genistin enhance 
the growth of human MCF-7 cell tumour xenoplants,646,64 which appears to hinge on the 
activation of ERα.601  The effect of soy protein isolates and genistein in this context is 
dose-dependent. 645,647 Dietary daidzein had only a slight but significant effect on tumour 
growth while equol did not stimulate the growth of oestrogen-dependent tumours in 
athymic mice, even though total daidzein or equol plasma levels in these mice were in 
the range that stimulated MCF-7 cell growth in vitro.648  This may suggest that 
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pharmacokinetic factors attenuate the oestrogenic effects of daidzein and equol in 
vivo.648  Fermented soy milk products, however, have shown growth-inhibitory effects on 
various human breast carcinoma cell lines, especially on MCF-7 cells in severe immune 
deficient mice,649 and on induced mammary carcinogenesis in the rat.650  
Relevance of in vitro studies and rodent models to humans 
Findings from in vitro studies and rodent models are, however, of questionable relevance 
to humans.  It has been pointed out that the lack of immune function in athymic mice, 
and the oestrogen-depleted environment do not accurately reflect the situation in either 
pre- or post-menopausal women.651  Studies using parenteral doses of purified 
isoflavones are of limited interest, as are those using scaled oral doses 8 to 16 times 
higher than the typical intake from traditional Asian diets.651  In humans, at least 95% of 
isoflavones are conjugated and largely inactive.652 A higher percentage of genistein and 
daidzein appears in the free/aglycone form in rats.653 In addition, the metabolite, equol, is 
effectively formed by gut bacteria in rodents and predominates in the serum of rodents, 
whereas only 30-50% of humans are equol-producers.654  Daidzein and genistein remain 
the predominant isoflavones in human serum after ingestion of soy or mixed 
isoflavones.593,653,654  
 
Biphasic effects of dose have been observed both in vitro655,656 and in vivo.657  In vitro, 
genistein at higher concentrations (>10 µM), inhibits growth of MCF-7 cells656,658 
(probably by oestrogen-independent mechanisms, such as modulating genes658) but 
stimulates growth at relatively low and physiologically-relevant concentrations659 (<1 µM) 
via oestrogen-dependent mechanisms.659,660  In standard rodent models, isolated soy 
protein or isoflavones were shown to suppress rather than stimulate growth of tumours in 
mice implanted with MCF-7 cells,661 and even enhance the efficacy of tamoxifen.662  Han 
and co-workers found that both genistein and daidzein were able to inhibit the 
proliferation-stimulating activity in MCF-7 cells in a high-oestrogen environment,663 
suggesting that the hormonal milieu may be of relevance to the in vivo effects.  In rodent 
models, the timing of soy or isoflavone exposure relative to the implantation of cancer 
cells or the administration of carcinogens may be a critical factor in determining whether 
tumour development or growth is suppressed or enhanced.657 Prepubertal administration 
of high–dose genistein induced a premature differentiation of breast tissue that 
diminished susceptibility of adult rats to carcinogen-induced breast cancer.664   
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An additional limitation with the observation of in vitro binding to ERα and ERβ is that 
ER-binding alone is a poor predictor of in vivo activity.665 ER ligands often have very 
different/opposite effects depending on dosage and the type of tissue studied.585 
The low nanomolar serum concentrations of unconjugated free genistein achieved with 
high-nutritional intakes of soy isoflavones are near the binding affinity of genistein for the 
beta receptor, but are about an order of magnitude lower than genistein’s affinity for the 
“classical” alpha isoform of the oestrogen receptor (ERα).601  Only about 4% of the total 
genistein is in free or sulphated from, while the remainder, consisting of glucuronate 
conjugate, is thought to have limited intracellular access.592,666  Setchell and co-
workers667 found that unconjugated genistein constituted about 1.1-1.5% of the total 
plasma pool of genistein, the higher percentage being observed transiently in the first 2 
hours following soy ingestion.  These concentrations are far too low to inhibit tyrosine 
kinases or topoisomerase II,  often cited as potential mediators of its physiological effects 
of genistein in vitro.668 
Clinical studies and Epidemiological Evidence for Soy and Breast cancer 
Findings from clinical studies have generally been favourable in regard to breast cancer 
risk, although not exclusively.  In premenopausal women, soy supplements resulted in 
stimulation of oestrogen-sensitive markers and increased breast epithelium 
proliferation,669,670 consistent with reports that low concentrations of isoflavones 
(isoflavone supplement 40mg per day equivalent)  stimulates ER positive cells.  Another 
study reported that after 6 months of soy protein isolate, hyperplastic epithelial cells were 
present in 7 of 24 completing subjects, compared with 1 at baseline.671  
 
However, no increase in breast cell proliferation (a marker of potential tumour promotion) 
was observed following supplementation with isoflavone or isolated soy protein in four 
clinical studies (three with breast cancer patients672-674 and one with healthy women294) in 
which breast biopsies were taken before and after. Two pilot studies on breast cancer 
survivors showed no significant effect of isoflavone supplementation on breast cell 
proliferation, over 2 weeks672 and one year674 respectively.  Recently conducted one year 
and two-year-long studies indicated that isoflavone supplements do not affect breast 
density in premenopausal women.675,676   
 
Case-control studies have found an inverse association between soy intake and risk for 
premenopausal breast cancer in Asian populations, and two such studies have found a 
similar association with postmenopausal breast cancer.640,641,677-679 In one of these, high 
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soy intake among Asian Americans during adolescence was found to predict a lower risk 
for postmenopausal breast cancer, especially for those maintaining the high soy 
consumption into adult life.679 Breast cancer survival is unrelated to soy food intake in 
epidemiological studies.680,681 
Differential activation of ERα and ERβ? 
McCarty601 has proposed an interesting hypothesis that may account for the conflicting 
findings from soy studies and provide a rationale for genistein’s clinical activities and 
safety potential.  His theory is that the physiological effects of genistein are mediated by 
ERβ activation, and that ample activation of ERβ, but only minimal or modest activation 
of ERα, is achieved by physiological serum levels of free genistein achieved by a soy-
rich diet.  ERα and ERβ have opposing effects on cell proliferation in certain tissues, 
such as breast tissue, where ERα promotes epithelial proliferation, whilst ERβ has a 
restraining influence.  This supports suggestions that soy isoflavones do not increase 
breast cancer risk, and may possibly diminish it.  Their lack of uterotrophic activity may 
be due to ERα being the exclusive mediator of oestrogen’s impact in this regard.  
Reported modest benefits of isoflavones on menopausal hot flushes may reflect the 
presence of ERβ in certain regions of the hypothalamus 682 to which soy isoflavones 
have access.  Furthermore, the favorable influence of soy isoflavones on endothelial 
function in postmenopausal women and ovariectomised rats is explained because 
vascular endothelium expresses both ERα and ERβ, each of which has the potential to 
induce and activate nitric oxide synthase.  The ERβ expressed in osteoblasts may 
mediate the reported beneficial impact of soy isoflavones on bone metabolism.   
While current evidence suggests that isoflavone intake at dietary levels is unlikely to 
increase breast cancer risk, or oestrogen-sensitive breast cancer recurrence, most 
studies have been relatively short-term.  Concerns exist regarding long-term safety.  The  
possibility has been raised that, by promoting low-level activation of ERα, nutritional 
intakes of genistein could modestly boost cancer growth.601  Additionally, breast cancer 
patients taking SERMs are advised to limit their intake of soy foods and avoid isoflavone 
supplementation due to concerns these may interfere with SERMS such as 
tamoxifen.601,651 However, all these concerns are theoretical in nature. 
11.4 Linum usitatissimum L.(Linseed/Flaxseed, Family: Linaceae) 
 
Lignans are nonsteroidal polyphenolic substances that have been shown to bind to 
oestrogen receptors and exert partial agonist or antagonist action depending on the 
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target tissue.683,684  They influence hepatic oestrogen metabolism and increase the 
synthesis of SHBG, involved in the binding and availability of sex steroids.683 
 
Data from a cross-over study685 with 25 hypercholesterolaemic menopausal women  
indicate that after 2 months of treatment, 40 g of crushed linseed was as effective as 
0.625 mg of conjugated oestrogens in relieving mild menopausal symptoms measured 
on the KI, and in lowering serum levels of glucose and insulin, but produced no 
significant change in lipid profile.  In another study, linseed supplementation (40 g/d) for 3 
months was shown to improve lipid profile in postmenopausal women compared with a 
wheat-based regimen.686  Elsewhere it was found to favourably but not significantly affect 
blood cholesterol, compared to wheat germ, after 12 months.687 
11. 5 Trifolium pratense  L. (Red clover, Family: Fabaceae [subfamily: 
Papilionaceae])  
 
Red clover extracts are also quite popular for the treatment of menopausal symptoms,688 
and have received attention for their phytoestrogen content. A preformulated extract of 
red clover was found to contain the coumestan, coumestrol; isoflavones, daidzein, 
genistein, and their methylated precursors, formononetin, biochanin A; as well as 
flavonoids including naringenin.    Daidzein, genistein, formononetin, biochanin A, and 
naringenin were oestrogenic in the alkaline phosphatase assay, and all of these, except 
formononetin, bound to one or both ERs. 689  In addition to SERM-activity of the 
phytoestrogen components, biochemical analysis shows they act as selective oestrogen 
enzyme modulators (SEEMs), have antioxidant activity and interact with transcription 
factors such as NF-kappa-β.690 
 
11.5.1 Clinical trials of Red clover in hot flushes 
 
Several RCTs have been conducted on Promensil®, an extract of red clover leaf and 
flower standardised for isoflavone content, administered in a 500mg tablet, containing 
40mg per tablet of total isoflavones.  However, results have largely been disappointing, 
with only one showing superiority over placebo to date.  In a 12 week RCT with 30 
symptomatic women aged 49-65, (26 completed), Van der Weijer and Barentsen691 
found red clover extract, Promensil® (80mg/day), to be superior to placebo for alleviating 
hot flushes, p = 0.015, although no significant effect was observed for overall 
menopausal symptoms rated on the Greene Climacteric scale. In a study by Baber and 
colleagues,692  no significant difference was observed in flushing scores or Greene 
Climacteric scale scores (p = 0.158),  in a cross-over trial with Promensil® 40mg/day and 
placebo for 3 months each. Fifty-one women aged 45-64 with a minimum of 3 flushes per 
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day were recruited; 43 completed both arms.   Lack of superiority was similarly found in 
another 12 week RCT that randomised 37 women with 3+ hot flushes per day to either 
40mg or 160 mg/day Promensil®, or placebo, although flushing frequency decreased in 
all arms over the 12-week period.75  No between-group differences were observed in 
these studies in vaginal cytology, endometrial thickness as measured by 
ultrasonography, or serum hormone levels.  While these studies may have been subject 
to lack of power due to the low numbers recruited, or lack of adequate symptom severity 
at baseline, a larger RCT by  Tice and co-workers693  similarly failed to support the 
superiority of  Promensil® (82 mg total isoflavones/day) or of Rimostil® (57 mg 
isoflavones/day) over placebo.  This RCT recruited 252 participants aged 45 to 60 years, 
with at least 35 hot flushes per week and followed them up for 12 weeks.  
 
11.5.2 Other potential effects of Red clover extracts 
 
Some evidence supports the role of red clover isoflavones in reducing bone loss induced 
by ovariectomy in rats, probably by reducing bone turnover via inhibition of bone 
resorption.694  In an uncontrolled study involving  46 postmenopausal women, the BMD 
of the proximal radius and ulna rose significantly over 6 months with two doses of 
isoflavones extracted from red clover (Rimostil®), namely by 4.1% over 6 months with 57 
mg/day (p = 0.002) and by 3.0% with 85.5 mg/day (p = 0.023) of isoflavones).695  The 
effect was not dose-related.  In another RCT of 205 women aged 49-65, all women lost 
BMD, but the group assigned to red clover-derived isoflavone supplement (providing a 
daily dose of 26 mg biochanin A, 16 mg formononetin, 1 mg genistein, and 0.5 mg 
daidzein for 1 year) lost significantly less.696   
A significant increase in HDL cholesterol  has been observed with administration of red 
clover isoflavone 40 mg/day (Promensil®) over 3 months,75 and Rimostil® at 28.5 mg, 57 
mg, and 85.5 mg over a 6-month period (15.7-28.6%),695 although the magnitude of the 
response was independent of the dose used.  The latter uncontrolled study also 
demonstrated a significant fall in serum apolipoprotein B (by 11.5-17.0%) after 6 months 
of treatment.695  Also of relevance to atherosclerosis risk is the evidence from one study 
of improved systemic arterial compliance and elasticity with red clover supplementation 
in postmenopausal women.697 
Concerns have been raised regarding the safety of use of red clover isoflavone 
supplements in patients with breast or endometrial cancer698 based on data suggesting a 
weak oestrogenic action in the ovariectomised rat model.699  However, a recent three-
year RCT of a once-daily standardised 40 mg red clover isoflavone dietary supplement 
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(Promensil®, Novogen) in 401 women aged 35-70 years with a family history of breast 
cancer reported no adverse effect on breast density, skeletal strength or cardiovascular 
status.700  No significant differences in endometrial thickness were detected between 
those taking red clover isoflavones and placebo, consistent with findings from a rodent 
model.701  
11.6 Cimicifuga racemosa Nutt. (Black cohosh, Family: Ranunculaceae) 
 
More evidence from scientific studies exists to support the efficacy of Cimicifuga 
racemosa root and rhizome in the treatment of menopausal symptoms than for any other 
herbal intervention used in Western phytotherapy practice.702-718 Many studies have been 
conducted on an isopropanolic extract of the rhizome, Remifemin®.  Studies on the 
combination of Hypericum perforatum and C. racemosa are included in the section on St 
John’s wort below.  
 
11.6.1 Chemical constituents 
 
Chemical constituents of the roots and rhizomes of black cohosh include cycloartenol-
type triterpenoids, (such as actein, 23-epi-27-deoxyactein and cimicifugoside); cinnamic 
acid derivatives (ferulic acid, isoferulic acid, and piscidic and fukiic acid esters).719 There 
is some controversy over the presence of the isoflavone, formononetin, previously 
believed to be a constituent of black cohosh, as this has not consistently been detected 
in methanolic or aqueous methanolic extracts of the root/rhizome, and is unlikely to be 
present.720,721  
 
11.6.2 Mechanism of action of C. racemosa 
 
Previously regarded as a phytoestrogenic herb, more recent research has proposed an  
organ-dependent ER agonist-antagonist mode of action for black cohosh.722,723  Its role 
as a SERM is supported by evidence from in vitro studies, in vivo studies of animals, and 
human epidemiologic and dietary intervention studies.715,722,724  For example, the 
ethanolic C. racemosa extract BNO 1055 was found in a rodent model to act on the 
hypothalamo-pituitary unit and in the bone, but not in the uterus.715,724  Findings from 
clinical studies also suggest favourable effects in the brain/hypothalamus, bone718 and 
vagina,718 in the absence of  uterotrophic effects.723,725  Lack of change in vaginal 
cytology measures was reported following 24-weeks administration of two different doses 
(39 mg and 127.3 mg) of C. racemosa rhizome,708 and lack of endometrial proliferation 
was evident after 12 months administration of extract CR BNO 1055 to 375 
postmenopausal women.726  The Herbal Alternatives for Menopause (HALT) study found 
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that 12 months administration of black cohosh, used alone (160 mg/d 2.5% triterpene 
glycosides, 70% ethanol extract) or as part of a multibotanical product (200 mg/day), had 
no effects on vaginal epithelium or the endometrium.725] 
 
A central activity has also been proposed for C. racemosa based on evidence from in 
vitro and in vivo studies suggesting dopaminergic activity, possibly D2 receptor 
agonism,727,728 and serotonergic activity.729 Analysis of ligand binding data from  in vivo 
rodent studies suggested that a black cohosh methanol extract acted as a partial agonist 
at the serotonergic 5-HT(7) receptor.729   The reductions in hot flushes induced by 
administration of black cohosh may, therefore, not be due to oestrogenic properties.  It 
has thus been suggested that black cohosh should not be regarded as a phytoestrogenic 
herb, nor a phyto-SERM.730  
  
11.6.3 Research on black cohosh for menopausal symptoms/hot flushes 
 
In RCTs examining its effects on hot flushes/night sweats and other menopausal 
symptoms such as irritability and sleep disturbances, extracts of black cohosh have 
shown superiority to placebo,706,723,731,732 although one study found it only to be 
significantly superior for symptoms of moderate severity.706  A RCT on 304 women 
administered isopropanolic extract of black cohosh rootstock 5 mg/day (equivalent to of 
Cimicifuga racemosa 40 mg daily) or placebo for 12 weeks and found a significant effect 
over placebo on Menopause Rating Scale (MRS) scores, p < 0.001, and the hot flush, p 
= .007 subscore, with a  clinically-relevant effect size (0.03 to 0.05 MRS units).731  
Because this study used a validated questionnaire to measure hot flushes, rather than a 
daily diary record, the actual frequency and severity of hot flushes and night sweats is 
unknown.  Equivalence to conjugated oestrogens (0.6 mg/day) was also established with 
12 weeks administration of extract CR BNO1055 (Klimadynon®/Menofem 40 mg /day) for 
symptoms rated on the Menopause Rating Scale (MRS); both groups showed an 
improvement from baseline, p = 0.05.723  C. racemosa (40 mg, 150 mg dried herb 
equivalent) was also equivalent to low-dose transdermal oestriol  (25µg per week) over 3 
months in 64 women for hot flushes, as well as anxiety and depression.733  Both 
interventions significantly reduced the number of hot flushes per day (p < 0.001) and 
vasomotor symptoms (p < 0.001), from the first month of treatment, and anxiety (p < 
0.001) and depression (p < 0.001) at the end of 3 months.  However, no significant effect 
over placebo was found for hot flushes in the HALT Study which assigned 351 women to 
one of five groups to compare 4 different interventions, including black cohosh 160 mg 
daily, with placebo for 12 months.734  
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11.6.4 C. racemosa and Kupperman Index 
On KI scores, black cohosh (extract equivalent to 160 mg/day) produced an 
improvement similar to three different HT interventions (oestriol 1mg/day; CE 1.25 
mg/day; oestrogen-progestin 2mg + 1 mg/day respectively).735  At all intervals measured, 
statistically significant reductions in symptoms were observed on the modified KI for all 
treatment groups, p < 0.01. However, this is a very low dose of a weak oestrogen that 
has questionable clinical effects.  Doses of 39 mg/day and 127.9 mg/day resulted in a 
similar decrease in KI scores over 6 months (responder rate 70% and 72%, respectively) 
in both perimenopausal and postmenopausal women.708 A further study in 244 Chinese 
women, found C. racemosa 40 mg crude drug/day to be equivalent to orally-administered 
tibolone 2.5mg/day for 3 months in reducing symptoms (including moderate to severe 
symptoms) measured on the KI, p (non-inferiority) = 0.002).704  Large-scale observational 
studies have also shown favourable effects of black cohosh extracts on hot flushes717,726 
and KI scores.717   However, the ethanolic black cohosh root extract, Cr 99 (daily intake 
6.5 mg dried rhizome extract, corresponding to an average of 42 mg crude drug), 
showed no superiority to placebo in the intention-to-treat population as a whole.  By 
contrast, in the subgroup of participants with a KI of 20 or more, significant superiority 
was demonstrated (p < 0.018). The weekly weighted flushing scores (p < 0.052) and the 
Menopause Rating Scale (p < 0.009) showed similar results for the women with 
symptoms of at least moderate severity.706  
In premenopausal breast cancer survivors, tamoxifen induced hot flushes were 
significantly reduced in number and severity with co-administration of black cohosh, 
compared with standard care alone.736 Almost half of the patients of the intervention 
group were free of hot flushes, while severe hot flushes were reported by 24.4% of 
patients of intervention group and 73.9% of the usual-care group (p < 0.01).  However, in 
another placebo-controlled trial with C. racemosa in breast cancer survivors, no between 
group differences were observed for mean number of hot flushes, flush severity, sleep, 
irritability , depression headaches or palpitations.707   
 
11.6.5 C. racemosa and Breast cancer risk 
 
While oestrogenic properties have not been established with certainty for black cohosh, 
herbs exerting oestrogen-like effects elicit concerns regarding their effects in women with 
a history of, or at risk of developing, oestrogen-dependent cancers such as breast 
cancer.  The majority of the evidence for the effects of black cohosh on breast cancer 
cells has come from in vitro research, principally using the ER+ breast cancer cell line, 
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MCF-7, but occasionally T-47D.  Only one study found black cohosh extract to stimulate 
breast cancer cell lines,737 while many others have shown either lack of stimulation738 or 
inhibition of breast cancer cell growth for C. racemosa.578,738-742 In some instances, it was 
found to kill both the ER+ MCF-7 as well as ER- MDA-MB231 cells by induction of 
apoptosis.741,743 The proliferation-inhibiting effects of tamoxifen were enhanced by black 
cohosh.739  In addition, some in vitro studies have failed to support an oestrogenic activity 
for C. racemosa,709,738 while others have demonstrated anti-oestrogenic properties.578,742  
However the relevance of in vitro studies to oral dosing in humans is questionable in this 
context, since the putative major constituents of black cohosh, the triterpene glycosides 
(saponins) need to be metabolised to the active form by bacteria in the gastrointestinal tract.   
 
In vivo research on ovariectomised rats found a lack of stimulating effects on oestrogen-
dependent mammary gland for a propanolic extract of C. racemosa.744  Elsewhere, no 
differences were detected in the incidence or onset of mammary tumors in black cohosh-
treated transgenic mice (fed an adjusted dose to correlate to a human dose of 40 mg/d) 
versus control females.745  This suggests no increased risk of breast cancer in healthy 
women with black cohosh. In contrast, black cohosh significantly increased the incidence of 
lung metastases in tumour-bearing transgenic mice compared with mice fed the isoflavone-
free control diet.745 However, the use of transgenic mice as model systems for assessing the 
impact of treatments on cancer risk is highly controversial.746 Limitations include the variable 
mouse strains used, which can greatly influence the latency and even the type of the tumor 
caused by the transgenic oncoprotein, and our rudimentary understanding of the pathways 
that control normal mammary physiology in the mouse and human.747 
 
A prospective, open, uncontrolled drug safety study found that isopropanolic extract of black 
cohosh (Remifemin® 40 mg/day) did not increase mammographic breast density or breast 
cell proliferation after 6 months of treatment in 65 postmenopausal women.748 A recent 
review of the literature supported the safety of black cohosh in breast cancer patients without 
risk of liver disease.749 Nonetheless, many of the human studies on black cohosh have been 
of relatively short duration, while treatment for menopause is rarely limited to 3 months.  As 
such concerns have been expressed regarding the longer term safety of black cohosh with 
respect to hormone-dependent tissues such as the breast.  Reassurance regarding safety 
with long term use still needs to be established in trials of at least 12 months duration.750  
 
Beneficial effects on bone metabolism have been demonstrated with C. racemosa 
extracts.718,724,751  An analyses of the black cohosh preparation CR BNO 1055 on bone 
turnover markers in postmenopausal women indicated a stimulation of osteoblast activity 
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and benefits on bone remodeling.718  Treatment of the ovariectomised rats over a period 
of 3 months with the same extract showed osteoprotective effects; it significantly reduced 
the loss of BMD in tibia and exerted oestrogenic effects particularly in osteoblasts.724  
Findings of a further study of the isopropanolic extract of black cohosh on human 
osteoblasts, supported the potential of black cohosh for positive skeletal effects.751  
 
11.6.6 Hepatotoxicity  
  
Several countries, including Australia, UK, US and Canada, currently require black 
cohosh products to carry a warning label about the (rare) potential for liver damage.  
These fears were generated by published reports of liver injury that was attributed to 
consumption of black cohosh products. 752-755  Although many of these were found to be 
of dubious reliability, they prompted further investigation by authorities both in the US 
and Europe. The Dietary Supplement Information Expert Committee of the US 
Pharmacopeia’s Council of Experts analysed thirty reports on the use of black cohosh 
products concerning liver damage. All the reports of liver damage were assigned 
‘possible’ causality, and none was ‘probable’ or ‘certain’ causality. The clinical 
pharmacokinetic and animal toxicological information did not reveal unfavorable 
information about black cohosh.756  The European Medicines Agency Committee on 
Herbal Medicinal Products (HMPC) analysed 42 cases of hepatotoxicity attributed to 
black cohosh collected from European National Competent Authorities.757  Two were 
rated as ‘probable’ using the Roussel UCLAF Causality Assessment Method (RUCAM), 
despite the failure to identify black cohosh in the products used.  Current evidence 
concerning liver toxicity is inconclusive749 as a direct association between hepatotoxicity 
and the ingestion of Cimicifuga has not been demonstrated.758 
11.7 Other phytoestrogenic herbs 
 
11.7.1 Humulus lupulus L. (Hops, Family Cannabinaceae) 
 
The strobiles of hops contain the potent phytoestrogen 8-prenylnaringenin (8-PN).759  
The ability of 8-PN to exert systemic endocrine effects in healthy postmenopausal 
women was demonstrated in a dose-escalation RCT, using single oral doses of 50, 250 
or 750 mg 8-PN. 760  Decreases in LH serum concentrations were found after the highest 
dose.  Methanol extracts of hops showed significant competitive binding to ER alpha and 
ER beta, and exhibited oestrogenic activity with cultured Ishikawa (endometrial) cells.709 
In rodent models, H. lupulus extracts were not found to affect uterine weight gain, but 8-PN 
at equivalent doses to those used in human studies did show a dose-related oestrogenic 
effect on the uterus, raising concerns about a potential deleterious effect in women.701 
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Convincing evidence from robust clinical trials is lacking to support the efficacy of hops 
extracts for reduction of hot flushes.  A RCT was conducted on a standardised (on 8-PN) 
hop extract administered to postmenopausal women at doses corresponding to 100 μg 8-PN 
and 250 μg 8-PN.761  At the lower dose, a significant reduction in the incidence of hot flushes 
and other menopausal symptoms (sweating, insomnia, heart palpitation, irritability) 
measured on the modified KI was found, compared to placebo, after 6 weeks, p = 0.023, but 
not after 12 weeks, p =0.086.  At the higher dose, hop extract was superior to placebo for hot 
flushes at 6 weeks, p < 0.01.  Hops was one component of the morning/evening formula 
found to reduce vasomotor, anxiety, and depression scores on the Greene Climacteric Scale 
(GCS) by 50%, 56%, and 32%, respectively at the end of 8 weeks.762 However, the lack of a 
control group in this study is a serious limitation. The efficacy of hop extracts in reducing 
menopausal hot flushes has been reported by Goetz based on treatment of patients treated 
using different types of non-standardised hops preparations.763  
The effects of a topical gel containing hyaluronic acid, liposomes, vitamin E and hop extract 
was assessed on vaginal dryness and associated atrophic vaginitis (itching, burning, 
dyspareunia, vaginal inflammation/oedema and rash in 100 postmenopausal women in a 
multicentre, open, non-controlled design.764 Following application of 2.5 g of gel/day for 1 
week, reduced to two applications/week for 11 weeks, symptoms were significantly reduced, 
as assessed by a 4-point scale and presence of vaginal abrasions and disepithelialisation. 
An overall judgment on the acceptability of the treatment was made by the subjects, as well 
as an overall judgment on the efficacy and safety of the device by the investigator. 
11.7.2 Trigonella foenum-graecum L. (Fenugreek, Family: Fabaceae) 
 
Fenugreek has been the subject of one comparator trial with HRT that assessed the 
effects on vasomotor symptoms in 50 postmenopausal women.765  Women were 
assigned to receive either 0.625 mg conjugated oestrogen with 10 mg medroxy 
progesterone acetate or 6 g fenugreek seed powder daily for 8 weeks. Significant 
reductions were observed in both groups after four and eight weeks of treatment.  
However, the HRT significantly outperformed the fenugreek.  
  
11.7.3 Pueraria montana var. lobata (formerly P. lobata) Lour. (Kudzu, Family: 
Fabaceae)  
 
Kudzu is a traditional Chinese herbal remedy for menopausal symptoms, as well as an 
ingredient in preparations for conditions such as osteoporosis, CHD and some hormone-
dependent cancers.766  Many different species of kudzu are used in Asia. In China, P. 
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montana (also known as P. thunbergiana) and P. thomsonii are used interchangeably. P. 
mirifica and P. tuberosa are also used frequently.767  Kudzu root extract contains 
isoflavonoid phytoestrogen components such as daidzin, daidzein and genistein768,769 
that may be responsible for its action.  Although not widely used in Australia by 
practitioners of Western phytotherapy, interest is growing in kudzu root for treating 
menopausal symptoms.767    
 
No data from RCTs on vasomotor symptoms could be found for kudzu in the literature. 
From a non-controlled trial of 6 months duration, data were obtained for two doses of 
Pueraria mirifica (50 mg/day and 100 mg/day) for 37 pre- and postmenopausal 
women.770 Significant reductions in scores, of a similar magnitude, on the modified 
Greene climacteric scale were seen for both groups, (decreasing from 35.6 to 26.6, 17.2 
and 15.1 with 50 mg/day, while 100 mg/day resulted in declines from 32.6 to 21.0, 14.8 
and 13.6 at 1-, 3- and 6-months respectively). 
 
A pilot study of isoflavones from kudzu and red clover, along with other nutrients, on 
menopausal symptoms was conducted over 12 weeks on 25 menopausal women 
suffering from severe hot flushes and night sweats. 771  A 46% decrease in hot flushes 
was observed, with an improvement in subjectively-rated quality of life, p < 0.001.  
Modest improvement was observed in cardiovascular risk markers, the ratio of total 
cholesterol to HDL-cholesterol, and homocysteine.  A statistically significant 
improvement was found for  a proposed marker of breast cancer risk, the ratio of 2-
hydroxyestrone to 16 alpha-hydroxyestrone, p < 0.001.  
 
A decocted root extract of Pueraria lobata, equivalent to 100 mg isoflavone, was 
compared with HT and no treatment in 127 postmenopausal women (n = 45, n = 43 and 
n = 39 respectively) for a 3 month period.766  Kudzu had no significant effect on lipid 
profile, FSH or LH, but did improve flexible thinking and attention span compared with no 
treatment, p < 0.05.  
 
A herbal supplement, Avlimil® containing eleven herbal components, including kudzu 
was observed to stimulate MCF-7 tumor growth in a dose-dependent manner, calling into 
question its safety for women with oestrogen-dependent breast cancer.772 However, no 
increase in uterine weight was observed in the animal model.  Similarly, in healthy 
postmenopausal women, no endometrial proliferation or hyperplasia was reported after 
24 weeks of Pueraria mirifica at doses of 20, 30, and 50 mg/d.773  Beneficial effects on 
bone loss are suggested from studies in both human and rodent models. 773  An 
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oestrogen-like effect on bone turnover rate was demonstrated with P. mirifica for a 24-
week period.773  In the rat model, significant dose-dependent prevention of bone loss 
with P. mirifica treatment for 90 days was also observed.774  
11.8 Saponin-containing herbs used in menopause  
 
Other herbs that may exert oestrogenic effects on oral administration include those 
containing steroidal saponins such as wild yam (Dioscorea villosa L. Family: 
Dioscoreaceae), false unicorn root (Helonias luteum (Ker-Gawl)/Chamelirium luteum L. 
(Gray.) Family: Liliaceae), and tribulus (Tribulus terrestris, Family: Zygophyllaceae), all of 
which are reputed to exert benefits in the treatment of menopausal symptoms.  It has been 
proposed that these herbs may exert their effects by binding with unoccupied receptors in 
the hypothalamus,775 notably ERβ.682  Thus, menopausal symptoms thought to be initiated 
via the hypothalamus may be reduced by this selective binding of the plant steroids.  
However, scant evidence exists from RCTs to support the roles of these herbs in this 
context. 
 
11.8.1 Tribulus terrestris L. (Family: Zygophyllaceae) 
 
In an open study, 50 menopausal women (both natural and surgically-induced) were first 
given placebo followed by a standardised extract of Tribulus terrestris leaf (dosage range 
of 500–750 mg/day), containing not less than 45% steroidal saponins. Predominant 
symptoms included hot flushes, sweating, insomnia and depression.  Placebo treatment 
did not result in a favourable result for any symptom in any patient.  After active 
treatment, however, 98% reported symptom improvement.  No significant changes were 
noted in FSH, LH, prolactin, oestradiol, progesterone or testosterone.776  This was an in-
house report not published in the peer-reviewed literature.   
 
11.8.2 Dioscorea villosa L . (Wild yam, Family: Dioscoreaceae) 
 
Wild yam root contains steroidal saponins, with diosgenin as the aglycone.777 An 
oestrogenic action of diosgenin, but no progestogenic action, has been reported 
following subcutaneous administration in the ovariectomised mouse.36  An extract of a 
related species of yam used in TCM, Dioscorea alata was examined for oestrogenic 
activity, and found to contain compounds that activate human ER  and ERβ, supporting 
a beneficial effect for menopausal women.778 D. alata administration also reversed 
ovariectomy-induced anxiety, despair behaviour and changes in neuroimmunological 
function in the rat cortex.779 In a further study on Dioscorea alata, 24 apparently healthy 
postmenopausal women replaced two-thirds of their staple food with 390 g of yam in 2 of 
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3 meals per day for 30 days.780  Following yam ingestion, there were significant 
increases in serum concentrations of oestrone (26%, p = 0.003), SHBG (9.5%, p = 
0.019), and a near significant increase in oestradiol (27%, p = 0.072).  Urinary 
concentrations of the genotoxic metabolite of oestrogen, 6alpha-hydroxyestrone, 
decreased significantly by 37%, p < 0.001. Plasma cholesterol concentration decreased 
significantly by 5.9%, p = 0.012. Lag time of low-density lipoprotein oxidation prolonged 
significantly by 5.8%, p = 0.02, and urinary isoprostane levels decreased significantly by 
42%, p < 0.001.  It was surmised that the beneficial effects on hormone status, 
antioxidants and lipids may potentially reduce the risk of breast cancer and 
cardiovascular diseases in postmenopausal women. 
 
No evidence from RCTs on oral administration of Dioscorea species in menopause could 
be found in the literature.  A negative RCT on topical administration of wild yam cream 
for three months in 23 healthy women found no difference between groups for hot 
flushes, mood, breast tenderness, libido or energy.781  This finding is unremarkable, and 
the study was designed to refute a common misconception regarding wild yam as a 
source of progesterone.  While a species of Mexican wild yam, Dioscorea macrostachya  
was employed as a rich source of the plant sterol, diosgenin, for the first large-scale 
production of progesterone, wild yams do not contain progesterone; nor have they been 
shown to promote the production of progesterone, or be converted to progesterone in the 
body.782 However, diosgenin, can be converted in the laboratory to steroidal compounds 
including progesterone.14   
 
11.8.3 Panax ginseng C.A. Mey. (Korean ginseng, Family: Araliaceae) 
 
Panax ginseng is a saponin-containing adaptogenic herb with some evidence of 
oestrogenic activity.783-785 Ginsenoside Rg1 has recently been shown to exert oestrogen-
like actions via ligand-independent activation of ERα pathway,784,785 failing to displace 
specific binding of [(3)H]17beta-estradiol from oestrogen receptors in MCF-7 whole-cell 
ligand binding assays.785  An in vitro study found an alcoholic extract of American 
ginseng root (Panax quinquefolius L. Family: Araliaceae) to significantly induce the 
growth of MCF-7 cells by 27-fold over that of untreated control cells, raising concerns 
over its use in humans, pending further study.738 The  glucocorticoid-like effects of 
ginseng in vivo may be explained by the affinity for progestin, mineralocorticoid and 
glucocorticoid receptors demonstrated by saponins from Panax root extracts in vitro.786  
Positive effects on well-being and psychological symptoms of menopause have been 
shown, and the physiological correlates examined in two studies.  Over a 16-week 
period, administration of Panax ginseng (Ginsana®  containing 100 mg of the 
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standardised extract G115, Pharmaton, SA, Lugano, Switzerland) resulted in improved 
quality-of-life measures, including well-being and depression, in a multicentre RCT with 
384 post-menopausal women, p < 0.05.787  However, it was concluded that its beneficial 
effects were most likely not mediated by hormone replacement-like effects, as 
physiological parameters such as FSH and oestradiol levels, endometrial thickness, 
maturity index and vaginal pH were unaffected by the treatment.  
 
In the form of red ginseng, in which Panax ginseng root has been steamed before drying, 
oral administration of 6 g daily for 30 days was found to improve psychological scores on 
the Cornell Medical Index psychosomatic state and fatigability scales, p < 0.001, and 
state anxiety measured on the State-Trait Anxiety Inventory (STAI-A), p < 0.001, in post-
menopausal women.788  The authors concluded that the improvements appeared to be at 
least partly attributable to the effects of red ginseng on stress-related hormones, 
exhibited by a decrease in cortisol, p < 0.05, and the cortisol:DHEAS ratio, p < 0.05. 
 
11.8.4  Glycyrrhiza glabra L. (Licorice Family: Fabaceae) 
 
As an adrenal tonic, licorice has a potential role in the context of menopause.  In 
addition, it has been found to possess oestrogenic properties. A proprietary formula was 
found to owe its oestrogenic property to glycyrrhiza, aletris, helonias and asclepias, but 
principally to the licorice.38 In vitro and in vivo two natural compounds derived from 
licorice root demonstrated oestrogen-like activity on vascular tissues: glabrene, an 
isoflavene, behaved as a partial agonist/antagonist of oestradiol while glabridin, the 
major isoflavan, demonstrated only oestrogenic activity.789 It may also have the potential 
to modulate bone disorders in post-menopausal women.790  However, evidence for all the 
above from RCTs is lacking.  
11.9 Clinical studies on other phytotherapeutic interventions 
 
11.9.1  Angelica sinensis (Oliv.) Diels (Dong quai, Family: Apiaceae)  
 
The root of Angelica sinensis has been introduced into Western herbal medicine from 
traditional Chinese medicine, in which it is used for tonifying the blood and treating 
female menstrual disorders (dysmenorrhoea, amenorrhea, irregular menstruation) as 
well as menopausal symptoms.791 Coumarins are among the 70+ compounds isolated and 
identified from dong quai, although the principal biologically active components are thought  
to be the essential oil, Z-ligustilide, other phthalides and ferulic acid.792  Studies of its 
oestrogenic activity reported only weak ER binding709 and no oestrogen-like responses in 
endometrial thickness or in vaginal maturation when dong quai is used alone.74 
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Some RCTs examining phytotherapeutic formulations including dong quai on vasomotor 
symptoms have shown positive results.793,794  However, an RCT evaluating the effects of 
dong quai as a simple (4.5g root/day standardised to 0.5mg/kg ferulic acid) found no 
significant differences between dong quai and placebo on symptoms evaluated by the KI 
and flushing diary after 24 weeks in 71 postmenopausal women.74  
 
Dong quai is one  component of PhytoFem®, which was shown to favourably influence 
symptoms of hot flushes and sleep disturbances in pre- and postmenopausal women.793  
(This study is further discussed in the section on Vitex agnus-castus.)  However, other 
RCTs reported in the scientific literature have produced inconsistent results.   
 
The herbal extract preparation, Climex®, containing Angelica sinensis 75 mg/day plus  
Matricaria chamomilla L. (flowers) 30 mg/day (German chamomile, Family: Asteraceae) 
was investigated in a placebo-controlled RCT for 12 weeks on 55 postmenopausal 
women complaining of hot flushes.794  The herbal combination was found to be superior 
to the placebo in reducing the number and intensity of hot flushes (p < 0.001). A 
significant response was noted as early as the first month of treatment in hot flushes as 
well as night sweats.  There was also a marked alleviation of sleep disturbances and 
fatigue. 
 
A TCM formulation, Dang Gui Buxue Tang, a 1:5 combination of Angelica sinensis with 
Astragalus membranaces root (Family: Fabaceae), 3 g per day of a spray-dried aqueous 
extract, was trialled for 6-months in a RCT with 100 symptomatic Hong Kong Chinese 
women.  No significant difference was observed between the herbal combination and 
placebo in the treatment of vasomotor symptoms in women. The frequency of mild, 
moderate and severe hot flushes decreased in both groups, but Dang Gui Buxue Tang 
was statistically superior to placebo only in the treatment of mild hot flushes.795  
11.10 The Phytotherapeutic Approach 
 
Because natural medicine takes the holistic approach of treating the person rather than 
the ‘dis-ease’, a wide range of other herbal actions may also be appropriate to the 
treatment of women with menopause-related complaints, since these vary according to 
the individual and the phase of the transition.  During the perimenopause, for instance, a 
woman may seek treatment due to changes to the menstrual cycle regularity, duration or 
flow, exacerbation of PMS-like symptoms and/or the psychological symptoms that tend 
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to be more prevalent during this phase.  Herbs most commonly indicated for relief of 
menopausal symptoms or their underlying cause are listed in Table 11.2 with some 
examples of herbs possessing these actions.  Available evidence from RCTs for these 
herbs is outlined below.  Rather than indefinitely ‘replacing’ hormones in decline, the aim 
of phytotherapeutic treatment is to ensure a comfortable adaptation to the fluctuating 
hormone levels of the perimenopause and the lower levels in the postmenopause.775  
TABLE 11.2   OTHER ACTIONS AND PHYTOMEDICINES RELEVANT TO THE TREATMENT OF 
MENOPAUSE-RELATED COMPLAINTS 
Herbal action Examples of herbs 
Latin binomial (Common name) 
Botanical family 
adaptogenic Eleutherococcus senticosus (Rupr. & Maxim.)    
                                     Maxim.(Siberian ginseng)777 
Panax ginseng  C.A. Mey..(Korean ginseng)796 
Astragalus membranaceus (Bunge)(astragalus)777 
Withania somnifera L.(Dunal.) (ashwagandha)797 
Asparagus racemosa Willd.(shativari)798 
Araliaceae 
 
Araliaceae 
Fabaceae 
Solanaceae  
Asparagaceae 
antihyperhidrotic/ 
reduces (night) 
sweats 
Salvia officinalis L. (sage)777 
Astragalus membranaceus (Bunge.)799 
Zizyphus spinosa (Bunge.) (sour Chinese date)797 
Lamiaceae 
Fabaceae 
Rhamnaceae   
anxiolytic Piper methysticum (Forster), (kava)796 
Hypericum perforatum L. (St John’s wort)800-802 
Rheum rhaponticum L.. (false rhubarb)803,804 
Valeriana officinalis  L. (valerian)777 
Passiflora incarnata L. (passion flower)777 
Zizyphus spinosa (Bunge.) (sour Chinese date)805  
Piperaceae 
Clusiaceae/Guttiferae 
Polygonaceae 
Valerianaceae  
Passifloraceae 
Rhamnaceae   
aphrodisiac Asparagus racemosa Willd. (shativari)798 
Tribulus terrestris L.  806 
Asparagaceae 
Zygophyllaceae 
astringent/ 
antihaemorrhagic 
Alchemilla vulgaris L.  (lady’s mantle)807 
Lamium alba L. (white deadnettle)807 
Trillium erectum L. (beth root)807 
Achillea millefolium L. (yarrow)777 
Viburnum prunifolium L. (black haw)807 
Rosaceae 
Lamiaceae 
Liliaceae 
Asteraceae 
Caprifoliaceae 
hepatorestorative 
&/or oestrogen 
clearance enhancing 
Silybum marianum L.(Gaertn) (St Mary’s thistle)796 
Cynara scolamus L. globe artichoke)796 
Rosmarinus officinalis L. (rosemary)777 
Curcuma longa L. (turmeric)796 
Asteraceae 
Asteraceae 
Lamiaceae 
Zingiberaceae 
hypnotic Humulus lupulus L. (hops)777 Cannabinaceae 
hypnotic and 
sedative 
Piper methysticum (Forster), (kava)796 
Valeriana officinalis  L. (valerian)777 
Passiflora incarnata L. (passion flower)777 
Zizyphus spinosa (Bunge.) (sour Chinese date)797 
Piperaceae 
Valerianaceae 
Passifloraceae 
Rhamnaceae   
nervine tonic Leonurus cardiaca L. (motherwort)777 
Hypericum perforatum L. (St John’s wort)796 
Turnera diffusa Urb.(damiana)777 
Lamiaceae 
Clusiaceae/Guttiferae 
Turneraceae 
nootropic Ginkgo biloba L.(ginkgo)796 Ginkgoaceae 
omega-6 fatty acid 
deficiency corrector 
Oenothera biennis L. (evening primrose) Onagraceae 
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1.11 Antihyperhidrotic herbs 
 
For symptomatic relief of sweating, antihyperhydrotic herbs are commonly incorporated 
into formulations in current Western phytotherapy practice.  These include Salvia 
officinalis (sage) and the Chinese herbs, Astragalus membranaceus root and Zizyphus 
spinosa seed.  Zizyphus is traditionally used in TCM for insomnia due to nervous 
exhaustion, excessive sweating and night sweats, especially when accompanied by 
anxiety, irritability and/or palpitations.  A Chinese herbal formula mainly containing 
Zizyphus has been shown in clinical trials to be effective for anxiety and sleep quality.808   
 
The efficacy of a plant product based on extracts of the leaves of sage and alfalfa 
(Medicago sativa L. Family: Fabaceae [subfamily Faboideae]) was investigated in the 
treatment of hot flushes in an open trial of 12 weeks duration with 30 menopausal 
women.809   Hot flushes and night sweating completely resolved in 20 women, good 
improvement was observed in 4 women and a reduction in symptoms was reported in 
the other 6.  Basal levels of oestradiol, LH, FSH, prolactin and TSH were unchanged at 
the end of the 3 month period.  However, a slight antidopaminergic action was observed 
with a significant increase in prolactin  and TSH response to TRH.  A good safety profile 
was reported.809  Sage also reduced sweat production in patients with hyperhidrosis in a 
number of open studies,46 although these were not specifically in the context of 
menopause. 
11.12 Omega-6 Fatty acid-deficiency corrector 
 
Evening primrose oil has shown efficacy in relieving PMS-associated symptoms.810,811  
Its use for menopause-related symptoms may only be relevant where these are due to 
an exacerbation of PMS-like symptoms, as no support exists from RCTs for a beneficial 
effect in relieving hot flushes.  No significant effect over placebo was observed on hot 
flushes with 2,000 mg evening primrose oil plus 20 mg vitamin E twice daily for 24 
weeks,812 although the small sample size (56 recruits of whom 35 completed) and the 
mild symptoms at baseline (3 or more flushing episodes per day) are severe limitations 
of this study.  A significant improvement was noted in the number of night time flushes in 
women allocated to evening primrose oil plus vitamin E, p  < 0.05.  However, for the 
placebo group, the reduction in both daytime, p < 0.001, and night-time flushes, p < 0.05, 
reached significance.  
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11.13 Anxiety and general well-being 
 
Several phytotherapeutic interventions have been examined for their effects on other 
menopausal symptoms such as the psychological symptoms.  Those with positive 
findings are included here. 
 
11.13.1   Piper methysticum Forster. (Kava, Family: Piperaceae) 
 
Several studies have supported the beneficial effects of kava root extracts in the 
treatment of menopause-related anxiety. 
 
An extract of Piper methysticum was found to favourably affect mood, particularly anxiety 
in perimenopausal women in a 3-month randomised prospective open study.813  Calcium 
plus kava at doses of 100 mg/and 200 mg/day were compared with calcium 
supplementation alone (control).  Anxiety measured on the STAI declined at 1 and 3 
months significantly more than in the control group, p < 0.001, while significant within-
group reductions were seen for depression at 3 months and climacteric scores at 1 and 3 
months, p < 0.003.  Symptoms rated on the Greene Climacteric scale declined 
significantly, p < 0.001 at 1 and 3 months. 
 
In a 12-week RCT with 40 women with predominantly anxiety and vegetative symptoms, 
Kavosporal® 150 mg twice daily (equivalent to 60 mg kavapyrones daily) resulted in 
significant reduction in symptoms measured on the KI scores, diaries and the Anxiety 
State Index, p < 0.001 from week 4 onwards.814  No reduction was found with placebo. 
 
In a subsequent RCT with 20 women with menopause-related symptoms, Kava WS 1490 
extract (3 x 100 mg/day) or a placebo was administered for a period of 8 weeks.815  
Overall anxiety measured on the Hamilton Anxiety scale (HAMA) significantly reduced in 
the kava group compared with the placebo group after only 1 week of treatment, p < 
0.001.  A beneficial effect on the neurovegetative and psychosomatic symptoms 
associated with menopause was suggested by improvements over the study period on 
depressive mood, p < 0.01, subjective well-being and symptoms as measured on the KI 
and Schneider climacteric scale, p < 0.01. 
 
The combined use of HT (with progestogens, and without (ET)) and kava extract was 
investigated for the treatment of menopausal anxiety with 6 months of treatment with HT 
plus kava/placebo.816  A significant reduction in HAMA score was observed in all four 
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groups of women at months 3 and 6, p <0.05, although the reduction was greater with 
kava extract, 55.5% for HT+ kava, and 53.3% for ET+ kava, than with HT only, 23% for 
HT and 25.8% for ET. 
 
Kava was one ingredient of the morning/evening menopause formula in the uncontrolled 
study previously described.  After the eighth week, the vasomotor, anxiety, and 
depression scores of GCS were reduced by 50%, 56%, and 32%, respectively762 
 
11.13.2 Rheum rhaponticum L. (False rhubarb; East Indian Rhubarb. Family: 
Polygonaceae) 
 
Heger and colleagues804 conducted a multicenter, prospective RCT to investigate the 
efficacy and safety of extract ERr 731 (identical to the finished product Phytoestrol N®)  
of the roots of R. rhaponticum in hot flushes, anxiety and the overall quality of life  in 
perimenopausal women.   The tested extract contained the stilbenoid compounds 
rhaponticin and desoxyrhaponticin and their aglycones, rhapontigenin and 
desoxyrhapontigenin.  The authors reported that the product, (one enteric-coated tablet 
(250 mg) containing 4 mg Rheum rhaponticum dry extract daily for 12 weeks), 
significantly decreased the number and severity of hot flushes, p < 0.0001, MRS II total 
score, p < 0.0001, and improved menopause-specific quality of life scores, p < 0.05,  in 
perimenopausal women compared with placebo.803,804  Anxiety (measured on the HAMA) 
scores also decreased significantly with ERr 731 (from 27.5+/-6.8 to 9.4+/-4.2 points) 
compared with placebo (from 25.1+/-6.0 to 21.6+/-8.6 points).803  The reduction in the 
severity of anxiety correlated well with the reduction in number and severity of hot 
flushes. They also suggested that, at least in the case of breast and uterine disease, the 
product does not have the same level of risk associated with HT.804 
11.14 Conclusion 
 
While a wide range of phytotherapeutic interventions is employed in the practice of 
Western phytotherapy for the relief of menopause-related symptoms, convincing 
evidence supporting this use from RCTs is still limited.  Most rigorous scientific research 
in this arena has focused on the phytoestrogenic options.  However, treatment of 
menopausal complaints is often required long-term, and concerns have arisen regarding 
long-term safety of the plant remedies believed to exert oestrogenic activity.  This 
highlights the need for rigorous scientific research on non-oestrogenic herbs commonly 
used in this context.   As discussed previously, CNS-acting agents in conventional 
pharmaceutical medicine have demonstrated efficacy for symptoms such as flushing, 
depression and anxiety.  In a similar fashion, CNS-acting phytomedicines with reputed 
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benefits in menopause could potentially exert benefits on the problematic vasomotor 
symptoms and psychological symptoms via the interaction between neurotransmitters 
and hormones.  The current study thus investigated two such herbs, namely Vitex agnus-
castus (Chaste tree) and Hypericum perforatum (St John’s wort).  
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Chapter Twelve 
  
 
 
Vitex agnus-castus  
(Chaste tree/berry) 
 
  
 
 
 
12.0  Introduction 
 
The origin of the current practice of administering Vitex agnus-castus in menopause-
related complaints is uncertain, but appears to be relatively recent.  This chapter reviews 
the evidence for this application of Vitex from pharmacological studies and clinical 
research, and explores the mechanisms of potential relevance in the context of 
menopause. 
 
A comprehensive review entitled Vitex agnus-castus (Chaste-tree/berry) in the Treatment 
of Menopause-related Complaints, compiled from the information presented in this 
literature review, has been peer-reviewed by the Journal for Alternative and 
Complementary Medicine.  A copy of the manuscript is included in Appendix 11. 
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12.1  Indications for Vitex agnus-castus 
 
Vitex agnus-castus belongs to the family Verbenaceae.  Its English common names 
include ‘Chaste tree’, ‘Chaste berry’ and ‘Monks’ pepper’.  In the Anglo-American and 
European practice of phytotherapy, Vitex fruit is most widely used for normalising the 
menstrual cycle, as well as for premenstrual syndrome,796 which can occur frequently in 
the perimenopausal years.224,225  In relation to female reproductive problems, it is also 
used in premenstrual mastalgia and fluid retention, other premenstrual aggravations 
such as mouth ulcers, orofacial herpes, hypermenorrhoea, polymenorrhoea, anovulatory 
cycles, secondary amenorrhoea, infertility and hyperprolactinaemia as well as latent 
hyperprolactinaemia*,483,817 insufficient lactation and acne.796,818  
 
12.2 Use of Vitex  in Menopause  
 
Vitex is a common ingredient of many herbal formulations marketed for relief of 
menopause-related symptoms (Table 12.1). 
TABLE 12.1  HERBAL MENOPAUSE FORMULATIONS CONTAINING VITEX AGNUS-CASTUS ON 
THE MARKET 
Manufacturer Product 
Forces of Nature  
Fusion Health 
Gaia Herbs  
Herb Farm 
Herbs of Gold   
Nature’s Alternatives 
Naturopathica 
Nature’s Sunshine 
Neways 
NutraLife  
Oona 
Oriental Botanicals  
Planetary Formulas  
Pretorius  
SuperHerb, Netanya 
Totally Natural Products 
Menopause Ease (Essential oil blend – transdermal)  
Menopause  
Supreme Vitex/Alfalfa - A Menopausal Corrective Formula  
Healthy Menopause Tonic (Pulsatilla + Vitex Comp)  
Menopause Night Relief  
Vitex / Black Cohosh Plus: Women’s Menopause Herb Tonic MenoEze 
Forte;  MenoEze Day Night formula; MeniThin 
Menopause support  
Wild yam and chaste tree cream  
MenoLife  
Herbal Supplement for Menopause, with Black Cohosh & Vitex  
Femaren  
MenoChange Cimicifuga-Vitex Compound  
EstroTrim :Menopause Weight Control  
Phyto-Female Complex 
Estro Balance plus Vitex: Menopause Relief 
 
As mentioned previously, the practice of using Vitex in the treatment of menopause-
related symptoms appears to have originated relatively recently, following the renewed 
interest in the herb for female reproductive disorders generated by Gerhard Madaus in 
                                                 
* Latent hyperprolactinaemia is a non-physiologically stimulated prolactin release often manifest 
during the time of decreasing progesterone and oestradiol levels, that is frequently also 
accompanied by an insufficient function of the corpus luteum.  
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Germany in 1930.42  However, it is possible that early references to its value for 
‘diseases of the uterus’39 and as an emmenagogue to promote menstruation40  
incorporate use in menopause.  In the published literature, the benefits of Vitex for 
menopausal complaints and menopausal bleeding are first mentioned in 1972 with the 
report of its clinical application by Warkalla and colleagues in Germany.41  In an article 
entitled Agnolyt® in the treatment of gynecological complaints, five clinicians report on 
their collective experience of its employment is several thousand cases for a variety of 
disorders.  [Agnolyt® is a patent medicine extracted from dried Vitex berries.] 
 
Its use in this context appears to have now become relatively popular in the Anglo-
American tradition.777,796,807,819  A survey of 155 members of the National Institute of 
Medical Herbalists (NIMH) in the UK found that 86.3% prescribed Vitex in the treatment 
of menopausal symptoms such as hot flushes;820 it is also used for HT withdrawal.796,820  
However, despite its apparent popularity in this context, no studies could be found in the 
literature on the oral administration of herbal extracts of Vitex as a sole agent for the 
treatment of menopausal symptoms.  There were only two poorly designed studies by 
the same investigators examining the effects of the essential oils used in aromatherapy 
measured by non-validated questionnaire-based surveys (reviewed below).821,822 The 
authors did, nonetheless, report the oils from both the leaf and berry to be effective in the 
treatment of menopausal symptoms.  Evidence is less than convincing from the several 
RCTs714,734,793 and one pilot observational study823 of formulations containing Vitex that 
have appeared in the literature. (These are reviewed below).  However, 
pharmacologically, there are some valid reasons supporting the potential utility of Vitex in 
menopause. 
12.3 Phytochemistry & Pharmacology of Vitex agnus-castus 
 
The part used in the Anglo-American and European traditions is the fruit.  Vitex berries 
have been found to contain an essential oil, flavonoids such as casticin and iridoid 
glycosides including aucubin, agnoside and eurostoside.483,796  In terms of active 
constituents, earlier research focussed on the volatile diterpenes824 whereas more recent 
research suggests other diterpenes may have more significant activity, and are 
responsible for the dopaminergic activity.483 The most active ones are relatively non-polar 
and probably cross the blood-brain barrier.483  
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12.3.1 Phytoestrogen content of Vitex 
 
Findings from recent cell culture experiments indicate that Vitex extracts may contain 
phytoestrogens.825 Using ligand binding assays, it was demonstrated that Vitex 
phytoestrogens are oestrogen-receptor (ER)ß-subtype-selective. The flavonoid apigenin 
was identified as the most active oestrogen-receptor-selective phytoestrogen; other 
isolated compounds were vitexin and penduletin.825  However, the compounds identified 
are only weakly oestrogenic, not unique to this herb, and present in relatively low levels 
compared to other herbal and dietary sources.  This finding is therefore unlikely to 
contribute to our understanding of the true mechanism of the action of Vitex.   
12.3.2 Relevance of Pharmacological Actions to Menopause 
 
Given the current understanding and hypotheses regarding the aetiology of menopausal 
symptoms, a number of pharmacological actions of Vitex may be of relevance.  These 
include correcting relative oestrogen excess/progesterone activity, addressing latent 
hyperprolactinaemia associated with PMS-like symptoms experienced during the 
perimenopause by its dopamine-agonist activity, enhanced melatonin release, 
‘normalising’ the menstrual cycle, and effects on opioid receptors.  
Corpus luteum-like Effect 
 
Pharmacological research in the early 1960s on guinea pigs suggested that, at normal 
doses, Vitex demonstrated a decrease of oestrogen effects and a promotion of 
progesterone effects, mediated through the pituitary gland: FSH secretion was 
decreased and LH and prolactin secretion were increased.826  At the high dose (about 20 
times normal dosage) an inhibition of all gonadotrophic hormones and growth hormone 
resulted.826 It was thus said to correct a relative progesterone insufficiency via an indirect 
effect rather than a direct hormonal action.  It was believed that the increase in LH 
production was responsible for effecting this shift in the ratio of oestrogen to 
progesterone, which gave it a corpus luteum-like effect and the ability to correct corpus 
luteum insufficiency.827,828 This view was supported by the previous clinical findings of 
Probst and Roth in their 1954 clinical study on Vitex.829 
Prolactin Inhibition 
However, later in vitro research using rat pituitary cultures found that Vitex agnus-castus 
extract inhibited pituitary prolactin release830 while gonadotropin secretion remained 
unaffected. 831  This suggested that enhancement of progesterone may be due to Vitex 
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decreasing the suppressive effect of prolactin on corpus luteal development, rather than 
by increasing LH.  It was found to contain an active principle that binds to the D2 
receptor831 thereby exhibiting a dopaminergic effect on the anterior pituitary and inhibiting 
prolactin secretion. (Dopamine inhibits prolactin secretion from the anterior pituitary.) The 
results of a placebo-controlled clinical study of prolactin secretion in 20 healthy male 
subjects suggest the effects of Vitex extract are dependent on the dose administered and 
the initial level of prolactin concentration.832   
Latent Hyperprolactinaemia and Female reproductive Disorders 
 
Increased prolactin levels are commonly associated with premenstrual mastalgia, corpus 
luteum insufficiency833 and its associated conditions of hypermenorrhoea, 
polymenorrhoea, persistent anovulatory bleeding, secondary amenorrhoea, anovulatory 
cycles, infertility, oligomenorrhoea, menorrhagia, metorrhagia and irregular menstrual 
cycles.483 Hyperprolactinaemia results in inhibition of secretion of GnRH, and decreased 
secretion of LH and FSH. In the ovary, this results in inhibition of progesterone secretion 
by the granulosa-lutein cells of the corpus luteum.818,834  Premenstrual symptoms, 
particularly mastodynia,  are often accompanied by latent hyperprolactinemia,835,836 
which can manifest during the times of decreasing progesterone and oestradiol during 
the late luteal phase, and can also be stimulated by stressful situations.833,817 The mild 
D2 receptor agonistic properties of Vitex agnus-castus extracts are said to be able to 
inhibit latent hyperprolactinemia837 in a similar way to synthetic D2 receptor agonist drugs 
used for menstrual mastalgia483 which, however, have severe side-effects.837  (The 
prolactin inhibiting effects of Vitex were demonstrated by a case study of a an 18 year-
old girl whose symptoms of prolactinoma were found to have resolved, with a 
concomitant decrease in prolactin levels, after 3 months’ use of Vitex (Agnolyt®).838)  In 
light of the suggestion that many of the menopausal symptoms may represent an 
exacerbation of premenstrual symptoms, targeting premenstrual latent 
hyperprolactinemia may also be appropriate during the perimenopause.  
Dopamine and Thermoregulation 
Dopamine has recently been found to be an important thermoregulatory 
neurotransmitter, with D2 receptors involved principally with the maintenance of body 
temperature in euthermia.345 Earlier research observed the dopamine agonist 
bromocriptine to increase the activity of the endogenous opioid system on the 
thermoregulation mechanisms that regulate body temperature in postmenopausal 
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women346 and to be effective in alleviating hot flushes.347  Hence, a postulated role for 
Vitex in this context is suggested. 
 
Oestrogen directly modulates dopaminergic activity.99  In the cerebral cortex, dopamine 
is involved in emotional responses. In postmenopausal women, the activity of the 
dopaminergic system was found to be significantly lower than in premenopausal women, 
but was significantly increased by HT administration, with a concomitant significant 
decrease in psychological symptoms.441   The dopaminergic properties of Vitex may, 
therefore, be of relevance to the relief of the psychological symptoms associated with the 
menopause transition. 
Melatonin  
A dose-dependent increase in melatonin secretion, especially during the night, was 
found after administration with Vitex extracts 120 mg & 480 mg per day (dried herb 
equivalent 0.6 g and 2.4 g) in an open placebo-controlled trial. 839  Total melatonin output 
was approximately 60% higher than in the placebo group. This has obvious potential 
relevance to menopause-related sleep disturbances.  However, data from a recent case 
report also demonstrated that melatonin was able to delay the characteristic endocrine 
parameters associated with menopause onset.840  While further studies are needed to 
confirm this finding, it is extremely interesting in view of: i) the possible role of declining 
melatonin secretion (that precedes FSH increase168) in the development of menopause 
and its symptoms;169 and ii) the effect of Vitex on melatonin secretion, which  may be part 
of the rationale for using it in menopause.   
Cycle Regulation 
The normalising action of Vitex on menstrual cycles is also of potential relevance in view 
of i) the potential role of melatonin in delaying onset of menopause; and ii) theories 
regarding the possible aetiology of PMS-like symptoms during the perimenopause.  For 
example, it has been observed that recruitment of a new follicle can occur during the 
mid-luteal phase (termed the ‘luteal-out-of-phase’ (LOOP) phenomenon). 493  This results 
in its subsequent ovulation at the beginning of the next cycle and is associated with high 
oestradiol levels peri-menstrually, and may account for the elimination of follicular phase 
remissions in the symptom of dysphoria.372 
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Endorphins/Affinity to opioid receptors 
In 2000, Meier and colleagues suggest additional pharmacological actions for Vitex 
agnus-castus via opioid receptors.841  They reported a relatively potent inhibition for 
opioid (mu and kappa subtypes) receptor-binding with extracts of Vitex, that was most 
pronounced in lipophilic fractions.  Additionally, binding to delta opioid receptors was 
found to be inhibited mainly by an aqueous fraction of Vitex.  In vitro research is of 
uncertain relevance to oral dosing in humans.  High levels of direct exposure of test cells 
to the herbal extract occur in in vitro research, whereas pharmacokinetic factors after oral 
administration affect the bioavailability of the phytochemicals in human and animal 
models.  However, it was subsequently also demonstrated in human and animal models, 
by Webster and co-workers, that Vitex acted as an agonist at the mu-opioid receptor.842  
Extracts with and without fatty acids removed showed significant affinities to the mu-
opioid receptor.   
 
These findings support the beneficial action of Vitex in PMS, as endorphins are shown to 
decrease in the late luteal phase843,844 and are found to be associated with symptoms 
such as mood disorders, migraines and fluid retention.845,846 However, they are also of 
potential relevance to its reputed value in treating menopausal symptoms, as the 
reduction of endogenous opioid activity may be responsible, at least in part, for the 
central noradrenergic instability associated with hot flushes.337,338  Increasing endogenous 
opioid peptide activity may effect a reduction in hot flushes via inhibition of noradrenergic 
activity below the threshold needed to activate heat loss.320  In an oestrogen-deficient 
environment, it is possible that mood enhancement may be effected by stimulating the 
activity of opiate-containing neurons438 and thereby increasing the synthesis and release 
of β-endorphin.439  
12.4 Clinical Studies with Vitex agnus-castus for Menopausal Symptoms 
 
Despite its apparent popularity with UK herbalists, and as a component of menopause 
formulations, evidence from clinical trials on oral doses of Vitex as a sole agent in 
menopause is lacking, and results from the limited number of studies of formulations 
containing Vitex for the treatment of menopausal symptoms have been inconsistent. 
12.4.1 Aromatherapy Studies 
 
The steam distilled essential oil of the fruit and leaves have been investigated in two 
studies that reported benefits for menopausal symptoms.821,822  The first study with 23 
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women contained several weaknesses, including different extracts and variable doses, 
different routes of administration (transdermal, inhalation, oral), lack of a standardised 
rating scale and failure to exclude other concomitant treatments such as HT, herbs and 
acupuncture.  Nonetheless, the percentage of women reporting improvements with the 
oils ranged from 27% for memory and concentration difficulties to 80% for mood swings 
and depression.  Interestingly, the most common ‘side-effect’ was resumption of regular 
periods.821 The subsequent study with 52 peri- or postmenopausal women aged 38 to 73 
used a 1.5% solution of the essential oil of Vitex aerial parts in a base cream or lotion. 
Participants applied 2.5 ml of the cream transdermally, once daily, 5–7 days per week for 
3 months.  Overall, 33% reported major improvement and 36% reported mild to 
moderate improvement in troublesome symptoms, with greatest improvement observed 
in the emotional symptoms, (16 responses), hot flushes/night sweats (15), and 
moderation of menstruation (12).  However, these results need to be interpreted with 
caution due to the lack of a control group.  The findings from aromatherapy studies are of 
uncertain relevance to administration of oral dosage forms. 
12.4.2 Studies on Orally administered Formulations containing Vitex extracts 
 
Two RCTs and one pilot study on formulations containing Vitex for the treatment of 
menopausal symptoms have been reported in the literature.  Results of these studies are 
reported here.  
 
Phyto-Female Complex 
 
Vitex agnus-castus was one component of a menopause herbal formulation, Phyto-
Female Complex, found to be significantly superior to placebo in an RCT on menopausal 
hot flushes and night sweats in 50 healthy perimenopausal and postmenopausal women, 
aged 44-65 years.793  In the 35 who completed the study, a 73% decrease in the number 
of hot flushes was observed at the end of the 3-month treatment period in the active 
treatment (n = 19) compared with 38% in the placebo group (n = 16), p = 0.026, and the 
number of night sweats was reduced by 69% and 29% respectively,  p  = 0.027. Hot 
flushes ceased completely in 47% of women in the study group compared with only 19% 
in the placebo group.  A significant benefit was also observed in terms of sleep quality.  
The other herbs in the formulation were Cimicifuga racemosa (black cohosh) root extract, 
100 mg (2.5 mg triterpen glycoside, 2.5%);  Silybum marianum (St Mary’s thistle/milk 
thistle) herb extract, 75 mg (60 mg silymarin, 80%); Angelica sinensis (dong quai) root 
extract, 75 mg (7.5 mg ligustilides, 1%); Trifolium pratense (red clover) flower extract, 50 
mg (4 mg isoflavone, 8%); and Panax quinquefolium (American ginseng) root extract, 50 
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mg (12.5 mg ginsenosides, 25%). The dose of Vitex agnus-castus fruit extract (2.5 mg 
vitexin, 5%) was 50 mg.  Tablets were administered twice daily. The potential synergistic 
effects of this combination do not permit conclusions about the contributions of individual 
herbs.   In view of the small sample size at the end of the treatment phase, these results 
are encouraging, although not adding specifically to the evidence for Vitex in this context.  
As discussed previously, black cohosh alone has demonstrated considerable clinical 
efficacy in the management of hot flushes.704,717,723,731-733,735 
 
The Herbal Alternatives for Menopause study 
 
The Herbal Alternatives for Menopause (HALT) study investigated 3 different herbal 
regimens compared with HT and placebo over a period of 12 months.734  It assigned 351 
peri- or postmenopausal women with 2 or more vasomotor symptoms per day to one of 5 
groups: 1) Cimicifuga racemosa (black cohosh 160 mg daily; 2) multibotanical 
formulation with Cimicifuga racemosa, 200 mg daily, and 9 other ingredients including 
Vitex agnus-castus; 3) multibotanical plus dietary soy counselling; 4) conjugated equine 
oestrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily; 5) 
placebo.  The multibotanical formulation contained the following daily doses: Cimicifuga 
racemosa (black cohosh), 200 mg; Medicago sativa (alfalfa) 400 mg; boron, 4 mg; Vitex 
agnus-castus (chaste tree), 200 mg; Angelica sinensis (dong quai), 400 mg; 
Chamaelirium luteum (false unicorn), 200 mg; Glycyrrhiza glabra (licorice), 200 mg; 
Avena sativa (oats), 400 mg; Punica granatum (pomegranate), 400 mg; Eleutherococcus 
senticosus (Siberian ginseng, standardised constituents 0.8% eleutherosides E and B), 
400 mg.  There was no significant difference at any of the time points measured (every 3 
months) between any of the herbal interventions and placebo as measured by the 
Wilkund vasomotor subscale, frequency or intensity of hot flushes and night sweats.  The 
exception was symptom intensity at 12 months, with the multibotanical plus soy 
intervention performing significantly worse than placebo (p = 0.016).  The average 
difference over all the time points between herbal interventions and placebo was less 
than 0.55 vasomotor symptoms per day, compared with - 4.06 for HT compared with 
placebo.  (For the multibotanical, the no significant differences were found between the 
study group and placebo at 3 months, p = 0.45, 6 months, p = 0.18, or 12 months, p = 
0.88).  While the sample size and duration of this study are definite strengths, a major 
limitation of this study is the recruitment of women with mild symptoms.  It is 
recommended by the U.S. Food and Drug Administration (FDA) guidelines that seven 
moderate to severe hot flushes per day, or 50 to 60 per week, be the minimum 
requirement for menopause studies.847  
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Pilot Study  
 
A pilot study of a formulation of 15 whole herbs suggested a potential benefit of the 
combination for improving moderate menopausal symptoms in women.823 Symptoms 
were measured on the Modified KI, daily hot flushes severity, and overall quality of life 
(QoL) using the SF-36 index. The herbs were administered in 550 mg capsules, 2 
capsules taken twice daily, providing a total of 2,200 mg of whole herbs per day.  
However, given the large number of herbs in the formulation (Cimicifuga racemosa - 
black cohosh root, Viburnum opulus - cramp bark, Mitchella repens - squaw vine, 
Valeriana officinalis - valerian root , Polygonatum multiflorum - King Solomon seed (also 
known as Solomon’s seal), Taraxacum officinalis - dandelion root, Vitex agnus-castus - 
chaste tree berry, Rosmarinus officinalis -  rosemary leaves, Nigella sativa - black seed 
(also known as black cumin), Eupatorium purpureum - queen of the meadow, Epimedium 
grandiflorum - epimedium leaf, Ligusticum chuanxiong - chuanxiong rhizome, Schisandra 
chinensis -schisandra berry,  Mentha piperita - peppermint leaves, Rubus idaeus - red 
raspberry leaves), the dose of each individual herb was quite low, ranging from 80mg to 
300mg per day.  The dose of Vitex was 140 mg per day, or 6% of the total.  From 
baseline to 3 months, a 42% decrease was observed in daily hot flushes p = 0.0003, and 
KI total symptoms score decreased by 24%, (p = 0.0028).   In addition to the low dose of 
Vitex in the formula, the inclusion of Cimicifuga racemosa (black cohosh), a herb for 
which there is evidence of efficacy in menopause-related symptoms717,723,731,733means 
that  no conclusions can be drawn about the individual contribution of Vitex agnus-
castus.  The lack of a placebo group is a major limitation.  Placebo effects for vasomotor 
symptoms in menopause studies are substantial, with 51% being the average for studies 
of HT according to a 2004 meta-analysis,499 and they are generally in the range of 30 to 
41% in RCTs of medicinal herbs.75,76,793,848,849 It is possible that the 42% reduction in 
vasomotor symptoms observed in this study would not be significant over placebo.  The 
small sample size in this study also suggests this result should be interpreted with 
caution. 
12.5 Vitex and Premenstrual Syndrome  
 
It is possible that the practice of using Vitex agnus-castus for menopausal symptoms 
refers to its use during the perimenopause when PMS-like symptoms are anecdotally 
reported to be prevalent, or at least less well-tolerated.224  Additionally, it has been 
proposed that some symptoms attributed to the menopause-transition such as mood 
changes and breast discomfort are more likely to be menstrual-cycle related, given that 
they improve after cessation of menstruation.225  [Theories regarding the aetiology of 
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PMS-like symptoms during the perimenopause have previously been reviewed (Refer to 
section 8.3).]  Thus, the research on Vitex in relation to PMS may well be relevant in this 
context. 
12.5.1 Clinical studies of Vitex for PMS  
 
Findings from one RCT, comparative studies and observational studies have reported a 
positive effect for Vitex in the treatment of PMS: 
 
In a randomised, double-blind, placebo-controlled trial on Vitex (extract Ze 440, 60% 
ethanol m/m; extraction ratio 6-12:1; standardised for casticin; 20mg tablet once daily) 
with 170 participants over three consecutive menstrual cycles, Schellenberg481 found 
Vitex caused significant improvement in premenstrual symptoms such as irritability, 
mood alteration, anger, headache, breast fullness and bloating as rated by their self 
assessment and changes in clinical global impression.  Responder rates (considered as 
50% reduction in symptoms) were 52% and 24% for active and placebo, respectively.  
Lauritzen and co-workers conducted a multi-centre, randomised, double-blind 
comparative trial of Vitex (Agnolyt®) dried extract 3.5-4.2 mg per day; extraction ratio 
9.58-11.5:1) and pyridoxine (Vitamin B6).850   Results showed that premenstrual tension 
syndrome symptoms improved for both groups, but that the characteristic symptoms of 
breast tenderness, oedema, abdominal tension, headaches, constipation and depressed 
mood were more significantly reduced by Vitex than pyridoxine.  In the Vitex group, 
77.1% showed an improvement on the Clinical Global Impressions (CGI) scale.  The 
efficacy of treatment with Vitex was rated as excellent by 24.5% of investigators and at 
least adequate by more than 80%.  Assessment by patients indicated that 36.1% of the 
Vitex group felt free from complaints. The obvious limitation of this study is the absence 
of a placebo control group.   
 
Findings from a placebo-controlled trial conducted in 1987 on Gerard Agnus castus 
tablets over three months were reported in a Gerard House promotional brochure.851 Of 
30 women randomised to the active treatment, 21 completed the trial.  Symptoms were 
rated on Abraham’s Menstrual Symptoms Questionnaire (MSQ).  Improvements were 
noted in all subscales for the treatment group using a percentage reduction from the 
mean baseline scores in each sub-cluster to the end of 3 months: for PMS-A (anxiety 
sub-cluster), 52%; in PMS-H (hydration), 41% ; PMS-C (cravings), 48% PMS-D 
(depressive symptoms), 64%.  These results were significantly superior to placebo for all 
sub-clusters except PMS-C where the placebo outperformed the active treatment.  
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In a single-blind, rater-blinded prospective study, Atmaca and colleagues compared the 
efficacy of 2 months’ treatment with fluoxetine, an SSRI, with Vitex extract in 41 patients 
with PMDD, diagnosed according to DSM-IV.852  The response rate was similar for both 
groups: fluoxetine 68.4%, and Vitex 57.9%. However, fluoxetine was more effective for 
psychological symptoms while Vitex was more effective for the physical symptoms.  
 
Forty-three women completed a  prospective, multicentre study that examined the 
efficacy of Vitex agnus-castus extract Ze 440 (20 mg/day) in 50 women with PMS over 
three menstrual cycles.853  Thirteen patients were concurrently using oral contraceptives. 
There was a 42% reduction in scores on the Moos’ menstrual distress questionnaire, 
mainly in fluid retention, negative feelings, pain and behavioural changes.  Symptoms 
remained 20% below baseline scores 3 cycles post-cessation of treatment. The lack of a 
placebo arm is again a limitation to this study.  The inclusion of women taking the OCP 
also limits the interpretation of these results. 
 
Loch and co-workers conducted a multicentre open study to investigate a solid 
preparation from an extract of Vitex berries (Femicur® capsules; 20mg/day) on 1634 
women suffering from PMS.854  After treatment for three menstrual cycles, 93% of 
patients reported a decrease in the number of symptoms or even cessation of PMS 
complaints, including psychological and somatic symptoms. A reduced incidence of 
mastodynia was also observed, falling from 81% to 27% over the treatment period.  
 
In a large, multicentre drug-monitoring study, 1592 women suffering from either PMS or 
menstrual disorders, predominantly corpus luteal insufficiency, were monitored for an 
average of six months while taking drop doses of Vitex tincture (mean of 43 drops per 
day).827  Physicians rated the efficacy of the treatment as good or satisfactory in 90% 
while in the patients’ assessments, 61% were good and 29% as satisfactory.  
12.6 Adverse events 
 
Serious adverse events have not been observed with Vitex agnus-castus.  In a few 
poorly-documented cases, its use has been associated with persistent headaches855 
Lauritzen observed mild adverse events including gastrointestinal and lower abdominal 
complaints, skin manifestations (2 subjects) and transitory headache (1 subject) in a 
small percentage of patients (5.5%).850  
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In the RCT by Schellenberg on Vitex agnus-castus in PMS, mild adverse events were 
reported in both the treatment group (4.7%) and placebo group (4.8%).481    Each of the 
following events was reported by one subject: acne, multiple abscesses, intermenstrual 
bleeding and urticaria, none of which caused discontinuation of the treatment.  
 
In the comparator study with fluoxetine and Vitex reported by Atmaca, the most 
frequently reported side-effects in the Vitex group (n = 19) were nausea (n = 5) and 
headaches (n = 4) over the 2 month treatment phase.852 
 
Loch found the most common symptoms, reported by 0.8% of participants to be acne, 
allergic reaction, eczema, hair loss, itching and urticaria.854  Six patients (0.4%) reported 
gastrointestinal problems, such as diarrhoea, stomach pains, nausea, vomiting and 
abdominal distension.  
 
Propping noted adverse effects in 2.4% of the 1,592 women monitored. 827  Nausea was 
reported in 7 cases, changes to the menstrual rhythm (5 cases), acne, skin rashes and 
headache (in 3 cases each), dyspepsia and skin reddening (2 cases each).  
 
Berger found that the most frequently reported adverse events were those commonly 
reported by PMS patients regardless of participation in a trial: acne (n = 7), headaches (n 
= 6),  spotting (n = 5), and gastrointestinal complaints (n = 5).853  Overall, 37 events were 
reported by 20 participants over a total of 344 menstrual cycles.  Laboratory and medical 
examinations showed no influence of any kind relevant to treatment.  
 
Observation of 551 patients treated with Vitex by 153 gynaecologists indicated 5% of 
patients experienced side-effects, predominantly nausea.856  
12.7 Contraindications  
 
Co-administration of Vitex agnus-castus and progesterone drugs, the contraceptive pill857 
or HT is not recommended.805 Due to its dopaminergic action, a possible antagonistic 
interaction may occur with dopamine receptor antagonists.796  In addition, Vitex  may 
aggravate pure spasmodic dysmenorrhoea not associated with PMS.858 Although its use 
in lactation is sometimes cautioned against due to its prolactin-inhibiting effects, at low 
doses Vitex berry is a galactagogue. 805  It should be used in the early stages of 
pregnancy only if indicated.805 
 
Toxicology data for Vitex in animals and is presented in Mills and Bone (2005: p335).805  
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12.8 Summary  
 
The origins of the practice of administering Vitex in menopause are unclear.  While 
several recent studies have suggested a benefit for formulations containing Vitex in the 
treatment of menopausal symptoms, evidence from rigorous RCTs to support its use as 
a sole agent in this context is lacking.  Recent evidence from pharmacological studies 
points to possible mechanisms that could account for beneficial effects in some of the 
symptoms of menopause, as well as possibly influencing its onset.  As the endocrinology 
and neuroendocrinology of menopause and its symptoms have not yet been fully 
elucidated, no firm conclusions can be drawn.  However, the emerging pharmacological 
evidence supports a role for Vitex agnus-castus in the management of menopause-
related symptoms. 
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Chapter Thirteen 
  
 
 
Hypericum perforatum  
 
(St John’s wort) 
 
 
  
 
 
 
13.0 Introduction 
 
This chapter of the Literature Review examines the research on St John’s wort with 
regard to its mechanisms of action, evidence from clinical studies of efficacy for 
symptoms relevant to menopause, and safety data that informed entry criteria to the 
current clinical trial. 
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13.1 Actions and Indications of Hypericum perforatum 
 
St John’s wort (the dried aerial parts of Hypericum perforatum, family 
Clusiaceae/Guttiferae) is best known today for its role in the treatment of mild to 
moderate depressive disorders, for which is has received much attention in the scientific 
literature.859-872 It also has anti-viral, antiseptic, nervine and vulnerary actions.796 
Traditionally it was a highly esteemed remedy for lacerated and punctured wounds and 
bruises, both internally and externally.27,47  Its many other traditional indications are 
largely centred around its actions on the spine and nervous system: spinal irritation and 
injuries, “shocks, or concussions; throbbing of the whole body without fever,” (p1038)27 
“neuralgia, fibrositis and sciatica” (p115)21 but also include “intermittent fever, dysentery, 
gravel, pectoral complaints, worms, and jaundice” (p36). 2   Traditional indications of 
potential relevance to menopause include menorrhagia and27 hemorrhages.47 Madaus in 
1938 recommended it “For menopausal bleeding.. with Viscum album” (p1592).42   Those 
indications involving the nervous system are also relevant, notably in Kings’ American 
Dispensatory “hysteria, nervous affections with depression”27 and subsequently in the 
1918 Dispensatory of the United States of America “hysteria, mania….“ It formerly 
enjoyed great reputation for the cure of demoniacs”(p36),47  a reference to the prevailing 
belief at the time that psychological disturbances were the work of evil spirits.  It appears 
in The British Herbal Pharmacopoeia of 1983 as specific for “menopausal neurosis” 
(p115).21   
13.2 Pharmacology of Hypericum perforatum 
13.2.1 Phytochemistry 
 
The key active constituents of H. perforatum include the naphthodianthrones, hypericin 
and pseudohypericin, collectively referred to as total hypericins; procyanidins; 
phloroglucinol derivatives including hyperforin, flavonoids such as quercetin and 
biapigenin; and xanthones.873  The hypericins have varying solubility in different solvents 
and thus, most preparations are standardised for total hypericin (hypericin plus 
pseudohypericin) content.874  The exact mechanism of action is not known. Hypericin 
was previously thought to be the active constituent in depression875-878 but more recent 
interest has focussed on hyperforin, an unstable compound, which has been shown to 
have antidepressant activity,879-882,863,883 although the evidence is conflicting.  The 
flavonoids have also received considerable attention in this context.884,885  However, the 
total extract appears to be more effective than isolated constituents886 in terms of the 
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antidepressant effect, which is therefore likely to involve many, if not all constituents of H. 
perforatum.887  
13.2.2 Postulated Pharmacological Actions of Hypericum perforatum 
 
The exact role of neurochemical mechanisms underlying in vivo actions of St John’s wort 
extracts are not well defined.  However, it has been demonstrated in the rodent brain 
that, in addition to inhibiting the uptake of the monoamine neurotransmitters serotonin, 
noradrenaline and dopamine, (like many other antidepressants), St John’s wort extract 
also inhibits uptake of the amino-acid neurotransmitters, GABA and L-glutamate.888-891   
There is also evidence for β-adrenoreceptor down-regulation892,893 and a significant up-
regulation of 5-HT2-receptors in the frontal cortex.893 
 
Other studies on plasma hormones and brain neurotransmitters in humans and rats after 
administration of Hypericum and its constituents, however, suggest that Hypericum may 
effect plasma hormonal changes via both serotonin and dopamine-mediated 
mechanisms, but do not involve noradrenaline.894 
 
Schulte-Lobbert and colleagues895 found that the potency of St John’s wort products in 
inhibiting the uptake of serotonin depended on their hyperforin content.  Further support 
for the antidepressant activity of hyperforin is derived from findings that it is a potent 
uptake inhibitor of serotonin, dopamine, noradrenaline, GABA and L-glutamate. 
Furthermore, the effects of two different Hypericum extracts in behavioral despair and 
learned helplessness closely correlated with their hyperforin contents.880  
 
Other mechanisms that have been observed include:  
• an effect on opioid systems in mesolimbic regions in the CNS in the rat brain, either 
by a direct or indirect mechanism896  
• different pharmacological effects like receptor bindings897  
• Improving resistance to stress and preventing exhaustion of the HPA system898 
• Suppression of interleukin-6 in blood samples ex vivo.899  This suppression may 
assist in deactivating the hypothalamic-pituitary-adrenal axis, leading to inhibition of 
elevated corticotrophin-releasing factor and other adrenal regulatory hormones.  
These changes could be linked to antidepressant activity. 
• Modulation of HPA axis function;885 influencing central neurotransmitters, thereby 
causing cortisol stimulation in a dose-dependent manner;900 reducing corticosterone 
and cortisol in brain frontal cortex tissue, but not serum901 
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• Inhibition of MAO-A and MAO-B activity in vitro (weak)893 
• A photosensitising effect for hypericin, since Hypericum treatment has lowered the 
amount of light necessary to obtain a clinical antidepressant effect796 
• Inhibition of sodium-dependent uptake of catecholamines and amino acids into 
synaptic nerve endings, probably by mechanisms controlling the synaptic sodium 
concentration902  
• Modification of specific membrane structures indifferent ways, decreasing the 
flexibility of fatty acids in the membrane hydrocarbon core, but fluidising the 
hydrophilic region of membrane phospholipids.903 
13.2.3 Relevance of Pharmacological Actions to Menopause 
 
The effectiveness of Hypericum in depression,49,859,861,868,904,905 and potentially 
anxiety48,49,800,801,880,906 and sleep21,49,907 suggest a beneficial role for Hypericum 
perforatum in these symptoms when associated with menopause.  Pharmacologically, 
the observed effect on opioid, and dopamine systems in mesolimbic regions in the CNS 
observed animal models896 may be of relevance to hot flushes, although extrapolating 
results from studies in animal models to the clinical situation must be done with caution.  
Dopamine has an effect on thermoregulation,345possibly via increasing the activity of the 
endogenous opioid system,346 so that dopamine agonists have been found to alleviate 
hot flushes.347 The evidence for β-adrenoreceptor down-regulation892,893 may also be 
relevant in this context. Elevated brain noradrenaline levels330 have been associated with 
the core body temperature elevations preceding hot flushes.198  It is possible that St 
John’s wort, by causing down-regulation of β-adrenoreceptors892,893 could result in 
inhibition of noradrenergic activity below the threshold needed to activate heat loss.  Its 
hypothesised action of improving resistance to stress and thereby preventing exhaustion 
of the HPA-system898 would be consistent with the observed effects of stress and anxiety 
on menopausal hot flushes.91,197  The action of St John’s wort on inhibiting GABA uptake 
is dissimilar to that of gabapentin.  Despite its effectiveness in hot flushes,552 gabapentin 
is not a GABA agonist, does not inhibit GABA uptake and acts independently of GABA 
receptors.321  
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13.3 Evidence from Clinical studies for the benefits of Hypericum in 
Menopause  
 
Research from rigorous RCTs on Hypericum perforatum as a sole agent in menopausal 
complaints is lacking.  However, its well-established efficacy in depression, and to a 
lesser extent, anxiety, suggest a role for Hypericum in the treatment of menopausal 
psychological and neurovegetative symptoms.  Furthermore, selective serotonin 
reuptake inhibitors (SSRI’s) have a potential role in the relief of hot flushes197 and 
Hypericum, like SSRI’s, may act by inhibiting the uptake of neurotransmitters,908 thus 
giving it a potential role in the treatment of hot flushes.   
 
Clinical studies on the effectiveness of H. perforatum have predominantly used the 
following preparations: 
a) Lichtwer LI 160, (such as Kira® Lichtwer Pharma), containing 0.3% hypericin and 
an undefined amount of hyperforin 
b) ZE 117 (Remotiv®, Zeller),containing 0.2% hypericin and little hyperforin 
c) WS 5572, (Movana®, Pharmaton), containing 3 – 7% hyperforin. 
The trials relevant to menopause are reviewed below. 
13.3.1 Observational Study on a Mono-preparation 
 
In an open, observational study of 111 women aged between 43 and 65 years, 
Hypericum perforatum  Kira® preparation (Lichtwer Pharma, Berlin, Germany) was found 
to significantly improve the psychological (irritability, depressive moods, inner tension, 
anxiety disorders, disturbed sleep and concentration disorders) and psychosomatic 
symptoms of menopause (hot flushes, outbreaks of sweating, palpitations, dizziness, 
headaches. 49  In addition, a significant improvement in sexual well-being was found. The 
total daily dose was 405 – 675 mg extract (extraction ratio not given), standardised to 
0.9mg hypericin (one tablet containing 135-225 mg St John’s wort extract, standardised 
to 300μg hypericin, three times daily) for a period of 12 weeks. The Menopause Rating 
Scale (MRS) and the CGI scale were used to evaluate treatment outcomes as well as a 
self-designed questionnaire to assess sexuality.  Participants were recruited from a 
general medical and psychotherapy practice and were experiencing symptoms classified 
as ‘pre’ (presumably ‘peri-) and post’ menopausal.  One hundred and six were included 
in the final analysis.  Total scores on the MRS fell from 63.4 ± 16.5 to 23.5 ± 25.7 (63%), 
or from marked intensity to slight intensity.  As rated by the CGI scale, symptoms 
disappeared or diminished in 76.4% women by self-rating, and in 79.2% by physician 
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rating (p <.0.001).  On the self-designed sexuality assessment scale, significant 
improvements were found in the feeling of attractiveness (p <.0.001) and participants’ 
rating of the importance of sexuality (p <0.001). 
 
The main limitation of this study is that, as an observational study, it lacked a control 
group.  As symptoms fluctuate throughout the menopausal transition, the response in the 
placebo group due to natural history can be substantial, with an average of 51% 
observed in RCTs of HT for hot flushes.499  However, total scores on the MRS and CGI in 
this study did fall by more than 50%.  As pointed out by Linde and Knuppel,866 non-
randomised observational studies are not subject to the same restrictions as RCTs in 
terms of strict inclusion criteria and limited resources that can result in small sample 
sizes and short observation periods. Large-scale non-randomised observational studies, 
such as this, can provide useful data regarding long-term outcomes, prognostic factors 
and rare adverse events.  Such studies add to the evidence base and provide the 
stimulus for further investigation.  Another limitation is that the MRS is not used as widely 
as the KI or the Greene Climacteric Scale in menopause studies, which may restrict 
comparison between this and future studies.  It could also be argued that participants’ 
psychological symptoms were not classified according to standardised symptom-rating 
instruments for depression or anxiety, but in a menopausal symptoms study, rating 
scales for menopause may be more appropriate.   In terms of reproducibility of findings, 
the lack of a standard dose is a limitation, as the wide range of extract contained in the 
daily dose meant that dosage varied for different individual participants.   
13.3.2 Comparison of Hypericum with Diazepam 
 
A 12-week drug monitoring study on a St John’s wort mono-preparation, published in 
1986, reported it to be of comparable efficacy to diazepam for climacteric depression.48  
On the clinician-rated CGI scale, Hyperforat® at the dose of 0.2 mg three times daily 
resulted in a 77.5% reduction in scores, compared with 50% for diazepam, 2 mg three 
times daily.  On the Hamilton Anxiety Scale (HAMA), scores reduced by 72% with 
Hyperfort® compared with 37% for diazepam.  The Self-rating Depression scale (SDS) 
found a 46% reduction with Hyperfort ® compared with 31% for diazepam.  This study 
suggests beneficial effects on both anxiety and depression in this cohort. However, since 
diazepam is an anti-anxiety agent, its superiority in depression is hardly surprising.  
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13.3.3 Combinations of Hypericum with Other Plant Extracts in Menopause 
 
Results of several studies support the benefit of the combination of Hypericum 
perforatum with Cimicifuga racemosa (black cohosh) in the treatment of menopausal 
complaints.702,703,705,716,909  
 
In a double-blind, placebo-controlled RCT of 301 women experiencing menopausal 
complaints with a pronounced psychological component, Remifemin® plus St John’s 
wort, a combination of  an ethanolic extract of isopropanolic C. racemosa and H. 
perforatum, was significantly superior to placebo (p < 0.001).716  The dosage regime was 
2 tablets twice daily for 8 weeks, reduced to 1 tablet twice daily for following 8 weeks.  
Each tablet contained St John’s wort extract equivalent 245-350 mg herb, standardised 
to 0.25 mg hypericins and black cohosh tablet extract equivalent 22.5 – 41.25 rootstock, 
standardised to 1 mg triterpene glycosides. Symptoms were rated on the Menopause 
Rating Scale and the Hamilton Depression Rating Scale (HDRS).  The mean decrease in 
scores on the MRS from baseline to week 16 was 50% in the treatment group, compared 
with 19.6% in the placebo group (p < 0.001). The HDRS total score decreased 41.8% in 
the treatment group and 12.7% in the placebo group (p < 0.001).  The inclusion criteria were 
based on the presence of ‘climacteric’ symptoms within the previous 3 months, and not 
according to menstrual status.  One third of participants in each arm had menstruated within 
the previous 6 months, although no mean time or range was provided. 
 
A randomised, double-blind, placebo-controlled clinical trial of Remifemin plus®, a 
combination of Hypericum perforatum and  Cimicifuga racemosa (St John’s wort and 
black cohosh) with 179 women over a period of 6 weeks  found significant improvement 
on ‘psychovegetative’ menopausal symptoms such as anxiety, impaired drive, 
depressive mood, nervousness and irritability, as well as good tolerability and 
compliance.703  Symptoms rated on the KI fell from 31.4 to 18.7 (40% reduction) in the 
treatment group, compared with the placebo group where the mean score fell from 30.3 
to 22.3 (26% reduction).  The herbal combination was found to be significantly superior 
to placebo, p < 0.001.   
 
The same preparation of H. perforatum and C. racemosa, Remifemin plus®, had 
previously been the subject of post-marketing surveillance involving 812 women for 12 
weeks. 909  Participants were recruited by 176 doctors.  Overall improvement was 
reported by 90% of the women in the ‘psychovegatative’ symptoms of menopause such 
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as hot flushes and poor concentration, with 82% rating the therapeutic effect as either 
very good or good.  An effect was demonstrated after 3 weeks’ treatment.  
 
A large-scale prospective, controlled open-label observational study of 6141 women at 
1287 outpatient gynecologists in Germany investigated the effectiveness and safety of 
Cimicifuga racemosa (black cohosh) alone or in fixed combination with Hypericum 
perforatum (St John’s wort) on menopausal symptoms. 910 The monotherapy was used 
for neurovegetative symptoms, while patients with more pronounced mood complaints 
were administered the combination. Treatment was selected by the participating 
physicians, and doses were consistent with those used in other studies. Patients were 
followed up for 6 months, optionally 12 months. The primary endpoint was the MRS 
PSYCH sub-score at month 3. The results supported the effectiveness and tolerability 
profiles of both therapies.  For the alleviation of mood symptoms, the fixed combination 
of black cohosh and St John’s wort was superior to black cohosh alone (p < 0.001).  The 
PSYCH and HOT FLUSHES subscales showed the greatest improvements for both 
therapies.  Improvement was maintained at 6 and 12 months for both treatments. 
 
A multicenter RCT with 89 peri- or postmenopausal women experiencing climacteric 
symptoms, investigated the effects of a combination of  St John's wort and black cohosh 
extract (Gynoplus®, Jin-Yang Pharm., Seoul, Korea, a 264 mg tablet containing 0.0364 
mL extract Cimicifuga racemosa  rhizome, equivalent to 1 mg tripterpene glycosides, and 
84 mg dried extract Hypericum perforatum equivalent to 0.25 mg hypericine, with 80% 
methanol) for 12 weeks.  The herbal combination was shown to be superior to placebo 
for hot flushes (p = 0.021), and overall menopausal symptoms rated on the KI (p < 
0.001).705   
13.4 Hypericum perforatum and Premenstrual Syndrome 
 
As mentioned above, it has been suggested that some of the so-called ‘menopausal’ 
symptoms may actually represent an exacerbation of premenstrual symptoms, although 
not necessarily recognised as such due to the irregularity of menstrual cycles in the 
perimenopause and the possibility of ovulation occurring in the absence of a subsequent 
menstrual bleed.55 In addition, women report an increase in PMS-like symptoms during 
the perimenopause.  Therefore, research on Hypericum perforatum in relation to PMS 
symptoms may also be of relevance in this context. 
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A pilot study involving 19 women suffering at least 6 consecutive months of PMS found 
Hypericum perforatum to significantly reduce the severity of premenstrual symptoms.911  
This open, observational study of Hypericum perforatum (St John’s wort One-A-Day 
Kira®, Lichtwer Pharma, Berlin, Germany) found significant reductions in all outcome 
measures after treatment for two cycles with Hypericum tablets standardised to 900μg 
hypericin per day.  The mood subscale (as opposed to pain, physical and behaviour), 
however, showed the most improvement, and the symptoms with the greatest reductions 
in scores were crying, depression, confusion, feeling out of control, nervous tension, 
anxiety and insomnia.  Scores on both the Daily Rating Scale and the HAMD were 
significantly reduced by the end of one cycle, p < 0.01.  This suggests a potential role for 
Hypericum perforatum in the treatment of PMS pending further evidence from RCTs with 
a larger sample size.  
 
However, data from a subsequent study did not support this initial finding. A placebo-
controlled RCT with Lichtwer Pharma UK Ltd Hypericum perforatum was conducted on 
125 normally menstruating women who experienced recurrent premenstrual 
symptoms.912 The primary endpoint was anxiety-related symptoms recorded on a 
menstrual diary based on Abrahams’ classification.  The daily dose of Hypericum was 
600 mg, standardised to contain 1,800 μg of hypericin. Although both groups improved 
significantly on all symptom subgroups, p < 0.007 for both groups, there was no 
difference between groups, p ≥ 0.57 for all symptom subgroups. 
 
A case report of premenstrual dysphoric disorder (PMDD) treated with St John's wort 
extract (900 mg/day) observed much improvement in symptoms for the five-month 
follow-up.913 
13.5 Hypericum in Anxiety Disorders 
 
As mentioned above, observational studies on menopausal symptoms suggest a 
beneficial role for St John’s wort in anxiety.48,49 Evidence from some RCTs on depression 
have supported an anxiolytic effect in these subjects.906, 802   In addition, three case 
reports have been published of its successful use in moderate to marked anxiety in 
patients diagnosed with DSM-IV-defined Generalised Anxiety Disorder (GAD).801  This is 
supported by a study of the aqueous extract of the aerial parts in mice that noted both 
anxiolytic effect and sedative effects.800  The anti-anxiety activity was not due to the 
hyperforin content.800  In depressive patients suffering from anxiety symptoms, St John’s 
wort, in comparison with fluoxetine, was found to be particularly effective.802  The 
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preparation Psychotonin® examined by Witte and co-workers also showed an anxiolytic 
effect in depressed subjects.906  Some of the mechanisms of action support a benefit in 
anxiety, such as GABA activity and serotonin reuptake inhibition.880 
13.6 Effects of Hypericum on Sleep 
 
The British Herbal Pharmacopoeia lists H. perforatum as sedatve.21 Hypericum extract LI 
160 was found to improve sleep patterns in older participants (59.8 ± 4.8 years) in a 
double-blind placebo-controlled cross-over trial with 12 volunteers. 907   Analysis of slow-
wave EEG activities showed it induced an increase of deep sleep during the total 
sleeping period, although no benefit was found for onset of the sleep, sleep duration or 
intermittent awakenings. Sleep disorders, as well as depressive agitation, were reduced 
by St John’s wort in patients suffering from depression with anxiety symptoms.802 
13.7 Hypericum perforatum and Depression Clinical Trials  
 
Extracts of H. perforatum have been the subject of many observational, drug-monitoring 
studies and clinical trials.859-872,914,915  The anti-depressant activity of many of these 
extracts has been established in cases of mild to moderate depression, both in 
observational studies,866 placebo-controlled trials861,867,868,904,905 and comparator studies 
with standard anti-depressant medication such as fluoxetine, sertraline (SSRI’s), 
amitriptyline and Imipramine (tricyclic anti-depressants), and moclobemide, a 
monoamine oxidase inhibitor.860,862,864,871,914,916-919 Meta-analyses of RCTs on St John’s 
wort between 1996 and 2000, including up to a total of 2,291 patients, reported that 
extracts of H. perforatum were superior to placebo for the treatment of mild or 
moderately severe depressive disorders920,921 (responder rate ratio 2.47; 95% CI 1.69 to 
3.61920) (rate ratio 2.67; 95% CI 1,78 to 4.01)921 and similarly effective as standard 
antidepressants (responder rate ratio 1.01; 0.87 to 1.16).920  In a systematic review of 8 
RCTs, Gaster and Holyroyd reported the absolute increased response rate with St 
John’s wort to range from 23% - 55% higher than with placebo, but 6% to 18% lower 
than tricyclic antidepressants.922 Large-scale observationals studies of patients with mild 
to moderate depression resport response rates between 65% and 100%.866  Details of a 
selection of depression studies using a range of St John’s wort extracts and including 
hypericin and hyperforin content, where provided, are given in Table 13.1.
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TABLE 13.1   SUMMARY OF A SELECTION OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES USING DIFFERENT EXTRACTS OF HYPERICUM  
PERFORATUM IN DEPRESSION 
 
Hypericum perforatum extracts compared with antidepressant drugs  
Source  Extract/ 
Preparation 
Hypericin 
content 
Dosage Dura-
tion 
Compared 
with 
Subjects Outcome 
Woelk, 2000918 ZE 117 
Remotiv 
Bayer Vital, 
Germany 
1 mg/day 
(0.2% hypericin) 
 
50% ethanol 
500 mg/day 
[250 mg bd] 
 
Imipramine 75mg 
bd 
6 weeks Imipramine 
(tricyclic) 
& placebo 
Mild-moderate major depression 
on HAMD-17 (14-25.  Mean = 
22.25) 
324 outpatients from psychiatric & 
general medical practices 
Therapeutically equivalent to 
Imipramine but better tolerated 
Schrader, 
2000917 
Ze 117 2.5 mg/day= 
(0.5%) hypericin 
500 mg/day 
[250mg bd] 
6 weeks Fluoxetine  
(Prozac-
SSRI) 
240 patients with mild-moderate 
major depression HAMD (21)  
score of 16-24 
Equivalent to Fluoxetine in mild-
moderate depression 
Szegedi et al, 
2005862 
WS 5572 
Hydro-
alcoholic 
extract 
3-7:1 extract 
ratio 
1 mg – 2.5 mg 
=0.12%-0.28% 
hypericin 
(increased to 2 
mg-5 mg in non-
responders 
3-6%  hyperforin = 
2.7-5.4 mg 
900 mg [300 mg 
tds] initially, 
increased to 
1,800 mg/day 
after 6 weeks in 
non-responders 
6 weeks Paroxetine 
(SSRI) 
Moderate to severe major 
depression.  HAMD-17 ≥22 and ≥ 2 
on depressive mood item. 
251 adults outpatients. (+ CGI, 
Beck & Montgomery-Asberg) 
Hypericum at least as effective as 
Paroxetine for moderate to severe 
major depression and better 
tolerated. 
Hypericum 57% reduction 
Aropax 45% reduction 
Between groups,  p = 0.08 
Hypericum 
Depression Trial 
Study group, 
2002870 
LI 160 
Lichtwer 
Pharma 
extract 
0.12%-0.28% 
hypericin  
(1-2.5 mg, up to 
2 – 5 mg/ day) 
900 mg/day 
increased to 
1200,1500 or 
1800 mg prn.  
Sertraline 50 
mg/day up to 
75,100 or 150 
mg prn 
8 weeks Sertraline 
(SSRI) & 
placebo 
340 adults patients with major 
depression and HAMD-17 item of 
20+ 
Did not support the efficacy of St 
John’s wort in moderately severe 
major depression 
HAMD:  
Hypericum vs placebo, p = 0.59 
Sertraline vs placebo, p = 0.18 
Brenner, 2000872 LI 160 
Lichtwer 
Pharma 
extract 
Not specified 600 mg/day 
Hypericum or 50 
mg sertraline 
Increasing to 900 
mg/day & 75 mg/ 
day after 1 wk  
7 weeks Sertraline 
(SSRI)  
Mild to moderate depression, 
including major depressive 
disorder, dysthymic disorder, 
adjustment disorder.  30 
outpatients. HAMD, CGI 
Severity of symptoms significantly 
reduced in both groups, p < 0.01. 
No significant difference between 
groups.   ≥50% improvement in 
47% Hypericum group and 
 40% sertraline arm  
147 
 
Hypericum perforatum extracts compared with antidepressant drugs cont 
Source  Extract/ 
Preparation 
Hypericin 
content 
Dosage Dura-
tion 
Compared 
with 
Subjects Outcome 
Wheatley, 
1996860 
LI 160 2.7 mg/day 
total hypericin 
equivalent = 
0.3% hypericin 
900 mg/day 
or 
Amitriptyline 75 
mg  
6 weeks Amitriptyline 
(tricyclic) 
149 patients with mild to 
moderate major depression DSM 
IV & 
HAMD 17-24 
Comparable efficacy to Amitriptyline 
on HAMD and CGI scores 
Vorbach et al, 
1996 (1997)914 
LI 160 5.4 mg/day = 
0.3% hypericin 
1800 mg/day 
[3 x 600 mg] 
or 3 x 50 mg 
Imipramine 
6 weeks Imipramine 
(tricyclic) 
209 patients with recurrent severe 
major depressive disorders 
HAMD (17) >20 
Equivalent to Imipramine for severe 
depression but better tolerated 
Vorbach et al, 
1993 
(1994)915,916 
LI 160 
6:1 extraction 
ratio 
2.7 mg/day = 
0.3% hypericin 
900 mg/day 
Dried herb 
equivalent 5,400 
mg/day 
6 weeks Imipramine 
(tricyclic) 
135 outpatients with HAMD-17 
>20; single episode, several 
episodes, depressive neurosis and 
adjustment disorder with depressed 
mood 
Equivalent to Imipramine for 
depression (ie comparable).  Not 
sufficiently powered to show non-
inferiority of Hypericum 
Philipp et al, 
1999864 
STEI 300, 
Steiner 
Arzneimittel, 
Berlin 
0.2%-0.3%  
hypericin &  
2%-3% 
hyperforin 
60% ethanol 
1,050 mg/day 
[350 mg tds] 
or 
Imipramine 
100mg/day 
8 weeks Imipramine 
(tricyclic) 
& placebo 
263 patients with moderate major 
depression on ICD-10 
HAMD (17) mean 22.6 
& CGI & Zung 
More effective than placebo and at 
least as effective as Imipramine  
Hypericum -15.4 (SD 8.1) reduction 
Placebo -12.1 (7.4) reduction  
Imipramine – 14.2 (7.3) reduction  
Harrer et al, 
1999919 
LoHyp57 
Dr Loges & 
Co, GmbH 5-
7:1 extract 
ratio 
60% ethanol 800 mg/day 
[200 mgx2 ] 
Fluoxetine 20 mg 
[5 mg x 2 bd] 
6 weeks Fluoxetine 
(Prozac-
SSRI) 
149 elderly patients, aged 60-80, 
with mild-moderate major 
depression acc to ICD-10. HAMD–
mean 25 
Equivalent to Fluoxetine in mild-
moderate depression on HAMD: 
Hypericum reduced from 16.6 – 7.91 
Fluoxetine reduced from 17.18 – 8.11 
Behnke et al, 
2002871 
Calmigen 2.7 mg/day (900 
µg hypericin per 
tablet) 
300 mg/day 
or 
Fluoxetine 40 
mg/day 
 
6 weeks Fluoxetine 
(Prozac-
SSRI) 
70 patients  (mean age 49.7) with 
mild-moderate major depression 
HAMD 17 item, CGI & von Zessen 
Therapeutically equivalent  
HAMD: 
Hypericum 50% reduction, p < 0.001 
Fluoxetine 58% reduction, p < 0.001 
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Hypericum perforatum extracts compared with placebo 
Source  Extract/ 
Preparation 
Hypericin 
content 
Dosage Dura-
tion 
Compared with Subjects Outcome 
Kasper et al, 
2006867 
WS 5572 2.7 mg/day total 
hypericin 
equivalent 
(0.3% hypericin) 
600 mg/day and  
1,200 mg/ day 
6 weeks placebo 332 patients with mild-
moderate major depression 
(DSM-IV); HAMD-17; CGI and 
Montgomery–Asberg DRS 
At both doses, H. perforatum extracts 
were superior to placebo, p < 0.001. 
Lecrubier et al, 
2002905 
WS 5572 2.7 mg/day total 
hypericin 
equivalent 
(0.3% hypericin) 
900 mg/day 
[300 mg tds] 
6 weeks placebo Mild-moderate major 
depression in 375 adults aged 
18-65, acc to DSM-IV 
HAMD (17 item) 18-25 & 2+ on 
depressed mood item 1. 
Percentage of responders (with 50%+ 
decrease in HAMD scores) 
significantly higher for WS 5570, p < 
0.05 
and Beck melancholia, p = 0.001 
Kalb et al, 
2001923 
WS 5572 2.7 mg/day total 
hypericin 
equivalent 
(0.3% hypericin) 
5% hyperforin 
900 mg/day 
[300 mg tds] 
6 weeks placebo 72 patients with mild- 
moderate major depression 
(Mean 20 on HAMD 21 item 
scale) & CGI & von Zerssen  
D-S  
p<0.001 
Laakman et al, 
1998882 
WS 5573 4.5 or 45 mg/ 
day hyperforin  
(0.5%) or  5% 
hyperforin) 
900 mg/day 
[300 mg tds] 
6 weeks 2 doses of 
hyperforin with 
placebo 
147 patients with mild or 
moderate depression 
according to DSM-IV criteria; 
HAMD-17; D-S 
HAMD scores compared with 
placebo: 
5% hyperforin group, p = 0.004  
0.5% hyperforin group -  NS 
Shelton et al, 
2001924 
LI 160 
Lichtwer 
Pharma 
GmBH, 
Germany 
2.7 – 3.67mg/ 
day total 
hypericin 
equivalent 
900 mg/day 
[300 mg tds] for 4 
weeks →  ↑ed to 
1,200 mg/day 
8 weeks placebo  200 outpatients (mean age 
42.2yrs) with major 
depression and HAMD-17 
score of at least 20; HAMD, 
CGI & Beck 
Not effective for treatment of major 
depression 
Within both groups, p < 0.001 
Between groups, p = 0.16 
Hängsen & 
Vesper, 1996868 
LI 160 2.7 mg/day total 
hypericin 
equivalent 
900 mg/day 
[300 mg tds] 
4 weeks placebo  102 outpatients with mild-
moderate major depression.  
HAMD (16+) & D-S scale 
p < 0.001 
Sommer & 
Harrer, 1994925 
 
LI 160 
(Jarsin® 300, 
Lichtwer 
Pharma) 
Not specified 900 mg/day 
[300 mg tds] 
4 weeks placebo 89 patients aged 20-65 years 
with mild depression (ICD- 
neurotic depression of brief 
depressive reaction) of short 
duration completed the study.  
 
HAMD scores fell from 15.8 to 7.2 in 
active group, and 15.8 to 11.3 in 
placebo by end of week 4. 
Between group difference. p < 0.01  
(After 2 weeks, p < 0.05) 
67% responded in active grouop; 
28% responded to placebo. 
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Hypericum perforatum extracts compared with placebo cont 
Source  Extract/ 
Preparation 
Hypericin 
content 
Dosage Dura-
tion 
Compared with Subjects Outcome 
Uebelhack et al, 
2004861 
STW 3-VI 
(Laif ®) 
Not specified 900 mg/day 8 weeks placebo Mild-moderate depression 
(not specified if major)  
140 outpatients with HAMD-17 
score of 20-24 
p<0.001 
Witte et al, 
1995906 
Psychotonin® 
forte 
Hersteller, 
Darmstadt 
1 – 1.2 mg/ day 
total hypericin 
(0.5% 
hypercins) 
 
200-240 mg/day 
[100-120 mg bd] 
6 weeks placebo 97 ambulant patients, 24 – 65 
years old with major 
depression according to   ICD-
10 & HAMD score ≥ 16 
HAMD - 79% response rate in active 
treatment group vs 56% in placebo 
group.  Between groups difference, p 
= 0.019. 
Volz et al,  
2000926 
D-0496 
(Reyneke; 
Crinan farm) 
1.03 mg/day 
(516 µg per 
capsule) 
500 mg/day 
[250 mg bd ] 
6 
weeks 
placebo 140 participants with mild to 
moderate major depression 
according to DSM-IV, and 
HAMD score ≥ 21 
HAMD-21 scores dropped from 21 to 
12 in St John’s wort group vs 20.7 to 
14.3 in placebo group, p =0.005 
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Drug monitoring studies on Hypericum perforatum extracts  
 
Source  Extract/ 
Preparation 
Hypericin 
content 
Dosage Dura-
tion 
Compared 
with 
Subjects Outcome 
Grube  et al, 
199949 
Kira ®  
Lichtwer 
Pharma, 
Germany 
900 μg 
(0.9 mg) 
(300 μg x 3) 
405-675 mg/ 
day 
[135-225 mg 
tds] 
12 
weeks 
Drug 
monitoring  
study 
111 women from general 
medical practice with 
‘climacteric’ symptoms –
aged 43-65 
Menopause Rating Scale & 
CGI 
76.4% (patient rating) reduction in 
psychological & ‘psychosomatic’ 
symptoms (79.2% by physician 
evaluation) 
Woelk et al,l 
1994859 
LI 160 
Jarsin 
2.7 mg/day 
(900 μg x 3)  
900 mg/day 
[300 mg tds] 
4 
weeks 
Drug 
monitoring 
study 
3250 patients from 663 
medical practices. Age 
range 20-90 years (mean 
51). Includes mild, 
moderate, severe, 
reactive and other. 
Zerssen scale (D-S) 
Severity & frequency of 
symptoms reduced by ≈ 50%. 
80% responded positively 
Holsboer-
Trachsler & 
Vanoni, 
1999927 
LI 160 
(Jarsin 300) 
2.7 mg/day 
(900 μg x 3)  
900 mg/day 
[300 mg tds]  
6 
weeks 
Drug 
monitoring 
study 
Mild-moderate temporary 
depression 
Von Zerssen depression 
scale 
Condition improved in 75% of 
patients.  (Somewhat slower in 
patients >65 yrs) 
Martinez et al, 
1993928 
LI 160 
Jarsin 300 
2.7 mg 
hypericin 
900 mg/day 
[300 mg tds]  
4 
weeks 
With bright or 
dim light 
therapy for 2 
hours daily 
Seasonal affective 
disorders acc to DSM-III-R 
criteria 
Significant reduction in HAMD 
scores for both groups, p < 0.001 
CGI = Clinical Global Impressions   DRS = Depression Rating Scale   D-S = Von Zerssen Depression Self-rating scale 
DSM = Diagnostic and Statistical Manual   HAMD = Hamilton Depression Rating scale 
 
These include a range of RCTs comparing Hypericum with placebo or a comparator antidepressant, using a variety of Hypericum extracts, 
including major and non-major depressions, conducted across a time span of 15 years. 
 
Please note:  For further information, the reader is directed to the systematic reviews and meta-analysis by Linde et al,865,866,929,930 published in 2005 and 
2008, after compilation of these tables had been largely completed.
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13.7.1 Hypericum in Severe Depression  
Whilst most of the research has focused on mild to moderate depression, H. perforatum 
extract has also been compared with imipramine for treating recurrent severe depressive 
disorder in the absence of psychotic symptoms or delusions.915  At the higher doses of 
1,800 mg (6:1 extraction ratio = 10,800 mg/day), the extract  LI 160 was found to be as 
effective as Imipramine in improving symptoms of severe depression, and was better 
tolerated.915 More recently, Szegedi and colleagues862 found WS 5572 extract at an initial 
dose of 900mg, increased to 1,800mg/day in non-responders, to be at least as effective 
as paroxetine for moderate to severe major depression (HAMD-17 entry score 22+ and 
2+  on the depressive mood item; p = 0.08 between groups), and to be better tolerated.  
The study used a hydro-alcoholic extract containing 3-6% hyperforin, equivalent to 2.7-
5.4mg, and a 3-7:1 extract ratio.  Nonetheless, St John’s wort is not generally 
recommended for the treatment of serious depression with psychotic symptoms or 
delusions,915 suicidal risk or severe signs and symptoms that do not allow family or work 
involvement to continue.796 
13.7.2 Hypericum perforatum and Major Depression 
 
Some confusion was generated regarding the efficacy of Hypericum in major depression, 
by the 2005 publication of a meta-analysis by Linde and co-workers929 reporting on 
pooled data from six large trials on major depression.  It suggested only minimal benefit 
for St John’s wort in this context, and that its beneficial effects may be confined to mild-
moderate depression not meeting the criteria for major depression (Refer to appendix 6 
for DSM criteria).  However, most studies on St John’s wort have been conducted on 
major depression (Table 13.1), and many of these have shown significant effects over 
placebo for various extracts of Hypericum,867,868,904,905 and equivalence to standard 
antidepressants,860,862,864,871,872,914,917-919 with superior  tolerability.871,917,919 (A review of 
some of these studies was undertaken by as a component of the current work,  including 
comparator trials with antidepressant drugs860,862,864,871,872,914,917-919 without/with a placebo 
arm,864,870 and placebo-controlled trials. 867,868,904,905,924 Details are included in Table 13.1 
and Appendix 12).  A further meta-analysis by the same authors of 29 studies (of 79 
identified) on major depression has very recently been published, concluding that the 
evidence for the St John’s wort extracts tested in the trials supports its superiority to 
placebo, and similar effectiveness as standard antidepressants, in major depressive 
disorders (MDD).930  In the 18 placebo controlled trials examined patients receiving 
Hypericum extracts were significantly more likely to be responders (RR = 1.48; 95%CI 
1.23 to 1.77) and study results were highly heterogeneous (I² = 75%).  For the 17 trials 
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comparing Hypericum extracts to standard antidepressant treatment the pooled 
responder rate ratio was 1.01 (95%CI 0.93 to 1.09; I² = 17%) based on an intention to 
treat approach.  Based on per protocol data, the pooled responder rate ratio was 0.96 
(95%CI 0.88 to 1.05; I² = 43%). 
13.7.3 The Conflicting Findings in Depression Studies 
 
Results have not been unanimously favourable, however. One drug comparison study by 
the Hypericum Depression Trial Study group,870 with an additional placebo arm did not 
support the superiority of Lichtwer Pharma LI160 extract of H. perforatum over placebo 
for MDD (Table 13.1).  However, it is noteworthy that the SSRI was not superior to 
placebo either.  In contrast to the results of many placebo-controlled trials,867,868,904,905 
Shelton and co-workers924 found St John’s wort (LI 160) to be ineffective for major 
depression when administered to 200 participants at a dose of 900mg/dayfor 4 weeks, 
increasing to 1,200mg/day for the subsequent 4 weeks.  In another study, however, the 
same extract at 900mg/day was found to be significantly superior to placebo when 
trialled for 4 weeks on 102 outpatients with mild-moderate major depression.868   
 
Several possible reasons have been proposed for the discrepancy in the findings 
between studies.   In their meta-analysis of studies on MDD, Linde and co-workers 
observed that trials from German-speaking countries reported more favourable findings 
than trials from other countries.930  In a univariable meta-regression analyses on the 
selected studies of major depression, they found that over half the variance (R² = 0.51) in 
effect sizes reported could be explained by three variables: country of origin (studies 
from German-speaking countries showing larger effect sizes, p = 0.002), precision (more 
precise studies showing smaller effects, p = 0.03) and baseline values (higher values 
associated with smaller effect sizes, p = 0.048) were significantly associated with effects 
sizes.930 
 
Other suggested factors for the discrepant findings relating to the antidepressant action 
of H. perforatum include:  
• the small sample size in some studies.924  Smaller trials tended to report larger 
treatment effects.  A possible reason suggested for this is publication bias or lower 
methodological quality of smaller trials.931  However, in studies with smaller sample 
sizes, there is less power to detect superiority over placebo.  Despite this, St John’s 
wort has been quite convincingly shown in a number of studies to be superior to 
placebo.  Therefore, power was clearly not an issue.  Additionally, many large-scale 
studies have been conducted.   
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• short duration of studies924. Once again, it may be expected that the placebo effect 
would be higher in studies of shorter duration, as it does not wash out before 6-
weeks.932  These studies have frequently found superiority over placebo.  Linde and 
Knuppel866 in a systematic review of large scale observational studies noted that the 
observation periods ranged from 4 to 6 weeks, with the exception of two studies of 52 
weeks.  They reported that results from both the short term and long-term studies 
indicate significant improvement, although the response rates tended to be slightly 
lower in long-term than in short-term studies. 
• diagnostically heterogeneous groups,924 sometimes within one study.  This has in fact 
occurred in some studies.872  However, as mentioned previously, there have been 
many studies restricting inclusion to participants with major depression, while others 
have focused on mild-moderate depressive symptoms in people who would not meet 
the criteria for major depressive disorders.  The majority of studies have focused on 
mild-to-moderate depression but a limited number of severely depressed patients 
have been included.866,914 Older trials often included patients with neurotic depression 
and brief depression, and may have included more patients with somatisation and 
atypical depressive features.  Thus, as pointed out by Murck, newer trials may be 
excluding patient groups that are particularly responsive to Hypericum extracts.933 
• different diagnostic tools used.924  These include ICD-10 criteria and DSM-IV.  In 
terms of outcome measures, the HAMD-17 and HAMD-21 have predominantly been 
employed. 
• lack of equivalence between preparations trialled.865  Among the 16 large-scale 
observational studies reviewed, with total of 34,804 patients (minimum of 100 
participants per trial) (range 101 to 11,296), Linde and Knuppel866  found the total 
number of different products to be twelve, and the daily extract dose to range from 
360 to1,200mg.  However, a meta-analysis of 37 double-blind, placebo–controlled 
RCTs on Hypericum found little evidence of an association between response and 
daily dosage and type of extract.929   Comparison of the different extracts is 
confounded by several factors. The amounts of active constituents such as 
hypericin, hyperforin and the flavonoids can vary enormously between products.  A 
study of Hypericum products on the German markets showed that a number contain 
only minor amounts of bioactive constituents.934  Most studies have tested  
Hypericum products standardised for hypericin content, as this was previously 
thought to confer the anti-depressant activity.  Relatively few specify the hyperforin 
content, variation in which could potentially account for the different findings.  An 
additional limitation is that hyperforin is most unstable in solution and rapidly 
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decomposes at an acidic pH.  Galenicals of St John’s wort that are older than a few 
months contain no hyperforin at all.935  The quality of Hypericum preparations can 
also differ according to the raw plant material, extraction process, ratio of raw 
material to extract and the solvents used.  The effect of the  extraction solvent on the 
percentages of constituents extracted is demonstrated in Table 13.2 below: 
TABLE 13.2  THE PERCENTAGES OF HYPERICIN AND PSEUDOHYPERICIN OBTAINED WITH 
 DIFFERENT EXTRACT SOLVENTS 
Solvent Hypericin % Pseudo- 
Hypericin % 
Methanol 75% 80% 
Ethanol 34% 37% 
Acetone 20% 20% 
Isopropanol 10% 10% 
Water 10-20% 30-40% 
From Bloomfield, HH & McWilliams, P. The Hypericum Homepage. 
www.hypericum.com/copy.htm936 
 
 
vi.  Several prognostic factors identified in different studies866 may also impact on the 
variability of findings.  Although findings have not been uniform, these include: 
• dysthymia versus major depression. Dysthymia has shown the best 
outcome.866,929 
• severity of depression, with those with higher baseline HAMD scores being less 
responsive.929  
• the duration of treatment.  Longer duration is a negative predictor.929 
• age. Older patients have shown slower improvement in some studies.937 
• organic disease has negatively predicted response.937 
• concurrent psychotropic co-medication is a negative predictor.937 
13.7.4 Criticisms made of St John’s wort depression studies 
 
Trials of St John’s wort for depression have been criticised for the failure to use 
standardised symptom rating instruments.924 While this may be of relevance to 
observational studies, often conducted for marketing purposes, the majority of RCTs 
appear to have used the well-validated HAMD-17 or HAMD-21 item scales, or to a lesser 
extent, the BDI.  Another drawback of observational studies conducted in primary care 
settings is that primary care physicians are not experienced in depression research.924  
However, this is unlikely to have biased findings in double-blind trials.  Several older 
trials have been criticised because they included patients with few or mild symptoms who 
did not meet criteria for major depression.929  These studies were mostly conducted on 
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mild-moderate depression, which is susceptible to a higher placebo response rate.924  
However, such RCTs constitute a minority of those conducted on Hypericum.  Moreover, 
despite the high placebo response in these RCTs, Hypericum was shown to be superior 
to placebo. 
 
It has been suggested that the dosages of the standard antidepressants used in 
comparator trials were too low, so that equivalence resulted because neither Hypericum 
nor the standard anti-depressants actually conferred substantial benefit.865  While the 
lack of a placebo control group does make it impossible to definitely rule out the 
ineffectiveness of both interventions, it is unlikely that antidepressant drugs with 
established efficacy would confer no benefit, even at lower doses.  Higher doses of 
antidepressants have not conclusively been shown to be more effective than lower 
doses.938   
13.8 Adverse events  
 
Adverse events associated with Hypericum perforatum tend to be mild, and to occur 
rarely.  From 1968 to1998, WHO Uppsala Monitoring Centre received 57 reports of 
suspected adverse drug reaction associated with St John’s wort, namely nervousness (5 
cases), eczema, sleep disorders and paraesthesia (3 each).939 St John’s wort appears to 
be free of any cardiac as well as anticholinergic side-effects normally seen with 
antidepressant medications.940  
 
In clinical trials and observational studies involving St John’s wort, mild adverse events 
are often reported no more frequently than in placebo arm.  In a review of large-scale 
observational studies comprising a total of 34,804 patients, the tolerability and 
acceptability of tested extracts was reported to be very good.866  The percentage of 
patients reporting side-effects ranged between 0% - 5.9%.  St John’s wort extracts were 
associated with only mild side-effects, the most frequent being gastrointestinal 
symptoms.  Increased sensitivity to light and skin symptoms were the second most 
frequent, and a variety of nervous symptoms such as agitation or restlessness were 
reported in a number of studies.  No serious side-effects of interactions with drugs were 
reported.   
 
Another systematic review of 8 studies found only 1.1% of patients discontinued 
Hypericum extract because of side-effects.922  In placebo-controlled trials, the 
percentage of patients reporting at least one adverse drug reaction (ADR) with 
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Hypericum was 4.1% compared with 19.8% where Hypericum was compared with an 
antidepressant drug.  The percentage of patients dropping out of clinical trials because of 
ADRs was lower for Hypericum than for the all other drugs.939   
 
Post-marketing surveillance of 3,250 patients taking Hypericum extract (equivalent to 
2.7mg per day of total hypericin) observed side-effects in 2.4% of patients. 859   
Consistent with the findings of Linde and Knuppel mentioned above866, the most 
frequently noted were minor gastrointestinal irritations (0.6%),  allergic reactions such as 
pruritis (0.5%), tiredness (0.4%) and restlessness (0.3%).  
 
In the drug-monitoring study of 111 menopausal women taking 900 μg hypericin/day, 
there were only 4 reported adverse events, namely one case of each of slight nausea, 
dizziness, headaches and sleep disturbances.49   
 
In a comparison with imipramine, at 1050 mg/day of Hypericum, nausea, headache and 
palpitations (3.8%) occurred more frequently than for the placebo group.864  
 
A review of 8 studies (total n = 611) found nausea, rash, fatigue, restlessness and 
photosensitivity to occur most frequently.922 
Adverse events from individual case reports often involve concomitant medication or 
other pathologies, making it difficult to establish a causal connection with the 
administration of St John’s wort.  Cases where the link is considered probable will be 
included here: 
• Photosensitivity developed in a 61-year-old woman after taking St John’s Wort-
extract for three years, which resulted in elevated, itching red lesions in light-exposed 
areas.941  
• Four cases of sensory nerve hypersensitivity reactions, with increased sensitivity to 
heat and cold, and pain in the hands and/or feet were reported.  These resolved 
within 1 –2 weeks of ceasing the herb.942 It is suggested that the preparations 
involved were from the late-harvested herb that contained high levels of resinous 
constituents.796  
• One case of subacute toxic neuropathy with sharp pains in sun-exposed areas (face 
and hands) occurred after 4 weeks’ ingestion but disappeared on cessation of the 
Hypericum product.943  
• After 2 weeks administration of Hypericum, a 67-year-old woman developed 
adynamic ileus, which resolved completely on discontinuation.944 
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• Delayed emergence from anaesthesia occurred in one case after 3 months’ ingestion 
of up to 3 g/day.945  
• Multiple side-effects in a 47-year-old woman, including dyspnoea, hyperventilation, 
palpitations, tremor, flushing, mydriasis and rhinitis, suggestive of an allergic 
reaction.946 
13.9 Herb-Drug Interactions with St John’s wort 
 
Hypericum perforatum induces hepatic drug metabolism via activation of the pregnane X 
receptor947,948 and thus can potentate certain enzymes of the cytochrome P450 enzyme 
system, notably CYP3A4.316,948-950 Some evidence exists for induction of other 
cytochrome P450 isoforms such as CYP1A2951,952 and CYP2D6953 (modest).  However, 
the most important in this context is CYP3A4 which is involved in the oxidative 
metabolism of over 50% of all conventional medications,947 and implicated in most 
clinically significant drug-drug interactions.950  St John’s wort extracts therefore have the 
potential to induce metabolism of some co-administered medications, thus resulting in 
lowered serum concentration of a number of drugs, namely: 
• immunosuppressants (cyclosporine)954,955,956 
• cardiac glycosides (digoxin) for doses of St John's wort greater than 1 g/day 
(dried herb equivalent)957 
• HIV medication including protease inhibitors,(indinavir),958 the non-nucleoside 
reverse transcriptase inhibitor, nevirapine959, and other anti-retroviral drugs960 
• chemotherapy drugs, (irinotecan)961  
• anti-coagulant medication such as warfarin, phenprocoumon962,963  
• low dose oral contraceptives962  
• theophylline (bronchodilator)964  
• triptans (migraine medication)965 
• midazolam (benzodiazepine)949 
• fexofenadine (antihistamine)966   
• the HMG-CoA reductase inhibitor simvastatin967 and atorvastatin968 (but 
pravastatin was unaffected) 
• phenytoin (theoretical concern)965  
• amitriptyline (tricyclic antidepressant).969,970   
 
A comprehensive and up-to-date review of herb-drug interactions has subsequently been 
published by Mills and Bone.805   
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Other than hepatic and gastrointestinal enzyme induction, administration of St John’s 
wort may also affect intestinal absorption, distribution and renal clearance of drugs such 
as digoxin, by activation of P-glycoprotein.957,971,972 In conjunction with SSRIs, it may 
result in synergistic serotonin uptake inhibition.  There have been reports of elderly 
patients developing ‘serotonin syndrome’ type symptoms with co-administration of  
Hypericum and SSRIs 973,974 This may apply to  paroxetine, trazodone, sertraline, and 
other serotonergic agents such as nefazodone, venlafaxine975 as well as triptans 
(migraine medication such as sumatriptan, naratriptans, rizatriptan and zolmitriptan).965 
 
Because photosensitivity is a potential adverse reaction that has been associated with 
higher doses of Hypericum,976 photosensitising agents (delta-aminolaevulinic acid, 
piroxicam, tetracycline)i977 should be avoided in conjunction with Hypericum.  However, 
studies using high dose extracts (1800mg, equivalent to 5.62 mg/day of total hypericin) 
over 15 days found a moderate increase in sensitivity to UVA light, but not to UVB light.  
Prolonged or intense exposure to UVA radiation whilst taking Hypericum is advised 
(p550).796  It should be avoided by people with known photosensitivity.805 
 
Research shows that the pharmacokinetic drug interactions are dose-related, and also 
depend on the preparation administered.978  The compound most implicated in the herb-
drug interactions is hyperforin, found to be responsible both for activation of P-
glycoprotein979 and  the metabolic drug interactions.978,980-983  As hyperforin is most 
unstable in solution and rapidly decomposes at an acidic pH,984 tinctures and fluid 
extracts are low in hyperforin.935 Thus, pharmacokinetic drug interactions should not be 
an issue with such preparations, nor at doses less than 2 g St John’s wort herb per day 
or its equivalent.935 However, hyperforin is also believed to be responsible for the 
antidepressant effects, although evidence is conflicting in this regard.882,981 
 
Pharmacokinetic data is available;796 toxicology data in animals is presented in Mills and 
Bone (2005: pp590-1).805   
13.10 Conclusion   
 
Although the mechanisms of action of Vitex agnus-castus and Hypericum perforatum 
have not yet been fully elucidated, both herbs have been subject to considerable 
investigation in the scientific arena.  Current knowledge, based on in vitro and in vivo 
models, supports CNS mechanisms involving neurotransmitters and/or opioid receptors.   
It is hypothesised that these herbs may, therefore, exert effects on menopausal 
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symptoms similar to those observed with CNS-acting agents such as the anti-depressant 
selective serotonin reuptake inhibitors and the anticonvulsant gabapentin, which have 
been demonstrated to ameliorate vasomotor symptoms in menopausal women.  Their 
proposed mechanism in this context is via the complex interaction between hormones 
and neurotransmitters involved in the physiology of hot flushes.   Based on their known 
pharmacology, both Vitex and Hypericum could be expected to confer additional benefits 
to menopause-related psychological symptoms.  
Findings from a limited number of clinical studies with potential relevance to 
psychological and physiological symptoms of menopause have supported the benefits of 
phytotherapeutic menopause formulations that include Vitex and/or Hypericum.   Most of 
the limited, and often conflicting, evidence in this arena is for the phytoestrogen-
containing plants, long-term use of which has now raised safety concerns.  Evidence 
from rigorous research is thus needed for the benefits of non-oestrogenic phytotherapies 
employed in clinical practice for the amelioration of menopause-related symptoms.   
The information provided regarding the indications, contraindications, herb-drug 
interactions and adverse events associated with these two herbs informed the selection 
criteria and exclusion criteria for the RCT to be reported.  Before outlining the 
methodology of this study, however, contributing factors to the placebo effect, and its 
implications will be examined more closely as this has been shown to be substantial in 
menopause studies. 
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Chapter Fourteen 
  
 
 
The Placebo Response 
 
 
  
 
 
 
14.0 Introduction 
 
The final chapter of the Literature Review examines some of the issues surrounding 
placebo effects that can be substantial in studies of CAM as well as of menopausal 
symptoms.   The resultant risk of inappropriate rejection of potentially valuable 
treatments had led to efforts to understand this phenomenon and to control its effect in 
randomised, controlled trials.  This includes identification of unique characteristics of 
placebo responders. 
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14.1   Magnitude of Placebo Effect in Relevant Conditions 
Randomised controlled trials (RCTs) of therapy for vasomotor symptoms in menopause 
commonly report substantial placebo effects, averaging 51% trials in hormone treatment 
according to a 2004 meta-analysis,499 and generally in the range of 30 to 41% in RCTs in 
trials of phytotherapy/medicinal herbs,75,76,793,848,849 and 1% - 59% for phytoestrogen 
supplements.985 This phenomenon is also observed in RCTs of treatments of 
depression, with placebo response rates averaging approximately 30%, ranging from 
12% to beyond 50% and found to be on the increase.929,986 This change in placebo 
response rates in depression studies has been observed for conventional 
pharmacological (7% per decade) and phytotherapeutic interventions alike, with a 1.5% 
per year increase in Hypericum trials (and a concomitant decrease in treatment 
response of 1.1% per year.929  In terms of premenstrual symptoms, a  1997 meta-
analysis of controlled treatment trials for premenstrual dysphoric disorder (PMDD) 
showed rates of placebo response ranging from 6% to 35%.987  Earlier PMS studies 
indicated rates of placebo response as high as 94%.988  In a PMS study with Vitex 
agnus-castus  there was a 24% placebo responder rate (≥ 50% reduction in symptoms) 
or a 30% reduction in symptoms measured on a self-rating scale.481   
 
It has been suggested that conditions with a strong psychological component, such as 
depression, anxiety and pain, all common corollaries of illness, are particularly susceptible 
to the placebo effect.989 However, many studies on physical conditions such as obesity,990 
mild neurological deficits,991 angina pectoris,991 as well as surgical interventions for 
Parkinson’s disease992 and arthroscopy993 have also reported high placebo effects.   
14.2 Natural History and Regression to the Mean 
 
The placebo response in trials is partly dependent on the condition being treated.994  
Unless an untreated control group is also included, such estimates of the magnitude of 
the placebo response do not account for regression to the mean or the natural history of 
symptoms.  Natural history refers to the spontaneous variations that occur in most 
conditions.  Regression to the mean is a statistical phenomenon that assumes people 
receive their initial assessment/join clinical trials when the intensity of their symptoms is 
greatest, and that the level of intensity is likely to be less on the subsequent assessment.  
(These are not generally considered to be part of the true placebo effect,995 although 
Ernst996 includes them among ‘non-specific effects’).   To investigate the effect of 
placebos beyond that of natural history, Hrobjartsson and Gotzsche conducted a  meta-
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analysis of  RCTs that included  a no-treatment control group in addition to a placebo 
group and concluded that placebo interventions had no clinically important effects.997  The 
data from this study were subsequently reanalysed by Wampold and colleagues, who 
reported that , when disorders are amenable to placebos and the design is adequate to 
detect the effects, the placebo effect is robust and approaches the treatment effect.998 
14.3 Problems associated with Substantial Placebo Effects 
 
Although attempts to harness it in clinical practice have been referred to as 
‘unscientific’,999 the placebo effect can interact synergistically with the specific 
intervention to enhance treatment outcomes, especially where the patient’s subjective 
viewpoint is the optimum outcome measure, (for example, quality of life) and thus may 
be a boon in clinical practice.  However, it continues to be regarded as the bane of RCTs 
assessing the efficacy of potential treatments.  A substantial placebo response can result 
in smaller effect sizes and failure to demonstrate superiority over placebo of new 
treatments,1000 due to type II errors (that is, erroneous conclusions that there are no 
differences between the efficacy of the treatment and placebo).  A high placebo 
response may account for the frequent failure of well-designed CAM trials to report 
significant effects over placebo.  Similarly, the equivocal results from trials of Trifolium 
pratense, (Red Clover), in menopause symptoms,75,691,692 may reflect different placebo 
responses.  In addition to contributing to the rejection or discontinuation of potentially 
viable treatments, high placebo responses and subsequent ‘negative’ results of trials add 
time and cost to the development new treatments,1001 which may further discourage the 
already-limited financial investment in research.  As a result, studies attempting to 
understand the placebo effect are largely being directed at reducing its effect in RCTs in 
order to increase the power to detect drug-placebo differences.  
14.4 The Meaning Response 
 
The inclusion of placebo arms in drug studies began in 1962 when the USA FDA 
regulations first required drugs to be proven effective.1002 Since then, placebo-controlled 
trials have come to be considered the gold standard among research designs.  A 
placebo-controlled trial employs a sham intervention such as dummy pills that lack a 
specific effect – that is, an effect for which an empirically supported theory exists for its 
mechanism of action – for the condition being treated, in order to control for effects of the 
treatment setting.  The placebo effect is, thus, the effect seen in patients who have 
received an intervention which is believed to lack a specific action for the condition under 
investigation. Because placebos are, by definition, inert substances, they cannot actually 
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cause placebo effects themselves.995 However, their meaning can, and the term ‘meaning 
response’  or meaning-induced responses’1003 have been proposed to embrace both the 
desirable responses of the placebo effect and the undesirable effects of the ‘nocebo 
effect’.995,1004  As pointed out by Wolf in 1950,1005 the mechanisms of the body are capable 
of reacting not only to direct physical and chemical stimulation but also to symbolic stimuli, 
words and events which have somehow acquired special meaning for the individual.   
14.5 Contributors to the Placebo Response 
 
Hypotheses regarding factors that produce the placebo effect have focussed on  i) 
sociocultural perspectives, emphasising the system of beliefs that the patient and 
practitioner bring to the treatment setting; ii) biological perspectives, emphasising the 
role of  the endogenous opioidergic and, more recently, dopaminergic pathways,1006 as 
well as a proposed genetic predisposition;1007 and iii) clinical trial methodology and 
investigator effects.   
14.5.1 The Socio-Cultural Perspective 
 
The psychosocial context, also referred to as ‘non-specific effects’, includes individually 
or culturally based expectations for a treatment1008 that are influenced by general beliefs 
in the culture about what constitutes good treatment as well as the individual patient’s 
previous experience with pharmacological agents and treatment during his/her lifetime.  
As such, classic conditioning effects also form part of the placebo response.  Other 
meaningful elements of the situation or context include practitioner effects such as  
provider-induced expectancies, credibility of the setting, therapist and treatment, positive 
information about the treatment or illness and support/reassurance.1009 Practitioner 
certitude even affects the magnitude of the placebo effect in double-blind RCTs.1010 The 
practitioner’s costume, manner, style, language, mood, time available and charisma can 
also affect the placebo response, as can the degree of illness and even the diagnosis 
and prognosis.995 The attention, time, support and reassurance that modulate the anxiety 
and expectations contribute to the therapeutic alliance and are believed to be potent 
factors, particularly (but not exclusively) in psychiatry.1011 The pivotal role of expectancy 
in the placebo effect 1012 suggests that depression should be very reactive to the 
placebo effect, as placebos instil an expectancy for improvement, whereas at the core of 
depression is hopelessness, which is “an expectancy that an intolerable situation will not 
improve.” 1013  (Indeed, from a meta-analysis of antidepressant medication, Kirsch and 
Sapirstein1014 concluded that 25% of the effect was due to the true drug effect, 25% to 
the natural history of the condition and 50% to the expectancy effect.) The power of 
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expectancies to override the pharmacological effects of drug has been shown in several 
studies. In a recent series of RCTs for four different painful conditions using real or sham 
acupuncture, patients with higher expectations about acupuncture treatment experienced 
larger clinical improvements than patients with lower expectations, regardless of the 
allocation to real acupuncture or sham acupuncture.1015  Moreover, the effects were long-
lasting, still being evident at 6 month follow-up. Other studies highlighting the power of 
expectancies include those where participants’ expectancies were contrary to the 
pharmacological effects of the drug,1016,1017 and where participants were misinformed of 
the action of a sympathomimetic drug.1018  Participants who expected to receive active 
treatment showed more significant changes in brain metabolic activity than those who 
expected to receive placebo, even though both groups were given an active drug.1019 
The group to which participants believed they were assigned was more powerful than the 
than actual assignment.1020 
 
A unifying model for understanding the placebo response in clinical trials proposed by 
Klosterhalfen and colleagues, is based on three components: regression to the mean, 
Pavlovian conditioning, and signal detection theory.1007,1021  Patients’ expectations and 
beliefs together with classical conditioning influence the ‘signal-to-noise ratio’ which 
describes the ability of the patient or the investigator/therapist to identify a change in 
symptoms. 1021 This is of major importance to the validity of studies using subjective 
outcome measures.  Regression to the mean, natural history, experimenter or subject 
bias and errors in measurement of reporting995 are elsewhere excluded from the 
definition of the ‘meaning response’. 
14.5.2 The Biological Perspective 
 
In terms of neurobiological mechanisms, both neuropharmacological studies and brain 
imaging investigations have found endogenous opioids to be involved in the production 
of placebo analgesia.1022,1023 Inhibition of the analgesic placebo response was effected 
by the opioid antagonist, naloxone,1024 and higher β-endorphin levels were found in their 
cerebrospinal fluid of placebo responders compared with non-responders.1025  It has also 
been suggested that placebo-induced dopamine release could be a major biochemical 
substrate for the placebo effect not only in pain, but also in other conditions such as 
motor disorders and depression.1026-1028  In vivo research on Parkinson’s Disease, 
indicated that the placebo effect in Parkinson’s Disease is mediated through activation of 
the damaged nigrostriatal dopamine system.1006  Expectation of reward has also been 
shown to be at least partly mediated by the dopamine system,1029-1032stimulation of which 
may be activated by the brain opioid system.1033  Placebo-induced dopamine release in 
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response to the expectation of reward (clinical benefit, in this case) has been suggested 
as representing a common biochemical substrate in many conditions.1026  Opioid 
mechanisms are likely to be activated during the routine therapist-patient interaction.1020 
 
There is evidence from studies of antidepressant medication that, while both placebo 
and active treatment exerted nearly equal benefits, their effects on the brain were quite 
different.1034,1035 Quantitative electroencephalography revealed that placebo treatment 
induces changes in brain function that are distinct from those associated with 
antidepressant medication.  Placebo responders showed a change in prefrontal 
cordance* that differed in direction and time course from the change in antidepressant 
medication responders, casting a new light on the assertion that 50% -75% of the 
antidepressant effect consists of placebo effect, since symptom improvement was not 
associated with a similar physiological alteration in the placebo responder and 
medication responder groups.1036   
 
Brain imaging studies of placebo analgesia using positron emission tomography (PET) 
found that the same regions of the brain to be affected by both placebo and an opiate 
agonist, 1037 indicating placebo-induced psychosocial analgesia occurs via a related 
mechanism to the opioid-induced pharmacodynamic effect.1020  Another study using 
magnetic resonance imaging  indicated that placebos reduce nocioceptive transmission 
along the pain pathways.1038  Further, the release of endogenous opioids might be 
activated in the anticipatory phase of the placebo response.1039  Benedetti suggested that 
there is no certainty that painkillers administered to subjects act on the pain pathways, 
as they might also, or only, act on the expectation pathways (the uncertainty 
principle).1033  Indeed, almost all pharmacological substances might act on the 
neurotransmission of the expectation pathways.1020    [Using a classical double-blind 
RCT design followed by an open-hidden paradigm†* to eliminate the context effects, 
Benedetti and colleagues1040  found that placebo effect accounted for the whole of the 
                                                 
* Cordance is a measure derived from QEEG power that has a moderately strong association with 
cerebral perfusion. It is calculated with a three-step algorithm that normalises power across both 
electrode site and frequency bands.  It has been described in detail in Leuchter et al. 1999.1033  
 
 †  The open-hidden paradigm involves both overt and covert administration of an active treatment. 
In the ‘open’ administration, participants are given the treatment by a practitioner or researcher in 
full knowledge that they are receiving it.  During the ‘hidden’ administration, the treatment is 
administered via a pre-programmed infusion pump so that the participant does not know when 
he/she is receiving it.  It thereby allows for comparison between the specific effect of the drug 
(hidden component) and combination of specific component and context effects (open 
component).  The difference between open and hidden administration is the non-specific effects,  
which are believed to be similar to, if not the same as, placebo effects. It has been suggested that 
the open-hidden paradigm may offer a way to render the expectation pathways silent.1030  
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‘analgesic’ effect attributed to proglumide, a cholecystokinin antagonist, in the classic 
double-blind trial, which had shown it to be superior to placebo.]  
 
Neural changes following a placebo procedure are not confined to pain and depression 
but are also present in other systems and pathological conditions, such as immune 
disorders1041 and Parkinson’s Disease,1006 among others.1042  
 
Although challenging an underlying assumption of placebo-controlled RCTs, it is not 
impossible that different mechanisms operate in the two treatment arms, with the 
placebo having its effect via psychological mechanisms and the active treatment, 
indistinguishable in appearance from the placebo, acting through pharmacological 
mechanisms.998  It has been argued by Kirsch and colleagues, that it is not logically 
necessary for the effects of the active treatment to be additive, or composed of the two 
components – the placebo effect and the specific treatment effect.1043 It is proposed that 
the effects may be non-additive, or only partially additive (Figure 14.1).1043  The rationale 
is based partly on meta-analyses of antidepressant drugs, which find that 65% - 80% of 
the response to the drug is duplicated in the placebo condition, including in long-term 
maintenance studies.1014,1044,1045  This suggests that if drug effects and placebo effects 
are additive, then the pharmacological effect of antidepressant drugs is really quite 
small.1043    
 
 
FIGURE 14.1   DRUG EFFECTS AND THE PLACEBO RESPONSE: ADDITIVE AND NONADDITIVE   
MODELS.   
From Kirsch, I.  Are drug and placebo effects in depression additive? Biol Psychiatry 
2000;47(8):733-5.1043  Reproduced with permission from Elsevier.  
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14.5.3 Clinical trial Methodology and Investigator Effects  
 
Aspects of clinical trial methodology that are thought to contribute to the rising placebo 
response include failure of trial design, investigator behaviour and the populations 
studied.1000 This includes extra time being spent by the researchers with participants, 
increased non-specific supportive contact, reassurance, comorbid conditions that can 
compromise response to treatment and the recruiting of participants with disorders that 
have a fluctuating course or with mild disorders.  Some depression studies suggest that 
more severely ill patients respond poorly to placebo, whereas those who are mildly ill 
respond equally well to antidepressants and placebo.1046   
14.6 Predictors of the Placebo Response 
 
Attempts to identify personality and demographic characteristics of placebo responders 
have yielded inconsistent results.  An analysis of a range of anxiety disorders and major 
depressive disorder (MDD) suggests that the predictors of placebo response rate may 
vary according to the condition under investigation.1046  Despite the suggestion that 
unique placebo characteristics do not exist, and the sometimes contradictory findings, 
attempts to identify predictors of placebo responders continue and have identified the 
following variables (Table 14.1).  
 
Placebo rates also increase with overall treatment effect of the active agent being 
studied (IBS study,1047 consistent with observations derived from a meta-analysis of 52 
placebo-controlled antidepressant trials.1048)   It is also interesting to note that the 
response to active treatment can be affected by the inclusion of a placebo arm, as 
shown in acute migraine studies which noted a significantly lower drug effect when a 
placebo group was included.1049 
 
As mentioned previously, predictors of placebo effects may be condition-specific,1046 
rendering generalisability of findings uncertain. 
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TABLE 14.1  PREDICTORS OF THE PLACEBO RESPONSE IN STUDIES OF VARIOUS CONDITIONS  
Demographic variables  
• younger age (PMS study)1050  
• aged 60+ years (depression study,1051 but not supported by meta-analysis986) 
• male gender (peptic ulceration,1052 functional dyspepsia,1053 migraine,1053,1054 depression1051 but not 
consistently986) 
• European study location/population (vs USA)1046 (anxiety disorders and MDD) 
• married compared with widowed/separated/divorced or single subjects1051 
• higher BMI (functional dyspepsia) 1053 
Affective state and symptom characteristics 
14 positive response to prior therapies1055 (depression) 
15 higher (positive) patient expectations of treatment outcome929,1015 
16 acquiescence,1056 which could result in obliging reports 
17 practitioner/investigator confidence in efficacy of therapy used1010 
18 high levels of neuroticism, including depression and anxiety (low back pain)1057 
19 comorbid anxiety1058; (lower baseline ratings of somatic anxiety1059for recurrent depressive 
episodes) 
20 severity of symptoms/disease at baseline:  (antidepressant medication: milder 
severity1051,518,986moderate severity.1055  Social Anxiety Disorder: decreased severity.1046)  
21 chronicity of disease/symptoms. (In depression studies, 932,1060 this has been the most consistent 
finding, but not universally supported.986,1055) 
22 worsening or limited change during placebo lead-in in depression; limited change in anxiety, 
melancholia, helplessness, and paranoia (depression studies).1061 
23 less stable symptom pattern (functional dyspepsia)1053 
14 suggestibility was not associated with healing or relief of symptoms in the patients receiving placebo 
(peptic ulceration).1052 
Methodological factors 
• frequency of administration of intervention (IBS study1047 and migraine prophylaxis.1054) 
• quality of study994 
• duration/length of the study 994,1062 
• patients’ awareness that they are receiving treatment (open vs hidden paradigm.1040 Open are 
more effective than hidden at eliciting ‘treatment‘ effects.)1003 
• unbalanced active:placebo randomisation ratios1063 (Controversial)1064 
• documentation of dropouts and additional treatments994 
• prevention trial994 
• recruitment of participants with less severe symptoms/disease (in depression studies1046,1065 and 
first episodes of depression1059) 
• comparison with active placebo possibly due to the side-effects of the active control1066  
• perceived assignment to treatment.  (Sham acupuncture1015 Sham surgery for Parkinson’s 
disease;992  
• placebo lead-in was not significantly associated with placebo response rate in a meta-analysis of 
depression studies.986 
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14.7 Complementary Medicine Issues  
CAM research faces the challenge of demonstrating that CAM therapies have more than  
placebo effects, especially since well-designed clinical studies of CAM frequently fail to 
find significance over placebo.  It has been proposed that CAM has an enhanced 
placebo effect and could be an especially successful placebo-generating health care 
system,1067 possibly by its emphasis on personal responsibility, commitment and active 
participation in the treatment, which can facilitate adherence.  Other aspects of the 
setting such as the therapeutic alliance, amount of time spent, enhancing patients’ 
expectations through positive information about the treatment or illness while providing 
support and reassurance, all shown to significantly influence health outcomes,1009 could 
also contribute to greater non-specific effects.  It has been suggested that an increased 
anxiety among users of CAM renders them more susceptible to the placebo 
response.1067 A national survey of trends in CAM use in the US from 1990-’97 reported 
that alternative medicine was predominantly used for chronic conditions, including back 
problems, anxiety, depression, and headaches,1068 conditions described by Kaptchuk as 
“highly subjective symptoms lacking identifiable physiologic correlates, chronic 
conditions with a fluctuating course often influenced by selective attention, and affective 
disorders.”1067  
Conversely, it has been argued that if the placebo effect represents a conditioned 
response, complementary medicine would be expected to produce lower placebo 
response rates than pharmaceutical interventions since the latter have well-known large 
effects1008 and a high degree of correlation between response to treatment and response 
to placebo has been shown.1014   
 
Although the placebo response rates in studies of herbal medicine may not compare with 
rates seen in studies of HT for the vasomotor symptoms of menopause or 
antidepressant drugs, less pronounced specific treatment effects are often associated 
with CAM.  Thus the magnitude of the context effects continues to present a challenge in 
CAM research. 
14.8 Conclusion 
 
Substantial placebo effects plague research on menopause, depression and CAM.  This 
can potentially result in treatment effects being missed due to type II errors, as well as 
increasing the sample size required to detect a statistically significant effect.  Where both 
arms improve significantly, an intervention found to be no better than placebo cannot be 
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concluded to be ineffective999 in terms of improving the wellbeing of the participants. 
However, to meet the criteria of scientifically rigorous research, the specific effect must 
be determined, and the results must be replicable.  It is therefore necessary to 
understand, as well as control, the placebo effect.  In menopause studies, as well as 
depression, the natural history of the conditions may contribute substantially to the high 
response rate in the placebo arm.  As recruits often enrol in clinical trials when their 
symptoms are at a peak, regression to the mean can confound studies of any condition.  
These threats to validity can only be distinguished from the placebo effect by the addition 
of an untreated arm to the design,996,1069 although this further increases costs in terms of 
financial and human resources.  It is thus imperative to design protocols that are both 
scientifically rigorous and maximise the likelihood of accurately detecting the specific 
treatment effect of active interventions, by controlling the context effects. To that end, 
different paradigms have been proposed and trialled – not exclusively for CAM research.   
These will be discussed further in chapter 19.   
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Chapter Fifteen 
  
 
 
Methodology 
 
 
 
  
 
 
15.10 Introduction 
 
This chapter describes the aims and objectives of the study, the research design and 
methodology.  Details of selection criteria, screening and baselines assessment are 
included.  Information on the phytotherapeutic intervention is provided according to the 
elaborated CONSORT checklist.  A rationale is given for the instruments used, and 
details of data collection, adverse events monitoring and statistical methods are outlined. 
 
The methodology has been reported according to The CONSORT statement for 
reporting Randomised Controlled Trials1070 and the Elaborated CONSORT statement  for 
reporting Randomised Controlled Trials of  Herbal Interventions.1071 
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15.1 Study Overview 
 
The principal study was a randomised, placebo-controlled, double-blind parallel trial with 
a 16 week treatment phase, a 2 week non-treatment run-in and an 8 week non-treatment 
follow-up.  Two further studies were conducted on subgroups of the same population.  
Three separate papers are included: 
 
1.  the RCT examined a phytotherapeutic combination for menopausal symptoms; 
2.  a sub-study of premenstrual symptoms was included on peri-menopausal subgroup 
who continued to menstruate infrequently; and 
3.  predictors of the placebo response were assessed from data obtained from RCT. 
15.2 Study Population 
 
Approval for the study was obtained from the Human Research Ethics Committee at 
Royal Melbourne Institute of Technology University. All participants gave written 
informed consent prior to entering the study. Baseline visits were completed in a clinic 
setting.  Follow-up contacts were conducted by telephone. 
15.2.1 Recruitment 
 
To recruit participants, advertisements were placed in The Herald-Sun, the Leader and 
other local newspapers, including MX.  Articles appeared in The Age newspaper, 
professional journals and special interest group newsletters.  Two radio interviews were 
done with ABC 774 and a rural radio station.  Fliers were displayed in waiting rooms of 
doctors’ and allied health professionals’ clinics, health food shops and The Jean Hailes 
Foundation for Women’s Health information centre.  Posters were displayed at university 
campuses and colleges of natural medicine, and websites at RMIT and The Jean Hailes 
Foundation advertised the trial.  The numbers of participants recruited through each 
source are detailed in appendix 13. 
15.2.2 Inclusion criteria 
 
To be eligible for inclusion, women had to be aged between 40 and 60 years, which 
encompassed the age range within which women are likely to become peri- or 
postmenopausal.57,59,64  Clinical criteria for entry to the study were based on menstrual cycle 
alterations and symptoms.65  Participants were either naturally post-menopausal defined by 
amenorrhoea for 12 months or more, or late perimenopausal, defined as at least 3 
months’ amenorrhoea in the previous 12 months.53,65   
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Entry requirements were a minimum of five flushes (including sweating episodes) per 24 
hour period (total 35 per week), consistent with baseline scores from previous positive 
studies,19,25 and a minimum score of 20 on the Greene Climacteric scale, consistent with a 
menopause clinic sample, as distinct from the general population of menopausal women1072 
and baseline data from a comparable study.75  
 
Before inclusion in the trial, medical clearance from a general medical practitioner (GP) 
was required after a general medical check-up, including heart rate, systolic and diastolic 
blood pressure and breast examination. Mammography and pap smear were performed 
if not conducted within the previous two years.  Pregnancy was excluded at baseline.  
The GP was provided with a list of exclusion criteria for the trial and asked to advise 
whether there were any known reason why the person should not take part in the trial. 
(Appendix 14)  Hysterectomised women were admitted if they were over the age of 53 
and FSH levels were greater than 25IU/L, despite the questionable reliability, of FSH 
levels in determining menopausal status.66   
 
Participants were advised to avoid excessive exposure to sunlight or artificial UVA light 
for the duration of the trial, due to the risk of developing an increase in  UVA 
photosensitivity.796  
15.2.3 Exclusion Criteria 
 
Exclusion criteria were based on safety for participants, National Health and Medical 
Research Council (NHMRC) guidelines for involvement in clinical trials, as well as 
exclusion of potentially confounding factors.  They therefore included concurrent major 
health conditions, substance abuse, concurrent menopause treatment or any medication 
known to interact with the study intervention, pregnancy, attempting to conceive or 
concurrent participation in another trial. 
 
Concurrent Medications Excluded 
 
Based on known herb-drug interactions (discussed in the relevant sections on the study 
herbs), women in any of the following were excluded:  
• immunosuppressants (cyclosporine)954,955,956 
• cardiac glycosides (digoxin) for doses of St John's wort greater than 1 g/day 
(dried herb equivalent)957 
• HIV medication including protease inhibitors,(indinavir),958 the non-nucleoside 
reverse transcriptase inhibitor, nevirapine959, and other anti-retroviral drugs960 
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• chemotherapy drugs, (irinotecan)961  
• anti-coagulant medication such as warfarin, phenprocoumon962,963  
• low dose oral contraceptives962  
• theophylline (bronchodilator)964  
• triptans (migraine medication)965 
• midazolam (benzodiazepine)949 
• fexofenadine (antihistamine)966   
• the HMG-CoA reductase inhibitor simvastatin967 and atorvastatin968 (but 
pravastatin was unaffected) 
• phenytoin (theoretical concern)965  
• amitriptyline (tricyclic antidepressant).969,970   
• progesterone drugs, the contraceptive pill or HT796  
• dopamine receptor antagonists.857 
 
The cholesterol-lowering pro-drug simvastatin, was also later found to be contraindicated 
with Hypericum perforatum and was added to the exclusion criteria. (However, this did 
not concern any of the remaining participants.)  
 
To eliminate any medication that could potentially confound the results, women were 
also excluded if taking any medications/supplements thought to affect the symptoms 
under observation throughout the trial.  These included 
• Hormone Replacement Therapy (Hormone Therapy) 
• Other concomitant treatment for menopausal symptoms including 
phytoestrogen products, Vitamin E supplements, herbal menopause formulas 
• anti-depressants, anxiolytics or hypnotics (psychotropic medication) 
• herbal medicine that included Hypericum or Vitex 
• anti-convulsant medication  
• steroid therapy. 
 
Based on accepted wash-out periods for different medications,1073 participants were 
required to have been free of oral HRT or anti-depressant medications for four weeks 
(five weeks for fluoxetine or MAO-Inhibitors) preceding the trial.  They could not have  
been using hormone implants or injectables for 1 year or 6 months respectively. Due to 
the possibility of conceiving during the perimenopause, any woman electing to 
discontinue oral contraceptives would be recommended other means of contraception. 
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As a precautionary measure, in the interests of participant safety, women with current 
major health conditions, derived from comparable studies,77,304,540,550,707,1074 or any 
condition suspected to be aggravated by either intervention were excluded.  These were 
• undiagnosed vaginal bleeding (in post-menopausal women) 
• history of epilepsy or seizures 
• pre-existing cancer, renal or liver disease, diabetes mellitus requiring 
treatment, uncontrolled hypertension 
• substance abuse 
• bipolar disorder, severe depression, current major psychiatric disorder796 
• history of mania 
• spasmodic dysmenorrhoea not associated with premenstrual syndrome, 
which has been observed to be aggravated by Vitex agnuscastus796 
• known photosensitivity, a potential side effect of Hypericum perforatum796 
• known intolerance to Hypericum or Vitex. 
 
Other exclusion criteria were 
• medically or surgically induced menopause [due to the symptom severity50 
and lack of ovarian function]  
• anyone in a dependent relationship with the principal investigator(s), such as 
patients and students. 
 
In the case of unblinding, the participant was to be removed from the trial.   Numbers 
excluded at interview and reasons for exclusion are included in appendix 15. 
15.2.4 Baseline Assessment 
 
Pre-trial symptoms were assessed at baseline using the primary and secondary outcome 
measures, the Greene Climacteric scale, the self-rated Hamilton Depression Inventory 
(HDI), Utian Quality of Life questionnaire and a daily flushing diary for the two week non-
treatment run-in period.  Details of these measures are provided below. 
 
Because some studies on dietary phytoestrogens support a salutary effect of these plant 
constituents, especially isoflavones and lignans, on some of the outcome measures, 
participants were asked to maintain their baseline phytoestrogen intake throughout the 
trial, and were advised of the relevant foods.   
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15.2.5 Initial Screening Procedure 
 
Women who expressed interest were screened by telephone to ascertain suitability for 
inclusion in the trial. Interested persons were only selected if they met all the criteria, 
which were established to determine their suitability for the research. 
Telephone screening involved the investigator reading out a standard preamble to 
ensure all participants received the same information and were treated equally. 
(Appendix 16).  This was piloted initially with an ineligible volunteer from the study 
demographic in order to ensure complete information was provided within a reasonable 
length of time.  All calls were taken by the principal investigator for consistency.  (The 
results of telephone screening are included in appendix 17.)  This involved 
1. thanking them for their enquiry  
2. finding out the source of their information about the trial 
3. giving an overview of what participation involved, including the herbs being trialled 
4. outlining some of the inclusion criteria, without specifying the exact score so as not to 
encourage  women to misrepresent their symptoms 
5. outlining the exclusion criteria, including a detailed list of medications and health 
conditions to be excluded.  This enabled respondents to self-select out without being 
required to divulge details of their personal medical history 
6. the requirements of involvement in the study 
7. ensuring they understood it was placebo-controlled 
8. informing them that they may not benefit from their involvement in the study 
9. informing them of the risks of side-effects and safety monitoring procedure 
10. advising them that, if shown to be superior to placebo, the intervention would be offered 
free of charge for a period of 3 months to the placebo group at study termination.  
 
If the woman was still interested and eligible, an interview time was arranged at her 
preferred venue (of three available) and a participant information sheet (Appendix 18 
Plain language statement) sent out with directions to the interview venue.  A contact 
number was obtained for confirming the interview time and place the day before. 
15.2.6  Screening Interview  
 
Interviews were held at Clinicare Medical Centre, North Fitzroy, RMIT city campus 
psychology clinic, RMIT Bundoora psychology clinic and a small percentage of rural 
participants were interviewed by telephone.  In the case of telephone interviews, the 
interview consent form and Greene climacteric scale were sent out prior to the interview.   
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Consent to obtain background information was obtained prior to an interview (Appendix 
19).  All interviewees were informed that the study had the approval of the Human Ethics 
Committee of RMIT University, Melbourne. They were also informed that the purpose of 
the interview was to establish eligibility for the study,  that they would be asked to 
provide personal information, that all information would be safeguarded by code and that 
they had the right to withdraw at any time from the interview.   
 
To ensure confidentiality, an interim code number was assigned to each interviewee; the 
screening form was identified only by this number and contained no identifying information.   
Personal contact details were completed on a separate form, subsequently filed in a locked 
filing cabinet along with copies of consent forms and medical clearance form once obtained. 
 
In addition to establishing eligibility for the study, the interview was used to collect 
pertinent information including menopausal status, health status, history of premenstrual 
symptoms, diet and lifestyle and current experience of menopausal symptoms (Appendix 
20). Height and weight were measured and Body Mass Index calculated.  For women 
attending the RMIT venues, where such measurement was not possible, a machine-
recorded weight measurement was required, available from a variety of pharmacies. 
 
During the interview, data were collected regarding the number and intensity of hot 
flushes and night sweats per 24 hour period.  Interviewees also completed the Greene 
Climacteric scale, without being informed that a minimum score was being sought, the 
HDI and Utian Quality of Life Scale.  The completed Greene scale was scored 
immediately to determine eligibility for the study. 
 
Data from the HDI was double-entered into the computerised Hamilton Depression 
Inventory Scoring Program V1.0. All completed scales were scored in accordance with 
the appropriate scoring procedures and double checked before being entered into 
Statistical Package for Social Science (SPSS) Version 11 for statistical analysis. 
 
For the HDI and Utian scale, these scores constituted baseline data. Although the HDI is 
not recognised as a diagnostic tool,1075 interviewees with scores suggestive of severe 
depression were considered to fall within the exclusion criteria, and were consequently 
excluded and referred to a medical practitioner for further investigation. 
 
All prospective participants were required to report any existing symptoms to the investigator 
before administration of the herbal treatment.  Interested persons were reminded during the 
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interview that there that they may not benefit from their involvement in the study.  Information 
regarding possible adverse effects or side effects of the herbal treatment was reiterated 
during the interview. Participants were also briefed thoroughly on the protocol they should 
follow in the event of an unwanted side-effect occurring during the treatment phase.  
 
Options for obtaining medical clearance from a GP were also outlined during the interview.  
Participants were able to consult a GP of their choice. Ten GP’s had been recruited in 
various suburbs of Melbourne to assist with the medical examination for participants who did 
not have a GP or chose not to consult their own GPs.  Medical Clearance costs were 
charged to RMIT and paid for from the grant provided by Australian College of Phytotherapy.  
15.3 Study Intervention 
  
Details of the herbal intervention are provided in accordance with the Proposed 
Elaboration of CONSORT Checklist Item 4.1071 
15.3.1 Herbal Product Name and Characteristics  
 
Both the placebo and active treatment were administered in the form of tablets, identical 
in size, colour, coating, weight and packaging. All tablets were manufactured according 
to the Code of Good Manufacturing Practice1076 by MediHerb Australia Pty Ltd.  Both 
products are included on the Australia Register of Therapeutic goods in as Listed 
Medicines and are readily available over-the counter in Australia, Europe and the USA.  
Both were administered within standard dosage levels, as described below.   
 
The extract was obtained from the dry herb flowering top of Hypericum perforatum L. 
(Clusiaceae/Guttiferae; St John’s wort) (extraction ratio 6:1(g/ml)) and dried Vitex agnus- 
castus L, (Verbenaceae; Chaste tree/berry) fruit (extraction ratio 1:2(g/ml); the extraction 
solvent was 60% ethanol/water. The extract was purchased and identified and analysed by 
MediHerb’s Quality Assurance Laboratory. Retention samples of raw materials and 
finished tablets are kept at MediHerb; these were validated by chemical fingerprinting 
against verified botanical samples maintained at the Southern Cross University Herbarium. 
The St John’s Wort Tablets were Batch 125178 and Chaste Tree Tablets Batch 124324. 
15.3.2 Dosage regimen and Quantitative description 
 
Each St John’s Wort  tablet contained Hypericum perforatum extract equivalent to 
1,800mg dry herb flowering top standardised to contain hypericins 990 mcg, 9mg 
hyperforin  and 18 mg flavonoid glycosides. Each Vitex agnus-castus (Chaste Tree) 
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tablet contained extract equivalent to 500mg dry fruit.  This tablet was not a standardised 
preparation. A total of three Hypericum perforatum (one in the morning and two later in 
the day) and two Vitex agnus-castus tablets (in the morning) or placebo were given daily 
for 16 weeks. The hypericin content was consistent with effective doses for mild-
moderate depression used in RCTs.915 The dosage regimen was determined by referring 
to previous RCTs on Hypericum perforatum in depression, which used a daily dose of 
900mg of 6:1 extract,915 and Vitex agnus-castus 839 and is consistent with current 
usage.820  
15.3.3 Qualitative testing 
 
The high-performance liquid chromatography (HPLC) chromatogram for Hypericum 
perforatum can be seen in figure 15.1. The method for performing this analysis was as 
follows:  HPLC separation was achieved using a C18, 5μm column with dimensions (150 
mm x 4.6mm) with a gradient elution program using a three solvent program 
B=methanol, C = 50mM phosphoric acid in deionised water and D = acetonitrile. The 
elution program was 0 min B=0%, C=85%, D=15%; 20 min B=10%, C=70%, D=20%; 30 
min B=15%, C=10%, D=75%; 55 min B=15%, C=5%, D=80% at a flow rate of 
1.0mL/min. The analysis was done by an individual with over 20 year’s experience in 
analytical chemistry. Thin Layer Chromatography was employed for Vitex agnus-castus.  
Concentrations of heavy metals were measured by inductively coupled plasma mass 
spectroscopy (ICP/MS). 
 
 
 
 
 
 
 
 
 
 
FIGURE 15.1  ST JOHN’S WORT (HYPERICUM PERFORATUM) HPLC CHROMATOGRAM 
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Hypericin was tested utilising the British Pharmacopeia UV method.1077  The levels of 
flavonoid glycosides were determined using a proprietary MediHerb HPLC analytical 
method, (conditions above).   
 
Herbs are chemically complex and, as with most herbal medicines, the active ingredients 
remain undetermined.  However there are candidates such as flavonoids, hypericin and 
hyperforin in Hypericum perforatum and iridoids, diterpenes and essential oil in Vitex 
agnus-castus.  All were present in the products used, which characteristically resembled 
the plant in terms of phytochemicals. 
15.3.4 Placebo tablets 
 
The placebo tablets contained the excipients used in the active tablets, namely modified 
starch, cellulose, magnesium stearate, calcium hydrogen-phosphate. These excipeints 
are commonly used in making pharmaceutical tablets and are known to be inert.  The 
tablets were identical to the herbal tablets in size, colour, coating, weight and packaging. 
All tablets were packaged in amber glass jars with Tamper Tel plastic lids.  They were 
labelled with code number, ‘Treatment A or B’ to denote Hypericum and Vitex 
respectively (or matching placebos), dosage instructions, time of administration, institute 
name (RMIT), clinical trial identification, investigator’s contact number, expiry date and 
storage instructions.   
15.3.5 Determination of Treatment and Dosage 
 
The clinician choosing the treatment and determining the dosage had 8 years experience 
as a chemist and 22 years as a medical herbalist. 
15.3.6 Safety and Quality data 
 
Toxicology data are available for both herbs in animals and are presented in Mills and 
Bone (2005: pp335 & 590-1).805  Pharmacokinetic data is available for Hypericum 
perforatum.796  Safety monographs were provided by MediHerb and stability data and 
post-production quality control data was available for both products.  There are no known 
adverse herb-herb interactions between these herbs.805  
15.3.7 Assessment of Compliance  
 
At the end of the study, all remaining tablets were returned to the study centre and 
manually counted to calculate percentage compliance. (Appendix 21) 
181 
15.4 Objectives 
 
The objective of the principal study was to evaluate the effectiveness of a 
phytotherapeutic intervention comprising a combination of Hypericum perforatum (St 
John’s wort) and Vitex agnus-castus (Chaste tree/berry) in the management of 
menopausal symptoms. 
 
The null hypotheses were 
1.  That the combination of Vitex agnus-castus and Hypericum perforatum is no different 
to placebo in the treatment of vasomotor symptoms associated with menopause. 
2.  That the combination of Vitex agnus-castus and Hypericum perforatum is no different 
to placebo in the treatment of psychological symptoms associated with the menopausal 
transition. 
3.  That the combination of Vitex agnus-castus and Hypericum perforatum is no different 
to placebo in improving quality of life of women during the menopausal transition. 
 
Based on previous research on Hypericum on menopausal symptoms,49 it was also 
anticipated that sexual well-being may be favourably affected. 
 
Secondary objectives were to i) assess the effect of the combination in PMS-like 
symptoms in perimenopausal women, and ii) to examine the role of placebo therapy in 
these groups.  It was therefore further hypothesised that  
 
• the PMS-like symptoms in the perimenopausal women would be relieved 
• the placebo would have a significant impact on the menopausal symptoms and 
would be predicted by psychological factors and baseline symptom severity. 
15.5 Outcome Measures  
 
The following tests or measures were used to determine the effects of the herbal 
combination on the psychological and vasomotor symptoms of menopause.  All scales 
have been well validated and widely used in previous clinical trials. (See Instruments 
Used below for further details.) 
• A daily diary was used to record flushing and sweating episodes; 
• The Greene Climacteric scale was used to assess menopausal symptoms at 
baseline and changes in these symptoms throughout the trial;  
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• The HDI was used to exclude any prospective participants who were suffering 
from severe depression.  The HDI and Greene Climacteric subscales were also 
used to monitor changes in depression, anxiety and sleep throughout the trial; 
• The 4-weekly lifestyle diary was used to monitor possible confounding variables 
and to monitor any side-effects and their severity; 
• The Utian Quality of Life scale was used to assess general well-being and 
monitor any changes that occur during the trial; and 
• A Menstrual Symptoms diary was used monthly with the perimenopausal group to 
monitor changes in premenstrual symptoms.  
All were piloted on a group of seven volunteers within the demographic.  Adjustments 
were made accordingly to typographical features and clarity of instructions and questions 
with respect to instruments designed for the project. 
15.5.1 Timing of Data Collection   
 
Weeks 1 –2   Run-in    2 weeks  
Weeks 3 – 18   Treatment    16 weeks 
Weeks 19 - 26  Non-treatment follow-up  8 weeks from completion of treatment 
 
Contact was made with participants at interview, end of run-in (baseline) and at 4 weekly 
intervals throughout the treatment phase and non-treatment follow-up (Table 15.1).  
Initially, with the pilot group, the non-treatment follow-up period was 12 weeks, but this 
was subsequently altered to 8 weeks to facilitate participant recall of return of symptoms, 
and thus provide a more accurate picture of the washout period for the trial products.  
TABLE 15.1   DETAILS OF MEASURES ADMINISTERED DURING TRIAL PHASES 
 Baseline Treatment Phase Follow-up 
Test or Measure Weeks 
0-2 
Week 6 Week 10 Week 14 Week 18 Week  
26 
General physical 
examination by GP 
?                                                 If required 
Utian Quality of Life Scale ?    ?  
HDI ? ? ? ? ? ? 
Menstrual diary 
(where applicable) 
? ? ? ? ?  
Greene Climacteric  ? ? ? ? ? ? 
Vasomotor Symptoms diary ? daily daily daily daily ? 
Lifestyle & Side-effects diary ? ? ? ? ? ? 
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15.5.2 Non-treatment Run-in 
 
A two week non-treatment run-in was commenced as soon after the interview as was 
convenient for each participant, except over the Christmas period when participants were 
asked to wait until their normal lifestyle was re-established.  During the run-in period, 
participants were required to complete the same daily flush diary that they would complete 
for the 16 weeks of the treatment phase.  At the end of the 2-week period, they again 
completed the Greene Climacteric Scale and the Lifestyle questionnaire which recorded 
illness/accidents, new medications/supplements as well as possible confounding factors 
such as stress, caffeine and alcohol intake. (Refer to sample booklets in Appendix 22). 
 
The objectives of this were  
1.  to ensure the women did have the minimum required number of flushing  episodes, 
namely 35 per week 
2.  to obtain more accurate baseline flushing data than could be provided at interview 
3.  to exclude any non compliers with completing records 
4.  to allow for regression to the mean 
5.  to control for the Hawthorne effect, an observed phenomenon of behavioural changes 
once people enter a study.  Greene scores at the end of the run-in periods were used as 
baseline scores, as were the flushing counts. 
 
Interviewees who were eligible and willing to continue with their participation at this point 
signed an informed consent form, witnessed by a third party, and given a copy for their 
own records. (Appendix 23)  They were advised of the voluntary nature of their 
participation and that they had the right to withdraw at any time.   
 
Documentation provided  
Upon commencement of the treatment phase, participants received the tablets for the 
entire 16 weeks, a folder containing four 4-weekly booklets and reply paid envelopes for 
their return at the end of each four week period.  In addition, a copy of the HDI was 
enclosed to enable them to complete the self-rating scale at the end of each booklet.  
Two self-sealing plastic bags labelled ‘Treatment A’ and ‘Treatment B’ were included for 
participants to return any unused tablets at the end of the treatment phase to the study 
centre  These were then counted to assess compliance. 
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Participants were asked to keep dietary phytoestrogen intake stable throughout the study, 
although evidence from clinical trials does not consistently support the efficacy of 
phytoestrogens for menopausal symptoms.75,76,604,611,612,616,1078 Participants were also asked 
to avoid starting any new supplements during the trial, unless on prescription, and to notify 
the investigators in that event.  Each 4-weekly booklet contained a list of medications and 
conditions that were excluded and instructed participants to notify the investigators in the 
event that they were prescribed/diagnosed with any of these.  Instructions for completion of 
study questionnaires were clarified with the aid of sample materials.   
15.5.3 Follow up 
 
Telephone contact was made at the end of week 1 and at the end of every 4 weeks with 
all participants.  Case report forms were completed at each contact and a series of 
standard questions elicited information regarding compliance with taking tablets, 
counting vasomotor symptoms, illnesses/accidents, new medications, changes in 
phytoestrogens and stress levels. (Appendix 24) 
 
Participants were also contacted in the non-treatment follow-up period to ascertain any 
potential continued benefits that had been experienced since the active treatment and to 
determine the length of the washout period.  Participants were to be offered 
complementary treatment post participation for a period of 12 weeks had treatment been 
shown to be superior to placebo.  It was intended to continue monitoring them during that 
period.  They were asked to advise of any changes to contact details before code 
breaking. 
 
Each participant was terminated from the study once the data from the non-treatment 
follow-up had been received and scored. 
 
Where a participant had neglected to complete an item, she was contacted by phone if 
this was possible within 2 weeks of the due date of completion. 
 
Because women were recruited over a period of 16 months, some participants’ 
involvement ended well in advance of code-breaking and data analysis.  Participants 
were notified at regular intervals of the progress of the trial and expected code breaking 
date.  When the results became available, participants were invited to a meeting where 
the results were presented, talks were given by the principal investigator and supervisor, 
Professor Henry Burger, (a leading endocrinologist and researcher in the field), 
regarding treatment options and self-help measures, and information booklets provided 
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by The Jean Hailes Foundation were distributed.   Women unable to attend were sent 
the information packs by post. 
15.6 Instruments Used 
 
Measures used throughout the treatment phase of the study were divided into four 4-
weekly questionnaire booklets. (Appendix 22)  Each provided contact details of the 
principal investigator on every page, the RMIT supervisor and safety monitor on the 
cover.  Inside the front cover of each booklet was a list of medications not to be taken in 
conjunction with the herbs being trialled as well as medical conditions that would require 
withdrawal from the study.  It also reiterated that participants were requested to maintain 
their current intake of phytoestrogen- containing foods, particularly soy and linseeds for 
the duration of the trial.   
 
A schedule for completion of tests and records was provided, along with a statement of 
confidentiality and complaints procedure.  Each booklet was clearly marked with the 
participant identification number and contained the following measures: 
15.6.1 Daily Symptoms Diary 
 
Four  weekly daily symptoms diaries for participants to record the number of mild, 
moderate and severe flushing and sweating episodes they experienced each day and 
night, where night was defined as ‘while in bed’.   These were subjectively categorised 
according to the following definitions: 
 
 Mild   flush without perspiration or clamminess 
 Moderate  hot flush associated with perspiration or clamminess 
 Severe  hot flush associated with intense perspiration that requires   
   changing of clothing304 
 
These definitions were consistent with whose used in previous menopause studies and 
were selected to permit comparison between studies.304,305  Measures do not exist that 
include quantification of intensity of sensation of heat within a hot flush and duration of 
flushes, so these are typically not assessed.  In order to calculate the daily and weekly 
weighted scores, a mild flush was quantified as 1, moderate as 2 and severe as 3. 
 
Methods of keeping count varied between participants, with some using counters or golf 
watches while others used notebooks or buttons.   
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15.6.2 The Greene Climacteric Scale 
 
Previously the most popular menopause rating scale was the Blatt-Kupperman Index, 
developed in the 1950s.  This has subsequently been discredited for its omission of 
measures of loss of libido, overlapping scores in different categories, lack of statistical 
justification for the weightings used, and scores being summed without being based on 
independent factors.1079   
 
Currently, the most widely used menopause rating scale is The Greene Climacteric 
Scale,153,1080,1081 a 21-item self-report inventory.  It was developed in 1976 using factor 
analysis,153 which analyses a large series of intercorrelated variables, establishing the 
relationships among them and delineating a smaller number of underlying factors. The 
current scale was first published in 1991, the earlier version having been modified in 
consideration of six subsequent factor analytic studies undertaken by different 
researchers.1072 It was originally constructed on the basis of symptoms of women 
presenting at a Scottish menopause clinic. However examination all seven factor analytic 
studies found that the same three main factors emerged regardless of whether the 
sample was from a clinical or general population.1080   
 
The 21 items on the scale are separated into four sub-domains:  Items 1 – 11 address 
the psychological symptoms, which are further subdivided into anxiety (items 1 – 6) and 
depression (items 7 – 11) scores.  Items 12 – 18 are somatic symptoms; items 19 – 20 
are the vasomotor symptoms of hot flushes and night sweats and item 21 is a ‘probe’ 
question for sexual dysfunction.  The total Greene Climacteric score is the sum of all 21 
scores.  Women rate each symptom according to a four-point scale: not at all (score = 0); 
a little (score = 1); quite a bit (score = 2); extremely (score = 3).   
 
Content and construct validity have been well established and test-retest reliability 
coefficients reported for 50 women over a 2 week period.  These were 0.87 for the 
psychological scale. 0.84 for the somatic scale and 0.83 for the vasomotor scale (Greene 
1998).  The scale has been widely used in previous clinical trials on menopausal 
symptoms.691, 75,77  
 
The current study sought to recruit women with symptom severity representative of 
women who seek treatment.  Therefore a minimum total Greene score for inclusion was 
based on a clinic sample, as distinct from a general population sample.  Normative data 
using the scale is available from three sources, namely  
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1. the Scottish sample studied by Greene in 1991 which included 400 ‘menopausal 
and postmenopausal’ women aged between 40 and 55 years drawn from the 
general population as well as a menopause clinic 
2. a Dutch sample of 504 women from the general population aged 45 – 65 years, 
subdivided into pre-menopausal, perimenopausal, postmenopausal and post 
hysterectomy184  
3. an Australian study of 500 premenopausal, perimenopausal and postmenopausal 
women aged 40 – 80 derived from the general population.  As this study reported 
medians and used non-parametric tests, its results are not directly comparable 
with the two mentioned above, which reported mean values and used analysis of 
variance techniques.1082  
 
Data available for sub-domains from the Dutch and Scottish general population samples 
yield good agreement (Table 15.2). 
TABLE 15.2   NORMATIVE DATA FOR GREENE CLIMACTERIC SUBSCALES 
 
Subscale  
Scottish 
Menopause clinic 
sample1072 
Scottish General 
Population 
sample1072 
Dutch 
Perimenopausal 
sample184 
Dutch 
Postmenopausal 
sample184 
Psychological 
Somatic 
Vasomotor 
Total 
12.33 (6.15) 
 6.16 (4.25) 
 4.41 (1.79) 
Not available  
7.42 (6.41) 
3.25 (3.64) 
1.79 (1.12) 
Not available 
7.67 (5.27) 
4.53 (3.76) 
2.82 (1.75) 
15.78 (9.09) 
7.44 (5.48) 
4.23 (3.43) 
2.67 (1.92) 
15.33 (9.01) 
 
For total scores, means are only available from the Dutch sample, in which both 
perimenopausal and postmenopausal women scored were significantly higher than 
women in the pre-menopause (10.53 +/-7.36).184  
 
In order to identify women suffering from severe anxiety or depression and establish 
need for further investigation, individual scores were checked against Greene’s 
recommended cut-off points for severe and possibly clinical anxiety and depression.1072  
These were based on a comparison with the Hospital Anxiety and Depression Scale: 
 
3. Clinically Anxious = Anxiety score of 10 or more 
4. Clinically Depressed = Depression score of 10 or more1072 
15.6.3 Hamilton Depression Inventory 
 
A further secondary endpoint was depressive symptoms.  In studies of menopause-
related mood changes, the Center for Epidemiologic Studies Depression Scale (CES-D), 
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a 20-item scale that screens for depressive symptoms in the previous month,1083 has 
been widely used.59,273,362,367,370,376,384   However, in depression studies of Hypericum 
perforatum (St John’s wort), as in psychiatry, the most widely used severity measures of 
depressive symptomatology is the clinician-rated Hamilton Depression Rating Scale 
(HDRS or HAMD).  To permit comparison between those studies and the current study, 
use of the same scale was considered ideal.  Because administration of the HAMD by 
trained clinicians was prohibited by funding limitations, the self-rated Hamilton 
Depression Inventory (HDI) was employed instead.   
The full-scale HDI consists of 23 items, while the HDI-17 is comprised of the first 17 
items of the full-scale.  This 17-item HDI form corresponds in content and scoring to the 
standard clinician–rated 17-item HAMD, and allows comparable interpretation (p10).1075   
Six additional items (including hypersomnia, detachment, feelings of worthlessness, 
helplessness–pessimism, hopelessness, and difficulty making decisions) are included in 
the HDI-23 to enhance its content validity by including symptoms of major depressive 
disorder and dysthymic disorder as defined by the Diagnostic and Statistical Manual of 
Mental Disorders.1084   
 
The HDI, emulating the clinician-rated HAM-D, evaluates multiple sub-symptoms or 
components of a symptom, and determines the duration and frequency of symptom 
occurrence, thereby providing for a more comprehensive evaluation of individual 
symptoms than is typically assessed by self-report depression measures.  As a result of 
the multiple questions, the 23-item full-scale HDI includes 38 questions and the HDI–17 
consists of 31 questions.1084  the current study collected data for the complete 
questionnaire, but the analysis used the 17-tiem scale because it allows comparison with 
studies of H. perforatum using the HAMD. 
 
Reliability and validity has been established for the HDI as a measure of the severity of 
depression and as a self-report version of the HAMD clinical interview. In addition, the 
HDI also demonstrated a high correlation with the Beck Depression Inventory.1084 All 
versions of the HDI demonstrate high internal consistency and test–retest reliability as a 
self-report measure of severity of depression in adults. Extensive validity evidence 
includes content, criterion-related, construct, and clinical efficacy of the HDI cut-off 
score.1084 
   
The HDI is not a diagnostic tool for depression according to the DSM-IV.  However the 
protocol does include the Major Depression (MD) Checklist for identification of levels of 
symptom severity consistent with the nine primary symptoms for a diagnosis of major 
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depression delineated by the DSM-IV (pp8,34),1075namely depressed mood, loss of 
interest/pleasure, weight loss, insomnia/hypersomnia, psychomotor agitation/retardation, 
fatigue or loss of energy, worthlessness or guilt, indecisiveness and suicidal 
ideation/behaviour.  Scores on the MD checklist was calculated at the baseline interview 
in order to identify any prospective participants potentially suffering from major 
depressive disorder so that they could be referred for further investigation.   In addition, 
seven critical items have been identified as clinically relevant. (These are dysphoria; 
suicidal ideation or attempt; loss of interest/poor work performance; somatic symptoms 
of fatigue and muscle-aches; feelings of worthlessness; pessimism/hopelessness; and 
indecision.)   Women with high scores (≥ 2) on three or more of these items were 
referred for further examination, as was anyone scoring ≥ 1 on suicidal ideation. 
 
The HDI evaluates the severity of depressive symptoms over the previous 2 weeks.1084  
Cut-off scores for clinical severity levels on the HDI-17 scale are:1075 
TABLE 15.3  CUT-OFF SCORES ON HDI-17 SCALE 
Range of Scores Clinical Description 
0-9.5 Not depressed 
10-14.5 Subclinical 
15-19.5 Mild 
20.0-24.5 Moderate 
25.0-29.5 Moderate to severe 
≥ 30 Severe 
15.6.4 Utian Quality of Life Scale  
 
To measure changes in quality of life and differentiate between women according to their 
quality of life, many studies have used the Menopause-Specific Quality of Life 
questionnaire (MENQOL), 1085a validated menopause-specific instrument comprising 
physical, vasomotor, psychosocial and sexual domains. This scale developed in 1992 
was subsequently modified in 2003 for use where certain treatment side effects could 
negatively impact the quality of life.1086   However, there is considerable overlap with this 
scale and symptoms reported on the Greene Climacteric scale, , with 16 of the 29 items 
relating to physical symptoms, 3 to vasomotor, 7 to psychosocial and 3 to sexual 
symptoms.1085  The impact of the symptoms on quality of life is more clearly delineated 
as in the Utian Quality of Life scale, which was therefore selected for use in this study. 
 
The Utian Quality of Life scale, administered at study entry and the end of the treatment 
phase (end of Week 16), is a validated scale developed specifically to measure quality of 
life (QOL) in peri- and postmenopausal women.  As distinct from a symptom inventory, 
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its purpose is to measure the impact of the symptoms on the sense of well-being and 
QOL of the woman.1081   The four subscales - occupational, health, emotional and sexual 
- were derived from an exploratory factor analysis.  Validity was established in reference 
to the Short Form-36, a widely used instrument with established reliability and validity for 
measuring QOL.  Test-retest reliability was also established.1081  The 23 items in the 
questionnaire are scaled on a 5-point Likert scale where 1 represents ‘Not true of me’, 3 
denotes ‘Moderately true of me’ and 5 ‘Very true of me’.1081 (Appendix 22). 
15.6.5 Menstrual Symptoms Record  
 
In order to gather data for a sub-analysis of PMS-like symptoms among perimenopausal 
women, the women who were still irregularly cycling were additionally required to 
complete, when relevant, a Premenstrual Symptoms questionnaire for the week 
preceding the menstrual period.   The commonly used Moos’ 47-item Menstrual distress 
Questionnaire (MDQ – 1968 and 1969) (MMDQ)1087  containing 8 clusters, and  
Halbreich’s 95-item (18 clusters) Premenstrual Assessment Form (PAF)1088 were 
considered too extensive for the current purposes.  A broad range of scales for 
measuring PMS has been employed, as confirmed by a 1994 review that identified 65 
different PMS scales used in clinical trials for assessing entry eligibility and treatment 
outcomes.  Of these, 18 grouped the symptoms or items into clusters or subgroups.1089   
 
For the purposes of the current study, a scale containing symptom sub-clusters was 
sought, which also had the advantages of brevity and, consequently, acceptance by 
participants already completing several other measures.  This would permit differential 
analysis of symptoms potentially having different underlying aetiologies, and comparison 
with sub-domains of the Greene Climacteric scale.   Hence, the Menstrual Symptoms 
Questionnaire (MSQ) developed by Abraham463,1090 was chosen despite its current lack 
of use in PMS research.  Abraham used the terminology ‘Premenstrual Tension 
Syndrome’ (PMT-S); his modified questionnaire contains nineteen symptoms (having 
removed PMS- P for pain/ dysmenorrhoea), divided into four subgroups: PMT-A (anxiety, 
irritability, mood swings, nervous tension), PMT-H (weight gain, swelling of extremities, 
breast tenderness, abdominal bloating), PMT-C (headache, craving for sweets, 
increased appetite, heart pounding, fatigue and dizziness or fainting) and PMT-D 
(depression, forgetfulness, crying, confusion, insomnia). (Table 15.4)  This categorisation 
arose from his recognition that PMT-S may represent a group of syndromes with 
different pathophysiologies.463,464   
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TABLE 15.4  ABRAHAMS MENSTRUAL SYMPTOMS QUESTIONNAIRE 
PMS-A PMS-H PMS-C PMS-D 
Nervous tension   
Irritability   
Mood swings   
Anxiety    
Weight gain   
Swelling of extremities 
Breast tenderness    
Abdominal bloating   
Headaches   
Cravings for sweets    
Increased appetite  
Pounding heart   
Fatigue   
Dizziness  
Depression   
Forgetfulness   
Crying   
Confusion   
Insomnia   
 Symptoms were graded according to the following criteria: 
0 = none  
1 = mild –present but does not interfere with activities 
 2 = moderate – present and interferes with activities but not disabling     
3 = severe-disabling; unable to function 
TABLE 15.5   SEVERITY RATINGS OF SCORES ON ABRAHAM’S MSQ  
                     PMT 
subscale   
Severity 
PMT-A PMT-H PMT-D PMT-C 
Mild < 5 < 5 < 6 < 7 
Moderate 5 – 8 5 – 8 6 – 10 7 - 12 
Severe 9 – 12 9 – 12 11 – 15 13 - 18 
 
To qualify for PMT-S, the symptoms in at least one subgroup must be mild to absent in 
the mid-follicular phase and moderate to severe during the late-luteal phase Table 15.5), 
and the follicular phase score must be greater than the follicular phase score by at least 
4 points for PMT-A and PMT-H, 5 points for PMT-C and 6 points for PMT-D.  In addition, 
symptoms reports should be collected prospectively for at least two consecutive cycles in 
order to confirm the diagnosis of PMS at baseline.  However, as this was primarily a 
menopause study, rather than a PMS study, retrospective recall was used for baseline 
scores. 
15.6.6 Dietary and Lifestyle questionnaire 
 
Potential confounding factors were recorded on a weekly lifestyle diary and included 
phytoestrogen intake recorded on a food frequency questionnaire, caffeine and alcohol 
consumption, smoking, formal exercise in hours per week, stressful life events recorded 
on a 5-point Likert scale, concurrent illnesses and medication. The total lignan and 
isoflavone intake was calculated according to the values reported in quantification 
studies.1091,1092 Adverse events were recorded and reported 4-weekly. (Refer to sample 
booklet in Appendix 22). 
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The total isoflavone content was calculated according to the values reported in an 
Australian study by King and Bignell, ‘Concentrations of Isoflavone phytoestrogens and 
their glucosides in Australian soya beans and soya foods’,1092 which were in good 
agreement with those listed in the USDA-Iowa State University Isoflavone Database:   
• Soy milk, 1 cup/225 mls = 22.5 isoflavones 
• Tofu, 50gms = 11; 100 gms = 22 
• Tempeh, 100 gms = 43 
• Soy beans, dry 20gms or canned, 50gms = 38mg 
• Miso, 1 tablespoon/23 gms = 10 
• Soy bread, 1 slice/40gms = 6 
• Soy grits, 1 tablespoon/11.36 gms = 18.74gms583,1092 
 
The secoisolaryciresinol diglucoside (SDG) content of linseeds varies from 0.4% to 
1.2%.1091  Therefore the median, 0.08%, was used to calculate the SDG content.1091 
The quantity of linseeds in soy and linseed bread was calculated at 2.8gms (equivalent 
to 0.02gms secoisolaryciresinoldiglucosides) using information from the labels of 
commercially-available breads, counting the slices and weighing one slice.   
Linseeds per tablespoon were taken to be 12gms, calculated by weighing a rounded 
tablespoon, the normal dose of linseeds. (0.1gm secoisolaryciresinoldiglucosides) 
15.7 Adverse Events Monitoring 
 
Adverse events were actively sought at each contact.  In addition, participants were 
briefed thoroughly at interview on the protocol they should follow in the event of an 
unwanted side effect occurring during the participation phase. They were required to 
report any adverse events immediately to the investigator who was accessible by 
telephone 24 hours a day.  Professor Helena Teede, a registered medical practitioner, 
would then liaise with the participant and advise her to cease therapy temporarily if 
required and assess whether she needed to seek GP review.  If a GP visit was required, 
Dr Teede was to contact the GP, who would complete the Suspected Adverse Events 
Report Form (Appendix 25) and forward this to Dr Iggy Soosay, GP in charge of 
monitoring adverse events, for independent safety review.  If her symptoms were not 
thought relevant by the safety committee, the herbs would be recommenced in 
conjunction with her local GP, and she would be monitored. If the symptoms recurred, 
the medications would be ceased.   In a severe case, the participant would be instructed 
not to restart the medication.  
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If the independent safety committee were concerned, Dr Soosay would have access to a 
copy of the code. However, the code was only to be broken in a case where breaking it 
would alter management.   Any such serious events were to be reported immediately to 
RMIT HREC, the Therapeutic Goods Administration and the Adverse Drug Reactions 
Advisory Committee (ADRAC).  The randomisation code was readily accessible should 
an adverse event or serious adverse event occur.  A hard copy was located in Professor 
Marc Cohen’s office, accessible by another staff member from the Complementary 
Medicine Department in case of necessity. 
15.8   Sample size 
 
A power calculation was performed to estimate the required sample size. Anticipating a 
placebo effect of 30% for flushing symptoms74,692,1074 based on phytotherapeutic 
menopause RCTs,  and 30% for depression,904 it was calculated that a sample size of 
102 would permit sufficient power (0.8) for the detection of moderate effects (d = 0·5) in 
any outcome variables at an alpha level of 0·05.  
15.9 Randomisation and Blinding  
 
The tablets were randomised by MediHerb using a computer generated random number 
table, and labelled with code numbers. Women who satisfied the inclusion/exclusion 
criteria were randomly assigned by the principal investigator using block random 
sampling (blocks of four) to ensure both post and perimenopausal women were evenly 
assigned to each group.  Within each block of four were two placebo and two active 
treatments.  Upon entry, participants were assigned code numbers sequentially within 
blocks. The perimenopausal group were allocated numbers starting from the lowest, and 
the postmenopausal group participants started with the highest numbers and were 
allocated to numbers in descending order.  A copy of the code, concealed in sequentially 
numbered, opaque, sealed envelopes, was sent to RMIT and stored in a locked filing 
cabinet.  The code was concealed from all of the investigators and was not broken until 
the last participant had completed the treatment phase and data had been scored and 
entered into the database, when MediHerb sent a copy of the randomisation plan to the 
investigators.   
 
As a further check on the validity, the veracity of the code was checked at the conclusion 
of the trial by Dr Kerry Penman of MediHerb Australia, using TLC assessment.  The 
report returned can be found in appendix 26. 
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15.9.1   Evaluation of the Success of Blinding 
 
Evidence for the success of blinding was obtained by participants’ retrospective 
assessment of group allocation following the treatment phase.    In order to evaluate the 
success of blinding of the principal investigator, prior to code breaking, the principal 
recorded her assessment of each participant’s allocation, based on their reported 
symptom experience throughout the trial.   
15.10 Statistical Methods 
 
All data scoring was double checked.  HDI scores were double entered by the principal 
investigator.  All other scales were checked by a third party.  After being entered into 
SPSS, all entries were double checked in conjunction with a voluntary research 
assistant.  Cleaning and screening of data was conducted with the complete data file as 
well as those subsequently derived from it.  This included checking minimum and 
maximum scores, range of scores, checking for outliers and further investigation of 
outlying scores, checking the number of valid cases and the distance of trimmed means 
from means. 
 
Data were analysed using Versions 11, 15 and 16 of SPSS, with the assistance of a 
biostatistician.  Parametric tests were used as they are more commonly reported in the 
literature, and are more powerful than non-parametric tests, although they do require 
assumption checking.  Assumption tests carried out were normality, homogeneity of 
variance, and for analyses of covariance, linearity and homogeneity of regression slopes.  
However, linear modelling does not require separate assumption testing as it is 
incorporated into the program in SPSS.  For the regression analyses, the relevant 
assumption tests were carried out, including Mahalanbois distance for detecting outliers, 
multicollinearity and singularity, normality, linearity, homescedasticity and independence 
of residuals.  Results of assumptions testing are not included in the manuscripts but are 
discussed in the results section following the manuscripts accepted for publication.   
 
Intention-to-treat analysis was used in order to preserve randomisation and thereby 
avoid introducing serious bias, and to represent the practical impact of the treatment.   
 
Equality at baseline was assessed using independent t-tests for the continuous variables 
and chi square tests for the categorical variables.  Contingency table analysis was also 
used to determine if adverse events affected both groups equally. 
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For the primary study of the phytotherapeutic combination on menopausal symptoms as 
well as the substudy on PMS-like symptoms, a mixed model, treating group as the 
between-subject factor and phase as the within-subject factor, was performed on the 
main variables. The interaction between group and phase was also examined.  Where 
groups were not equal at baseline for a potential confounder, which covaried significantly 
across the treatment phase, it was included in the analysis as a covariate.  Post-hoc 
testing using pairwise comparisons of the estimated marginal means was used for within 
group analysis across the trial phases.  Exact details differed for each study and are 
reported in the relevant chapter.  
 
Although there were multiple outcome measures in these studies, multivariate analysis of 
variance (MANOVA) was not used for several reasons:  i) the sample size is 
considerably reduced as it excludes all cases without a complete data set, ii) all of the 
underlying assumptions, except for the assumption of linearity, were violated, iii) the 
dubious value of interpreting the joint distribution of outcome variables, and iv)  it is 
considered by some to be “a poor strategy for controlling experiment-wise error rates 
across multiple outcome variables”, when used as a follow-up to univariate F tests.  
“Bonferroni-based procedures in conjunction with univariate F tests are..(considered).. 
preferable”.1093  
 
Bonferroni adjustments, which are considered to be quite strict, were used for the study 
of premenstrual-like symptoms as both herbs had previously been trialled successfully in 
this condition.  It was therefore considered appropriate to use a more conservative 
threshold.  However, fundamental hypothesis testing for the exploratory menopause 
study did not use Bonferroni corrections, in order to avoid prematurely excluding a 
potentially useful therapy.   
 
Relationships between variables were also examined, using different techniques 
according to the study, which included simple bivariate correlations, linear regression, 
hierarchical regression, multiple regression and logistic regression.  As the outcome 
measures were continuous, rather than categorical, linear regression was preferred as 
this gave more power.  However, results of logistic regressions analyses are also 
included.   
 
As reported above, the data collected was used for three main papers.  Methods relating 
to data collection were common to all studies.  Information specific to individual studies is 
included in the respective chapters.   
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Chapter Sixteen 
 
  
 
 
  Hypericum perforatum with Vitex agnus-castus 
 
 in Menopausal Symptoms 
 
  
 
16.0  Introduction 
 
The results are divided into four chapters, each containing a manuscript that has been 
submitted and/or accepted for publication by a relevant journal.  Additional analyses 
were conducted that could not be included in the manuscripts.  These are included as 
addenda to the respective chapters. 
 
This chapter reports on the results of the principal study, a randomised, controlled trial of 
a phytotherapeutic combination for the treatment of menopausal symptoms.  The 
manuscript has been accepted for publication and is to appear in the journal Menopause 
in January 2009,  PubMed citation: Van Die MD, Burger HG, Bone KM, Cohen MM, 
Teede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a 
randomized, controlled trial. Menopause 2008 Sep 10. [Epub ahead of print] 
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16.1 Abstract 
 
Objective: To evaluate the effectiveness of a phytotherapeutic intervention comprising a 
combination of Hypericum perforatum (St John’s wort) and Vitex agnus-castus (Chaste 
tree/berry) in the management of menopausal symptoms. 
 
Design: A double blind, randomised, placebo controlled parallel trial was performed over 
16 weeks in 100 eligible late-perimenopausal or postmenopausal women experiencing 
hot flushes and other menopausal symptoms. Herbal combination therapy or placebo 
tablets were administered twice daily. The primary end-point was flushing episodes. 
Secondary end-points included Greene Climacteric scale scores, Hamilton Depression 
Inventory scores and Utian Quality of Life Scale scores.  
 
Results: Ninety-three completed the study. Data analysis on an intention-to-treat basis 
found no significant differences between the two groups for any of the endpoints. 
Analyses performed at interim data time-points revealed no significant differences at 
weeks 4, 8 or 12 for daily weighted flushes, scores on the Greene Climacteric scale or 
Hamilton Depression Inventory. However, significant improvements across the treatment 
phase were observed in both the placebo and active treatment groups for these 
endpoints. No significant change was found for either group on Quality of Life. 
 
Conclusion: The herbal combination of Hypericum perforatum and Vitex agnus-castus 
was not found to be superior to placebo for the treatment of menopausal symptoms. The 
herbal combination was well-tolerated with no significant adverse events noted in the 
short term. Robust findings from quality studies such as this are important for informing 
the community, health-care providers and regulatory authorities. 
 
198 
16.2 Introduction 
 
Despite the incontrovertible efficacy of hormone therapy (HT) for menopausal symptoms, 
safety concerns generated by reports from large-scale trials1094 resulted in a significant 
decline in HT use562 and increased interest in alternatives. In terms of CAM, a recent 
study found that 54% of Australian women transitioning through menopause use some 
form of treatment or product for the alleviation of menopause-related symptoms.569  
 
Of the phytotherapeutic remedies, the phytoestrogen-containing plants have received the 
most attention in the scientific arena, with relatively little research conducted on other 
herbs traditionally used for menopausal symptoms.577 However, concerns have now 
been raised over the safety of long-term use of some phytoestrogens, specifically on 
breast and endometrial tissue proliferation.578,579 The present study, therefore, took a 
novel approach in that it focused on two non-oestrogenic herbs commonly prescribed for 
menopausal symptoms.21,820   
 
Phytotherapeutic menopausal formulations are often found to include the herbs 
Hypericum perforatum (St John’s wort)21 and Vitex agnus-castus (Chaste-tree/berry),820 
both of which have been demonstrated to act via neurotransmitters and/or opioid 
receptors.831,842,896,908 Efficacy of central nervous system (CNS)-acting agents for 
vasomotor symptoms has been demonstrated with pharmaceuticals such as the anti-
depressant selective serotonin reuptake inhibitors and the anticonvulsant gabapentin549 
that are believed to exert their effects via the complex interaction between hormones and 
neurotransmitters involved in the physiology of hot flushes.198  Various CNS mechanisms 
for Hypericum perforatum and Vitex agnus-castus have also been proposed based on 
in vitro and in vivo models.831,839,842,896,908 For Hypericum perforatum, these include 
inhibition of the uptake of the monoamine neurotransmitters, serotonin, noradrenaline 
and dopamine, GABA and L-glutamate; downregulation of beta-adrenergic receptors, 
upregulation of serotonin 5-HT(2) receptors and the regulation of genes that control 
hypothalamic-pituitary-adrenal axis function.908 It also resulted in differential modulation 
of the binding properties of 5-HT(1A), 5-HT(2A)- and mu-opioid receptors.896 Vitex 
agnus-castus extracts have been shown to act as agonists at the kappa- and mu- 
opiate receptors,841,842 exert a dopaminergic action mediated by D2 receptor activation831 
as well as stimulate melatonin release.839  
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In addition to its well-demonstrated effectiveness for the treatment of mild to moderate 
depression,865 evidence has suggested Hypericum perforatum improves vasomotor, 
psychological and psychosomatic menopausal symptoms.49 Several randomised 
controlled trials (RCTs) have demonstrated its efficacy when combined with Cimicifuga 
racemosa (black cohosh) for menopausal hot flushes and associated psychological 
symptoms.702,703,705,716 Vitex agnus-castus was one component of a phytotherapeutic 
menopause formulation found to be significantly superior to placebo in an RCT on 
menopausal hot flushes and night sweats793 and has also shown positive effects for 
premenstrual syndrome.481  
 
The present study investigated the efficacy of a combination of Hypericum perforatum 
and Vitex agnus-castus on the physiological and psychological symptoms of menopause 
in late- perimenopausal and postmenopausal women in a double-blind, randomised, 
placebo-controlled trial.  
  
16.3 Methods  
 
Approval for the study was obtained from the Human Research Ethics Committee at 
Royal Melbourne Institute of Technology-University. All participants gave written 
informed consent prior to entering the study. Baseline visits were completed in a clinic 
setting. Follow-up contacts were conducted by telephone. 
 
Women recruited were aged between 40 and 60 years, post-menopausal (at least 12 
months’ amenorrhoea) or in the late peri-menopause, defined by an intermenstrual 
interval of at least 3 months in the previous 12 months,65 experiencing a minimum of five 
flushing/sweating episodes per 24 hours and scoring 20+ on the Greene Climacteric 
scale, consistent with a menopause clinic sample.1072 Hysterectomised women were 
admitted if they were over the age of 53 and FSH levels were greater than 25IU/L. 
 
Women were ineligible if using formulations that included trial herbs, pharmacological 
agents known to interact with either herb, or concomitant therapies for menopausal or 
psychological symptoms (including HT and CAM within the previous 4 weeks, hormone 
implants or injectables within the previous year or 6 months respectively and anti-
depressant medications within the previous four to five weeks.  
 
Women with major pre-existing illness, a history of mania or substance abuse were 
excluded. Other exclusion criteria were medically or surgically induced menopause, 
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undiagnosed vaginal bleeding (post-menopausal women), pregnancy or attempting to 
conceive, or concurrent participation in another clinical trial. 
Pre-trial symptoms were assessed at baseline using the Greene Climacteric scale, the 
self-rated Hamilton Depression Inventory (HDI), Utian Quality of Life questionnaire and a 
daily flushing diary for the two week run-in period prior to the treatment phase. 
 
Before inclusion in the trial, medical clearance from a GP was required after a general 
medical check-up, including heart rate, systolic and diastolic blood pressure and breast 
examination. A pap smear was performed if not conducted within the previous two years. 
Participants were asked to maintain their baseline phytoestrogen intake and advised of 
the relevant foods. 
 
Both the placebo and active treatment were administered in the form of tablets, identical 
in size, colour, coating, weight and packaging. All tablets were manufactured Code of 
Good Manufacturing Practice by MediHerb Australia Pty Ltd. Both products are included 
on the Australia Register of Therapeutic goods in as Listed Medicines and were 
administered within standard dosage levels.  
 
The active treatment was a combination of two herbal extracts, Hypericum perforatum L. 
(Clusiaceae/Guttiferae; St John’s wort) and Vitex agnus-castus L, (Verbenaceae; Chaste 
tree/berry). Each Hypericum perforatum tablet contained 300 mg extract equivalent to 
1,800mg dry herb flowering top standardised to contain hypericins 990 mcg, 9mg 
hyperforin and 18 mg flavonoid glycosides. A total of three Hypericum perforatum (one 
in the morning and two later in the day). This is consistent with dosages used in 
depression studies. Each Vitex agnus-castus tablet contained extract equivalent to dry 
fruit 500 mg; two tablets (in the morning) or placebo were given daily for 16 weeks. The 
dosage regimen was determined by referring to previous RCTs on Hypericum 
perforatum in depression915 and Vitex agnus-castus839 and is consistent with current 
usage.820  Placebos contained the excipients used in the active tablets (see Appendix 1 
for further details). At the end of the study, all remaining tablets were returned to the 
study centre and manually counted. 
 
The primary end-point was the frequency and severity of hot flushes (including night 
sweats). Secondary endpoints were scores on the Greene Climacteric scale, the 
Hamilton Depression Inventory and the Utian Quality of Life scale. 
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Flushes were recorded on daily symptom diaries for the 16 week treatment phase and 
one week during post-treatment follow-up (week 24). Participants recorded the number 
and severity of flushing and sweating episodes experienced each day and night, defined 
as ‘while in bed’. These were subjectively categorised as: 
 
Mild   flush without perspiration or clamminess 
 Moderate  hot flush associated with perspiration or clamminess 
 Severe  hot flush associated with intense perspiration that required   
   change of clothing304  
 
The Greene Climacteric scale and the Hamilton Depression inventory were completed at 
4-weekly intervals throughout the treatment period and at the 8-week follow-up. The 
Utian Quality of Life Scale was completed at baseline and week 16.   
 
Potential confounding factors were recorded on a weekly lifestyle diary and included 
phytoestrogen intake recorded on a food frequency questionnaire, caffeine and alcohol 
consumption, smoking, formal exercise in hours per week, stressful life events recorded 
on a 5-point Likert scale, concurrent illnesses and medication. Total lignan and 
isoflavone intakes were calculated according to the values reported in quantification 
studies.1091,1092 Adverse events were recorded and reported 4-weekly. 
 
A power calculation was performed to estimate the required sample size. Anticipating a 
placebo effect of 30% for flushing symptoms74,692,849 based on phytotherapeutic 
menopause RCTs, and 30% for depression,904 it was calculated that a sample size of 
102 would permit sufficient power (0·8) for the detection of moderate effects (d = 0·5) in 
any outcome variables at an alpha level of 0·05.  
 
The tablets were randomised by MediHerb using a computer generated random number 
table, and labelled with code numbers. Women who satisfied the inclusion/exclusion 
criteria were randomly assigned by the principal investigator using block random 
sampling to ensure both post and perimenopausal women were evenly assigned to each 
group. Upon entry, participants were assigned code numbers sequentially within blocks. 
The code was concealed from all of the investigators and was not broken until the last 
participant had completed the treatment phase and data had been scored and entered 
into the database. The success of blinding was evaluated by the principal investigator 
and participants ‘guessing’ their allocation retrospectively, prior to code-breaking.   
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Data were analysed using Statistical Package for Social Science (SPSS) Version 11 with 
the assistance of a biostatistician. A mixed model, treating group as the between-subject 
factor and phase as the within-subject factor, was performed on the main variables 
(flushing, Greene scores, depression and Quality of Life). The interaction between group 
and phase was also examined. Isoflavone intake (mg/week) was included in the model 
as a co-variable where relevant as the groups were not equal at baseline (Table 16.1). 
Unadjusted means are included in Appendix 2. Post-hoc testing using pairwise 
comparisons of the estimated marginal means was used for within group analysis across 
the trial phases. Flushing episodes were weighted 1 for mild, 2 for moderate and 3 for 
severe to take into account the severity as well as the frequency. The daily weighted 
score was calculated by dividing the weekly weighted total by 7. Missing values from the 
questionnaires were imputed through expectation maximisation algorithms (EM 
algorithms) in SPSS. 
 
Participants were recruited from January 2004 to May 2005 through newspapers, a radio 
interview, websites at RMIT and the Jean Hailes Foundation for Women’s Health and 
fliers at community clinics.  Participants were followed up at the end of a two-week non-
treatment run-in, at the end of weeks 1, 4, 8, 12 and 16 of the treatment phase, and the 
end of the 8-week post-treatment follow-up period. 
16. 4 Results 
 
The two groups were similar at baseline on all categorical variables except nulliparity. 
However a Pearson’s correlation found no relationship between null-parity and flushing, 
depression or Greene scores at baseline for either the completing or enrolled 
participants.  
 
The two groups were similar at baseline on all continuous variables except isoflavone 
intake, mean difference = 38·3 mg/week, p = 0·04, 95% CI, (1·42 to 74·97), with the 
placebo group having the higher intake, and standard drinks per week, mean difference 
= 1·92, p = 0·035, 95% CI, (-3·71 to -0·13), with the active group consuming the greater 
quantity. 
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TABLE 16.1 BASELINE CHARACTERISTICS OF ENROLLED PARTICIPANTS, N = 100 
 Mean (SD)  
 Placebo 
n = 50 
Hypericum & Vitex 
n = 50 
Age at trial start (years) 
Weight in kg 
Height in cm 
BMI  
Peri-menopausal, No. 
Post-menopausal, No. 
Unknown (endometrial ablation), No. 
Hysterectomy, No. 
Two ovaries retained, No. 
One ovary, No. 
Months since last period 
Months since onset of symptoms 
Prior herbal medicine use, No. (found it effective, No.) 
Prior HRT use, No. (found it effective, No.) 
Vegetarian, No. 
Isoflavone intake per week in mg 
Lignans in linseeds, gm p/wk 
Caffeine: cups of tea/coffee per day 
Cigarettes per day 
Standard alcoholic drinks per week 
Satisfaction with relationships, No. 
No partner, No. 
Neg. attitude to menopause, No. 
High stressful life events (more than average), No. 
Regular stress reduction, No. 
Exercise – hours per week 
Total exercise days per week 
Nulliparity, No. 
Employed outside home, No. 
52·5 (3·8) 
70·1 (13·8) 
163·7 (6·1) 
26·2 (5·0) 
16 
24 
10 
9 
8 
1 
48·6 (61·9) 
57·3 (44·7) 
37 (19) 
15 (13) 
3 
76·6(114·3)* 
0·1(0·2) 
4·2(2·1) 
2·0(5·8) 
3·6(3·7)* 
44 
11 
27 
27 
14 
3·7(3·7) 
3·9(2·6) 
13† 
40 
51·9 (4·3) 
72·0 (13·1) 
163·8 (6·0) 
26·8 (4·4) 
17 
25 
8 
8 
7 
1 
48·7 (67·4) 
59·2 (50·1) 
36 (16) 
17 (12) 
1 
38·4(69·2)* 
0·03(0·2) 
4·0(2·4) 
1·6(4·7) 
5·6(5·2)* 
44 
13 
26 
23 
14 
3·2(2·6) 
3·8(2·3) 
5† 
43 
Endpoints Unadjusted Mean (SD)   
Flushing episodes (per day) 
     Daily weighted score 
 Greene score 
HDI-17 score 
Utian score    
9·42(3·31) 
16·35(6·69) 
22·48(8·7) 
14·30(4·25) 
77·8(12·06) 
9·65(4·00) n = 49 
16·53(9 ·02) 
22·00(6·47) 
14·76(4·42) 
79·04(10·31) 
* significant difference p < .05   
† significant difference p < .05 using chi-square χ2 
 
 
Data were analysed from one hundred participants, fifty in each group, on an intention-
to-treat basis.   Of the 100 participants who were randomised, 47 in the active group and 
46 in the placebo group completed the study (Figure 16.1). 
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FIGURE 16.1   PARTICIPANT FLOW 
 
 
 
 
 
 
 
 
 
Assessed for eligibility   
 (n= 761) 
Excluded  (n=  661) 
  Ineligible (n= 634) 
  Refused to participate (n= 19) 
  Other reasons  (n=  8) 
Analysed  (n= 50) 
Lost to follow-up  (n= 0) 
 
Discontinued intervention (n= 3) 
-insufficient treatment effect (1) 
-nausea (1)  
-protocol violation (1)* 
Allocated to intervention (n= 50) 
Received allocated intervention 
(n=  50) 
Lost to follow-up  (n= 0) 
    
Discontinued intervention (n=  4) 
-insufficient treatment effect (1)   
-stressful life events (2)  
-taste of tablets (1) 
Allocated to placebo (n= 50) 
Received allocated intervention 
(n= 50) 
Analysed  (n= 50) 
Allocation
Analysis
Follow-Up
Enrolment
Randomised 100 
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There was no significant difference between the two groups for any of the endpoints at 
week 16, nor at any time point measured: daily weighted flushing scores, (1·54; 95% CI, 
-2·23 to 5·31), p = 0·42; Greene Climacteric scale, (2·39; 95% CI, -0·68 to 5·45, p = 
0·13); [Psychological subdomain 1·76, 95% CI, -0·29 to 3·81, p = 0·09; anxiety 0·89, 95% 
CI,-0·25 to 2·03, p = 0·13; depression 0·87; 95% CI, -0·19 to 1·93, p = 0·11; somatic 
0·30, 95% CI, -0·70 to 1·30, p = 0·55; vasomotor 0·24, CI’s -0·36 to 0·85, p = 0·43; 
sexual 0·34, 95% CI, -0·07 to 0·75, p = 0·11]; Hamilton Depression Inventory-17, (0·89; 
95% CI, -1·27 to 3·04, p = 0·42); Utian Quality of Life scale, (3·94; 95% CI, -1·45 to 9·32, 
p = 0·15). Sub-group analysis of the clinically depressed group (HDI-17) did not change 
the finding. 
 
However, significant improvements were observed for both groups for flushing, Greene 
Climacteric scores and depression (HDI-17) at week 16 (figure 2). The reduction in 
flushing scores was significant for the placebo group at p < 0·001 and p < 0·01 for the 
active group. Improvement of 50% or more in mean daily weighted flushing scores were 
observed in 45·6% of placebo participants and 43·5% of the active treatment group. 
Improvements for both groups were significant at p < 0·001 on the Hamilton-Depression-
Inventory and Greene scale for overall scores and all subdomains, except for the sexual 
domain which was not significant for the active group.  
16.4.1 Ancillary analyses 
 
Prior use of phytotherapies modified the effect, with the herb-naïve group showing a 
significantly greater reduction in flushing scores, -57·67% (95% CI, 40·49 to 74·86) than 
the prior users, -32·48% (95% CI, 19·58 to 45·39), β= -0·215, p = 0·041.  Previous 
positive experience with phytotherapies predicted overall percentage improvement in 
depression (HDI-17) [β= -0·28, p = 0·007], anxiety-subscale scores [β= -0·23, p = 0·03] 
and sleep [Greene item 3; β= -0·26, p = 0·02] but did not differ between the active and 
placebo groups.  
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FIGURE 16.2   EFFECT OVER TIME OF INTERVENTION ON PRIMARY OUTCOME MEASURES 
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TABLE 16.2 EFFECT OF INTERVENTION ON ENDPOINTS MEAN (SE) 
Placebo Herbal Combination  
Baseline After 16 
weeks 
Mean 
change 
Baseline After 16 
weeks 
Mean 
change 
Difference 
between 
groups at 
week 16 
 n = 50 n = 46  n = 50 n = 47  p-value 
Flushes, daily weighted  16·35(1·30) 9·32 (1·36) 7·03(1·89) 16·53(1·32)1 10·86(1·34) 5·67(1·89) 0·42 
95% CI 13·79,18·92 6·64,12·00 3·32,10·75 13·93,19·12 8·21,13·51 1·96,9·38  
Greene total score2 22·52(1·06) 13·35(1·11) 9·17(1·53) 21·98(1·06) 15·73(1·10) 6·25(1·52) 0·13 
95% CI 20·43,24·61 11·17,15·52 6·16,12·19 19·89,24·06 13·58,17·89 3·25,9·24  
Greene Subscales: 
  Psychological2 
 
11·48(0·71) 
 
6·73(0·74) 
 
4·75(1·02) 
 
11·73(0·71) 
 
8·49(0·73) 
 
3·24(1·02) 
 
0·09 
95% CI 10·08·12·88 5·28,8·19 2·74,6·76 10·34,13·13 7·06,9·94 1·29,5·24  
   Anxiety2 6·36(0·41) 3·71(0·41) 2·65(0·57) 6·33(0·39) 4·60(0·41) 1·73(0·57) 0·13 
95% CI 5·59,7·14 2·90,4·52 1·53,3·77 5·56,7·11 3·80,5·40 0·62,2·85  
   Depression  5·12(0·37) 3·02(0·39) 2·10(0·53) 5·40(0·37) 3·89(0·38) 1·51(0·52) 0·11 
95% CI 4·40,5·84 2·27,3·78 1·05,3·14 4·68,6·12 3·15,4·64 0·47,2·55  
   Somatic 4·94(0·35) 2·83(0·36) 2·11(0·50) 4·64 (0·35) 3·13(0·36) 1·51(0·50)  0·55 
95% CI 4·26,5·62 2·12,3·54 1·13,3·10 3·96,5·32 2·43,3·83 0·53,2·49  
   Vasomotor 4·28(0·21) 2·59 (0·22) 1·69(0·30) 3·92(0·21) 2·83 (0·22) 1·09(0·30) 0·43 
95% CI 3·87,4·69 2·16,3·02 1·10,2·29 3·51,4·33 2·41,3·25 0·50,1·68  
   Sexual 1·72 (0·14) 1·15 (0·15) 0·57(0·21)  1·74 (0·14) 1·49 (0·15) 0·25(0·21) 0·11 
95% CI 1·44,2·00 0·86,1·45 0·16,0·97 1·46,2·02 1·20,1·78 -0·15,0·65  
   Sleep 1·80(0·13) 1·26(0·13) 0·54(0·18) 1·85(0·13) 1·31(0·13) 0·54(0·18) 0·59 
95% CI 1·55,2·05 1·00,1·52 0·18,0·90 1·65,2·15 1·11,1·62 0·18,0·90  
Hamilton Depression 14·30(0·75) 8·40(0·78)  5·90(1·08) 14·76(0·75) 9·29(0·77)  5·47(1·07) 0·42 
95% CI 12·83,15·77 6·87,9·93 3·78,8·02 13·29,16·23 7·78,10·80 3·37,7·58  
Utian Quality of Life 77·80(1·85) 77·22(1·93) -0·58(2·67) 79·04(1·85) 81·15(1·93) 2·11(2·67) 0·15 
95% CI 74·15,81·45 73·41,81·02 -5·86,4·69 75·39,82·69 77·35,84·96 -3·16,7·38  
1 n = 49 
2 Covariates appeared in the model: isoflavone intake 
 
Overall compliance with taking the tablets was excellent with a mean of 95% of all tablets 
taken for both groups. Of the 93/100 completing the trial, only one participant consumed 
less than 85% of the medications provided (77% medication taken by one placebo group 
participant).  
 
The main adverse events during the trial were upper respiratory tract infections, not 
thought to be related to the intervention. There was no significant difference between the 
two groups for adverse events, chi square χ2 (1, N = 100) = 1·100, p = 0·58. 
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16.5 Discussion  
 
No significant difference was found between the herbal combination and placebo in 
reducing hot flushes, menopausal symptoms or depression. This trial reported a high 
placebo response, which was especially marked for the clinically depressed sub-group. 
Prior phytotherapy use was associated with a significantly reduced improvement in 
flushing compared with the phytotherapy-naïve group.  Previous positive experience with 
phytotherapy predicted overall percentage improvement in depression (HDI-17 scores), 
anxiety and sleep (Greene Climacteric) but there was no significant difference between 
groups for this effect. 
 
The strengths of this study include the robust study design; adequate power and 
excellent retention and compliance. It included a homogenous group of participants with 
moderately severe overall symptoms. Factors incorporated to control the Hawthorne 
effect and placebo response include the non-treatment run-in period, trial duration and a 
single contact-investigator. The intervention trialled was produced with high quality 
assurance levels, was well-tolerated and there was an absence of noteworthy adverse-
events. Potential limitations of the trial include the lack of severity of depression and 
other psychological symptoms at baseline. Another is the inability to separate the effects 
of each individual herb in the combination. A criticism made of RCTs on fixed 
formulations in herbal research is that this protocol does not reflect the clinical practice of 
individualised prescriptions. 
 
There have been no previous published studies of this combination of herbs, nor any 
randomised placebo-controlled trials (RCT’s) of either herb individually in menopause. A 
1999 observational study49 on Hypericum perforatum in 111 women over 12 weeks found 
a 63% reduction in overall menopause symptoms compared with 32% in the present 
study. The study is not directly comparable with the present study, a robustly designed 
double-blind, placebo-controlled RCT. Also there was lack of consistency in 
nomenclature used for describing the different phases of the menopause transition and 
the menopausal rating scales, extracts used and the administration of a combination in 
the current study, rather than a single herb; the Hypericum perforatum extract used was 
the phytoequivalent of LI 160 trialled in depression studies.  
 
The high placebo response in the current study was consistent with findings from other 
RCTs of hot flushes or depression.870,1095 Our finding that women with no prior use of 
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phytotherapy were more likely to respond to active treatment or placebo has previously 
been reported in another study of herbal medicine and menopause.849 The effect of 
previous positive experience with phytotherapy in predicting improvements in 
depression, anxiety and sleep is a novel finding.  
 
The lack of efficacy of these non-oestrogenic herbs in comparison to the prescription 
non-oestrogenic drugs, suggests that the herbs may differ in terms of potency or 
mechanisms of action, since their pharmacology has not yet been fully elucidated. An 
antagonistic interaction between the two herbs is unlikely based on the current 
knowledge of their pharmacology. The failure of this study to demonstrate superiority 
over placebo for depression with Hypericum perforatum in combination with Vitex-agnus-
castus may be due to inadequate symptom severity at baseline, with only 37 women in 
the clinically depressed subgroup. However, there is an important distinction between 
depressive syndromes detected by instruments such as the HDI, and depressive 
symptoms, with the latter considered to be more relevant in association with 
menopause.354 The other negative findings in the current study are unlikely to be 
attributable to inadequate symptom severity as baseline hot flushes were as severe as 
baseline scores from previous positive studies,23,28 and overall menopausal symptoms 
measured by the Greene climacteric scale were consistent with a menopause clinic 
sample.1072   
 
The effect of previous positive experience with phytotherapy in predicting improvements 
in depression, anxiety and sleep suggests that these parameters may be more 
susceptible to the placebo effect, and supports the contribution of expectation to the 
placebo response.1033  Much has been written on ways of controlling the placebo 
response in clinical trials, as well as of harnessing the true placebo effect in clinical 
practice to enhance treatment outcomes. Other factors potentially contributing to the 
placebo effect in this trial include the natural history of the symptoms, the therapeutic 
alliance, and experimenter as well as participant expectations of Hypericum perforatum, 
given its reputation in treating mild-moderate depression. The findings of effect 
modification of lack of previous experience and positive previous experience with 
phytotherapy for some parameters warrant further investigation. These could have 
implications for future research and should potentially be considered when analysing 
results of studies.  
 
While an adverse interaction between the two herbs in the combination seems unlikely, 
any effect of the individual herbs cannot be established from this trial. Due to synergistic 
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effects, it is not possible to extrapolate from these findings to the effects of formulations 
combining a greater number of herbs, as is common in clinical practice. A recently 
trialled example is the formulation of six herbs including Vitex agnus-castus and 
Cimicifuga racemosa (Black cohosh) that showed a positive effect over placebo for 
menopausal symptoms.793  Trialling phytotherapies in a way that is both scientifically 
rigorous and reflects clinical practice is one of the biggest challenges facing evidence-
based CAM.  A protocol using three arms has been designed and trialled to address this 
limitation and to reflect the practice of individualised prescribing.1096 
 
This is the first RCT of the combination of Hypericum perforatum and Vitex agnus-castus 
for menopausal symptoms. The combination was well-tolerated and had a significant 
effect, although not superior to placebo. This was a robust study that further contributes 
to the growing body of scientific knowledge about complementary therapies from RCTs. 
Findings from such quality studies are important to inform the community, health-care 
providers and regulatory authorities on the role of CAM. 
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16.6 Manuscript Appendix 1 
16.6.1 Herbal Medicine Intervention  
 
(according to Proposed Elaboration of CONSORT Checklist Item 4) 
 
The herbal medicine intervention was a combination of two herbal extracts, Hypericum 
perforatum L. (Clusiaceae/Guttiferae; St John’s wort) and Vitex agnus-castus L, 
(Verbenaceae; Chaste tree/berry) manufactured under the Code of Good Manufacturing 
Practice by MediHerb Australia Pty Ltd in their Warwick manufacturing facility. These 
products are included on the Australian Register of Therapeutic goods in as Listed 
Medicines.  
 
The extract was obtained from the dry herb flowering top of Hypericum perforatum 
(extraction ratio 6:1(g/ml)) and dried Vitex agnus-castus fruit (extraction ratio 1:2(g/ml); 
the extraction solvent was 60% Ethanol/water. The extract was purchased and identified 
and analysed by MediHerb Quality Assurance Laboratory. Retention samples of raw 
materials and finished tablets are kept at MediHerb; these were validated by chemical 
fingerprinting against verified botanical samples maintained at the Southern Cross 
University Herbarium. The St John’s Wort Tablets were Batch 125178 and Chaste Tree 
Tablets Batch 124324.  The V. agnus-castus tablet was not a standardised preparation.  
The dosage regimen for H. perforatum  was consistent with a previous study using a 
daily dose of 900mg of 6:1 extract.915  
 
16.6.2 Qualitative testing 
 
The high-performance liquid chromatography (HPLC) chromatogram for Hypericum 
perforatum can be seen in figure 15.1. The method for performing this analysis was as 
follows: HPLC separation was achieved using a C18, 5μm column with dimensions (150 
mm x 4.6mm) with a gradient elution program using a three solvent program 
B=methanol, C = 50mM phosphoric acid in deionised water and D = acetonitrile. The 
elution program was 0 min B=0%, C=85%, D=15%; 20 min B=10%, C=70%, D=20%; 30 
min B=15%, C=10%, D=75%; 55 min B=15%, C=5%, D=80% at a flow rate of 
1.0mL/min. The analysis was done by an individual with over 20 year’s experience in 
analytical chemistry. Thin Layer Chromatography was employed for Vitex agnus-castus. 
Concentrations of heavy metals were measured by ICP/MS. 
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16.6.3 Standardisation 
 
Hypericin was tested utilising the British Pharmacopeia UV method. The levels of 
flavonoid glycosides were determined using a proprietary MediHerb HPLC analytical 
method, conditions above.  
 
The placebo tablets contained the excipients used in the active tablets, namely modified 
starch, cellulose, magnesium stearate, calcium hydrogen-phosphate. They were identical 
to the herbal tablets in size, colour, coating, weight and packaging. All tablets were 
packaged in amber glass jars with Tamper Tel plastic lids. 
 
The clinician choosing the treatment and dosage had 8 years experience as a chemist 
and 22 years as a medical herbalist. 
 
As a further check on the validity, the veracity of the code was checked at the conclusion 
of the trial by Dr Kerry Penman of MediHerb Australia, using TLC assessment. (Report 
available on request).  
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16.7   Manuscript Appendix 2 
 
 TABLE 16.3 UNADJUSTED SCORES FOR GREENE CLIMACTIC SCALE AND SUBSCALES  
Mean (SE) 
Placebo Herbal Combination  
Baseline After 16 
weeks 
Mean 
change 
Baseline After 16 
weeks 
Mean 
change 
Difference 
between 
groups at 
week 16 
 n = 50 n = 46  n = 50 n = 47   
Greene total score 22·48(1·11) 13·33(1·11) 9·15 22·00(1·06) 15·77(1·09) 6·23 0·12 
95% CI 20·40,24·56 11·16,15·50 6·15,12·16 19·92,24·08 13·62,17·91 3·24,9·23  
Greene Subscales: 
  Psychological 
 
11·54(0·71) 
 
6·76(0·74) 
 
4·78 
 
11·70(0·71) 
 
8·45(0·73) 
 
3·25 
 
0·11 
95% CI 10·15·12·93 5·31,8·21 2·77,6·79 10·31,13·09 7·01,9·88 1·25,5·25  
   Anxiety  6·42(0·40) 3·74(0·41) 2·68 6·30(0·40) 4·55(0·41) 1·75 0·16 
95% CI 5·64,7·20 2·93,4·55 1·56,3·80 5·52,7·07 3·75,5·35 0·63,2·86  
 
16.8 Additional Statistical Analyses 
 
Additional analyses performed that could not be included in the preceding manuscript 
are presented here. 
16.8.1 On-treatment analysis 
 
In the manuscript, results are reported of the intention-to-treat analysis.  On-treatment 
analysis was also performed for the completing participants, but results did not differ 
from the intention-to-treat analysis. 
16.8.1 Data screening 
 
The 5% Trimmed Means and the original means were close for all endpoints at baseline 
for both the enrolled and completed participants.  No outliers in either sample were found 
to have scores more than five standard deviations from the mean for any continuous 
variable at baseline, so the whole sample was included in each analysis.   
6.8.2 Groups equal at baseline 
 
The two groups were similar at baseline on all categorical variables except null parity for 
both the enrolled and completed participants.  Additionally, three of the four vegetarians 
were in the placebo group.   
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However, Pearson’s correlations found no relationship between null-parity and the 
endpoints of flushing, depression or Greene Climacteric scores at baseline for either the 
completing or enrolled participants. [Null parity and flushing for the completing 
participants: r(N=92) = 0·06, p = 0·57; and the enrolled participants, r(N=99) = 0·07, p = 
0·47.  Nulliparity and depression scores on the HDI-17: r(N=93) = -0·02, p = 0·86; 
r(N=100) = 0·01, p = 0·93; nulliparity and Greene Climacteric scale at baseline: r(N=93) = 
0·05, p = 0·62; r(N=100) = 0·09, p = 0·37  Table 16.4.] 
 
For the distribution of the vegetarians, a contingency table analysis found no significant 
difference between groups χ2 (1, N = 100) = 1·04, p = 0·31, but due to the small numbers 
in each cell, this needs to be interpreted with caution.  However, the relevance of 
vegetarian diet is the increased phytoestrogen content it contains; this was measured 
separately (Table 16.4).   
  
TABLE 16.4    RESULTS OF CHI SQUARE TESTS FOR CATEGORICAL VARIABLES FOR 
COMPLETING (N = 93) AND ENROLLED (N = 100) PARTICIPANTS 
Variable χ2 value p-value χ2 value p-value 
 n = 93  n = 100 
menopausal status 
marital status 
hysterectomy 
number of ovaries intact 
prior herb use (n = 92/99) 
herbs effective (n =68/ 73) 
prior HT use 
HT effective (n = 29/32) 
stress reduction 
vegetarian 
high/low isoflavone intake 
attitude to menopause 
relationship satisfaction 
season entered trial 
employed outside home 
nulliparity 
  0·53 
1·40 
0·11 
0·00 
0·10 
0·18 
0·36 
4·10 
0·02 
3·17 
0·39 
0·27 
0·67 
1·10 
1·31 
6·67 
0·77 
0·24 
0·74 
0·99 
0·75   
0·67 
0·55 
0·25 
0·88 
0·08* 
0·53 
0·60 
0·41 
0·58 
0·25 
0·01* 
 
0·27 
0·22 
0·07 
0·00 
0·00 
0·31 
0·18 
4·43 
0·00 
1·04 
0·71 
0·04 
0·44 
1·22 
0·64 
4·34 
0·87 
0·64 
0·79 
1·00 
0·95 
0·58 
0·67 
0·22 
1·00 
0·31* 
0·40 
0·84 
0·51 
0·54 
0·42 
0·04 
Baseline categorical variables chi square and significance values    n = 92 and n = 100 
* At least one cell contained <5, therefore interpret with caution. 
 
Marital status, isoflavone intake and attitude to menopause were recoded as not all cells 
had originally contained adequate numbers for chi square test to be reliable. Isoflavone 
intake was recoded as’ high/low’ where ‘high’ was 20mg+ per day, according to the 
findings of Guthrie and colleagues that the average isoflavone intake among Australian 
women was 17mg per day.1097  
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16.8.4 Assumption testing 
 
In the manuscript, results of an intention- to- treat analysis (n = 100) were reported.  Prior 
to this analysis, assumption testing was conducted: 
 
Normality testing  
 
For enrolled participants in the active treatment group, the Shapiro-Wilk normality test 
showed that the assumption of normality had been violated in relation to average daily 
weighted flushes at baseline, p < 0·001, total Greene score, p = 0·003, and scores on the 
Hamilton Depression-17-item scale, p = 0·02.  For the placebo group, normality was 
violated for total Greene score, p = 0·002.  However due to the large sample size, visual 
inspection was considered more reliable.  The normal Q-Q plots did not show significant 
deviation from the linear line for any of these variables. 
 
Homogeneity of Variance 
 
For enrolled participants, the Levene test found that the assumption of homogeneity of 
variance was violated for isoflavone intake, p =0.02 and secoisolariciresinol diglycoside 
intake, p = 0.000, therefore two-tailed independent samples t-tests based on unequal 
variances were carried out. No significant difference between the two groups was found 
for secoisolariciresinol diglycoside intake, p = 0·05, but a significant difference was found 
for isoflavone intake between the two groups at baseline t(98) = 2·07, p = 0·035, 95% CI 
(1·42 to 74·97), with the placebo group having the higher intake (Figure 16.3). 
 
For all other continuous variables at baseline, the Levene test found that the assumption 
of homogeneity of variance was met, therefore two-tailed independent samples t-tests 
based on equal variances were carried out. No significant difference between the two 
groups was found for any variable except standard drinks per week t(98) = -2·73, p = 
0·035, 95% CI (-3·71 to -0·13), with the treatment consuming the greater quantity (Figure 
16.3).   
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FIGURE 16.3   BASELINE ALCOHOL AND ISOFLAVONE INTAKE BY GROUP 
 
16.8.5 Time-dependent covariates 
 
Alcohol was found to vary significantly between the two groups across time but did not 
covary significantly with any of the endpoints across the treatment phase (Figure 16.4).  
Isoflavone intake covaried significantly with total Greene Climacteric Scale scores p = 
0·047, Greene psychological, p = 0·02, and Greene anxiety, p = 0·02, subscale scores, 
and was therefore used as a covariate in these cases, due to the baseline differences 
between groups.  The assumption of homogeneity of slopes was met for isoflavone 
intake F(1, 89) = 0·57, p = 1·04, η2 = 0·01.   
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FIGURE 16.4   TIME-DEPENDENT CO-VARIATES 
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16.9 Additional Results 
16.9.1 Effect sizes 
 
Cohen’s d effect sizes were calculated for the active treatment group using the means 
and standard deviations for baseline and week 16 scores. 
Flushing, Cohen’s d = 0.54 (medium effect size) 
Greene total score, Cohen’s d = 0.82 (large effect size) 
HDI-17 scores, Cohen’s d = 1.01 (large effect size) 
 
For the subscales of the Greene Climacteric scale, large effect sizes were found for all 
subscales except the sexual subscale. 
Greene psychological subscale, Cohen’s d = 1.20 
Greene anxiety subscale, Cohen’s d = 1.01 
Greene depression subscale, Cohen’s d = 1.13 
Greene somatic subscale, Cohen’s d = 1.12 
Greene vasomotor subscale, Cohen’s d = 1.24 
Greene sexual subscale, Cohen’s d = 0.49 (medium) 
16.9.2 Additional Analyses Daily weighted Flushing score  
 
Individual weekly flushing scores are included in appendix 27.  
 
No significant between-group difference at any time point measured 
 
As reported in the manuscript, the difference between groups in mean daily weighted 
flushing scores (MDWFS) was not significant at week 16. Nor were significant between-
group differences found on MDWFS at week 4 (F = 0·09, p = 0·77, η2 = 0·00), week 8 (F 
= 0·11, p = 0·74, η2 = 0·00) or week 12 (F = 0·21, p =·65, η2 = 0·001). 
 
Improvements across treatment phase in each group for Vasomotor Symptoms 
 
However, significant improvements were observed for both groups from baseline to week 
16 (placebo p < 0·001 and active p < 0·01). The percentage reductions in the placebo 
and active groups were 41% and 36% respectively. Significant improvements in both 
groups were also seen at weeks 8 and 12.  (For the active treatment group, p = 0·001 at 
week 8; and at week 12, p = 0·003.)  The sharpest decline, of 22%, occurred between 
weeks 0 and 2 (26% placebo; 19% active). 
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16.9.3 Additional Analyses of Greene Climacteric Scale scores 
 
Percentage improvement on Green Climacteric scores within groups 
 
Overall menopausal symptoms, as measured by the Greene Climacteric scale, reduced 
significantly in the placebo and active groups by -40% and -29% respectively.  A table of 
scores on the Greene Climacteric subscales, including follow-up scores, is included in 
Appendix 28. 
 
Significant improvement during non-treatment run-in 
 
For the total Greene Climacteric scale scores, a significant difference between screening 
and baseline (after the 2-week run-in period) was found using two-tailed paired samples 
t-tests for the placebo group, t(50) = 7·78,  p = 0·001, and for the treatment group, t(49) = 
3·62, p < 0·001. This constituted an overall 17·6% reduction in scores: 15% for the 
placebo group (mean difference 4·06) and 20% for the active treatment (mean difference 
5·44).  
16.9.4 Additional Analyses of Hamilton Depression Inventory scores 
 
Percentage improvement on depression for whole group Vs clinically depressed 
subgroup 
 
The difference between the two groups was not significant at week 16, p = 0·51.  A 
significant reduction in scores was seen for both groups on the HDI-17, - 41% for 
placebo compared with -39% in the active group.  Analysis of the clinically depressed 
subgroup did not affect the outcome, (mean change in scores was - 46% for placebo (n = 
19) and -42% for active (n = 18), p = 0·54 [placebo -9·2; 95% CI, 4·3 to 14·2; active -7·8; 
95% CI, 2·7 to 12·9].   
 
Percentage improvement on depression among responders 
 
Depression scores decreased for 82% of the sample. Among these responders, there 
was a mean improvement of 49% for placebo and 52% in the active group. 
Responder Rates for Depression 
The percentage of participants experiencing a 50% or greater reduction in HDI-17 scores 
across the treatment phase was 32·6% of placebo and 44·7% of active treatment group 
for the whole sample.  For those who were sub-clinically or clinically depressed at 
baseline (n = 81), 32·5% responded by 50% or more to placebo and 44% to active 
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treatment.  However a chi square test found that the difference between groups was not 
statistically significant, χ2 = 1·43, p = 0·23.  
Significant treatment response among herb-naive group 
 
Among the herb-naive group, a reduction in depression scores of 50% or more was 
observed for a significantly greater percentage of the active treatment group (67%), than 
the placebo group (25%), using a  chi-square test,  χ2 = 4·20,  p = 0·04.  In the active 
treatment group, (n = 12), a significant improvement was observed, -51·2%, p = 0·007, 
while no significant reduction was seen in the placebo group, (n = 12), -31·3%, p = 0·20.  
It will be noted, however, that the sample size was very small.   
16.9.4 Follow-up data   
 
The effects persisted in the active treatment group but not in the placebo group (Table 
16.5 and Figure 16.5).  However, the difference from week 16 to the end of the non-
treatment follow-up 8 weeks later was not significant for any of the endpoints using 
mixed model anlysis.    
  
TABLE 16.5   FOLLOW-UP DATA COMPARED WITH BASELINE AND END OF TREATMENT PHASE 
  Baseline Week 16   Follow-  up 
Hot Flushes     
placebo Mean(SE) 16·35(1·30) 9·32(1·36)‡ 11·74(1·40)* 
 95% CIs 13·79,18·92 6·64,12·00 9·00, 14·48 
active Mean(SE) 16·53(1·32) 10·86 (1·34)† 10·94(1·40)† 
 95% CIs 13·93,19·12 8·21,13·51 8·19, 13·68 
Greene Total     
placebo Mean(SE) 22·48(1·11) 13·33(1·11)‡ 15·75(1·13)‡ 
 95% CIs 20·40,24·56 11·16,15·50 13·53,17·96 
active Mean(SE) 22·00(1·06) 15·77(1·09)‡ 16·12(1·13)‡ 
 95% CIs 19·92,24·08 13·62,17·91 13·91,18·33 
HDI-17     
placebo Mean(SE) 14·30(0·75) 8·40(0·79)‡ 9·34(0·78)‡ 
 95% CIs 12·83,15·77 6·85, 9·95 7·81, 10·88 
active Mean(SE) 14·76(0·75) 9·29(0·77)‡  9·56(0·78)‡ 
 95% CIs 13·29,16·23 7·78,10·80 8·03, 11·10 
 
* difference from baseline significant at p < 0.05  
† difference from baseline significant at p < 0.01 
‡ difference from baseline significant at p < 0.001 
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FIGURE 16.5   EFFECTS OF INTERVENTION ON ENDPOINTS, INCLUDING 8-WEEK POST-
TREATMENT FOLLOW-UP  
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Somatic subscale
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FIGURE 16.5   EFFECTS OF INTERVENTION ON ENDPOINTS, INCLUDING 8-WEEK POST-
TREATMENT FOLLOW-UP CONT 
16.10  Ancillary analyses 
16.10.1  Menopausal status 
 
There was no significant difference between groups according to menopausal status on 
any of the outcome measures.  However due to the small sample size (n = 50) in each of 
the peri- and postmenopausal subgroups, these sub-population analyses were 
underpowered.  
16.10.2  Bias 
 
For the primary endpoints, positive previous experience with phytotherapy did not result 
in a significant difference between active and placebo groups according to a repeated 
measures analysis of the two sub-groups: previous positive experience with herbs 
versus none (using alcohol as a covariate). 
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16.10.3  Adverse Events 
 
One participant withdrew due to an aggravation of depressive symptoms.  She was 
referred to the safety monitor, but did not attend.  No other adverse events occurred that 
warranted the intervention of the safety monitor.  There was no significant difference 
between the two groups for adverse events, χ2 (1, N = 100) = 1·10, p = 0·58. The main 
ones were colds and ‘flu’s/upper respiratory tract infections.   A complete itemised list of 
adverse events can be found in appendix 29. 
16.10.4  Allocation concealment 
 
Unblinding did not occur.  Fifty one percent of participants retrospectively guessed their 
allocation correctly, 50% of the placebo group and 51% of the active treatment group. 
(Table 16.6). 
 
TABLE 16.6   PROSPECTIVE ASSESSMENT OF GROUP ASSIGNMENT BT PARTICIPANTS 
 
Assessment of Allocation
Count
23 23 46
23 24 47
46 47 93
placebo
active treatment
subject
group
Total
placebo active
active or placebo
Total
 
 
In her estimations made prior to code breaking, the principal investigator was 45% 
correct for the placebo group and 46% for the active treatment group.   
16.10.5  Accuracy of Data scoring and Data Entry 
 
All questionnaires were double-scored; the error rate detected on checking was 0·19%.  
Data entry was also double-checked and the error rate found to be 0·12%. 
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16.11  Discussion 
16.11.1   Statement of Findings 
There was no difference in findings between the on-treatment analyses and intention-to-
treat analyses.  Analysis of data according to menopausal status showed no significant 
difference between groups, although the sample size in each was small.   Improvements 
during non-treatment run-in were significant for both arms.  The greatest improvement on 
flushing scores was observed between weeks 0 and 2 of the treatment phase.  
Statistically significant improvements were observed from week 8 onwards for both 
groups.  Substantial improvements were also noted for the endpoints of overall 
menopausal symptoms and depression in both arms across the treatment phase.  
Within-group effect sizes were medium to large for these three endpoints. Although the 
differences were not statistically significant, higher responder rates (≥50% reduction in 
symptoms) were observed for the active treatment group than placebo for depression 
scores on the HDI-17.   Among the herb-naïve group, this difference did reach statistical 
significance, although the sample size was very small.  Any potential bias from prior 
positive experience with phytomedicines affected both arms equally.  The follow-up data 
showed a washout effect for the placebo group on all the endpoints, but no washout 
effect was observed for the treatment group, except the somatic subscale of the Greene 
Climacteric Scale.  However, the difference was not statistically significant at week 8 of 
the post-treatment follow-up.  The investigator’s retrospective guessing of allocation was 
less than 50% accurate. 
16.11.12 Interpretation 
 
As mentioned previously, the placebo response in menopause studies is largely 
attributable to the natural history of the symptoms, which follow a fluctuating course.  
Although no significant difference was found between the two subgroups according to 
menopausal status, the small sample size in each subgroup means that the possibility 
cannot be ruled out that including the perimenopausal women in the sample may have 
contributed to a higher placebo response.  The significant improvement during non-
treatment run-in may attest to impact of psychosocial factors, such as anxiety and need 
for support, as contributors to symptom intensity.  Determination to take charge of one’s 
own health by joining clinical research can also coincide with other concomitant lifestyle 
changes. The substantial initial improvement in flushing is consistent with the placebo 
effect.  The significant improvements on the three endpoints of flushing, overall 
menopausal symptoms and depression, despite lack of superiority over placebo, raises 
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the question of what constitutes a clinically meaningful effect.  This will be discussed 
further in chapter 19.   The higher responder rates observed for depression, while not 
statistically significant, are consistent with previous findings on studies of St John’s wort 
as a sole agent for depression, and suggest no negative interaction occurred between 
the two combined herbs in this study.  The finding that this difference reached statistical 
significance for the herb-naïve group cannot be readily explained.  It is unlikely that 
previous experience with phytomedicines resulted in negative expectation, as 
participants expecting no benefit would be unlikely to volunteer for such a study.  The 
observation of wash-out of placebo effects, but not generally of improvements 
experienced in the treatment arm is interesting.  While no firm conclusions can be drawn 
for this, it does lend support to the possibility of subtle effects of the phytomedicines 
being overshadowed by the substantial placebo effect in this study.  Further evidence for 
the success of blinding is provided by the investigator’s low success rate in her 
retrospective assessment of participant allocation. 
16.12 Conclusions 
 
The majority of participants benefited during their enrolment in the current study.  
However, because of the lack of statistical significance over placebo, the 
phytotherapeutic intervention is deemed ineffective.  Whether such an improvement can 
justifiably be dismissed is questionable, and will be discussed further in chapter 19.  
Factors contributing to the substantial improvement in the placebo arm undoubtedly 
include an appreciable impact of natural history, but the washout effects post-treatment 
suggest that other factors also operated.  This warrants further investigation, and gave 
rise to the subsequent studies reported in chapter 18. 
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Chapter Seventeen 
 
  
 
 
  Hypericum perforatum and Vitex agnus-castus 
 
 for PMS-like symptoms in perimenopause 
 
  
 
17.0  Introduction 
 
The second of the results chapters reports on a sub-study of the principal randomised, 
controlled trial.  Data were analysed from women in the late-perimenopausal subgroup 
who continued to experience intermittent menstruation and recorded associated 
premenstrual symptoms during the trial.  The manuscript has been submitted as a brief 
communication to The Journal of Alternative and Complementary Medicine. [Citation: 
Van Die MD, Bone KM, Burger HB, Reece JE, Teede HJ. Hypericum perforatum and Vitex agnus-
castus for PMS-like symptoms in perimenopause. submitted to J Alt Comp Med Nov 2008.] 
Additional analyses not incorporated into the manuscript are included as an addendum.  
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17.1 Abstract  
 
The effect of a combination of Hypericum perforatum and Vitex agnus-castus on 
premenstrual syndrome (PMS)-like symptoms was investigated in a small sub-population 
(n = 14) of late-perimenopausal women participating in a randomised controlled trial on 
menopausal symptoms.  Significant treatment group trends across the five phases were 
observed for total PMS and all subscales, all in the clinically expected direction.  No 
significant trends were evident in the placebo group. 
 
17.2 Introduction 
 
It has been suggested that some of the symptoms typically attributed to menopause may 
be more related to premenstrual syndrome (PMS)225 which is observed to be quite 
prevalent, or less well-tolerated, in perimenopausal women. However, the menstrual 
cyclicity of the symptoms may not always be apparent, not only because of the 
unpredictable nature of cycles, but also because ovulatory cycles can occur in the 
absence of subsequent menstruation during the perimenopause.55  When PMS co-exists 
with menopausal symptoms, management with hormone therapy (HT) is difficult, as 
progestins are found to aggravate PMS symptoms and combined HT regimes may 
induce PMS-like symptoms in susceptible women.456   
 
PMS is thought to result from sensitivity to normal hormonal fluctuations in the late luteal 
phase of the menstrual cycle, possibly due to neurotransmitter dysfunction.465  As these 
hormonal fluctuations depend on the occurrence of ovulation, which is less frequent 
during the late-perimenopause, symptoms during this phase are more appropriately 
termed ‘PMS-like’.  
 
The herb Vitex agnus-castus (Chaste tree/berry) has been shown to effect significant 
improvement in premenstrual symptoms such as irritability, mood alteration, anger, 
headache, breast tenderness and bloating.1098 It is also widely prescribed for the 
treatment of menopausal symptoms by UK herbalists.1098 Various mechanisms have 
been proposed including prolactin inhibition, conferring benefit in latent 
hyperprolactinaemia, an opiate-agonist effect and stimulation of melatonin secretion.1098  
 
Hypericum perforatum (St John’s wort), in addition to its efficacy for mild-moderate 
depression,920 has been observed to significantly reduce the severity of premenstrual 
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symptoms.911  Hypericum extracts have been shown to influence serotonergic, 
noradrenergic, dopaminergic and GABA-ergic mechanisms.908 Other potentially relevant 
mechanisms of action include the regulation of genes controlling hypothalamic-pituitary-
adrenal axis function and opioid receptor binding activity.908 
 
This study aimed to investigate the effects of a combination of Hypericum perforatum 
and Vitex agnus-castus on PMS-like symptoms in a small sub-population of late-
perimenopausal women participating in a double-blind, placebo-controlled randomised 
trial on menopausal symptoms.848  
17.3 Methods 
 
The study protocol was approved by the Royal Melbourne Institute Technology- 
University Human Research Ethics Committee.  All participants gave written informed 
consent prior to study entry.   
 
Of one hundred volunteers recruited to the larger study, fourteen late-perimenopausal 
women provided baseline data for PMS-like symptoms and menstruated at least once 
within the last 12 weeks of the treatment phase.  Exclusion criteria included concurrent 
major illnesses, substance abuse and concurrent treatment for menopausal or PMS-like 
symptoms, and any medication known to interact with the study intervention. 
  
The daily dose of Hypericum perforatum was extract equivalent to 5,400mg dry herb 
flowering top administered via three tablets, each standardised to contain 990mcg 
hypericins, 9mg hyperforin and 18mg flavonoid glycosides.848  The daily dose of Vitex 
agnus-castus was extract equivalent to 1,000mg dry fruit.848  Tablets and matching 
placebos were manufactured by MediHerb Australia according to the Code of Good 
Manufacturing Practice, and are included as Listed Medicines on the Australian Register 
of Therapeutic goods. They were randomised by MediHerb using a computer-generated 
random number table.  
 
Participants recorded the severity of their PMS-like symptoms at study entry and 
premenstrually throughout the 16-week treatment phase, on Abraham’s Menstrual 
Symptoms Questionnaire (MSQ),1090 consisting of 4 clusters, namely PMS-A: nervous 
tension, irritability, mood swings and anxiety; PMS-H: weight gain, swelling of 
extremities, breast tenderness and abdominal bloating; PMS-C: headaches, cravings for 
sweets, increased appetite, pounding heart, fatigue and dizziness; PMS-D: depression, 
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forgetfulness, crying, confusion and insomnia.  Potentially confounding dietary and 
lifestyle factors and adverse events were monitored. 
  
Data were analysed using Statistical Package for Social Science Version 16. 
Assumptions for parametric tests were met. Last observation carried forward was used 
to deal with missing week-16 PMS data, provided the last observation was at week 8 or 
later. Three sets of data analysis were conducted on the overall PMS scores and its four 
subscales.  First, single-factor between subjects analyses of covariance (ANCOVAs) 
were used to evaluate the overall treatment effects with the baseline scores serving as 
the covariates, and the equivalent week 16 scores as the dependent variables. The 
treatment and placebo groups formed the between-subjects factor. Second, focussed 
linear mixed model single degree of freedom F-test comparisons, with appropriate 
Bonferroni corrections, were used to examine specific phase-within-group and group-
within-phase differences. Finally, analyses of orthogonal polynomials (trend analyses), 
using a linear mixed model approach, were conducted across the five phases, separately 
for the treatment and placebo groups, to examine the pattern of change across the 
phases. 
17.4 Results 
 
There were no significant baseline differences between the two groups in terms of 
sociodemographic characteristics or outcome measures. The mean age was 49 in each 
group. All fourteen participants in this sub-group completed the study and were included 
in the analyses. 
 
Figure 17.1 shows the pattern of change for the five measures across the five phases for 
the treatment and placebo groups. At a descriptive level, it is evident that there was no 
notable difference between the groups on any measure at either baseline or week 4, with 
differences emerging subsequently in the clinically expected direction. Notable group 
differences are evident for all measures at week 16. 
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FIGURE 17.1   EFFECT OF INTERVENTION ON PMS TOTAL AND SUBCLUSTER SCORES  
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This interpretation was confirmed by statistical analysis. Three of the five ANCOVAs 
revealed significant group differences at week 16 (Table 17.2): Total-PMS, F(1, 11) = 
7·33, p = 0·02; PMS-C, F(1, 11) = 6·53, p = 0·03; and PMS-D, F(1, 11) = 11·61, p = 
0·006.  
 
Focussed single degree of freedom tests revealed no significant differences between 
groups on any measure at either baseline or at week 4, but significant differences in the 
clinically expected direction at week 16 for PMS-Total, F(1, 39·81) = 4·82, p = 0·03; 
PMS-C, F(1, 35·57) = 4·69, p = 0·04; and PMS-D, F(1, 39·33) = 8·07, p = 0·007.   
 
The trend analyses revealed no significant trends for any test involving the placebo 
group, but four of the five measures in the treatment group revealed significant quadratic 
trends: PMS-Total, t(18·89) = 5·39, p < 0·001; PMS-A, t(19·48) = 4·10, p = 0·001; PMS-
C, t(18·52) = 2·98, p = 0·008; and PMS-D, t(18·95) = 3·53, p = 0·002· PMS-H failed to 
show a significant quadratic trend, but did reveal a significant linear trend, t(18·26) = 
4·65, p < 0·001. All quadratic trends reflected the same pattern of clinical change: a 
steep decrease in symptoms from baseline to week 8, followed by a pattern of 
maintained change to week 16. 
17.5 Discussion 
 
In this sub-population of irregularly menstruating late-perimenopausal women, the 
combination of Hypericum perforatum and Vitex agnus-castus was superior to placebo 
for total PMS-like symptoms and the sub-clusters, PMS-D (depression) and PMS-C 
(cravings).  The active treatment group also showed significant improvements on PMS-A 
(anxiety) and PMS-H (hydration), although this effect was not superior to placebo.   
 
The observations from the present study support results from previous studies on the 
efficacy of Vitex agnus-castus in overall premenstrual symptoms,1098 as well as pilot 
studies with Hypericum perforatum in PMS, particularly for depression-related 
symptoms.911  However, they contrast with findings from the larger study of this 
combination in menopausal symptoms (measured on the Greene Climacteric scale) in 
late peri- and postmenopausal women,848 and in the particular subgroup investigated 
here.  This suggests that benefits to PMS-like symptoms do not simply reflect 
improvements to actual menopausal symptoms. 
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To our knowledge, this is the first study of this phytotherapeutic combination in PMS-like 
symptoms.  The duration of the trial was adequate to allow for wash-out of the placebo 
effect, randomisation resulted in equivalent groups, and blinding was successful. Good 
quality assurance data were available for the phytotherapeutic intervention, for which 
overall tolerability and acceptability were good and compliance high.   
 
The main limitations in this study were the small subgroup sample size and the late-
perimenopausal status of the sample, with associated infrequent ovulatory menstrual 
cycles.   As this was a sub-study of a menopause study, the diagnosis of PMS at 
baseline was not confirmed by 2 months of ratings, but relied on recall of symptoms, 
allowing for potential recall bias.   
 
The current study suggests a potentially significant clinical application for the 
combination of Hypericum perforatum and Vitex agnus-castus for largely-neglected 
symptoms among perimenopausal women. Due to the limitations of this study, however, 
these findings should be interpreted with caution until replicated.  This phytotherapeutic 
combination warrants further investigation in a dedicated study of PMS-like symptoms 
with a larger sample of women.  
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17.6 Additional Statistical Analyses 
 
Additional analyses and results that could not be included in the brief communication in 
the preceding section are presented here. 
17.6.1 Assumption Testing 
 
Prior to conducting the analyses reported in the manuscript, assumption testing was 
carried out:   
 
Normality testing  
 
For enrolled participants in the active treatment group, the Shapiro-Wilk normality test 
showed that the assumption of normality had been violated in relation to PMS-C at 
baseline, p = 0·029.  However visual inspection of the normal Q-Q plots did not show 
significant deviation from the linear line.  Transformation or use of non-parametric tests 
was therefore not considered justified as parametric tests are quite robust to violations of 
normality.  In addition, hypothesis tests of assumption testing are open to type II errors. 
 
Homogeneity of Variance 
 
The Levene test found that the assumption of homogeneity of variance was violated for 
total PMS, p =0.048, therefore two-tailed independent samples t-tests based on unequal 
variances were carried out. No significant difference between the two groups was found, 
p = 0·71. 
17.6.1 Further Analyses 
 
Further analyses conducted included  
• ANCOVAs using week 4 data as the co-variate,  
• paired samples t-tests for within-group changes from baseline,  
• ANCOVAs on the Greene Climacteric Scale scores for this subgroup 
• independent t-tests to compare the PMS and non-PMS subgroups of 
perimenopausal woman, and the postmenopausal group. 
• Examination of data for one participant providing PMS data at all trial phases.  
 
Details of adverse events and compliance are also included here. 
 
233 
17.7 Results 
17.7.1 Baseline characteristics 
 
The two groups in the PMS sample were equal at baseline: 
  
TABLE 17.1  BASELINE CHARACTERISTICS OF STUDY PARTICIPANTS N = 14 
 MEAN (SD)  
  
Placebo 
Herbal 
Combination 
 n = 6 n = 8 
DEMOGRAPHICS 
Age at trial start (years) 
Weight in kg 
BMI  
Caffeine: cups of tea/coffee per day 
Standard alcoholic drinks per day 
Stress 
Exercise – hours per week 
 
48.8(4.1) 
65.8(11.8) 
24.5(3.7) 
4.0(1.9) 
3.0(4.4) 
2.3(0.9) 
3.2(2.9) 
 
48.8(3.4) 
66.7(11.8) 
24.7(4.1) 
4.1(1.0) 
5.3(6.5) 
2.5(0.8) 
3.3(3.1) 
PRIMARY ENDPOINTS    
Total PMS  24.83(14.33) 22.38(6.80) 
PMS-A 6.00(4.15) 5.12(2.48) 
PMS-C 6.50(4.23) 5.88(3.52) 
PMS-D 6.67(4.03) 6.25(3.01) 
PMS-H      5.67(3.50) 5.13(2.17) 
 
17.7.2 ANCOVA results for PMS-like symptoms at week 16 
 
Further details of the single-factor between subjects analyses of covariance (ANCOVAs), 
using the baseline scores as the covariates, are given in Table 17.2.   
TABLE 17.2  EFFECT OF INTERVENTION ON PMS-LIKE SYMPTOMS AT WEEK 16 
 COVARIATE ADJUSTED MEANS 
 
Subscale 
  
Std. 
95% 
Confidence 
 
 
 N Mean Error Interval p-value 
PMS-total  placebo 6 18·39a 3·28 11·30, 25·76 0·02 
 active  8 6·73a 2·84 0·48, 12·98  
PMS-A  placebo 6 3·15a 1·02 0·91, 5·40 0·25 
 active 8 1·51a 0·88 -0·43, 3·44  
PMS-C  placebo 6 6·19a 1·06 3·86, 8·53 0·03 
 active 8 2·61a 0·92 0·59, 4·62  
PMS-D  placebo 6 4·89a 0·95 2·79, 6·98 0·006 
 active 8 0·59a 0·83 -1·23, 2·40  
PMS-H placebo 6 3·97a 1·13 1·47, 6·46 0·29 
 active 8 2·28a 0·98 0·12, 4·43  
a. Covariates appear in the model: baseline scores 
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17.7.3 Effects of Intervention at each phase 
The effects of the intervention across the 5 phases is recorded in table 17.3 based on a 
mixed model, treating group as the between-subject factor and phase as the within-
subject factor, and using last observation carried forward for missing data.   
  
TABLE 17.3   EFFECT OF INTERVENTION ON PMS SUBSCALE SCORES  
(MEAN +SE) 
Cluster  
 
       Phase 
Group 
Baseline 
n=6, n=8 
Week 4 
n=2, n=4 
Week  8 
n=3, n=5 
Week 12 
n=3, n=5 
Week 16 
n=5, n=4 
PMS-Total Placebo 
95% CIs 
24.83(3.75) 
17.26, 32.41 
11.00(6.49) 
-2.12,24.12 
17.00(5.30) 
6.29,27.71 
18.67(5.30) 
7.96,29.38 
18.00(3.75) 
10.43,25.57 
 Active 
95% CIs 
22.38(3.25) 
15.82,28.93 
11.25(4.59) 
1.98,20.52 
7.00(4.10) 
-1.30,15.30 
8.00(4.10) 
-0.30,16.30 
7.13(3.25) 
0.57,13.69 
PMS-A Placebo 
95% CIs 
6.00(1.05) 
3.88,8.13 
1.50(1.82) 
-2.18,5.18 
3.00(1.49) 
-0.008,6.01 
3.33(1.49) 
0.33,6.34 
3.00(1.05) 
0.87,5.13 
 Active 
95% CIs 
5.13(0.91) 
3.28,6.97 
1.75(1.29) 
-0.86,4.36 
1.00(1.15) 
-1.33,3.33 
1.60(1.15) 
-0.73,3.93 
1.63(0.91) 
-0.22,3.47 
PMS-C Placebo 
95% CIs 
6.50(1.24) 
4.00,9.00 
4.50(2.15) 
0.16,8.84 
6.00(1.75) 
2.46,9.54 
7.00(1.75) 
3.46,10.54 
6.17(1.24) 
3.66,8.67 
 Active 
95% CIs 
5.88(1.07) 
3.70,8.04 
4.25(1.52) 
1.18,7.32 
1.80(1.36) 
-0.94,4.54 
2.60(1.36) 
-0.14,5.34 
2.63(1.07) 
0.46,4.80 
PMS-D Placebo 
95% CIs 
6.67(1.12) 
4.40,8.93 
2.50(1.94) 
-1.42,6.42 
4.00(1.59) 
0.80,7.20 
4.00(1.59) 
0.80,7.20 
4.83(1.12) 
2.57,7.10 
 Active 
95% CIs 
6.25(0.97) 
4.29,8.21 
2.25(1.37) 
-0.52,5.02 
1.20(1.23) 
-1.28,3.68 
0.60(1.23) 
-1.88,3.08 
0.63(0.97) 
-1.66,2.58 
PMS-H Placebo 
95% CIs 
5.67(1.17) 
3.31,8.02 
2.50(2.02) 
-1.58,6.58 
4.00(1.65) 
-1.58,6.58 
4.33(1.65) 
1.00,7.66 
4.00(1.17) 
1.65,6.35 
 Active 
95% CIs 
5.13(1.01) 
3.09,7.16 
3.00(1.43) 
0.12,5.88 
3.00(1.28) 
0.42,5.58 
3.20(1.28) 
0.62,5.78 
2.25(1.01) 
0.21,4.29 
Data are expressed as mean ± (std error). 
Data were derived using mixed model analysis and last observation carried forward 
 
Last observation carried forward was used for missing week 16 data, provided that the 
last observation was reported at week 8 or later.  As women reported symptoms at the 
end of every 4 weeks, PMS-like symptoms reported at week 4 would include those 
occurring in the first weeks of the trial, before any effect of the phytotherapeutic 
intervention would be noticed.  Women who had no subsequent menstrual cycles 
throughout the treatment phase were therefore not included in the sample for analysis. 
 
Raw descriptive data for the 5 trial phases, not adjusting for missing data, are shown in 
table 17.4 and Figure17.2. 
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TABLE  17.4  EFFECT OF INTERVENTION ON UNADJUSTED  PMS SUBSCALE SCORES  
(MEAN +SE) 
Cluster  
 
       Phase 
Group 
Baseline 
n=6, n=8 
Week 4 
n=2, n=4 
Week  8 
n=3, n=5 
Week 12 
n=3, n=5 
Week 16 
n=5, n=4 
PMS-Total Placebo 
95% CIs 
24.83(5.85) 
9.79,39.87 
11.00(8.00) 
-90.65,112.65 
17.00(6.00) 
-8.82,42.82 
18.67(9.56) 
-22.48,59.81 
14.40(4.50) 
1.90,26.90 
 Active 
95% Cis 
22.38(2.41) 
16.69,28.06 
11.25(3.28) 
0.83,21.67 
7.00(1.87) 
1.18,12.19 
8.00(1.23) 
4.60,11.40 
7.00(2.12)0.
25,13.75 
PMS-A Placebo 
95% Cis 
6.00(1.69)1.
65,10.35 
1.50(1.50) 
-17.56,20.56 
3.00(1.00) 
-1.30,7.30 
3.33(2.40) 
-7.01,13.68 
2.00(1.30) 
-1.62,5.62 
 Active 
95% Cis 
5.13(0.88) 
3.06,7.19 
1.75(0.63) 
-0.25,3.75 
1.00(0.48) 
-0.24,2.24 
1.60(0.40) 
0.49,2.71 
2.25(0.85) 
-0.47,4.97 
PMS-C Placebo 
95% Cis 
6.50(1.73) 
2.06,10.94 
4.50(1.50) 
-14.56,23.56 
6.00(1.53) 
-.057,12.57 
7.00(2.65) 
-4.38,18.38 
5.20(1.16) 
1.99,8.41 
 Active 
95% Cis 
5.88(1.25) 
2.93,8.82 
4.25(1.97) 
-2.03,10.53 
1.80(0.58) 
0.18,3.42 
2.60(0.40) 
1.49,3.71 
2.75(1.11) 
-0.78,6.28 
PMS-D Placebo 
95% Cis 
6.67(1.65) 
2.43,10.90 
2.50(2.50) 
-29.27,34.27 
4.00(1.53) 
-2.57,10.57 
4.00(2.52) 
-6.8314.83 
4.00(1.38) 
0.17,7.83 
 Active 
95% Cis 
6.25(1.07) 
3.73,8.77 
2.25(1.03) 
-1.03,5.53 
1.20(0.74) 
-0.84,3.24 
0.60(0.25) 
-0.08,1.28 
0.75(0.75) 
-1.64,3.14 
PMS-H Placebo 
95% Cis 
5.67(1.43) 
1.99,9.34 
2.50(2.50) 
-29.27,34.27 
4.00(2.00) 
-4.61,12.61 
4.33(2.33) 
-5.71,14.37 
3.20(1.28) 
-0.36,6.76 
 Active 
95% Cis 
5.13(0.77) 
3.31,6.94 
3.00(0.91) 
0.09,5.91 
3.00(1.41) 
-0.93,6.93 
3.20(1.16) 
-0.01,6.41 
1.25(0.48) 
-0.27,2.77 
Data are expressed as mean ± (STD ERROR)  
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FIGURE 17.2   EFFECT OF INTERVENTION ON  UNADJUSTED PMS TOTAL AND SUBCLUSTER 
SCORES  
 
17.7.4 Within-group changes from baseline 
 
As shown in the line graphs in the manuscript in the preceding section, there were 
significant improvements on all endpoints for the active treatment group, but not for the 
placebo group across the 16 week treatment phase.  This finding was supported by 
paired-sample t-tests, the results of which can be seen in table 17.5. 
 
TABLE 17.5  PMS PAIRED SAMPLES T-TESTS  
(Mean + SD) 
 Placebo n = 6 Active  n = 8 
 baseline Week 16 p-value baseline Week 16 p-value 
Total PMS 24·83(14·33) 18·00(12·60) 0·53 22·38(6·80) 7·13(3·83) < 0·001 
PMS-A 6·00(4·15) 3·00(3·58) 0·35 5·12(2·48) 1·62(1·51) 0·003 
PMS-C 6·50(4·23) 6·17(3·31) 0·91 5·88(3·52) 2·63(1·69) 0·01 
PMS-D 6·67(4·03) 4·83(3·43) 0·52 6·25(3·01) 0·63(1·06) 0·001 
PMS-H 5·67(3·50) 4·00(3·23) 0·47 5·13(2·17) 2·25(2·19) 0·002 
 
Significance levels from paired samples t-tests between baseline and all data collection 
points for the active treatment group are included in appendix 30.  Mean differences 
within groups from baseline to week 16 were also calculated using a mixed model 
analysis, and can be found in appendix 30. 
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17.7.5 Week 4 scores as baseline  
 
As mentioned previously, baseline scores were based on recall and therefore potentially 
susceptible to recall bias.  To address this, analyses of covariance (ANCOVAs) were 
also carried out using week 4 scores as the covariate.  Only PMS-D showed a significant 
difference between groups, F(1, 3) = 30·06, p = 0.01.  However, by the time these 
symptoms were reported, the intervention had been administered for up to 4 weeks, so 
cannot be considered as more reliable baseline scores.  Additionally, week 4 only had 
data for n = 6.  Paired t-tests for weeks 4 and16 found Total PMS, p = 0.067, and PMS-
D, p = 0.058, to approach significance. 
17.7.6 Greene Climacteric Scale scores for the PMS subgroup 
 
For the subgroup experiencing PMS-like symptoms, ANCOVA revealed no significant 
group differences at week 16 for Greene Climacteric Scale scores, F(1, 11) = 0.44, p = 
0·53, after controlling for baseline scores.    
17.7.7 Perimenopausal PMS-sufferers compared with non-PMS sufferers and Post-
menopausal women 
 
Comparing the intermittently-menstruating late-perimenopausal women (all of whom 
reported associated PMS-like symptoms) with those no longer experiencing 
menstruation, and with the postmenopausal women, more severe symptoms at baseline 
on all endpoints were observed for the intermittently-menstruating group than the other 
two groups, with one exception.  Loss of interest in sex was greater in the 
postmenopausal women.   However, none of these reached statistical significance on 
independent t-tests, possibly due to the small sample size.  The symptom profile of the 
non-menstruating, late-perimenopausal women approximated that of the post-
menopausal women. Table 17.6. 
TABLE 17.6   BASELINE SCORES OF POSTMENOPAUSAL PARTICIPANTS COMPARED WITH 
PERIMENOPAUSAL PMS-SUFFERERS NON-PMS SUFFERERS  
 
Post Menopause 
n = 49 
Late-perimenopause 
No menstruation   
n = 19 
Late-perimenopause 
PMS-like symptoms 
n = 14 
Flushes, daily weighted 15.78(6.71) 15.96(6.98) 19.59(12.29) 
Greene total 22.78(6.34) 20.47(7.25) 24.71(11.61) 
Greene psychological subscale 11.98 (4.33) 10.68(4.51) 13.29(6.39) 
Greene anxiety subscale 6.73(2.71) 5.74(2.40) 6.86(3.46) 
Greene depression subscale 5.24(2.45) 4.95(2.76) 6.43(3.39) 
Greene somatic subscale 4.86(2.65) 4.95(2.76) 5.43(5.27) 
Greene vasomotor subscale 4.08(1.22) 3.89(1.29) 4.36(1.48) 
Greene sexual subscale 1.86(0.98) 1.47(1.07) 1.64(1.22) 
HDI-17  14.46(4.45) 14.47(4.30) 15.93 (4.27) 
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17.7.8 Further Details of Compliance and Adverse Events 
 
Compliance was excellent with 96% of tablets taken by both groups.  No participant was  
less than 85% compliant with the Hypericum perforatum, or less than 91% compliant overall.  
There were no significant adverse events and no significant difference between the two 
groups for these, Pearson’s R with chi square, χ2 (1) = 0.04, p = 0.85 (Table 17.7). 
TABLE 17.8   ADVERSE EVENTS BY SUBJECT GROUP 
ADVERSE * subject group Crosstabulation
Count
1 1
2 1 3
1 1
1 1
2 2
3 4 7
1 1
1 1
2 2
2 2
1 1
1 1
1 1
4 4
2 2
1 1
1 1
1 1
16 17 33
UTI
accidents, injuries,
anxiety
breast tenderness
cardiovascular
cold/flu
constipation
cyst
depression
dysmenorrhoea
fatigue
flooding
migraine
other GI complaints
other URTI
paraesthesia
repro
vomiting
ADVERSE
Total
placebo
active
treatment
subject group
Total
 
In order to perform the chi square test, adverse events were recoded to form two groups, 
namely upper respiratory tract infections and gastro-intestinal complaints compared with 
other symptoms (Table 17.8). 
TABLE 17.7 ADVERSE EVENTS RECODED 
adverse events recoded * subject group Crosstabulation
Count
7 8 15
9 9 18
16 17 33
URTI/GIT
Other
adverse events
recoded
Total
placebo
active
treatment
subject group
Total
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17.7.9 Examination of Data provided at all phases by one participant, N = 1 
 
One participant provided PMS data at all five trial phases, despite having met the 
inclusion criteria for the menopause study of 3 consecutive months of amenorrhoea 
within the previous 12 months.  She was on the active treatment.  Visual inspection of 
graphs of her data suggests significant improvements on total PMS, PMS-A, PMS-D and 
PMS-H, that is, all endpoints except PMS-C (Figure 17.3).   
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FIGURE 17.3   EFFECT OF INTERVENTION ON  PMS TOTAL AND SUBCLUSTER SCORES  
                         FOR N = 1 
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Given that the baseline data were based on recall and therefore susceptible to recall 
bias, inspection of the difference from week 4 may be recommended, in which case, only 
PMS-D and PMS-H appear to show marked improvements.  However, as mentioned 
previously, by that point the study intervention had been administered for up to 4 weeks.   
17.8 Discussion 
17.8.1 Principal Findings  
 
For this participant, as for the whole sample, improvements are suggested for the 
phytotherapeutic combination on total PMS and all sub-clusters, although the effect for 
PMS-C in the case of the individual participant appears negligible.  In both instances, the 
decline in scores from baseline to week 4 was followed by a further decline in the active 
treatment arm from weeks 4 to 8 on four of the scales (all except PMS-H for whole 
sample and PMS-C for n = 1).  From weeks 8 to 12, there was a slight worsening of 
symptoms for all scales except PMS-D (and PMS-C for n = 1).  Between weeks 12 and 
16, scores levelled off on 3 of the five scales, except PMS-D (for n = 1) and PMS-H for 
whole sample, and consequently total PMS, (which includes the sub-cluster scores), 
where further slight improvements were noted.  There was no significant difference on 
overall menopausal symptoms (measured on Greene Climacteric scale) for this particular 
sub-population.   
17.8.2 Comparison with Other studies 
 
These trends observed for n = 1 are consistent with previous studies on Vitex agnus-
castus and Hypericum perforatum in PMS, where symptoms of PMS-H such as fluid 
retention, breast tenderness and bloating have been observed to improve, as well as 
irritability and depressed mood,481,850,851,911 but not PMS-C (characterised by sweet 
cravings, headaches, palpitations and dizziness) in one pilot RCT on Vitex agnus-castus 
as a sole agent.851  The observations from the individual participant supported the 
findings of that pilot study.  For the whole PMS sample in the current study, however, 
PMS-H was the only sub-cluster on which significant improvements over placebo were 
not observed. Schellenberg, similarly, found bloating to be unaffected by treatment with 
Vitex.481 
17.8.3 Interpretation 
 
As mentioned previously, the decline in scores from baseline to week 4 may reflect recall 
bias.  However, there was a further decline in intensity of symptoms in the active 
treatment arm from weeks 4 to 8 on four of the scales, and week 4 to week 16 on four 
241 
(three for n = 1).  In addition, recall bias can be bi-directional.  Evidence regarding recall 
bias has been found to result in both under-reporting of PMS symptoms,1099 including 
dysphoria among women attending a menopause clinic,372 and the reporting of the most 
severe PMS symptoms rather than the most frequent.1100  The slight worsening of 
symptoms on some scales between weeks 8 and 12 could suggest washout of any 
placebo effect.    
 
It is common that expectancy effects result in an initial placebo effect, followed by a 
slight worsening of symptoms in the active treatment arm and a more marked worsening 
in the placebo arm, which was observed for all subscales for the placebo group, and 
most of the subscales for the treatment arm.  While the slight improvement in the 
placebo arm on four of the subscales between weeks 12 and 16 cannot be easily 
explained, the pattern seen in the treatment arm is consistent with genuine specific 
effects of treatment, namely a levelling off, or continued, less-marked improvement.   
The sustained improvement in symptoms of PMS-D to week 16 is not surprising, given 
the inclusion of Hypericum perforatum in the intervention.   
 
As previously mentioned, the lack of a significant difference between groups at week 16 
for Greene Climacteric Scale scores suggests that the finding in relation to PMS-like 
symptoms does not simply reflect the effect of the phytotherapeutic combination on 
overall menopausal symptoms in this sub-population. 
 
In the light of the theory that some symptoms during perimenopause may be more 
appropriately attributed to menstruation, it is interesting to note that baseline scores on 
the flushing diaries, Greene Climacteric scale and HDI-17 tended to be higher in late-
perimenopausal women who experienced menstruation over the subsequent 16 weeks 
compared with both i) those who did not, and ii) postmenopausal women.  However, as 
none of these differences reached significance with the small samples in each of these 
subgroups, no firm conclusions can be drawn from this observation.   
17.8.4 Strengths and Limitations 
 
There were several limitations of this small sub-study.  In addition to those already 
discussed, is the selection of a measurement scale that is used less commonly in 
research nowadays, but conferred the advantage of containing sub-clusters, and brevity, 
necessary for maximising compliance where participants were completing several other 
measures for the main study.  Because PMS-like symptom reports were not collected in 
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the post-menstrual phase to confirm their cyclic patterns of exacerbation and remission, 
misclassification bias may also have occurred. 
17.9 Conclusions  
 
The observations from the individual participant, and for the subgroup as a whole, were 
consistent with findings from other clinical and observational studies of Vitex agnus-
castus and Hypericum perforatum for PMS symptoms.  There is a need for safe, 
effective, well-tolerated treatment for PMS-like symptoms occurring in conjunction with 
menopausal symptoms during the perimenopause.  This is especially important as 
conventional medicine currently offers limited treatment options, for which the evidence 
is controversial.  Further investigation from an RCT comparing the combination with 
Hypericum perforatum to Vitex agnus-castus as a sole agent would contribute useful 
evidence-based information with potential clinical application for healthcare providers 
and women in the community.   
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Chapter Eighteen 
 
  
 
 
Predictors of Placebo Response in a  
Randomised, Controlled Trial of Phytotherapy  
in Menopause  
 
  
 
18.0  Introduction 
 
This chapter is divided into two sections.  Both report on sub-studies of the principal 
randomised, controlled trial of phytomedicines in menopause.  The manuscript in the first 
section examines predictors of the placebo response, and reports on the results of data 
analyses from the completing participants assigned to the placebo group.  This 
manuscript has been submitted to the journal, Menopause.  [Citation:  Van Die MD, Teede 
H, Bone K, Reece J, Burger H. Predictors of Placebo Response in a Randomised, Controlled Trial 
of Phytotherapy in Menopause. Peer-reviewed by Menopause 2008; Reference will be provided 
when available.] 
 
The manuscript in the second section reports on a comparison of predictors of the 
placebo response with predictors of the response in the treatment arm.    
 
Additional analyses relevant to both papers are included as an addendum. 
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18.1 Abstract   
 
Objectives:  To evaluate predictors of the placebo response in a randomised, placebo-
controlled, double-blind trial of a phytotherapeutic combination for the treatment of 
menopausal symptoms.   
 
Methods:   A post hoc analysis was conducted on data from 46 placebo participants 
completing the study. Variables at baseline were investigated for prediction of 
imporvement on any of the endpoints of flushing, depression measured on the Hamilton 
Depression Inventory, and menopausal symptoms measured on the Greene Climacteric 
scale.  Hierarchical linear regression analyses were carried out on the individual 
endpoints, controlling for baseline scores.  Multivariate linear regression analysis was 
also conducted on these three endpoints in combination. 
 
Results:  Anxiety at study entry predicted placebo response on all three outcome 
measures (flushing, p = 0.03, depression, p < 0.001, and Greene Climacteric score, p = 
0.04) individually and in combination, p = 0.002, as did total Greene scores at study 
entry, p = 0.005.  Improvement during non-treatment run-in predicted further 
improvements for depression, p = 0.005, menopause symptoms, p = 0.013, and the 
three combined endpoints, p = 0.015.  Severity of scores at baseline predicted 
subsequent improvement on the Greene Climacteric scores only, p = 0.009. 
 
Conclusions:  These findings may facilitate identification of potential placebo 
responders in future randomised controlled trials on menopausal symptoms, and have 
relevance to study design in this context.  Further research is required. 
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18.2 Introduction 
 
In clinical practice, a substantial placebo response, if harnessed reliably, may enhance 
treatment outcomes, especially where the patient’s subjective viewpoint is the optimum 
outcome measure.  However, in randomised controlled trials (RCTs) designed to assess 
the efficacy of potential treatments, a substantial placebo effect continues to be 
considered a nuisance as it can result in smaller effect sizes or failure to demonstrate the 
superiority of new treatments or established reference drugs over placebo.1000  This can 
lead to the rejection or discontinuation of potentially useful treatments due to type II 
errors (that is, erroneous conclusions that there are no differences between the efficacy 
of the treatment and placebo).  In addition, it can increase sample sizes required to 
adequately power RCTs, adding time and cost to the development of new treatments.1001  
 
The magnitude of the placebo response is found to be partly dependent on the 
condition,994,1046 with depression, anxiety and pain found to be particularly susceptible to 
the placebo effect.989  In studies of antidepressant medications, placebo response rates 
average approximately 30%, ranging from 12% to beyond 50%, and have been observed 
to be on the increase.865,986  In RCTs of hormone therapy for vasomotor symptoms in 
menopause, the placebo response rate averages 51%.1095  While natural history may 
contribute significantly to the non-specific effects in these conditions, it does not fully 
account for the placebo response, as many other studies such as sham surgery for 
Parkinson’s disease992 and arthroscopy993 have also reported high placebo effects.   
 
The challenge of rigorous scientific research is to accurately determine the effect of a 
specific intervention over and above the placebo effect, also referred to as ‘non-specific 
effects’, or ‘context effects’.  Attempts to increase our understanding of placebo effects 
have largely been directed at reducing the placebo response in RCTs to increase the 
likelihood of detecting specific treatment effects.  A growing body of research has 
focused on identifying the characteristics of placebo responders.  Findings from such 
studies have yielded inconsistent results.  For example, in terms of the demographic and 
personality characteristics of participants, various predictors of the placebo response 
have been reported, such as age,1050,1101 marital (married) status1101 and higher BMI,1053 
chronicity of disease or symptoms,1060 relatively short illness and a precipitating event,1055 
higher positive patient expectations of treatment outcome865,1015 and acquiescence.1056 
Predictors of response to placebo in menopause studies have not been explored to date. 
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In this setting, the current study aimed to identify predictors of the placebo response in 
an RCT of a phytotherapeutic combination for menopausal symptoms in late-
perimenopausal and postmenopausal women.  Endpoints included flushing, depressive 
symptoms measured on the Hamilton Depression Inventory (HDI) and overall 
menopausal symptoms measured on the Greene climacteric scale.  It was hypothesised 
that the placebo response would be predicted by psychological factors.  
18.3 Methods 
 
This study was a post hoc analysis of data from an investigation of 46 completing 
participants randomly assigned to the placebo group of a randomised, placebo-
controlled, double-blind trial of a phytotherapeutic combination containing Hypericum 
perforatum and Vitex agnus-castus for the treatment of menopausal symptoms.  After 
entry to the study, there was a two-week non-treatment run-in prior to baseline, followed 
by a 16-week treatment phase.  The trial was approved by the Human Research Ethics 
Committee at Royal Melbourne Institute of Technology University.  
18.3.1 Study intervention   
 
As previously discussed,848 women in this sub-population were assigned to the placebo 
intervention, which consisted of a daily dose of two placebo tablets matching the Vitex 
agnus-castus tablets administered to the active treatment group, and three placebo 
tablets matching the Hypericum perforatum tablets, administered in divided doses.  The 
placebos contained the inert excipients used in the active tablets, namely modified 
starch, cellulose, magnesium stearate, calcium hydrogen-phosphate. They were identical 
to the herbal tablets in size, colour, coating, weight and packaging. All tablets were 
manufactured under the Code of Good Manufacturing Practice by MediHerb Australia 
Pty Ltd.  Further details of the herbal intervention, according to the Elaborated Consort 
checklist have been provided elsewhere.848   
18.3.2 Participants 
 
 Fifty of the total 100 women recruited had been randomised to the placebo arm.  All 
were late-perimenopausal or postmenopausal women, aged 40 to 60 years who had 
experienced a minimum of 3 months’ amenorrhoea, not due to any other cause, in the 
previous 12 months.  They were experiencing moderately severe menopause symptoms, 
measured by the Greene Climacteric scale, and at least 5 flushing episodes per 24 
hours.  Exclusion criteria included concurrent major illness, medication for any symptom 
under investigation within the previous 4-5 weeks if orally administered, 6 months for 
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injectables and 1 year for hormone implants, and current use of any medication known to 
interact with either study intervention.  Informed consent was obtained prior to study 
entry.  Baseline visits were conducted in a clinic setting and follow-up contact by 
telephone.  Medical clearance was obtained from a general practitioner prior to inclusion 
in the trial. Participants were requested to maintain their baseline dietary phytoestrogen 
intake during the trial. 
 
Baseline data were collected for age, marital status, employment, parity, menopausal 
status, hysterectomy, date of last menstruation, onset of symptoms, prior use of herbal 
medicine, trial herbs, HRT and perceived effectiveness of these, relationship satisfaction 
and attitude to menopause, lifestyle factors such as exercise, stress, stress reduction, 
smoking, intake of dietary phytoestrogens, caffeine and alcohol.  Daily ambient 
temperature ranges were obtained from the Climate centre at the Bureau of Meteorology 
and recorded at baseline and the end of the treatment phase.  Data were collected for 
the endpoints: frequency and severity of hot flushes, depressive symptoms, rated on the 
Hamilton Depression Inventory (HDI), and menopausal symptoms rated on the Greene 
Climacteric scale (Figure 18.1). 
FIGURE 18.1  TIMELINE OF DATA COLLECTION  
STUDY ENTRY            BASELINE           END                  POST-TREATMENT   
TREATMENT             FOLLOW-UP 
 
18.3.3 Statistical Analyses  
 
In order to assess the relationship between various predictors and the placebo effect, a 
series of hierarchical regression analyses were carried out for each endpoint.  In each 
instance, the baseline scores for the dependent variable were accounted for by being 
entered into the first step, followed by the predictor of interest.  A significant R2 for the 
entry of the predictor of interest was taken as an indicator of importance.  A response 
was defined as a change in a favourable direction, that is, a decrease in severity of 
symptoms.   
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unknown 9 (22%)  
4 discontinued 
perimenopausal 2 
postmenopausal 1 
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Multivariate linear regression analyses were also performed on the three outcome 
variables in combination in order to determine predictors of the multivariate construct 
formed by combining the three separate measures.  The three different outcomes were 
combined into a single variable using MANOVA.  The linear combination is created using 
all three outcomes. 
 
All variables were examined using exploratory data analysis procedures and regression 
diagnostics to ascertain (a) the presence of data entry errors, (b) outliers, and c) whether 
the main variables of interest met the assumptions for parametric analysis, particularly 
regression modelling. Whilst there was some evidence of minor skew and outlier 
influence, the impact of these was not enough to justify transformation or other 
modification of the data or analytic approach.  
18.4 Results 
 
Of the 93 women completing the trial, 46 had been randomised to placebo (Figure 18.2). 
FIGURE 18.2   PARTICIPANT FLOW 
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Variables found to have significant predictive ability, using hierarchical linear regression 
analysis and controlling for baseline scores, are shown in Table 18.1.  No significant 
predictive ability was found for any of the other variables examined.  As is conventional, 
a negative beta co-efficient means that more severe scores at study entry were 
associated with milder symptoms at week 16. 
TABLE 18.1   PREDICTORS OF ENDPOINTS’ WEEK 16 SCORES  
 Placebo Group  
n = 46 
 
 
Variable Flushes Greene 
Scale 
HDI-17 
Age at trial start  NS NS –0.31 * 
Previous phytotherapy effective NS NS –0.32 * 
Total Greene score at study entry –0.38 † –0.38 * –0.47 † 
   Greene anxiety at study entry –0.28 * –0.29 * –0.66 ‡ 
Improvement during non–treatment run–in     NS –0.64 * –0.41 † 
 Standardised β-coefficients (p-significance level) after controlling for baseline scores) 
* p < 0.05 
† p < 0.01 
‡ p < 0.001 
18.4.1 Anxiety at Study entry 
 
Higher anxiety at study entry significantly predicted decreases for the placebo group on 
all the endpoints individually: flushes R2 = 0.33, Std. β = –0.28, p = 0.03; HDI-17 scale R2 
= 0.34, Std. β = –0.66, p < 0.001; Greene climacteric scale R2 = 0.24, Std. β = –0.29, p = 
0.04.   
 
More severe overall menopausal symptoms (total Greene score) at study entry 
significantly predicted improvements on all the endpoints individually, flushes R2 = 0.39, 
Std. β = –0.38, p = 0.003; HDI-17 scale R2 = 0.23, Std. β = –0.47 p = 0.007; Greene 
climacteric scale R2 = 0.28 Std. β = –0.38, p = 0.01.   
18.4.2 Change in Scores during Non-treatment Run-in 
 
Improvement during run-in (measured on Greene scale) predicted further improvement 
on HDI depression scores to week 16, R2 =0.24, Std. β = –0.41, p = 0.005, and on 
Greene scores to week 16, R2 = 0.28, Std. β = –0.64, p = 0.01.   
 
There was no significant correlation between anxiety at study entry and improvement 
during run-in (in anxiety or total Greene score). 
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18.4.3 Age 
 
For depression scores on HDI-17, older age at study entry was associated with a lower 
scores (milder/fewer symptoms) at end of trial, R2 = 0.18, Std. β = –0.31, p = 0.03.   
18.4.4 Previous Positive Experience  
 
As reported previously,848 for depression scores on HDI-17, prior positive experience 
with phytotherapy was associated with a greater reduction in depression, evidenced by 
lower scores at the end of the treatment phase, R2 = 0.18, Std. β = –0.32, p = 0.03.  
18.4.5 Multivariate Regression analyses 
 
Controlling for baseline scores for the three major endpoints, multivariate linear 
regression analyses were also performed on the three outcome variables in combination.   
Significant predictors were: higher anxiety at study entry, Wilks’ λ = 0.69, F (3,39) = 5.77, 
p = 0.002; more severe overall menopausal symptoms (total Greene scores) at study 
entry, Wilks’ λ = 0.72, F (3,39) = 5.03, p = 0.005; more severe baseline depression on 
Greene Climacteric subscale, Wilks’ λ = 0.79, F (3,39) = 3.44, p = 0.03; and greater 
change in scores during run-in, Wilks’ λ = 0.77, F (3,39) = 3.92, p = 0.02. 
18.4.6 Baseline severity of scores 
 
For Greene climacteric scores, a positive correlation was found between baseline 
severity of scores and subsequent improvement, using Pearson’s bivariate correlations, r 
= 0.38, p = 0.009. This was mirrored by anxiety on the Greene Climacteric subscale: 
severity of anxiety at baseline was significantly correlated with improvement during 
treatment phase on Greene anxiety, r = 0.36, p = 0.01. However, no significant 
correlations were found between baseline severity of symptoms and percentage 
improvement over trial for flushing, r = -0.05, p = 0.73, or depression (on HDI-17 scale), r 
= -0.001, p = 0.19.   
18.5 Discussion 
To our knowledge, this is the first study to examine predictors of the placebo response in 
the context of menopausal symptoms.  We found that anxiety at study entry predicted 
placebo response on all of the endpoints (flushing, depression and Greene Climacteric 
scale scores) individually and in combination, as did total Greene scores at study entry.   
Improvement during non-treatment run-in predicted placebo response for depression, 
menopause symptoms measured on the Greene Climacteric scale, and the three 
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combined endpoints.  Severity of scores at baseline predicted subsequent improvement 
measured on the Greene Climacteric scale scores only.  Women with more severe 
baseline scores showed the greater response to placebo on the Greene Climacteric 
scale.   
 
Previously identified predictors of the placebo response, predominantly from studies of 
analgesia and antidepressants, include  positive response to prior therapies,1055 
comorbid anxiety;1058 lower somatic anxiety,1059 high level neuroticism including 
depression and anxiety,1057 worsening or limited change in depression, anxiety or 
melancholia during placebo lead-in treatment1061 and milder symptom severity at 
baseline.518,986,1046,1055,1101  The finding from the current study that anxiety at study entry 
predicted the placebo response on all endpoints is consistent with findings from previous 
studies in the areas of pain and depression.1057,1058  Anxiety itself is found to be 
particularly susceptible to the placebo effect.989 It has been suggested that factors 
modulating anxiety in RCTs include the attention, time and support from investigators 
that contribute to the therapeutic alliance, and impact on the placebo response.1009,1011  
Support and reassurance have been shown to significantly influence health 
outcomes.1009  The concomitant improvement in anxiety and other menopausal 
symptoms in the placebo group is consistent with the role of anxiety in triggering hot 
flushes in menopausal women,91 and the salutary effect of relaxation techniques in this 
context.1102,1103  The observation that more severe scores on the Greene Climacteric 
scale predicted placebo response may be largely attributable to the impact of the anxiety 
subscale.   
 
Improvement during non-treatment run-in predicted the response in depression during 
the treatment phase.  This is not consistent with previous observations of the placebo 
response in depressive symptoms,1061 which may be due to the natural history of 
menopausal symptoms, which follow a fluctuating course.  Alternatively, it may reflect the 
difference between depressive syndromes per se and the neurovegetative symptoms 
associated with menopause.  The value of a non-treatment run-in period in identifying 
placebo responders is supported by this study, contrary to previous findings that such a 
practice makes no difference.1000  Severity of symptoms at study entry as a predictor 
remains controversial.  In several studies, including social anxiety disorder1046 and 
depression,518,1101 milder baseline symptom severity has been found to predict higher 
placebo response rates, although in one study of antidepressant medication,  moderate 
symptom severity was associated with a higher placebo response.1055  In the current 
study, more severe symptoms as rated on the Greene Climacteric scale were associated 
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with a greater placebo response.  However, baseline severity of symptoms did not 
predict response to placebo for flushes or depression.  This may be the result of having 
recruited only women with moderately severe symptoms.  
  
The findings that improvement during non-treatment run-in and anxiety at study entry 
predicted the placebo response are both of importance in the design of future RCTs on 
menopausal symptoms.  Excluding highly anxious participants from the sample could 
restrict the magnitude of the placebo response.  However, it may result in loss of power 
and bias the sample, making it non-representative of the population, and thereby limit the 
generalisability of the findings.  An alternative may be to stratify the study sample by 
anxiety, and to ensure recruitment of sufficient numbers of participants for adequate 
power.  Data from highly anxious participants could be analysed separately.  
 
The inclusion criteria of moderately-severe symptoms may have been responsible for the 
lack of association between symptom severity at baseline and the placebo response for 
flushing and depression.  This supports the requirements of some bodies, such as the 
FDA, for inclusion of a minimum symptom severity when recruiting for clinical trials.847   
 
Strengths of this study include controlling for baseline scores in the analysis by entering 
them as the first step of the hierarchical linear regression analyses. However, study entry 
scores (prior to commencement of non-treatment run-in) were considered more relevant 
to investigation of the placebo response, as enrolment in a clinical trial would be 
expected to elicit changes in psychological measures, as well as behaviour.  The 
inclusion of a non-treatment run-in period controlled to some extent for regression to the 
mean and the Hawthorne effect.  However, as a non-treatment arm was not included, 
natural history cannot be distinguished from the placebo response.  Because the 
outcome measures were subjective, obliging reports may also have biased results.  An 
additional limitation was the small sample size, which may have resulted in important 
predictor variables not being detected. The improvement during non-treatment run-in 
was only measured on the Greene Climacteric scale, as the HDI-17 was not re-
administered at the end of this period.  
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18.6 Conclusion 
These findings have application for the designing of future studies. Randomised 
controlled trials of vasomotor symptoms in menopause are affected by substantial 
placebo effects.  The observations from the current study may facilitate identification of 
placebo responders in menopause studies, according to high anxiety at study entry and 
improvement during run-in.  Such identification may be used to inform strategies to limit 
the magnitude of the placebo response.  This could be achieved by excluding such 
individuals (with recruitment of additional participants as necessary), stratifying according 
to these variables, and/or performing separate analyses of data from these participants.  
 
The value of a non-treatment run-in is supported in this context.  The findings from this 
study also support the recruitment of participants with moderately severe symptoms. 
 
Controlling the magnitude of the placebo response may facilitate accurate determination 
of the specific effects of interventions.  These findings need to be replicated in a larger 
study. 
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Chapter Eighteen (Part II) 
  
 
 
Are we drawing the right conclusions from  
 
randomised placebo-controlled trials? 
 
 
 
  
 
 
18.7 Introduction 
 
This section contains a manuscript entitled Are we drawing the Right Conclusions from 
Placebo-controlled Trials?  As no significant difference was found between groups, it 
was hypothesised that predictors of the response in the two arms would be the same.  
Predictors of the placebo and active treatment responses were compared.  The findings 
are discussed with reference to the existing literature regarding placebo effects. This 
manuscript has been submitted to BioMed Central Medical Research Methodology, and 
is cited as Van Die M, Bone K, Burger H, Teede H. Are we drawing the right conclusions 
from randomised placebo-controlled trials? submitted to BMC Med Res Methodol 2008.  
 
Additional analyses relevant to this and the previous paper are included as an 
addendum. 
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18.8 Abstract  
 
Background:  The assumptions underlying placebo controlled trials include that the 
placebo effect impacts on all study arms equally, and that treatment effects are 
additional to the placebo effect.  However these assumptions have recently been 
challenged, and different mechanisms may potentially be operating in the placebo and 
treatment arms.  
 
Objectives:  To  explore the nature of placebo versus pharmacological effects by 
comparing predictors of the placebo response with predictors of the treatment response 
in a randomised, placebo-controlled, double-blind trial of a phytotherapeutic combination 
for the treatment of menopausal symptoms. The treatment contained Hypericum 
perforatum and Vitex agnus-castus.  No significant difference in efficacy was found 
between the two arms, and a substantial placebo response was observed.   
 
Methods:   A post hoc analysis was conducted on data from 93 participants who 
completed this previously published study.  Variables at baseline were investigated as 
potential predictors of the response on any of the endpoints of flushing, menopausal 
symptoms measured on the Greene Climacteric scale, and depression measured on the 
Hamilton Depression Inventory.  Hierarchical linear regression analyses were carried out 
on the individual variables, controlling for baseline scores, for all three endpoints and for 
both groups separately.  Significant variables were then entered into a multiple 
regression model for each separate endpoint.  These findings are discussed in relation to 
the existing literature on placebo effects. 
 
Results:  Distinct differences in predictors were observed between the placebo and 
active groups.  None of the variables found to predict the placebo response was relevant 
to the treatment arm.  Anxiety at study entry predicted placebo response on all three 
outcome measures individually.  In contrast, low anxiety was significantly associated with 
improvement in the active treatment group.  Improvement during non-treatment run-in 
predicted placebo response on depression and overall menopausal symptoms.  
However, this was not mirrored in the treatment group.   
 
Conclusions:   This study was a post hoc analysis of predictors of the placebo versus 
treatment response.  Whilst this study does not explore neurobiological mechanisms, 
these observations support the hypothesis that ‘drug’ effects and placebo effects are not 
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necessarily additive. They also suggest that the same magnitude of effect in both arms 
may involve different mechanisms.  The need for more research in the area of 
mechanisms of placebo versus active responses is also supported. 
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18.9 Introduction 
 
The placebo-controlled trial is considered the gold standard among clinical research 
designs.  The challenge of rigorous scientific research is to accurately determine the 
specific effect of an intervention over and above the placebo effect, (also referred to as 
‘non-specific effects’, or ‘context effects’).  Failure to do so may result in the rejection of 
the intervention as ineffective as a potential treatment, as any benefits are ascribed to a 
placebo effect.  We question this approach and suggest that inappropriate rejection of 
potentially viable treatments may be occurring.  
 
The underlying assumption of placebo-controlled trials is that, for participants blinded as 
to their group assignment, the placebo component affects both/all arms equally, with the 
specific effect of the active intervention/s being additional to the placebo effect in the 
intervention arm/s.  This has been termed the ‘additivity’ of effects.  However, this 
assumption has recently been challenged.  It has been argued by Kirsch and colleagues1  
that it is not a logically necessity for the effects of the active treatment to be additive, or 
composed of the two components – the placebo effect and the specific treatment effect 
(Figure 18.3).  
 
 
FIGURE 18.3  ‘DRUG EFFECTS AND THE PLACEBO RESPONSE: ADDITIVE AND NONADDITIVE 
MODELS.’1043   
Reprinted by permission of Elsevier from ‘Are drug and placebo effects in depression additive? by 
Kirsch, I.   Biological Psychiatry 47(8):733-5. Copyright 2000 by the Society of Biological 
Psychiatry.  
 
 In support of their position they suggest that, if drug effects and placebo effects are 
additive, then the pharmacological effect of antidepressant drugs must be quite small,1043 
since meta-analyses of antidepressant drugs have found that 65% - 80% of the response 
to the drug is duplicated in the placebo arm, including in long-term maintenance 
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studies.1014,1044,1045  They thus proposed that the effects may be non-additive, or only 
partially additive,1043 suggesting different underlying mechanisms.  
 
One obvious conclusion from this observation is that antidepressant medication does, in 
fact, exert a very small pharmacological effect.  Another possible explanation that has 
been raised is that different neurobiological mechanisms may be operating in the two 
arms. In the absence of a pharmacological effect, the placebo may induce effects via 
psychological mechanisms, whereas the active treatment works through 
pharmacological mechanisms.998  Factors identified that may be responsible for the 
effects produced by placebos include Pavlovian conditioning resulting from prior 
exposure to the therapeutic intervention, and the expectation of reward (clinical benefit, 
in this case).1104 
 
In this setting, the current study analysed data from a previously published double-blind, 
placebo-controlled, RCT that had found no significant difference between the treatment 
and placebo on any of the endpoints, and compared predictors of the response in the 
placebo arm with predictors of the response to the active treatment.848  It was 
hypothesised that, if the additivitiy assumption is correct, then the same variables would 
predict the response in both groups.    
18.10 Methods 
 
This study was a post hoc analysis of data from an investigation of 93 participants who 
completed a randomised, placebo-controlled, double-blind trial.  We have previously 
published the outcome data on efficacy of the therapy848  and on predictors of the 
placebo response in the placebo group only.1105  Here, we extend this evaluation to 
examine whether these predictors are also relevant to the treatment arm, and include 
data from all study participants.  The original RCT had investigated the effect of a 
phytotherapeutic combination consisting of the herbs Hypericum perforatum and Vitex 
agnus-castus, for menopausal symptoms in late-perimenopausal and postmenopausal 
women.848  Following entry to the study, a two-week non-treatment run-in preceded the 
16-week treatment phase.  Endpoints included flushing, overall menopausal symptoms 
measured on the Greene climacteric scale and depressive symptoms measured on the 
Hamilton Depression Inventory (HDI), both well-validated widely available tools. The trial 
was approved by the Human Research Ethics Committee at Royal Melbourne Institute of 
Technology University.  
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18.10.1   Study intervention   
 
As previously described,848  two Vitex agnus-castus tablets or matching placebos were 
administered daily, in addition to three Hypericum perforatum tablets or matching 
placebos.  The placebos were identical to the herbal tablets in size, colour, coating, 
weight and packaging.  Placebo tablets comprised the excipients used in the active 
tablets; these were cellulose, modified starch, magnesium stearate and calcium 
hydrogen-phosphate.  The daily dosage of the herbs was 1,000 mg Vitex agnus-castus, 
and 5,400 mg Hypericum perforatum.  All tablets were manufactured under the Code of 
Good Manufacturing Practice by MediHerb Australia Pty Ltd.  
18.10.2   Participants  
 
Of the 93 women completing the trial, 47 had been randomised to the active treatment 
group and 46 to the placebo arm (Figure 18.4).  All were late-perimenopausal or 
postmenopausal women, aged 40 - 60 years.  Details of the inclusion and exclusion 
criteria have been published previously.848 Women were excluded if taking any 
medication known to interact with either study herb.  Informed consent was obtained 
prior to study entry.   Baseline visits were conducted in a clinic setting and follow-up 
contact by telephone.  Medical clearance was obtained from a general practitioner prior 
to inclusion in the trial.  Participants were requested to maintain their baseline dietary 
phytoestrogen intake during the trial. 
FIGURE 18.4   PARTICIPANT FLOW  
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Baseline data were collected for a range of variables, as previously published.848,1105  
These were tested individually for their predictive ability.  Measures administered at 
study entry, baseline and end of treatment phase are shown in Figure 18.5.  
FIGURE 18.5   TIMELINE OF DATA COLLECTION8 
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18.10.3 Statistical Analyses 
 
Data were analysed using Statistical Package for Social Science (SPSS) Version 16 with 
the assistance of a biostatistician.  In each analysis, hierarchical regression was 
conducted in order to control for the baseline scores for the relevant outcome measures.  
Independent variables were firstly assessed individually for their ability to predict the 
response in each arm on the three separate outcome measures.  Response was defined 
as change in a favourable direction. Based on the results of these hierarchical linear 
regression analyses, hierarchical multiple regression analyses were then conducted for 
each endpoint separately, in order to evaluate the predictive power of a set of relevant 
variables in combination.  Because total Greene scale scores and Greene anxiety 
subscale scores were not independent, these were not entered simultaneously into a 
multiple regression analysis. 
18.11 Results 
18.11.1   Hierarchical linear regression analyses 
 
Variables found to have significant predictive ability in the individual linear regression 
analyses for any of the three endpoints are presented in Table 18.2. 
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TABLE 18.2   PREDICTORS OF WEEK 16 ENDPOINT SCORES 
 Placebo Group      n = 46 Active Treatment Group     n = 47 
 
Flushes Greene Climacteric 
Scale 
HDI-17 Flushes Greene Climacteric 
Scale 
HDI-17 
 β (SE) p-value β (SE) p-value β (SE) p-value β (SE) p-value β (SE) p-value β (SE) p-value 
Age at trial start  0.03 (0.28) 0.93 –0.26 (0.24) 0.28 –0.39 (0.17) 0.03 0.38 (0.32) 0.25 –0.21 (0.25) 0.41 0.23 (0.19) 0.24 
Previous Herb Med effective –10.9 (0.07) 0.63 –3.07 (1.84) 0.10 –3.14 (1.37) 0.03 –1.80 (3.04) 0.56 –4.46 (2.40) 0.07 –2.27 (1.88) 0.23 
Attitude to menopause –0.63 (2.18) 0.77 0.66 (1.88) 0.73 –0.24 (1.45) 0.87 –3.30 (2.97) 0.27 –4.54 (2.09) 0.04 –3.16 (1.60) 0.055 
Flushes, daily weighted b/l na 0.08 (0.14) 0.59 –0.03 (0.11) 0.74 na  0.11 (0.12) 0.36 0.12 (0.09) 0.18 
Greene  score, study entry –0.53 (0.17) 0.003 –0.43 (0.16) 0.012 –0.38 (0.13) 0.007 0.23 (0.26) 0.37 0.38 (0.26) 0.15 0.36 (0.18) 0.03 
Greene  anxiety, study entry –0.97 (0.44) 0.03 –0.82 (0.39) 0.04 –0.33 (0.32) <.001 1.16 (0.47) 0.016 0.65 (0.44) 0.14 0.68 (0.31) 0.02 
HDI–17 score baseline –0.37 (0.24) 0.14 0.09 (.024) 0.72 na 0.11 (0.34) 0.75 0.25 (0.29) 0.40 na 
Change in Greene scores 
during non–treatment run–in   
–0.02 (0.04) 0.59 –0.15 (0.06) 0.013 –0.07 (0.02) 0.005 –0.04 (0.08) 0.68 0.13 (0.08) 0.13 –0.07 (0.05) 0.15 
RESULTS OF HIERARCHICAL LINEAR REGRESSION ANALYSES  
Unstandardised β–coefficient (SE) after controlling for baseline scores 
b/l = baseline 
na:  not applicable.  These variables were already entered as the first step in the hierarchical linear regression analysis. 
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Predictors of response identified, after controlling for baseline scores, were as follows. 
18.11.2   Anxiety at study entry 
 
As described previously,1105 anxiety at study entry significantly predicted placebo 
response on all the endpoints individually, with higher anxiety at entry associated with 
lower anxiety at end of treatment phase: flushes R2 = 0.33,  Std. β = –0.28, p = 0.03; 
Greene climacteric scale R2 = 0.24, Std. β = –0.29, p = 0.04; HDI-17 scale R2 = 0.34, 
Std. β =–0.66, p < 0.001.   For the active treatment group, however, anxiety at study 
entry predicted lack of response for flushing, R2 = 0.45, Std. β = 0.28 p = 0.02, and 
depression, measured on the HDI-17. R2 = 0.28, Std. β = 0.31, p = 0.03.    
 
None of the other predictors of the placebo response was relevant to the response in the 
active treatment arm (Table 1).  In the active treatment group, positive attitude to menopause 
predicted response on Greene Climacteric scores, R2 = 0.34, Std. β = -0.27, p = 0.04. 
18.11.3   Multiple Regression Analyses  
 
For the placebo group, controlling for baseline scores, simultaneous multiple regression 
analysis found week 16 Greene Climacteric scores to be predicted by the combination of 
anxiety at study entry and improvement during run-in on Greene Climacteric score, 
adjusted R2 = 0.25, F(3,42) = 5.91, p = 0.002, although neither of the predictors provided 
significant unique predictive variance in the model (Table 18.3).  Controlling for baseline 
scores, HDI at week 16 was predicted by the combination of anxiety at study entry, 
improvement on Greene score during run-in, age and previous positive experience with 
phytotherapy, adjusted R2 = 0.45, F(5,40) = 8.32, p < 0.001 (Table 18.3). 
TABLE 18.3   PREDICTORS OF ENDPOINTS FOR PLACEBO GROUP 
Predictor Greene Climacteric 
Scale 
HDI-17 
 β (SE) p-value β (SE) p-value 
Age   –0.11 (0.15) 0.47 
Previous Herbal Medicine effective   –2.51 (1.11) 0.03 
Greene  anxiety, study entry –0.45 (0.22) 0.30 –1.03 (0.31) 0.002 
Change in Greene scores during non–
treatment run–in 
–0.18 (0.07) 0.08 –0.05 (0.02) 0.01 
RESULTS OF MULTIPLE LINEAR REGRESSION ANALYSES, CONTROLLING FOR BASELINE SCORES   
Unstandardised β–coefficient (SE) 
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For the active treatment group, multiple regression analysis was not appropriate, due to 
the lack of individual predictors of the response. 
18.11.4   Baseline severity of scores 
 
As reported previously,1105 for the placebo group, Pearson’s bivariate correlations 
revealed positive correlations between baseline scores and subsequent percentage 
improvement during the treatment phase for Greene climacteric scores and the anxiety 
subscale scores.  No relationship between severity of scores and subsequent response 
was found for any of the endpoints for the active treatment group. 
18.12 Discussion 
 
In the current study, there were distinct differences in predictors of outcome observed 
between the placebo and active groups.  Anxiety at study entry predicted placebo 
response for all the endpoints.  In contrast, for flushing and depression in the treatment 
arm, study entry anxiety significantly predicted a lack of response to treatment, and had 
no effect on the Greene Climacteric scores.   None of the other variables that predicted 
the placebo response was relevant to the treatment response. Improvement during non-
treatment run-in predicted subsequent improvement during the treatment phase on 
Greene Climacteric and HDI-17 depression scores for the placebo arm.  This trend was 
not mirrored in the active treatment arm.  For depression scores, older age at study entry 
predicted placebo response, as did prior positive experience with phytotherapy.  
However neither of these variables significantly impacted on outcomes in the active 
treatment arm.  For the Greene Climacteric scale, baseline severity of symptoms was 
positively correlated with percentage improvement across the treatment phase in the 
placebo group, but not in the active treatment group. 
 
To our knowledge, no previous studies have compared the predictors of the response in 
both the placebo and active arms in a study where the intervention and placebo effects 
were equivalent in treatment outcomes.   
 
The variance in the predictors of placebo and active response observed in the current 
study may be related to different underlying mechanisms between placebo and treatment 
arms.  Evidence of neurobiological mechanisms involved in the placebo response is 
derived from both neuropharmacological studies and brain imaging 
investigations.1006,1035,1036,1041,1042  Much of this has focused on pain, where endogenous 
opioids have been found to be involved in the production of placebo analgesia.1022,1023  
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Placebo-induced dopamine release has also been suggested as a major biochemical 
substrate for the placebo effect, not only in pain, but also in other conditions such as 
motor disorders and depression.1026-1028  Expectation of reward (clinical benefit) has been 
shown to be at least partly mediated by the dopaminergic system,1029-1032 stimulation of 
which may be activated by the brain opioid system.1033  The release of endogenous 
opioids may be activated in the anticipatory phase of the placebo response1039  and 
hence during therapist-patient or investigator-participant interaction.1020  Brain-imaging 
studies using quantitative electroencephalography and PET  investigating the effects of 
antidepressant medication have found that, while both placebo and active treatment 
exerted nearly equal benefits, the changes in brain function that they induced were quite 
different.1034,1035  This calls into question the assertion that 50% -75% of the 
antidepressant effect consists of placebo effect, since symptom improvement was not 
associated with a similar physiological alteration in the placebo and medication 
responder groups.1036   
 
The implications of the finding that the predictors of placebo response did not predict the 
treatment response, despite the lack of difference in efficacy between the two groups, 
are intriguing.  It has previously been suggested that the assumption of additivity of 
effects that underlies the practice of using placebos may not be a logical necessity.1043 It 
is  possible that psychological mechanisms may operate in the placebo arm in the 
absence of pharmacological effects, whereas pharmacological mechanisms are 
activated by effective interventions, negating the need for activation of psychological 
mechanisms.998  Although it is generally accepted that there is a placebo component in 
the response to the active treatment when participants are blinded, this implies that the 
pharmacological effects of an active intervention could override this completely or 
partially.  Essentially, the trial participants would experience either placebo or 
physiological intervention effects, but not both.  This would render invalid the assumption 
that intervention effects are additive to placebo effects.  It is supported by the above-
mentioned neuroanatomical studies of depressed subjects, showing that placebos and 
active treatments have quite different effects on the brain, despite exerting similar 
benefits.1035,1036  Research on analgesia has suggested that expectation pathways, rather 
than pain pathways, may  be stimulated by placebo treatment.1020  While no evidence 
exists, to our knowledge, of this phenomenon in relation to menopause studies, 
depression measured on the Hamilton Depression Inventory and the Greene Climacteric 
subscale was one of the current study endpoints.  Different mechanisms operating in the 
two arms cannot, therefore, be ruled out.   
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It is interesting to note that higher anxiety at study entry was a significant predictor of the 
placebo response, but predicted lack of response to active treatment.  This supports the 
proposition that psychological mechanisms, rather than pharmacological mechanisms, 
are operating in the placebo response.   The observation that improvement during non-
treatment run-in predicted placebo response on two of the three endpoints, but did not 
predict treatment response, is consistent with the proposal that activation of such 
mechanisms occurs during the anticipatory phase of the placebo response.1039  The 
effect of investigator-participant interaction, and other context effects associated with 
enrolling in a clinical trial, on psychological mechanisms would be expected to occur 
from the point of study entry, rather than from the initiation of the intervention.1020   
 
Because changes in psychological measures as well as behaviour are expected from the 
point of enrolment in a clinical trial, study entry scores (prior to commencement of run-in) 
were considered relevant to an investigation of the placebo response.  However, 
pharmacological effects of the intervention would only be observable from the point of 
administration of the intervention.  For that reason, baseline scores were controlled for in 
the analysis (Figure 18.5).   
 
A limitation in the interpretation of these findings is that there is no evidence, to our 
knowledge, supporting this phytotherapeutic combination is an effective treatment for 
menopausal symptoms.  Therefore, a known pharmacological effect for this intervention 
in the treatment of menopausal symptoms has never been established.   
 
This study was a post hoc analysis of data from an RCT and as such, was not designed 
to explore neurobiological mechanisms. No definite conclusions can be drawn regarding 
any different mechanisms of action.  Other possible limitations include the relatively 
small sample size, the use of exclusively subjective outcome measures, and the single 
scale of measurement for improvement during non-treatment run-in.  
18.13 Conclusions 
 
In randomised, placebo-controlled clinical trials, greater understanding of the placebo 
response is needed to accurately dissect out placebo versus intervention effects.  In 
order to conclude that a pharmacological intervention is ineffective if shown not to be 
superior to placebo, it is essential to be confident that i) the placebo has no specific 
effect for the condition being examined, and ii) that the effects of the placebo and active 
intervention are completely additive, so that subtracting the placebo effect from the 
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treatment effect leaves the active intervention effect.  The assumption of additivitiy has 
been questioned, and early research on neuroanatomical and neurobiological 
mechanisms, primarily in the area of analgesia, suggests effects of placebo and 
intervention may differ.  The current findings are consistent with the theory of non-
additivity.  In this setting we hypothesise that different mechanisms may be operating in 
treatment and placebo groups with regard to menopausal symptoms.  To further test this 
hypothesis, comparing predictors of placebo and active responses from other studies 
showing non-superiority of the intervention may be useful, along with studies exploring 
underlying mechanisms of placebo action.   
 
This is a very important area for future research, with potentially significant implications 
for the interpretation of results from placebo-controlled RCTs.   
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18.14   Additional Analyses 
Additional analyses were performed that are not reported in the attached manuscripts.  
These are included here. 
18.14.1 Assumption testing for the hierarchical linear regression analyses  
 
All data were screened for common assumptions of multicollinearity and singularity, 
normality, linearity, homescedasticity and independence of residuals, and were checked 
for outliers.  No problems were found with multicollinearity for any of the variables 
investigated in either the placebo or active treatment groups.   The assumptions of 
normality, linearity and homoscedasticity were checked by inspection of the residual 
scatterplots and the normal probability plots of the regression standardised residuals, 
which suggested these assumptions were met for all variables examined for both the 
placebo and active treatment groups.   
 
Inspection of Mahalanbois distances identified three outlying cases (two in placebo 
group and one in the active-treatment group) for the following analyses. 
 
Flushes  anxiety at study entry (no. 62 –active treatment group, 14.4)  
total Greene score at study entry (no. 39 - placebo group, 15.07) 
   baseline anxiety (no. 62 –active treatment group, 14.57) 
 
Greene Climacteric    anxiety at study entry (no’s 39, & 45 -placebo group, 15.2 and 13.9   
respectively) 
total Greene score at study entry (no’s 39 & 45, - placebo group  
20.47 and 15.38 respectively) 
change in scores during lead-in (no 45 –placebo group, 14.98) 
 
HDI-17   total Greene score at study entry (no. 39 - placebo group, 15.14) 
 
Given the size of the data file, it is not unusual for some outliers to appear.  Due to the 
small number of outliers in these analyses, no action was taken.1106  
268 
18.14.2 Multiple Regression Analyses 
 
Simultaneous multiple regression analyses were reported in the preceding manuscript 
for each of the three endpoints of flushes, depression (on HDI-17) and overall 
menopausal symptoms (on Greene Climacteric scale) individually, including the 
variables found to be significant when entered alone.   Bonferroni procedures were not 
incorporated to adjust the error rate for the number of comparisons, as the Bonferroni-
corrected threshold is generally considered too strict for such cases.1107 
 
The histogram and scatterplot are included below for the simultaneous multiple 
regression for HDI-17 scores at week 16 for the placebo group (Figure 18.6).    
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FIGURE 18.6   HISTOGRAM AND SCATTERPLOT FOR SIMULTANEOUS MULTIPLE REGRESSION 
ON HDI17 AT WEEK 16. 
Independent variables entered into model: anxiety at study entry, change in scores during run-in, 
prior effectiveness of phytotherapy, age, baseline HDI-17 scores.  (Whole model was significant 
at p < .001.  Age did not provide significant unique predictive variance in the multiple regression 
models, as indicated by the t-tests.). 
 
As previously reported, after controlling for baseline scores, a number of combined 
characteristics of placebo responders were identified for this HDI-17 at end of treatment.   
Although age did not provide significant unique predictive variance in the multiple 
regression model, it was included in the model as it was found to be a significant 
individual predictor in a linear regression analysis, and is a meaningful predictor.   
Multiple regression analyses were not appropriate due to the lack of individual predictors 
of the response.  
 
269 
18.14.3  Multivariate Regression Analyses on Combined Endpoints  
 
In order to determine predictors of the of the multivariate construct formed by combining 
the three separate measures, a series of individual multivariate hierarchical linear 
regression analyses were also performed on the three endpoints in combination.   
Several individual variables were found to predict the outcome in the placebo group.  
These results have been reported previously.  However, a limitation is that the three 
dependent variables were not independent, as the Greene Climacteric scale includes 
measures of vasomotor symptoms (flushing) and a depression subscale.   For the active 
treatment group, multivariate regression found no significant predictors of response to 
treatment.   
18.14.4   Logistic Regression Analyses 
 
In the literature, results of logistic regression analyses are usually reported, comparing 
groups showing 50% or greater improvement with those showing less than 50% 
response.  A 50% reduction in symptoms has become a standard endpoint,1054 being 
considered indicative of a clinically significant response to placebo, or active 
interventions.  Therefore, in conformity with this convention, data from this study were 
also analysed using logistic regression analyses, having collapsed the continuous 
variables into a categorical variable with two categories, ≥50% improvement on any 
endpoint versus < 50 % improvement.   
 
Participants were considered to be placebo responders (PRs) if they had at least a 50% 
reduction in the relevant symptoms.   
 
18.15 Results of Logistic Regression Analyses  
18.15.1   Baseline Characteristics of Placebo responders versus Non-responders  
 
Table 18.4 presents the baseline characteristics of the whole placebo group, the group of 
participants with 50% or more improvement and those with less than 50% improvement.  
No significant difference was found between groups using independent t-tests and chi 
square tests on any of the demographic variables or endpoints at baseline. 
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TABLE 18.4   BASELINE CHARACTERISTICS OF ENROLLED PLACEBO PARTICIPANTS N = 50 
MEAN ± SD OR n 
 
 
Whole Placebo 
Group† 
n = 50 
Placebo 
responders* 
n = 27 
Placebo non-
responders 
n = 19 
Menopausal status: Unknown 10 (20%) 6 (22%) 3 (16%) 
Perimenopausal 16 (32%) 7 (26%) 7 (37%) 
Postmenopausal 24 (48%) 14 (52%) 9 (47%) 
Age at trial start (years) 52·5 ± 3·8 53.0 ± 4 52.0 ± 3.7 
BMI  26·2 ± 5·0 25.6 ± 4.4 26.3 ± 5.5 
Months since last period 48·6 ± 61·9 47.4 ± 47.7 45.2 ± 67.9 
Months since onset of symptoms 57·3 ± 44·7 62.2 ± 51.4 45.9 ± 31.6 
Ambient temperature baseline (oC) 20.7 ± 4.5 20.3 ± 4.4 19.7 ± 6 
Ambient temperature week 16 (oC) 19.9 ± 3.2  
(n = 46) 
19.2 ±  3.1 20.9 ±  3.1 
Dietary & Lifestyle variables MEAN ± SD 
Caffeine: tea/coffee p/day (cups) 4·2 ± 2·1 4.2 ± 2.4 4.2 ± 1.6 
Cigarettes per day 2·0 ± 5·8 2.2 ± 5.2 2.1 ± 7.1 
Standard alcoholic drinks/wk 3·6 ± 3·7 4.1 ± 4.2 3.0 ± 2.8 
Isoflavone intake per week in mg 76·6 ± 114·3 70.3 ± 119 81.5 ± 116.2 
Lignans in linseeds, gm p/wk 0·1 ± 0·2 0.1 ± 0.3 0.0 ± 0.1 
Exercise – hours per week 3·7 ± 3·7 3.5 ± 4.0 4.1 ± 3.6 
Total exercise days per week 3·9 ± 2·6 3.7 ± 2.5 4.3 ± 2.6 
Dietary & Lifestyle variables n (%) 
Vegetarian 3 (6%) 1 (4%) 2 (11%) 
Prior herbal medicine use 37 (74%) 18 (67%) 16 (84%) 
Prior positive effect of herbs (% users) 19 (51%) 12 (44%) 5 (26%) 
Prior HT use 15 (30%) 6 (22%) 7 (37%) 
Prior positive effect of HT (% users) 13 (87%) 5 (83%) 7 (100%) 
Relationships satisfaction  44 (88%) 24 (89%) 18 (95%) 
Negative attitude to menopause 27 (54%) 15 (56%) 10 (53%) 
Regular stress reduction, n 14 (28%) 10 (37%) 4 (21%) 
Nulliparity, n 13 (26%)  5 (19%) 7 (37%) 
Employed outside home, n 40 (80%) 20 (74%) 16 (84%) 
Endpoints MEAN ± SD 
Flushing episodes (per day) 9·4 ± 3·3 9.4 ± 3.6 9.8 ± 2.8 
Flushing, daily weighted score 16·4 ± 6·7 15.8 ±  6.8 17.7 ±  6.6 
Greene score baseline 22·5 ± 8·7 23.2 ±  9.5 22.7 ±  8.2 
   Greene anxiety baseline 6.4 ± 2.7 6.8 ± 2.9 6.2 ± 2.6 
   Greene depression baseline 5.1 ± 2.7 5.1 ± 2.6 5.3 ± 3.1 
   Greene psychological baseline 11.5 ± 4.9 11.9 ± 5.1 11.5 ± 5.1 
Greene score study entry 26.5 ±  5.8 27.9 ± 6.6 25.4 ± 4.5 
   Greene anxiety study entry 7.6 ± 2.4 8.3 ± 2.6 7.0 ± 1.7 
   Greene depression study entry 6.6 ± 2.4  6.8 ± 2.8 6.2 ± 1.9 
   Greene psychological study entry 14.2(4.1) 15.1(4.7) 13.2(3.1) 
HDI-17 score 14·3 ±  4·3 14.9 ±  14.2 13.8 ±  4.7 
Utian Quality of Life scale 77·8 ±  12·.1 80.3 ±  12.5 76.5 ±  11.2 
† includes participants who subsequently withdrew 
* Placebo responders includes participants who showed a 50% or greater response on any of the 
endpoints of flushes, Greene Climacteric scores or Hamilton Depression Inventory scores 
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18.15.2 Percentage of Responders by Menopausal Status 
 
The percentage of responders in either the placebo or treatment arms was not related to 
menopausal status (Table 18.3 above and Table 18.4). 
TABLE 18.4   PERCENTAGE OF RESPONDERS BY MENOPAUSAL STATUS  FOR ACTIVE 
TREATMENT GROUP 
 
 
Whole Active 
Group† 
n = 50 
Responders* 
n = 26 
Non-responders 
n = 21 
Menopausal status:  Unknown 8(16%) 5 (19%) 2 (10%) 
Perimenopausal 17 (34%) 9 (35%) 8 (38%) 
Postmenopausal 25 (50%) 12 (46%) 11 (52%) 
 
18.15.3   Placebo group 
 
Results of logistic regression analysis for the placebo group are shown here. 
 
Anxiety at Study Entry 
Anxiety at study entry predicted ≥50% improvement on flushes, p = 0.049, and on the 
Greene Climacteric scale, p = 0.02.   
 
Total Greene scores at Study Entry 
Total Greene scores at study entry predicted ≥50% improvement on the Greene 
Climacteric scale, p = 0.003.   
 
Improvement during non-treatment run-in 
Improvement during non-treatment run-in, measured on total Greene Climacteric Scale 
scores, p = 0.02, and the Greene anxiety subscale, p = 0.04, predicted improvement of 
≥50% on the HDI -17depression scale during the treatment phase.   
 
Prior Positive Experience with Phytotherapy 
Prior positive experience with phytotherapy predicted improvement on HDI-17 scores for 
the placebo group.   
 
Multiple Logistic Regression and Depression scores 
Although not all providing unique predictive ability, the combination of anxiety at study 
entry, improvement on Greene score during run-in, age and previous positive experience 
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with phytotherapy was predictive of week 16 HDI-17 scores in the placebo group,  using  
multiple logistic regression analysis, χ2 (4, N = 46) = 9.74, p = 0.045.   
18.15.4 Active treatment group 
 
Logistic regression and Depression scores 
Low anxiety at study entry predicted ≥50% improvement on HDI-17 scores, p = 0.02.  
Similarly, baseline anxiety (at end of run-in) negatively predicted HDI-17 scores at week 
16, p = 0.001. 
 
Multiple Logistic Regression and Depression scores 
Multiple logistic regression analysis found the combination of anxiety at study entry, prior 
positive experience with phytomedicines, and age to predict week 16 HDI-17 scores, χ2 
(3, N = 46) = 8.05, p = 0.045.  Lower age, lower anxiety scores and previous positive 
experience with phytomedicines were associated with lower scores at week 16 on the 
depression scale.   However, age and prior positive experience failed to provide 
significant unique predictive variance in the logistic regression model. 
18.16   Discussion 
 
In conformity with the convention of analysing data using logistic regression analyses, 
data from the continuous variables in this study were collapsed into categorical variables 
with two categories, 50% or greater improvement on any endpoint versus less than 50 % 
improvement.  The percentage of responders to placebo or active treatment did not differ 
according to menopausal status.  For the placebo group, logistic regression analyses 
found flushing and Greene Climacteric Scores to be predicted by anxiety at study entry, 
consistent with findings from linear regression analyses.  Unlike linear regression 
analysis, however, anxiety at study entry did not predict the week 16 HDI-17 scores.  
Total Greene Climacteric scale scores at study entry, which was shown to predict the 
placebo response on all three endpoints using linear regression analyses, was only 
relevant for the Greene Climacteric scale scores.  This is consistent with the finding 
reported previously that more severe baseline scores were positively correlated with 
percentage improvement on this scale.  Improvement during run-in continued to be 
predictive of week 16 HDI-17 scores.  However, it was not predictive of improvements on 
Greene Climacteric scores at week 16, contrary to the findings from the linear regression 
analyses.   The finding that improvement on HDI-17 scores for the placebo group was 
predicted by prior positive experience with phytotherapy was consistent with the results 
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of linear regression analysis.  However, age was no longer a significant predictor of HDI-
17 scores.  The results of multiple regression analysis for the placebo group were 
consistent with those of multiple linear regression analysis for HDI-178 scores, although 
the individual variables were not predictive, with the exception of greater improvement 
during run-in. 
 
For the active treatment group, the finding that low anxiety at study entry predicted 
improvement on HDI-17 scores was consistent with findings from the linear regression 
analysis, as were the lack of predictive ability of change in scores during run-in, prior 
positive experience with phytotherapy for depression scores.  No significant predictors 
were identified using logistic regression analysis for flushing or Greene Climacteric 
scores, unlike linear regression results.  Multiple logistic regression analysis found the 
combination of lower age, lower anxiety scores and previous positive experience with 
phytomedicines to predict improvement on the depression scale, although age and prior 
positive experience failed to provide significant unique predictive variance in the logistic 
regression model.   
18.17   Conclusion 
 
The results of logistic regression analyses are more conservative than those obtained 
from linear regression analyses due to the loss of power than results from dichotomising 
continuous variables.   The arbitrariness of the cut-off point of 50% as representing a 
clinically significant improvement, in conjunction with the loss of power when using 
logistic regression analyses, do not support the convention of conducting logistic 
regression analyses on continuous variables. 
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Chapter Nineteen 
  
 
 
General Discussion and Conclusions 
 
 
 
  
 
 
 
19.0  Introduction 
 
 
Relevant discussion of the work conducted has been included in the manuscript chapters 
in the body of this thesis. An overview is presented here, followed by the study 
conclusions and future directions. 
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19.1 Background  
With increased life expectancy and population growth, growing numbers of women are 
now reaching menopause, a significant cause of problematic symptoms that can impact 
on a woman’s quality of life for many years.  CAM is the preferred treatment approach to 
the management of their symptoms by increasing numbers of midlife and menopausal 
women with concerns about the publicised risks or contraindications associated with the 
conventional treatments, and by those who prefer a natural approach for a natural event. 
While a wide range of phytotherapeutic interventions is promoted and administered for 
the management of menopause-related symptoms, evidence to support their use from 
rigorous scientific research is limited, with most having focussed on the phytoestrogenic 
options. However, treatment of symptoms is often required long-term, and safety 
concerns have now been raised over the long-term use of the phytoestrogen plants.    
Research is thus needed into other non-oestrogenic phytotherapies employed in clinical 
practice for the amelioration of menopause-related symptoms.  Various CNS 
mechanisms have been proposed for the herbs selected for the current study, 
suggesting potential benefit for the problematic vasomotor symptoms and psychological 
symptoms via the interaction between neurotransmitters and hormones, in a similar 
fashion to the central nervous system (CNS)-acting pharmaceutical agents with 
demonstrated efficacy for symptom relief.   
19.2 Aims and Objectives 
 
The primary aim of the study was to investigate the effects of the combination of extracts 
of Hypericum perforatum and Vitex agnus-castus on the symptoms of  flushing and 
sweating, psychological symptoms and quality of life in late-perimenopausal and early-
post-menopausal women.  Secondary aims were to study the effect of this combination 
in PMS-like symptoms in late-perimenopausal women, and to examine predictors of the 
placebo response, comparing these with predictors of the response to active treatment.  
19.3 Principal Findings  
 
The herbal combination (Hypericum perforatum and Vitex agnus-castus) was not found 
to be superior to placebo for any of the endpoints - daily weighted flushing scores, 
scores on the Greene Climacteric scale and the Hamilton Depression Inventory, 
although significant improvements across the treatment phase were observed in both the 
placebo and active treatment groups on all of these outcome measures. No significant 
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change was found for either group on the Utian quality of life scale.  The herbal 
combination was well-tolerated with no significant adverse events noted over the 16-
week treatment phase.  Prior use of herbal medicine modified the effect, with the herb-
naïve group showing a significantly greater response overall and to the active treatment 
for flushing scores than the prior users.  Previous positive experience with 
phytotherapies predicted overall percentage improvement in depression, anxiety-
subscale scores and sleep for the whole sample, but did not differ between the active 
and placebo groups.    
 
On the PMS-like symptoms experienced by a small sub-population of late-
perimenopausal women, the intervention was found to be superior to placebo for total 
PMS-like symptoms and the sub-clusters, PMS-D (depression) and PMS-C (cravings). 
The active treatment group also showed significant improvements on PMS-A (anxiety) 
and PMS-H (hydration), although this effect was not superior to placebo.  
 
Predictors of the placebo response were found to include anxiety at study entry for the 
outcome measures of flushing, depression and overall menopausal symptoms 
(measured on the Greene Climacteric scale), and improvement during non-treatment 
run-in for depression and overall symptoms. In contrast, low anxiety was significantly 
associated with improvement in flushing and depression in the active treatment group.  
None of the other variables found to predict the placebo response was relevant to the 
treatment arm.  Milder baseline symptom severity did not predict improvement, although 
more severe scores on the Green Climacteric scale at baseline were associated with a 
greater placebo response for this measure. 
19.4 Comparison with other Studies  
Comparisons between these findings and those of other researchers have been 
presented in the relevant manuscript chapters.  These are synthesised here.    
The phytotherapeutic combination used in the present study had not previously been 
investigated in the context of menopausal symptoms.  While not directly comparable, the 
present study, reporting a 32% overall reduction in symptoms on the Greene Climacteric 
scale, did not support the findings of an observational study18 on Hypericum perforatum 
that found a 63% reduction in overall menopause symptoms.  Factors potentially 
contributing to the differing findings include lack of consistency in nomenclature 
regarding menopausal phases, the rating scales employed, ambient temperatures and 
extracts administered.   The comparator study with diazepam outlined previously found a 
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77.5% reduction in scores on the clinician-rated CGI scale with Hyperforat® 0.6 mg 
daily48, which is far in excess of the 39% reduction seen in the current study on the HDI-
17.  However, other studies have found significant effects over placebo, while achieving 
a treatment effect comparable to the current study’s placebo effect. A RCT examining 
the combination of H. perforatum with C. racemosa for menopausal symptoms,  found a 
41.8% decrease on the HDRS total score,716  which achieved significance over the 
12.7% reduction with placebo (p < 0.001).  The magnitude of the treatment effect 
achieved in the above study is comparable to the improvement in HDI-17 scores with 
placebo in the current study, namely a 41% reduction (and 46% for the clinically 
depressed subgroup).  Similarly, in another RCT of Remifemin plus®, (a combination of 
Hypericum perforatum and Cimicifuga racemosa), menopausal symptoms rated on the 
KI fell by 40%, which was found to be significantly superior to placebo, p < 0.001.  In the 
current study, the reduction in scores in the Greene Climacteric scale was 40% for the 
placebo group.  
 
In comparison with the studies examining Vitex for menopausal symptoms, a 73% 
reduction in symptoms was observed with a formulation containing Vitex, compared with 
38% in the placebo group.793  As previously discussed, however, the study is of uncertain 
relevance due to the number and combination of herbs, including Cimicifuga racemosa 
(black cohosh), in the formulation.  Findings from other studies on Vitex as a sole agent 
for menopause include a pilot observational study,823 and aromatherapy studies,821-823 
which reported treatment effects similar to the placebo effect reported in the current 
study, namely a 42% reduction in vasomotor symptoms,823 and 33% and 36% of women 
reporting major and mild improvements in symptoms respectively.822  (The current study 
reported a 41% reduction in flushing symptoms). 
 
The lack of superiority of the combination in depressive symptoms is not consistent with 
the many positive trials of St John’s wort in this context.920,930 The finding of effect 
modification of prior use of herbal medicine is consistent with findings of a previous 
group of CAM researchers.849  
19.4.1 Sub-population analyses 
 
The observations from the present study support results from previous studies on the 
efficacy of Vitex agnus-castus in overall PMS symptoms,481,827,850,852-854 as well as pilot 
studies with Hypericum perforatum in PMS, particularly for depression-related 
symptoms.911,913   
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No studies could be found in the literature of predictors of the placebo response in the 
context of menopausal symptoms.  However, the finding that anxiety at study entry 
predicted the placebo response supported findings from some studies of analgesics and 
antidepressants that report predictors to include co-morbid anxiety1058 and high level 
neuroticism including depression and anxiety.1057 However, this is not a uniform finding, 
with lower anxiety being a significant characteristic of placebo responders in one 
investigation of depressive disorders.1059  The concomitant improvement in anxiety and 
other menopausal symptoms in the placebo group is consistent with the role of anxiety in 
triggering hot flushes in menopausal women,91 and the salutary effect of relaxation 
techniques in this context.1102,1103  The current study observed improvement during non-
treatment run-in (on overall menopausal symptoms) to predict subsequent improvement 
in Greene Climacteric scale scores and HDI-17 depression scores to week 16.  This 
contrasts with findings in relation to synthetic antidepressant medications that limited 
change or worsening of symptoms of depression, anxiety or melancholia during placebo 
lead-in treatment predicted the placebo response.1061  These conflicting findings may 
represent the different conditions under investigation.  The neurovegetative symptoms 
associated with menopause do not necessarily constitute clinical depressive syndromes, 
and are prone to follow a fluctuating course due to their natural history.  The value of a 
non-treatment run-in period in identifying placebo responders is supported by this study, 
contrary to previous findings that such a practice makes no difference.1  In terms of 
baseline symptom severity as a predictor of the placebo response, several studies have 
found milder symptoms to be predictive.1046,1051,518   In the current study, baseline severity 
of symptoms did not predict response to placebo for flushes or depression, possibly due 
to recruitment of women with moderately severe symptoms.  The observation that more 
severe scores on the Greene Climacteric scale predicted placebo response may be 
largely attributable to the impact of the anxiety subscale.  No evidence could be found of 
other investigators having compared predictors of the placebo and treatment responses 
where superiority was not demonstrated. 
 
19.5 Interpretation of Findings 
There are several possible reasons for the lack of superiority of the phytotherapeutic 
combination in relation to the menopausal symptoms under investigation.  The first is 
that this combination is, in fact, ineffective in this context, and that these herbs differ from 
the synthetic non-estrogenic drugs in terms of potency or mechanisms of action.  As their 
pharmacology has not yet been fully elucidated, the latter is a possibility. An antagonistic 
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interaction between the two herbs is unlikely based on the current knowledge of their 
pharmacology.  Secondly, given that the response was, nonetheless, equivalent to the 
treatment response observed in other RCTs demonstrating superiority over placebo, the 
substantial placebo effect on all the endpoints may have contributed to the negative 
result.  Compared with pharmaceutical interventions, phytomedicines can produce less 
pronounced effects, which suggests that their effects may be overshadowed by 
substantial placebo responses, as are not uncommon in menopause or CAM research. 
This is supported by the observation that the effect persisted in the active treatment 
group at the week 26 follow-up (8 weeks post-treatment), but not in the placebo arm.  
The RCT design, where participants have a 50% expectation of being assigned to the 
active intervention, is suggested to maximise the placebo response.1027  Thirdly, 
symptom severity at baseline may have been inadequate to demonstrate a substantial 
effect.  In terms of depression, this is a distinct possibility as only 37 women were 
clinically depressed at baseline. However, there is an important distinction between 
depressive syndromes detected by instruments such as the HDI, and depressive 
symptoms, with the latter considered to be more relevant in association with 
menopause.37  It is unlikely that  the other negative findings were attributable to 
inadequate baseline symptom severity, as hot flushes were as severe as baseline scores 
from previous positive studies,23,28 and overall menopausal symptoms measured by the 
Greene climacteric scale were consistent with a menopause clinic sample.26  The fourth 
possibility is that, as suggested in chapter 14, different mechanisms are operating in the 
treatment and placebo arms, and that these effects are non-additive.  This is discussed 
further below.    
 
The effect of previous positive experience with phytotherapy in predicting improvements 
in depression, anxiety and sleep suggest that these parameters are more susceptible to 
the placebo effect, and supports the contribution of expectation to the placebo 
response.38 The finding of effect modification of positive previous experience with 
phytotherapy in relation to depression is unremarkable, given the reputation of St John’s 
wort in the context of mild-moderate depression. However, it highlights the questionable 
validity in phytotherapy research of the assumption of equipoise (indifference towards 
the treatment on the part of both the investigator and participant), which is central to the 
RCT paradigm, as both the investigator and participants are liable to be influenced by 
the existing body of traditional knowledge.  Effect modification of lack of previous use of 
herbal medicine is not readily explained, however, but is unlikely to reflect negative bias 
among the prior users, as this would not support their voluntary enrolment in a CAM trial.   
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The findings in relation to PMS-like symptoms were derived from a very small sample 
and must, therefore, be interpreted with caution. Nonetheless, they suggest a potential 
role for the phytotherapeutic combination of Hypericum perforatum and Vitex agnus-
castus in the amelioration of these symptoms in perimenopausal women, supported by 
the data from the individual who menstruated monthly throughout the trial (n = 1).  While 
no firm conclusions can be drawn, this finding does tend to support the suggestion that 
symptoms in perimenopausal women may be more appropriately attributed to menstrual 
cyclicity than to menopause per se.  Although current evidence suggests that ovulation is 
a pre-requisite for PMS, which is therefore relatively uncommon during late 
perimenopause, a different aetiology for these symptoms in this demographic is possible.   
 
The observation that predictors of the placebo response did not predict the response in 
the treatment arm, despite the equivalence in the magnitude of the response in both 
arms, may be explained is several ways.  Firstly, this analysis is based on a very small 
sample, which makes any conclusions tentative.  Secondly, as mentioned above, it may 
support the suggestion that placebo and treatment effects are non-additive. It is 
suggested that, in the absence of pharmacological effects, the ‘inert’ placebo may be 
activating expectation pathways due to psychological mechanisms, while the active 
treatment elicits pharmacological effects that activate a different pathway.  Thirdly, it is 
possible that unique placebo-responder characteristics do not exist, and that these 
findings occurred by chance.   
19.6 Strengths of Study 
Overall, the RCT was robustly designed, and conducted according to rigorous scientific 
practice, features lacking in much of the CAM research. The study had clearly defined 
endpoints with validated scales, which are commonly employed in RCTs, for the 
menopausal symptoms, depression and quality of life measures. It was adequately 
powered with excellent retention rates and compliance, and evidence for the success of 
blinding. The population recruited had moderately severe overall symptoms.  Control of 
confounders was incorporated by maintenance of baseline dietary intake of 
phytoestrogen-containing foods, diet and lifestyle monitoring and statistical adjustment of 
data, where relevant, according to the between-group differences.  A non-treatment run-
in period was included to eliminate non-compliers, and also to account to some extent for 
the Hawthorne effect and behaviour modification that may potentially enhance the 
magnitude of the placebo response.  The trial duration of 16-weeks was designed to 
allow for the wash-out of the placebo response. The intervention trialled was produced 
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with high quality assurance levels, was well-tolerated and there was an absence of 
noteworthy adverse-events.  
19.6.1 Retention rates  
Despite the intensity of involvement in the trial in terms of counting flushing episodes day 
and night for a total of 19 weeks and completing questionnaires on a 4-week basis, 
retention rates and compliance with procedures were excellent.  Factors that may have 
contributed to these include the contact with a single investigator, regular contact with 
the investigator (including the initial contact after 1-week of taking tablets) without being 
excessively frequent, a limited number of face-to-face visits that required travel to a 
clinic, the choice of 3 locations for interviews and tablet distribution, follow-up contacts 
being conducted by telephone and weekend and after hours availability of the 
investigator for follow-up contact.  Rapport with the investigator, an experienced 
practitioner of phytotherapy, may have contributed to retention rates as well as 
compliance.  This may have been facilitated by the regular updates sent out to 
participants regarding the progress of the trial, as recruitment continued for 16 months. 
Clarity of instructions on questionnaires may have impacted on compliance.  This 
suggests that attention to convenience for participants, the frequency of follow-up 
contacts and rapport with the investigator may be important to successful retention of the 
participant group, and compliance with procedures.  
19.7 Limitations of Study 
There are some limitations to this study design and methods.   
 
The main limitations with the classical gold standard RCT for phytotherapy research are 
i) that substantial placebo effects may overshadow subtle effects of herbs, and thereby 
lead to the inappropriate rejection of potentially valuable treatments due to type II errors; 
and, ii) that it does not reflect the clinical practice of individualising treatment regimens in 
phytotherapy or the ‘whole–person’ approach, as distinct from ‘dis-ease’ treatment.  An 
additional limitation with the current study in this regard is that it was limited to a 
combination of two herbs whereas formulations of a greater number of herbs are usually 
prescribed in clinical practice.   It is obviously not possible to extrapolate these findings 
to formulations containing a greater number of herbs.  The contribution of the two study 
herbs to such formulations cannot be gauged from the findings of the current study due 
to the synergistic effects of herbs in combination.1108-1111  (Nor is it possible to establish 
any effect attributable to either of the individual herbs, although an adverse interaction 
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between the two herbs in the combination seems unlikely based on their known 
mechanisms of action.) 
 
Because the original power calculation was done with an estimated 30% placebo 
response, based on other CAM trials in the literature at the time, it could be argued that 
this study lacked adequate power to detect any effect of the intervention over placebo.  
However, given that the placebo group tended to slightly outperform the active group on 
the endpoint of vasomotor symptoms, overall menopausal symptoms and depression, 
this not likely to have impacted on the findings. 
  
This study employed only subjective measures, which are not considered to be very 
robust endpoints.  Furthermore, the severity of symptoms recorded depended on the day 
the participant completes the questionnaires.  However, as the intended outcome of 
treatment for menopausal symptoms is a woman’s own subjective assessment of her 
quality of life, measuring change in subjectively-assessed symptoms and quality of life is 
clinically relevant.  (This is also true of many conditions treated with phytomedicines in 
general, particularly given the preference for the majority of users to self-prescribe OTC 
remedies and to self-diagnose and self-assess.1112,1113 In Europe, over-the-counter use 
of herbal remedies outstrips practitioner prescriptions probably by a factor of more than  
20:1.1112 In addition, because the selected herbs were non-oestrogenic, post-treatment 
hormone assays and mammography were not considered relevant.   As both herbs have 
previously been studied reasonably extensively in other conditions, liver function tests for 
safety monitoring purposes were not regarded as essential, particularly in consideration 
of the limited available resources. 
 
It is possible that some of the current instruments might not detect some clinically 
important changes in symptoms.  For example, anecdotal reports from some participants 
suggest that the duration and intensity of heat experienced with flushing episodes were 
reduced, but the measures of frequency and intensity used in the trial did not reflect 
these changes.  In relation to the depressive symptoms, as mentioned previously, it has 
been suggested that scales for diagnosing and measuring depression syndromes may 
not be sufficiently sensitive for measuring the depressive symptoms experienced in 
association with menopause.  A refined version of the CES-D that attempts to achieve 
more diagnostic specificity has been proposed as a simple but sensitive means for 
diagnosing and measuring  depressive disorders associated with menopause.447  
However, the current study incorporated the depression subscale of the Greene 
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Climacteric scale in addition to the HDI as instruments of measurement.  Moreover, 
measurement artefacts caused by unreliability of instruments affects both groups 
equally. 
 
Assessment of compliance with procedures could only be assessed by the participants’ 
reports.  While this appeared to be excellent in this study, lack of instruments to record 
flushes meant relying on women to record them, which introduces another element of 
uncertainty and potential imprecision in the data.  Compliance with taking study 
medications was assessed by counting the tablets returned by participants and assumes 
all were returned.  However, this reflects clinical practice, in which assessments are 
made in accordance with participants’ reports of symptoms and disclosure of 
medications used. 
 
Threats to internal validity that may have operated in this study include regression to the 
mean, the natural history of the symptoms, subject effects such as auto-correlation and 
the Hawthorne effect, experimenter effects and experimenter expectancy.  Because the 
symptoms under investigation follow a fluctuating course, and are eventually self-limiting, 
the impact of natural history is undoubtedly substantial in studies of menopause-related 
symptoms.  The principal investigator, who was the sole contact person, due to limitation 
of resources, is an experienced, practising phytotherapist.  Experimenter expectation 
operated in relation the St John’s wort for the depressive symptoms, although not with 
regard to the impact of the combination on the other endpoints.  However, experimenter 
expectancy affects both arms equally.  The reputation of St John’s wort for mild-
moderate depression is well-known and is likely to have resulted in participant 
expectations on this endpoint.  Experimenter effects may have impacted inasmuch as 
the length of follow-up contacts was not restricted, but varied according to the needs of 
the individual participants.  Hence, the personal contact, and experience of being 
listened to may have affected the outcome.  Auto-correlation may have occurred as 
participants became more aware of triggers of their symptoms through monitoring them 
so closely, and modified their behaviour accordingly, for example by adjusting their 
caffeine or alcohol intake, or engaging in stress reduction techniques.  As their behaviour 
modification impacted favourably on their symptoms, the motivation to avoid triggers may 
have declined.  However, dietary and lifestyle practices were monitored through the 4-
weekly questionnaires included.   The decision to enrol in a clinical trial can coincide with 
a determination to take control of the symptoms, and hence be accompanied by other 
health-enhancement practices.  Changes made during the trial were recorded on the 
Diet and Lifestyle questionnaire, and the 2-week non-treatment run-in prior to baseline 
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took account of any behaviour modification occurring immediately after acceptance into 
the study.   While these are considered nuisance factors in a study aiming to determine 
the effects of an intervention, they are all features of clinical practice. 
 
Other limitations with interpreting the outcomes of RCTs include the following.  Clinical 
trials involve homogenisation of patient populations, so that only an average effect is 
confirmed.  This means that genuine benefit for a minority of patients will be 
overlooked.1114  RCTs are only externally valid for the types of patients included in the 
trial. Inclusion criteria may sometimes be so stringent that the results are not 
generalisable to the population as a whole.  It has been suggested that this may 
particularly be relevant to studies of phytomedicines and other CAM interventions, in 
view of the type of conditions treated.   These tend to be conditions involving a lesser 
degree of morbidity, lower grade of symptoms and/or more variable symptom patterns, 
which results in the need to recruit larger samples (a requirement not always met), and 
often devise artificial exclusion criteria to constrain sample variability.1114  While 
enhancing internal validity, experimental control can jeopardise external validity (the ‘real 
world’ relevance of the findings, across time, populations and setting) by default.1115 
 
The relevance of findings derived from RCTs to the clinical setting, as well as to certain 
questions being investigated by phytotherapy/CAM research, has been questioned.  
These issues will be explored below. 
19.8 Implications 
There are several implications of the present research for RCTs, phytotherapeutic/CAM 
research and for clinical practice.    
 
The substantial response in the placebo arm observed in RCTs of menopause is at least 
partly attributable to the natural history of the symptoms.  Without the inclusion of a 
natural history arm, which would further add to the demands of resources, it is not 
possible to determine the magnitude of the actual placebo effect (or context effects).   
Nonetheless, a substantial placebo effect is clearly a major nuisance in RCTs of 
menopausal symptoms, particularly for phytotherapeutic interventions, which may 
produce milder effects than synthetic pharmaceutical agents and thus be overshadowed 
by context effects. (This has also been observed in a study of SSRIs in mood disorders.)  
Alternative paradigms may be needed for examining the effects of such interventions, 
and conditions found to elicit substantial placebo effects.   
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Attempts to control the placebo response in clinical trials have included identification of 
the unique characteristics of placebo responders.  The findings from the current study 
that improvement during non-treatment run-in and anxiety at study entry predicted the 
placebo response are both of importance in the design of future RCTs on menopausal 
symptoms.  Excluding volunteers from the sample who have been thus identified as 
placebo-responders could restrict the magnitude of the placebo response.  However, it 
may result in loss of power and bias the sample, making it non-representative of the 
population, and thereby limit the generalisability of the findings.  An alternative may be to 
stratify the study sample by anxiety, and to ensure recruitment of sufficient numbers of 
participants for adequate power.  Data from highly anxious participants could be 
analysed separately.   The practice of a lead-in prior to baseline is supported by these 
findings, as is the recommendation for a minimum symptom severity for inclusion when 
recruiting for clinical trials.30  
 
The observation that predictors of the responses in the placebo and treatment groups 
differed has potential implications.  As discussed above, it may imply that unique placebo 
characteristics do not exist.  However, the alternative explanation of different 
mechanisms operating in the two arms that are mutually exclusive, while not derived 
from the findings of the current study, have potentially significant implications for the 
interpretation of results from placebo-controlled RCTs as a whole, which rest on the 
assumption of additivitiy of effects.  As acknowledged previously, however, this was 
based on data from a small sample and should therefore be interpreted cautiously.  
However, it suggests that this assumption underlying the RCT design warrants further 
investigation. 
 
The findings of effect modification of lack of previous use of herbal medicine on flushing 
symptoms warrants further investigation, through separate analysis of data from prior-
users.  This has potential implications for the design of future studies, and should be 
considered when analysing results of studies.  (However, recruitment of participants with 
no prior experience with CAM would severely restrict the available pool of participants for 
CAM studies.)  The effect modification of positive previous experience with phytotherapy 
for depression suggests that the known efficacy of St John’s wort in this context may 
have impacted here. This effect of positive expectation in enhancing treatment effects is 
well-established, and highlights the importance of appropriate paradigms for exploring 
CAM, as inappropriate negative findings have the potential to undermine clinical effects 
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of treatments.  This finding needs to be replicated in other studies, and could have 
implications for future research as well as clinical practice.  Factors contributing to effect 
modification are of relevance to the design and interpretation of findings from research. 
 
While the findings regarding the combination of Hypericum perforatum and Vitex agnus-
castus in PMS-like symptoms should be interpreted with caution until replicated, they 
suggest a potentially significant clinical application in symptoms that are largely-
neglected in perimenopausal women. The combination warrants further investigation in a 
dedicated study of PMS-like symptoms with a larger sample of women.   The observation 
that women who continued to menstruate intermittently throughout the trial, and 
experience associated PMS-like symptoms, had higher scores on all the outcome 
measures than both those who did not and the post menopausal group (except for 
sexual subscale) supports the suggestion that some symptoms in the perimenopause 
may be more related to menstrual cyclicity than menopause.  
19.8.1 Clinical Implications of Findings 
 
Despite the lack of superiority over placebo, both arms showed a statistically significant 
reduction in symptoms on the endpoints of flushing, overall menopausal symptoms and 
depression.   As pointed out by Koshi,1033 to say that a treatment is no better than 
placebo does not mean that it does nothing.  This raises the question of what constitutes 
a clinically meaningful effect.  It is impossible to ascertain the impact of natural history in 
the current study.  However, the magnitude of the effect achieved may suggest the 
potential for a non-pharmacological intervention that could be of benefit to women.  A 
lesser reduction in symptoms without risk of adverse events may be considered 
worthwhile.  For the active treatment group, medium-to-large effect sizes were 
associated with each of the endpoints.  
 
However, less than half of the participants experienced 50% or greater reduction in 
symptoms with the phytotherapeutic intervention (43·5% for hot flushes; 23·4% for 
overall menopausal symptoms; 44·7% for depression), which would appear to indicate a 
need for different, more effective alternatives, especially in view of the cost to the 
individual of phytomedicines, and the disruption to everyday life of many menopausal 
symptoms.  Nonetheless, a number of participants continued to self-prescribe these two 
herbs after completion of the study, suggesting that at least some considered the 
benefits to outweigh the costs.  The question of efficacy versus effectiveness is further 
discussed below. 
287 
 
The finding that anxiety predicted the response to placebo suggests that menopausal 
symptoms in women with high anxiety could be ameliorated by non-pharmacological 
interventions as a first line of treatment.  This is supported by the observation that 
anxiety has been associated with an aggravation of menopausal symptoms, such as 
flushing.27   
 
The phytotherapeutic combination investigated here may have potential application in 
the management of PMS-like symptoms experienced by perimenopausal women who 
are still menstruating intermittently.  Targeting PMS-like symptoms in these women, 
rather than menopausal symptoms, may be an appropriate treatment strategy generally.  
However, this requires further investigation. 
 
It appears that some women on the study benefited from factors unrelated to the 
possibility of taking an active intervention.  Some expressed appreciation at having 
someone taking an interest in their symptoms.  On admission to the study, some retirees 
expressed the need for social contact and even gratitude at the opportunity to make a 
useful contribution to something worthwhile, and to feel needed.  Several commented 
retrospectively on the value of having observed their symptoms so closely in enabling 
them to identify triggers of their symptoms.  All of these factors could contribute to an 
enhanced placebo response, and support the health-promoting benefits of enrolment in a 
clinical trial.  Clinically, however, these anecdotes suggest that support, being listened to, 
personal contact and avoidance of trigger factors may improve outcomes.  For women 
who are willing to engage in behaviour change and/or seek out additional sources of 
support, these may constitute valuable components of a multi-factorial approach to the 
management of their symptoms. 
19.9 Directions for Future research 
There are several important factors to emerge from the current study that may inform 
future research.  These are explored below. 
 
The need for rigorous evidence to support the practice of phytotherapy is 
incontrovertible, not only to substantiate safety and efficacy claims as required by 
regulatory bodies, but also to clear up the confusion generated by conflicting information 
in circulation.  This is not to deny the value of traditional knowledge from hundreds or 
thousands of years of use.  However, researching phytotherapeutic and other CAM 
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interventions in a way that is scientifically rigorous, that avoids inappropriate rejection of 
potentially valuable treatments through false negative results (Type II errors), and 
reflects clinical practice is one of the biggest challenges facing evidence-based CAM.   
While the RCT is the paradigm of choice when attempting to isolate and measure 
specific effects of a treatment on selected outcomes, substantial placebo effects, or 
‘context’-effects’, may overshadow specific treatment effects and thus need to be 
controlled in clinical trials.  However, in clinical practice, the question arises as to 
whether it is ethical to ignore these ‘non-specific’ effects, or whether they might 
constitute a valid component that enhances outcomes of complex CAM interventions.  
As pointed out by Walach and colleagues (p39),1116 the question of specific efficacy is 
largely irrelevant to patients who are essentially interested in having a good chance of 
getting better. It has thus been suggested that the RCT paradigm may not be appropriate 
for examining the overall impact of potentially important complex interventions such as 
phytotherapy/CAM aimed at stimulating the organism’s self-healing without relying on 
one specific effect.  Alternative methods that may be more suitable for measuring the 
effectiveness of a ‘whole system’ treatment will be mentioned briefly below.  However, as 
the objective of the current study was to assess the specific effect of a particular 
combination of phytomedicines, the RCT was the appropriate design.   
19.9.1 Relevance of the RCT to the Clinical Setting 
 
The role of expectation in the placebo response has been discussed in the previous 
chapters.  In attempting to extrapolate the results of RCT to the clinic, the central 
assumption is that the research setting simulates the clinical setting.  However, in the 
latter context, the patient has a 100% expectation of receiving a proven active treatment, 
compared with the classic 2-armed RCT where the participant has a 50% expectation of 
receiving the active treatment. The effect of different expectations was compared in an 
interesting experiment by Kirsch and Weixel involving the deceptive administration of  
‘coffee’.1117  Certainty of having received an active intervention with known physiological 
effects (coffee) did, in fact, elicit the expected effects, despite the participants having 
actually received ‘sham’ (decaffeinated) coffee. In contrast, the “double blind” 
administration consistently produced placebo response curves that were approximate 
mirror images of those produced by deceptive administration, even on relatively 
independent subjective and physiological responses. In this example, a substance with 
well-known physiological effects was being tested, which may have impacted on the 
changes elicited.  However, other studies have also found expectation of benefit to 
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improve outcomes,1015 and even perceived assignment to be more powerful than actual 
assignment.1020,1033  
In contrast, the expectation model of de la Fuente Fernandez and co-workers1027 
suggests that placebo responses are maximised in 2-armed RCTs investigating 
disorders where dopamine release plays a role.  This is because such a design has an a 
priori probability of clinical benefit of 0.5, and a tonic (sustained) activation of dopamine 
neurons (which precedes a reward and seems to reflect uncertainty) is maximal when 
the probability of reward = 0.5 (29% of dopamine neurons show increases in activity).  As 
mentioned previously, placebo-induced dopamine release in response to the expectation 
of reward appears to represent a common biochemical substrate in many conditions.1026  
This suggests that the placebo effect may be greater in clinical trials of such conditions 
than in the usual clinical practice, in which the probability of receiving an active treatment 
is 1,1027 and thus raises doubts about the validity of the RCT to the clinical setting in 
many medical conditions.  This is represented diagrammatically in figure 19.1. 
 
 GET 
Placebo 
Placebo or 
active  
(Double blind 
design) 
Maximal Placebo effect 
following uncertain 
expectation of receiving 
active intervention 
 
 
 
     
TOLD 
Active treatment 
(Deceptive 
design) 
Lesser placebo effect 
following certain 
expectation of receiving 
active intervention 
 
FIGURE 19.1   DOUBLE BLIND VERSUS DECEPTIVE DESIGN.  Modulation of placebo effects 
according to expectation can be measured.  The double blind design produces uncertain 
expectations whereas the deceptive design produces certain expectations. Adapted from Colloca 
et al. 2008.1042 
 
 
In the open-hidden paradigm, higher treatment effects are elicited during the open than 
the hidden paradigm,1033 suggesting that knowledge that one may be taking placebo 
detracts from the overall effects of treatment as well.  Taking these findings together, it is 
possible that enhanced placebo effects in conjunction with reduced treatment effects are 
found in the RCT, thus artificially narrowing the margin between the placebo and 
treatment arms. 
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19.9.2 Alternative designs  
 
Alternative designs have been proposed in order to control the confounding effects 
elicited by the context or setting in which the intervention is administered.  The influence 
of expectation is especially important in this regard.   
 
The open-hidden paradigm proposed by Benedetti, where applicable, provides an 
effective means of eliminating the placebo or ‘context’ effects, and the opportunity to 
gauge the magnitude of the placebo effect without using a placebo.  It also overcomes 
some of the ethical constraints associated with inclusion of a placebo arm.  However, it is 
not applicable to most studies of phytomedicines as whole agents, as the hidden 
administration requires the patient to be completely unaware that it is being given. As 
such, it is not relevant to interventions that are administered orally, or that require longer-
term administration before a noticeable effect can be expected, as is the case with 
chronic conditions.   
 
The balanced placebo design (figure 19.2) is a 2 x 2 design that involves deception, 
formulated by Ross and colleagues in 1962.1118  Participants are assigned to active or 
placebo arms, with half in each arm being told their allocation while the other half are 
deceived: 
      
                GET 
 
 Placebo Active Treatment
 
Placebo  
Represents 
Natural History 
 
Represents 
Treatment Effect 
(Pr = 0) 
 
 
 
  TOLD  
Active 
Represents 
Placebo effect 
Represents 
clinical setting 
(Treatment effect 
 plus placebo effect, 
Pr = 1) 
Pr = probability of receiving treatment, as perceived by the participant 
 
FIGURE 19.2     BALANCED PLACEBO DESIGN showing what the participants are administered 
versus what they are told they are being administered.  This allows investigators to identify the 
modulation of an intervention by expectation of benefit. Adapted from Colloca et al. 2008.1042 
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Although an ethical limitation is that this design involves deception, it does overcome the 
limitation of potentially maximal placebo effects caused by the perceived probability of 
receiving treatment being 0.5, as in the double-blind design.  However, a treatment effect 
accompanied by the expectation of no benefit is totally irrelevant to the clinical setting.  It 
also provides information on the natural history of the symptoms against which both 
placebo and treatment effects can be measured.  Practically, however, it does add to the 
demands on resources in terms of sample size required, and may reduce compliance 
among those informed they have been assigned to placebo. 
 
Although also entailing deception, an obvious ethical constraint, another possibility for 
creating equal expectations and levelling the placebo response among the whole group 
(with regard to expectation, at least) is an RCT where all participants are told that they 
are receiving the active treatment (figure 19.3).  The placebo effect could then be 
subtracted from the response to active treatment in order to gauge the treatment effect.  
However, it is unlikely that any research would elicit an ‘expectation’ response equivalent 
in magnitude to that seen in the clinical setting, as research, by its very nature, involves 
uncertainty regarding treatment outcomes, and is thereby subject to different placebo 
effects from clinical practice, according to the theories outlined above.  
 
                GET 
 
 Placebo Active 
Treatment 
 
 
  TOLD   
Active 
Represents 
Placebo effect 
(Pr = 1) 
Represents 
clinical setting 
(Treatment effect 
 plus placebo effect, 
Pr = 1) 
Pr = probability of receiving treatment, as perceived by the participant 
FIGURE 19.3    RCT INVOLVING DECEPTION.  The differing modulation of effects according to 
expectation is controlled by informing all participants they are receiving the active treatment. 
 
As mentioned previously, the RCT answers the question, “Is this intervention better than 
placebo?”  However, a more appropriate question may be “Is this intervention better than 
other options available for these women who are unwilling to use HT?”  This suggests 
that comparator studies with non-oestrogenic options or other phytomedicines may 
provide useful information, although a placebo arm would still be required due to the 
magnitude of this effect in menopause studies.  The importance of examining effect sizes 
is also highlighted in this context. 
292 
19.9.3 Relevance of RCTs to phytotherapy/CAM approaches 
 
There is a noticeable discrepancy between the reports of substantial clinical benefits 
from CAM practitioners and users 1068,1119,1120 and results of many of the published 
studies on CAM interventions.   Even well-designed RCTs often fail to show superiority 
over placebo, which raises doubts about the appropriateness of this paradigm to answer 
questions about the often-complex treatment approaches of CAM. 
 
Placebo-controlled trials have several underlying assumptions that have now been 
questioned, especially in relation to CAM research.   The assumption that the results of 
RCTs are clinically relevant has been discussed above.  As mentioned above, the 
assumption of equipoise, which assumes that participants and providers are indifferent, 
with no beliefs or preferences for a treatment, is also questionable in relation to 
phytomedicines, for which there exists a large body of traditional knowledge.  This 
means that the influence of participant expectations needs to be investigated in relation 
to the effects that occur.  Furthermore, it is assumed there is a stable effect size that is 
independent of the context.  However, because pharmacological effects can sometimes 
change dramatically according to context effects such as expectation, it is suggested that 
psychological and pharmacological effects may be inseparable.1115  In a 1994 review of 
the interaction between specific effects and context effects, Kleijen and colleagues 
concluded that specific and non-specific effects may sometimes be synergistic and at 
other times antagonistic, which suggests that “the implicit additive model of the RCT is 
too simple.”1121 Another assumption is that only the specific effects attributable to 
interventions are therapeutically valid, which leads to the conclusion drawn from RCTs 
that a therapeutic intervention is deemed effective only if it performs better than placebo.  
However, the distinction between efficacy and effectiveness has been elaborated by 
Walach in what he terms the ‘efficacy paradox’ (figure 19.4).1115,1122  A treatment that is 
efficacious (having shown statistical superiority to placebo) can be less effective than 
another treatment that did not demonstrate efficacy.   
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FIGURE 19.4   ILLUSTRATION OF THE EFFICACY PARADOX.   
From Walach H. et al. Circular instead of hierarchical: methodological principles for the evaluation 
of complex interventions. BMC Med Res Methodol 2006;6:29. (No permission required) 
 
This raises the question of patient outcomes.  As pointed out by Jonas, “research should 
tell us what is useful and meaningful in patients’ lives.”1123  To ascertain the clinical 
relevance to patients of the intervention, it is useful to elicit retrospective participant 
ratings of the treatment (for example, as Ineffective, Moderately effective, Good, Very 
good, Excellent). 
 
The notion that only specific effects over and above placebo effects are worth 
demonstrating, and worth achieving has been termed the ‘placebo trap’.1122 But in 
relation to complex interventions as are studied in CAM research, it may not be 
meaningful to split into specific effects and context effects.  It may be more meaningful to 
investigate the effectiveness of a ‘whole system’ treatment.1124  In this case, research 
strategies need to be diversified to include multiple methods and to replicate results 
achieved with one method by another.  Suitable protocols could include pragmatic trials, 
in which treatment conditions closely simulate those of the clinical setting and which 
could therefore accommodate individualised treatments;1013 large outcomes studies; or 
pragmatically-selected comparative cohort studies in natural settings to address 
selection process.1122  Where it is sufficient to document the effects as different from the 
natural course of the disorder, randomised comparison trials of CAM therapies against 
standard care or against waiting lists would be an option as they permit quantification of 
general therapeutic effects.1122  Partially randomised trial designs allow patients to 
express a preference for the treatment allocated, and those with no preference to be 
randomised.  The effects of receiving a treatment of choice can be measured in this 
case, and if the sample is sufficiently large, separate analyses can be performed for the 
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randomised and non-randomised groups.1125  It is also suggested the where specific 
effects are likely to be small, but whole treatment effects large, due to the complex 
interaction of specific and non-specific effects, the RCT is inadvisable.1115  In order to 
reflect the practice of individualised prescribing, a methodologically rigorous protocol 
including three arms has been designed and trialled by Bensoussan.1096  In addition to 
the standard treatment and placebo arms, an individualised treatment arm is included, 
which has the advantage of allowing individualised care to be evaluated.   With regard to 
phytomedicines, an alternative methodology that may provide valuable information is the 
observation of the physiological effects of treatment in healthy human subjects, rather 
than its direct effects on morbidity.1114  Measuring objective parameters can be useful 
where these are reliable and expected to change over a reasonable course of time. 
19.9.4 Recommendations 
 
Future advances in this area will further elucidate the neuroanatomical and 
neurobiological mechanisms of the placebo response, and confirm or disprove the 
underlying assumptions of placebo-controlled trials.  In order to further investigate the 
non-additivitiy hypothesis,1043,1121 the possibility that different mechanisms may be 
operating in treatment and placebo groups with regard to menopausal symptoms, 
comparing predictors of placebo and active responses from other studies showing non-
superiority of the intervention may be useful.  (This assumes, of course, that unique 
placebo characteristics do exist.)  The findings that improvement during non-treatment 
run-in and anxiety predicted the placebo response in the current study are of importance 
in the design of future RCTs on menopausal symptoms.  Identification of the 
characteristics of placebo responders may be used to inform strategies to limit the 
magnitude of the placebo response.  This could be achieved by excluding such 
individuals (without impacting on recruitment of adequate sample size), stratifying 
according to these variables, and/or performing separate analyses of data from these 
participants. Controlling the magnitude of the placebo response may facilitate accurate 
determination of the specific effects of interventions. These findings need to be 
replicated in a larger study. 
 
Effect modification of lack of prior use of phytomedicines on flushing symptoms, and 
previous positive experience with phytotherapy in depression, anxiety and sleep also 
warrants further investigation, and should potentially be taken into account when 
designing and analysing data from future studies. 
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In future studies, the modifying effect of rapport could be monitored by including a 
measure of therapeutic alliance between the participant and investigator.  In order to 
restrict the magnitude of context effects elicited by investigator effects, and hence 
enhance the internal validity, tablets and questionnaires might be posted out to 
participants, although this does restrict the external validity of the results.   
 
Future advances in the areas of the endocrinology and neuroendocrinology of 
menopause and its associated symptoms, as well as PMS,  will further elucidate the 
aetiology of the bothersome symptoms experienced throughout the menopause 
transition and post-menopause, including the  PMS-like symptoms experienced during 
the perimenopause.    
 
This may point the way to alternative targeted management options that are well-
tolerated by symptomatic menopausal women.  The potential benefit on PMS-like 
symptoms indicated for the phytotherapeutic combination investigated in the current 
study warrants further investigation in a RCT involving a larger sample of women, in a 
study dedicated to those specific symptoms.  Given the evidence supporting Vitex in this 
context, inclusion of an additional arm to compare the effects of the combination with 
Vitex as a sole agent and placebo could yield potentially valuable information. 
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Conclusion 
 
The current study aimed to investigate the efficacy of a combination of two non-
oestrogenic medicinal herbs in the clinical management of menopausal flushing and 
psychological symptoms, as well as general menopausal symptoms and quality of life.  
Subpopulation analyses of the data investigated: i) the effects of the phytotherapeutic 
combination on  PMS-like symptoms in a small group of irregularly menstruating 
perimenopausal women; and, ii) predictors of the placebo response, which were then 
compared with predictors of the response to active treatment. 
19.10 Summary of Findings 
Conclusions from the individual studies have been reported in the respective chapters 
describing the findings incorporated into this thesis.   To summarise, the principal 
findings were as follows. 
• The combination was not found to be superior to placebo for any of the endpoints 
measured.  However, both groups improved significantly on the endpoints of 
flushing, depression and general menopausal symptoms.   A substantial placebo 
response was observed, consistent with other RCTs on menopausal symptoms, 
and depression.     
• Effect modification was observed for lack of prior use of phytotherapy on flushing 
scores.  Previous positive experience with phytotherapy predicted overall 
percentage improvement in depression and anxiety-subscale scores for the 
sample as a whole. 
• The placebo response in the menopausal symptoms study was predicted by 
anxiety at study entry for all three outcome measures. Improvement during non-
treatment run-in predicted placebo response on depression and overall 
menopausal symptoms.   Milder symptom severity at baseline was not predictive 
of subsequent improvement. 
• The hypothesis that the same predictors would predict the effect in both arms, 
due to the lack of superiority of the phytotherapeutic combination over placebo, 
was not supported.  The trend for anxiety was the opposite in the active treatment 
group, where low anxiety was significantly associated with improvement.  None of 
the other variables found to predict the placebo response was relevant to the 
treatment arm.   
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• The combination was found to be superior to placebo for PMS-like symptoms in 
the small sub-population of late-perimenopausal women for whom this was 
relevant. 
 
 These findings have implications for future research directions and trial design in 
CAM, as well as clinical practice. 
19.11 General Recommendations 
General recommendations include the following. 
• The substantial placebo effect observed in studies of menopausal symptoms 
renders a control or comparator group essential, as observational studies are 
likely to be susceptible to type I errors.   However, the less pronounced effects of 
phytomedicines, compared with HT and other pharmaceutical options, may 
necessitate prohibitively large sample sizes in placebo-controlled RCTs in order 
to achieve adequate power.  For this reason, alternative research paradigms may 
be more appropriate for researching phytomedicines in this context. 
• In order to accurately assess the efficacy and safety of phytotherapies in a way 
that is scientifically rigorous and reflects clinical practice of phytotherapy, 
alternative research paradigms are needed.  For the purposes of simulating the 
whole person approach, the design trialled by Bensoussan using an additional 
‘individualised treatment’ arm may be appropriate.  Studies investigating herbal 
combinations, while not permitting conclusions to be drawn about the individual 
contributions of the component herbs, more closely reflect clinical practice. 
• The findings of effect modification of lack of previous experience on flushing, and 
positive previous experience with phytotherapy for depression and anxiety-
subscale scores warrant further investigation. These could have implications for 
future research and should potentially be considered when analysing results of 
studies.  
• Future studies of potential interventions for menopausal symptoms may use the 
trial findings for early identification of placebo responders, according to high 
anxiety at study entry and improvement during non-treatment run-in.  
Investigators may be able to incorporate strategies to limit the magnitude of the 
placebo response, and thereby facilitate accurate determination of the specific 
effects of the intervention/s.  This could be achieved by excluding such 
individuals (with recruitment of additional participants as necessary), stratifying 
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according to these variables, and/or performing separate analyses of data from 
these participants.   These findings need to be replicated in a larger study. 
• In order to restrict the placebo response rates observed with milder baseline 
symptom severity, the recruitment of participants with a minimum of moderately 
severe symptoms is recommended in RCTs examining menopausal symptoms.  
This requirement is supported by the findings of the current study.   
• To further test the hypothesis that different mechanisms may be operating in 
treatment and placebo groups with regard to menopausal symptoms, predictors 
of placebo and active responses could be compared from other studies that show 
non-superiority of the intervention over placebo.   Further studies exploring 
underlying mechanisms of placebo action are also needed to examine this 
hypothesis.   
• Future developments in the area will contribute to greater understanding of the 
endocrinology and neuroendocrinology of symptoms in the perimenopause, 
which is required to establish their relationship to PMS-like symptoms in the late-
luteal phase. 
• Further research into the effects of this phytotherapeutic intervention in a robust 
study of PMS and PMS-like symptoms in the perimenopause, with a larger 
sample size is warranted.   
19.12 Overall conclusion  
The RCT described throughout this thesis was a well-designed, robust study of a 
phytotherapeutic intervention in the management of symptoms in perimenopausal and 
postmenopausal women.  Because many women wish to avoid therapy with synthetic 
pharmaceutical agents for these symptoms, there is a significant need for safe, well-
tolerated, effective alternatives that have been validated by results from controlled 
clinical trials. The findings from the current study contribute to the growing body of 
available evidence regarding phytomedicines from rigorous RCTs, in addition to 
highlighting some areas for future research into the symptoms experienced during the 
perimenopause, the placebo effect and paradigms for future research into 
phytomedicines and other CAM modalities.  In view of the demand for phytotherapeutic 
treatments for menopausal symptoms, this is a very important topic that is relevant to the 
community, health-care providers and regulatory authorities.   
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A.0  Introduction 
 
The appendices contain additional information and analyses related to the preceding 
chapters, the manuscript entitled ‘Vitex agnus-castus (Chaste-tree/berry) in the Treatment of 
Menopause-related Complaints’, submitted to the Journal of Alternative and Complementary 
Medicine, and all documentation relating to the randomised, controlled trial. 
Raw data is available on request from Diana van Die at diana.vandie@rmit.edu.au
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Appendix 1 Age at Menopause 
 
A1.1 Cross-cultural Findings regarding Age at Menopause 
 
An international WHO collaborative study reported a median age of 50 years (range  49 – 
52) among 18,997 women from 11 countries (Australia, Chile, People’s Republic of China, 
Colombia, the former German Democratic Republic, Israel, Kenya, Mexico, Nigeria, the 
Philippines and Thailand).  Limitations of this study included selection bias, as the women 
were hospital controls in a multi-centre case-control study of female cancers and may 
therefore have been of higher socio-economic status giving them more access to hospital 
care.  Additionally, the median age of the women in the sample was 40 years so not all had 
reached menopause, which was therefore estimated using a survival analysis approach.† 2   
On the whole, existing studies show similar findings with regard to age at menopause as 
data from the European studies selected for the WHO Scientific Group report.  This  showed 
that the mean age ranged from 47.5 – 49.5, with a median range of 49.6 - 51.4.3   Countries 
reporting mean ages outside these ranges are marked with an asterisk*.   
 
A somewhat lower age at menopause was observed among asymptomatic Mayan women of 
Mexico and the Indian women of Himachal Pradesh.  However, it is possible that the 
inconsistent findings could be due to the methodological limitations of the research, most of 
which has been retrospective or cross-sectional and subject to errors of recall, biased 
reporting of age, as well as sampling error, such as selection bias, or to the use of 
inappropriate statistical techniques. 
 
Additionally, most did not control for confounding variables that could potentially affect age 
at natural menopause. 
 
                                            
† Survival analysis aims to follow subjects over time and observe at which point in time they 
experience the event of interest. It often happens that the study does not span enough time in order 
to observe the event for all the subjects in the study.  Survival analysis therefore provides methods for 
estimating the distribution of survival times from a sample.1   1. UCLA. Academic Technology 
Services: www.ats.ucla.edu/stat/sas/seminars/sas_survival/default.htm. 
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TABLE A1   ESTIMATES OF THE AGE AT MENOPAUSE FROM SELECTED STUDIES 
Country and Year of Study/ 
Publication 
Mean or Median age at 
menopause (years) 
Sampling Method/ 
age/setting 
Brazil 20034 51.2 (mean) cross-sectional survey 
Canary Islands 1994 5 48.6 (mean) retrospective 
Czechoslovkia 19756 51.2 (mean) status quo method††
Finland 19897 51 (mean) cross-sectional survey 
*India, Himachal Pradesh 19878 43.6 (mean) unspecified 
*India, Northern 2005 9 46.7 (mean) 48 (median) cross-sectional survey  
obstetrics & gynecology clinic 
Iran 200510 48.3(mean) 49(median) cross-sectional survey 
Japan 198711 49.3 (mean) cross-sectional survey 
of 28-85 year-olds 
*Kenya, West[Luhya] 199712 4838 (median) cross-sectional survey 
Latin America 13  49.4 (mean) cross-sectional survey  
(health centre) 
Malaysia 199414 50.7 (mean) unspecified  
*Mexico (Mayan, asymptomatic) 
199315 
44.3 (median) cross-sectional survey 
*Mexico city 199616 47 (median) 46.5(mean) 
 
cross-sectional survey (natural 
menopause- retrospective)  
Pakistan, Lahore 200217 50 (median) 49 (mean) cross-sectional survey 
Poland 2007 18 51.3 (median) cross-sectional survey 
Puerto Rica, 200319 51.4 (median) cross-sectional survey  
30-59 year-olds 
Singapore 200520 49.0 mean cross-sectional survey 
South Africa [negro] 198421  49.5 rural; 48.9 urban 
(means) 
status quo method†† with probit 
analysis‡
Taiwan 199722  49.5 mean unspecified 
Thai 199323 49.5 (mean) cross-sectional survey  
health centres 
*UAE 199824  48 (median)  47.3 (mean) stratified cluster sampling 
USA 199725  51.5 (49.3 Afro-American) prospective 
 
A1.2 Factors Influencing Age at Menopause  
 
Factors that may influence the age at menopause have been the focus of much 
investigation.  Social and environmental factors that have been found in some studies to 
impact on earlier age at menopause include  
• current cigarette smoking26-31 
• increased body mass index (BMI)26,27 
                                            
†† The status quo method is considered to be a simple method with little bias.  It provides a sample or 
population estimate based on the age of each woman sampled and whether or not she has reached 
menopause.  A table is then constructed with a percentage of Yes/No answers at each age.  From 
this, the median age at menopause, standard deviation and standard error are calculated using either 
probit or logit transformation. 
 
‡ Probit analysis is an alternative to logistic regression analysis for producing predicted probabilities.  
In this case, the age-specific prevalence of the menopausal state is transformed to a probit scale, and 
these probits are then plotted against age.   
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• current use of weight reduction diets25 
• no prior use of oral contraceptives31,32 
• nulliparity/fewer children32-34 31 
• lower level of education28,31 
• lower socio-economic status35 
• low social participation28  
 
Many of these could potentially affect the hypothalamic-pituitary-gonadal axis and its 
regulation of gonadotropins and sex steroid hormones.31  This will be further elaborated in 
the section on the endocrinology of menopause. 
 
Of the above factors, cigarette smoking has most consistently been associated with a 1-2 
year earlier natural menopause.26-31  Large-scale cross-sectional studies such as the Study 
of Women’s Health Across the Nation (SWAN) and the Oslo Health Study,  found that 
current smoking was significantly associated with early menopause whereas the toxic 
effects of past smoking on the ovary could be reversible,30 with stopping smoking more than 
10 years before menopause considerably reducing the risk.28  While not borne out by the 
findings of the SWAN,31 data from some studies suggest a possible dose-response 
relationship between total exposure to smoking and early menopause, 28,29 even when 
controlling for possible confounding variables such as parity, weight, socio-economic status, 
nutritional variables and lower educational attainment. 29   The Oslo study found no 
association with passive smoking, alcohol or coffee consumption, although such correlations 
had been suggested in earlier research.36,37 
 
Increased BMI has also been shown to be associated with an early menopause in some 
studies,26,27 although others found low relative weight to correlate.  However it is also 
possible that lifestyle factors such as increased BMI may not only be the cause, but also the 
consequence of an early menopause, which cannot be differentiated in cross-sectional 
studies. 
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Additional factors associated with earlier menopause in the SWAN study were being 
separated, widowed or divorced, non-employment and history of heart disease, while 
Japanese ethnicity among Americans was associated with a later age.   Adverse socio-
economic circumstances across the life course are associated with an earlier age at 
menopause but this may co-vary with nutrition in childhood,35 smoking and physical activity. 
 
In terms of reproductive history, shorter intermenstrual intervals during the reproductive 
years,38 or limited number of ovulatory cycles per lifetime39 and irregular cycles prior to age 
2532 have been linked to earlier menopause. 
 
Earlier onset of menopause can also follow surgical procedures such as tubal ligation or 
hysterectomy, surgical removal of the ovaries, and damage to the remaining follicles by 
radiation, chemotherapy or other endocrine-disrupting agents.40   
 
A1.3 Implications of Earlier Age at Menopause 
Age at natural menopause may be an important marker for subsequent morbidity and 
mortality.  Earlier age at natural menopause has been linked with increased risk of coronary 
heart disease and stroke41,42 as well as atherosclerosis and osteoporosis43 (although the 
number of reproductive years is thought to be more relevant in determining osteoporosis risk  
than is age at menopause).43,44  Later age at menopause has been associated with an 
increased risk of cancer-related mortality,45 such as breast, endometrial and ovarian 
cancers.46-51  The relationship with oestrogen-dependent cancer risk  may be due to the 
duration of exposure to high circulating oestrogen levels as a result of cumulative number of 
menstrual cycles per lifetime.52  Later age at menopause has, however, also been linked to 
a longer overall survival rate and increased life expectancy.45,53,54 
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Appendix 2 Cohort Studies on Symptoms in Midlife and Menopausal women 
 
 
Descriptions of cohort studies on midlife and menopausal women are given in Table A2 
along with location and principal investigators. 
 
TABLE A2  DESCRIPTIONS OF COHORT STUDIES Adapted from NLM Health Services Technology 
Assessment Text [electronic resource] / National Library of Medicine. Bethesda, MD. : National 
Library of Medicine, 200255 
Cohort Description Investigators/authors 
Copenhagen 630 women 40 years old in 1976 selected from 4 
municipalities and served by one hospital in Copenhagen, 
Denmark. Women using postmenopausal hormone 
therapy or who underwent premature or surgical 
menopause were excluded. 
Koster, Garde 
Eindhoven 8,503 women recruited based on responses to an 
osteoporosis screening study in Eindhoven, Netherlands. 
Women were excluded if non-Dutch White, had 
hysterectomy with or without oophorectomy, had bilateral 
oophorectomy, are using postmenopausal hormone 
therapy, or were noncompliant with one or more items in 
the questionnaire. 
Maartens, Knottenerus, Pop 
Gothenburg 1,462 women 38 to 60 years old randomly selected in 
1968-69 and followed for over 25 years in Gothenburg, 
Sweden. Measures were assessed through periodic 
medical exams and interviews. 
Hallstrom, Rodstra, 
Samuelsson 
The Harvard Study of 
Moods and Cycles 
A longitudinal, prospective cohort study that followed 460 
premenopausal women as they entered perimenopause 
Harlow, Cohen,  
Otto, Soares, Spiegelman,  
Cramer, Wise, Otto,  
Manitoba Project on 
Women and Their 
Health in the Middle 
Years 
A cross-sectional and longitudinal cohort study that 
enrolled 2,500 women aged 40–59 years old from the 
general population of Manitoba, Canada. 
Kaufert, Milsom, Gilbert, Tate 
Massachusetts 
Women's Health 
Study 
Cross-sectional survey 1981-2 with 8,050 women aged 
45-55; and longitudinal study that enrolled 2,572 
premenopausal women from Massachusetts, U.S. 
Avis, Brambilla, McKinlay, , 
Crawford, Posner, Vass 
Medical Research 
Council (MRC) 
National Survey for 
Health and 
Development 
1,572 women identified from a socially stratified sample of 
all births in March 1943 in Britain. 
Kuh, Hardy, Wadsworth, 
Cardazo, Rogers 
Melbourne Women's 
Midlife Health Project 
Cross-sectional and longitudinal, community-based cohort 
that enrolled 2,000 women 45 to 55 years old from 
Melbourne, Australia. Longitudinal follow up of 492 
women has been ongoing since 1991. The study 
assesses women's health during midlife and the 
menopause including well being, sexuality, symptoms, 
and bone density and their relationship to a range of 
variables including hormones, age, stress, lifestyle, and 
other health experiences. 
Dennerstein, Dudley, Burger, 
Lehert, Sherburn, Guthrie, 
Hopper, Morse, Smith  
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Minnesota/Tremin Trust 
Longitudinal Research 
Program on Women's 
Health 
Longitudinal study that initially consisted of 2,350 University of 
Minnesota women. Between 1961-1963, a second group of 
1,600 women was added, and in 1965, a third group of 1,000 
native Alaskan women were added. Women in the study range 
from teens to mid-nineties and represent fifty states and twenty-
five foreign countries. 
Koch, Mansfield, 
Voda 
National Health 
Examination Follow-up 
Study 
Sample of 3,049 U.S. women 40 to 60 years old from the 
National Health and Nutrition Examination Survey (NHANES). 
Busch, Zonderman, 
Costa 
Ohio Midlife Women's 
Study 
208 women 40 to 60 years old, recruited with advertisements 
from a community in Ohio, U.S. Cohort includes 57% 
Caucasian, 43% African-American women. 
Glazer, Zeller, 
Delumba, L. 
Kalinyak, Hobfoll, 
Winchell,  
Hartman 
Pennsylvania Ovarian 
Aging Study 
Population-based cohort of 436 women from Philadelphia 
County, Pennsylvania, 35–47 years old at baseline including 
50% African American, 50% Caucasian. Ongoing longitudinal 
study. 
Freeman, Gracia, 
Sammel, Lin,  
Kapoor, Ferdousi, 
Liu, Nelson, 
Hollander 
Seattle Midlife Women's 
Health Study 
11,222 women from within Seattle, U.S. census tracts, 35 to 55 
years old, including multiple ethnicities and income levels and 
followed for 3 years. All women had active menstrual periods at 
baseline and were excluded if pregnant, using postmenopausal 
hormones, or non-English reading/speaking. 
Mitchell, Woods, 
Mariella, Lentz, 
Study of Women's 
Health Across the Nation 
(SWAN) 
U.S., community-based, multisite cross-sectional and 
longitudinal cohort study that enrolled 16,065 women 40 to 55 
years old. Longitudinal follow up of 3,306 women has been 
ongoing since 1995. The goal of the study is to describe the 
chronology of the biological and psychosocial characteristics of 
the menopausal transition and its effects on health and risk 
factors for age-related chronic diseases. 
Bromberger, Avis, 
Matthews, Sowers, 
Crawford, Gold, 
Kravitz, Randolf, 
Cordal, Schott,  
Brockwell, Everson-
Rose, Colvin, Ory, 
Schocken 
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Appendix 3 Physiology of the Normal Menstrual Cycle 
 
During the reproductive years, normal cyclic ovarian function depends on the coordinated 
activity of a feedback system involving the hypothalamic-pituitary-ovarian axis (referred to as 
the HPO axis) with associated structural and functional changes in the target tissues, the 
ovaries and uterus.  Each cycle culminates in menstrual bleeding, the first day of which is 
accepted as a clinical reference point marking the beginning of the menstrual cycle.56  
 
Central to the mechanisms of this feedback system are gonadotrophin releasing hormone 
(GnRH) secreted by the hypothalamus in a pulsatile fashion, modulated by 
neurotransmitters, including noradrenaline, serotonin, and endogenous opioids;57 the 
gonadotrophins, follicle stimulating hormone (FSH) and luteinising hormone (LH) secreted 
by the anterior pituitary;  ovarian hormones: the sex steroids oestradiol and progesterone; 
and the peptides- the inhibins and activins.58,59   
 
The human menstrual cycle can be divided into four phases according to stages of follicular 
and luteal development and levels of circulating sex steroids.  These are the menstrual 
phase, follicular phase, ovulation and luteal phase. 
A3.1.1 The menstrual phase 
 
• During the menstrual phase, 20 or so secondary (antral) follicles begin to enlarge under 
the influence of FSH.  However folliculogenesis begins in the late luteal phase of the 
preceding cycle when FSH and LH levels begin to rise with the demise of the corpus 
luteum and resulting low levels of oestrogen, progesterone and inhibin A.  GnRH from 
the hypothalamus stimulates the release of FSH & LH from the anterior pituitary so that 
levels of FSH and LH began to gradually rise 4 days prior to menses.60  FSH and LH 
are released in pulses that correspond to the pulsatile secretion of GnRH.  Pulsatility 
changes during the different phases of the menstrual cycle, increasing near ovulation 
and slows during the luteal phase.  In the absence of negative feedback, it occurs 
approximately every 60 minutes.56 
A3.1.2 The Follicular Phase 
 
• Stimulated by FSH and LH, these follicles continue to grow and develop and to secrete 
oestrogens.   LH stimulates theca cells of the ovarian follicle to secrete androgens 
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(androstenedione and testosterone) which are converted to oestrone (E1) and 17β-
oestradiol (E2) respectively by the enzyme P450 aromatase, but preferentially oestradiol 
in the ovary.  Secretion of aromatase is stimulated by the action of FSH on the granulosa 
cells of the developing Graafian (dominant) follicle. 
 
• In the early follicular phase, granulosa cells of the antral follicles also secrete inhibin B in 
addition to moderate levels of E2, which in turn inhibit the release of FSH secretion as 
well as LH via negative feedback on the hypothalamus, GnRH and anterior pituitary.  
This closed loop feedback system of FSH stimulating secretion of oestrogens and INH-B 
which together exert negative feedback on FSH is maintained in a continual state of 
balance in the normal menstrual cycle of normal reproductive aged women, and is of 
central importance when considering the endocrine changes that occur in later 
reproductive life. 
 
• Activins are other FSH regulatory peptides found to stimulate FSH production,61-63 
although their role in the endocrinology of the normal menstrual cycle is considered by 
many not to be major. 
A3.1.3 Late follicular phase 
 
• As the follicular phase progresses, selection of the dominant (Graafian) follicle, a single 
follicle destined to ovulate, occurs by about day 6 under the influence of  FSH & E2;  this 
continues to secrete E2 and Inhibin A.  It may also secrete small amounts of 
progesterone (P) one or two days prior to ovulation.  The other follicles undergo atresia. 
 
• In the late follicular phase, at day 12, high levels of E2  (>700-800pmols for 48hrs+), 
possibly facilitated by P, exert positive feedback on LH (and to a lesser extent  FSH) 
primarily via the anterior pituitary after priming with GnRH of high frequency:     
E2 stimulates the synthesis and storage of LH but initially inhibits its secretion.  
However, the sharp rise in the levels of E2 at day 12 triggers  the discharge  of LH and 
the resultant LH surge twelve hours later.  This positive feedback of LH is enhanced by 
the pre-ovulatory rise in P, which sensitises the anterior pituitary to E2, thus augmenting 
the LH surge.   
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The brief pre-ovulatory rise in P also suppresses E2 secretion, together with the effect of 
LH on the follicle, resulting in the fall in E2  levels prior to the LH-surge.64   
A3.2.4 Ovulation 
 
• The LH surge triggers ovulation and promotes formation of the corpus luteum by full 
luteinisation of the dominant follicle.   
• “Ovulation carries away the oocyte and a cumulus of granulosa cells; the remaining 
theca and granulosa cells organize into a progesterone-secreting corpus luteum, which 
is active for about 2 weeks and then regresses.”59  
A3.1.5 Luteal Phase 
 
• In contrast to the oestrogen dominated follicular phase, the luteal phase is characterised 
by progesterone dominance. The corpus luteum produces progesterone, some 
oestrogen, inhibin A and relaxin. Progesterone inhibits the release of LH.  It also stops 
the positive feedback of E 2 on the hypothalamus and anterior pituitary  and thereby 
contributes to the inhibition of FSH together with E2 and Inhibin A.  Moderate levels of E2 
inhibit the release of GnRH, FSH and LH possibly by reducing the sensitivity of the 
anterior pituitary to GnRH.  
• In the uterus, P transforms the endometrial cells from proliferative to secretory. 
• Progesterone levels reach a peak about 7-8 days post ovulation.  In the absence of 
implantation, luteolysis occurs with a decline in E2 and P levels during the last 4-5 days 
of the functional corpus luteum,(p196)56 precipitating a menstrual bleed.  Inhibin A levels 
also decline at his time, allowing FSH levels to begin to rise.  
 
• Four days prior to menses, in the low oestrogen, progesterone and INH-A environment 
resulting from degeneration of the corpus luteum, GnRH from the hypothalamus 
stimulates the release of FSH & LH from the anterior pituitary.  Levels of FSH and LH 
begin to gradually rise.  (See beginning). 
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FIGURE A3.1   DIAGRAMMATIC REPRESENTATION OF THE HYPOTHALAMIC-PITUITARY-OVARIAN AXIS DURING 
THE FOLLICULAR PHASE.  Reproduced with permission from Elsevier65 
Under the control of noradrenaline (NA), serotonin (5-HT), corticotropin-releasing hormone (CRH) , 
the opioids and other neurotransmitters, hypothalamic neurones in the pre-optic and arcuate nucleus 
secrete GnRH into the hypophyseal portal system in a pulsatile manner.  This stimulates the 
production and secretion of LH and FSH by the pituitary.66  This in turn stimulates secretion of 
ovarian oestrogen and progesterone, which feed back at the pituitary to modulate the relative 
amounts of LH and FSH and at the hypothalamus to regulate GnRH.  NA stimulates GnRH 
secretion; opiates, corticosteroids, dopamine and CRH are inhibitory.56,59,67  
 
 
TABLE A3.1  OVARIAN HORMONES, GONADOTROPHINS & INHIBINS THROUGHOUT THE MENSTRUAL CYCLE 
 Early Follicular Phase Late Follicular Phase Early–Mid Luteal Phase Late Luteal Phase 
Oestrogens Moderate levels inhibit release of 
GnRH, FSH & LH via negative 
feedback on anterior pituitary and 
hypothalamus 
High levels exert positive feedback 
on GnRH, LH & FSH (>700-
800pmols for 48hrs+) via anterior 
pituitary after priming with GnRH of 
high frequency. 
Day 12 surge =>  
12 hours later stimulates LH surge 
Moderate levels inhibit release of 
GnRH, FSH & LH 
[May do this by reducing sensitivity 
of anterior pituitary to GnRH]. 
Low levels exert no feedback on 
GnRH, LH or FSH => unrestrained 
FSH & LH 
[Declining levels of P & oestrogens 
caused by degeneration of the 
corpus luteum] 
Progesterone  Small amounts with E2 can 
enhance positive feedback of LH by 
sensitising anterior pituitary to E2 > 
Discharge of LH 
Suppresses LH  
Contributes to inhibition of FSH 
(with E2 & Inhibin A) 
[Stops positive feedback effect of 
oestrogens on hypothalamus & 
anterior pituitary] 
[Works with oestrogens to prepare 
endometrium for implantation.  
Transforms endometrial cells from 
proliferative to secretory]. 
Declining levels of P & oestrogens 
caused by degeneration of the 
corpus luteum causes uterine spiral 
arteries to constrict => cells they 
supply become ischaemic & die => 
stratum functionalis of endometrium 
sloughs off. 
 
FSH 
Stimulates 
granulosa cells => 
aromatase 
Stimulates the initial secretion of 
oestrogens by growing ovarian 
follicle (via action of aromatase 
from granulosa cells on androgens) 
Stimulates further development of 
growing follicles and the secretion 
of oestrogens, inhibins A & B (and 
possibly small amounts of P 1-2 
days pre-ovulation) 
Regulated by negative feedback 
(via hypothalamus and anterior 
pituitary) both by the ovarian 
steroids, E2 and P, and by the 
inhibins 
4 days prior to menses, with very 
low levels of P & oestrogens, FSH 
& LH start to rise again 
LH 
Stimulates theca 
cells => 
androgens 
Stimulates the further development 
of ovarian follicles and their full 
secretion of oestrogen (esp 
Graafian follicle) 
Triggers ovulation 
Promotes formation of corpus 
luteum 
 
Stimulates production of 
progesterone, oestrogens, relaxin & 
inhibin A by the corpus luteum 
4 days prior to menses, with very 
low levels of P & oestrogens, FSH 
& LH start to rise again 
Inhibins FSH stimulates Inhibin B & activin 
production by granulosa cells of 
antral follicles. Inh B in turn inhibits 
FSH secretion. 
 Corpus luteum secretes  
Inhibin A 
Levels of Inhibins  low =>  allows 
FSH/LH secretion 
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TABLE A3.2   SECRETION AND INHIBITION OF SEX HORMONES, GONADOTROPHINS & INHIBINS 
 
 Rises in response to Decreases as a result of Post-ovulation Functions 
Oestrogens FSH =>  granulosa cell of 
developing follicles, especially 
dominant one 
(& LH =>  theca cells => androgens) 
[ & adrenal cortex (limited amounts) 
throughout cycle] 
Brief rise in P pre-LH surge together 
with the effect of LH on the follicle. 
 
(Degeneration of corpus luteum in 
late luteal phase) 
E2 & Inhibins & relaxin secreted by  
corpus luteum (bit) 
 
Degeneration of corpus luteum in 
late luteal phase 
Selection of dominant follicle 
influenced by E2 & FSH 
 
Stimulates proliferation and repair of 
endometrium 
Progesterone LH 
 
 
[Enhances positive feedback =>  
contributes to FSH & LH mid-cycle 
peak] 
Lack of implantation =>  
degeneration of corpus luteum 
(luteolysis) 
Corpus luteum Transforms endometrial cells from 
proliferative to secretory 
 
Inhibits release of GnRh, LH (& FSH 
with E2 & Inh A)-by stopping 
positive feedback of oestrogen on 
GnRH 
FSH During positive feedback during E2 
surge, stimulated by high levels of 
oestrogen (via anterior pituitary after 
anterior pituitary already primed by 
high levels of GnRH) 
Suppressed by moderate levels of 
oestrogen,  
& P, E2 & Inh A & B 
Also by high levels except in the 
positive feedback phenomenon. 
  
LH Synthesis: stimulated by E2 
Secretion: inhibited by E2 except 
during positive feedback stage  
(high levels, predominantly on 
anterior pituitary)  
Progesterone 
 
Oestrogen inhibits its secretion 
except during positive feedback 
stage 
 Stimulates further development of 
ovarian follicles and full secretion of 
E2 by dominant follicle; Triggers 
ovulation; Promotes formation of 
corpus luteum 
Inhibins Inhibin A secreted by dominant 
follicle 
Inhibin B from antral follicles (& bit 
from dominant one) 
 Inhibin A secreted by corpus luteum  
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Hypothalamus 
GnRH 
Anterior pituitary 
FSH stimulates 
FSH  & LH 
LH stimulates
  Corpus luteum 
Production of Progesterone 
oestrogens, Inhibin A & relaxin 
P inhibits release of GnRH, LH 
(& FSH with Inh A & E2) 
Granulosa cells of 
Developing follicles 
Theca cells to produce 
androgens 
Bit E2 & 
Inhibin B 
Selection of 
Dominant follicle 
further devt- of follicles & 
full secretion of oestrogen
P stops +ve feedback of oestrogens on 
hypothalamus & anterior pituitary 
E2 in moderate amounts- inhibitory effect on 
GnRh, LH & FSH by ?ing sensitivity 
Positive feedback 
occurs at level of  
pituitary 
Sharp rise in E2 & Inh A  
Stimulates FSH (+ve feedback); 
P facilitates E2 ? synthesis & storage 
of LH but initially inhibits its secretion; 
high levels -> release of LH P 
augments LH surge 
LH surge → Ovulation 
E2 &P 
Stimulates aromatase 
=> secretion of E2, 
Inhibin A & bit 
Progesterone 
Day        2            4             6            8           10          12           14          16          18           20         22          24            26          28 
 
FIGURE A3.2  OVARIAN HORMONES, GONADOTROPHINS & INHIBINS THROUGHOUT THE MENSTRUAL CYCLE
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Appendix 4 Postmenopausal Morbidity 
A4.1.1 Effects on Bone Loss 
 
Bone loss accelerates after a natural or surgical menopause and some studies have shown 
that the rate of loss is dependent on the remaining oestrogen supply,68,69 as calcium loss 
from bone is related to decline in oestrogens.  Numerous studies have shown that oral 
oestrogen and oestrogen-progestin regimens prevented bone loss in early postmenopause , 
when bone remodeling seems to be most pronounced, with a dose-dependent effect for 
oestrogen.70 It is of interest, however, that among Mayan Indian women, there is no 
evidence of increased fracture even 20 years post menopause, despite showing the same 
endocrine changes and bone mineral density as their US counterparts.71  
A4.1.2 CHD and CVD 
 
Alterations in lipid profiles have been demonstrated during the perimenopause, with 
progressive decreases in high-density lipoproteins (HDLs)  and increases in total cholesterol 
preceding menopause by several years.72  However only the changes in HDLs appear to be 
related to the menopause per se,73 while other changes to lipid profiles, BMI and blood 
pressure appear to be more related to age.72,73 Epidemiological data show that 
cardiovascular disease (CVD) and coronary heart disease (CHD) are more prevalent in 
postmenopausal women than premenopausal women.  While oestrogens have been shown 
to confer vasculo- and cardio-protective effects, there has been disparity among findings 
from observational studies and RCTs on the effects of HT on CVD and CHD.  Observational 
studies suggest a protective role of oestrogen whereas recent RCTs report a negative effect 
of oral oestrogen in primary and secondary prevention of CV events.74 It has been 
suggested that this may be due to the inclusion in these trials of women older than the 
normal age for initiating HT in clinical practice, since they are more likely to have established 
atherosclerosis.  Oestrogen may have a primary preventive role on CHD and it may, 
therefore, be necessary to commence HT treatment in perimenopause.75   A ‘window of 
opportunity’ may exist for initiation of HT; close to the time of menopause (in women less 
than 60 years of age) it may be cardio- and probably neuroprotective, whereas after that 
time it can be harmful because of established pathological changes. (Burger, 2008 Personal 
communication). 
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A4.1.3 Cognitive function  
 
With regard to putative effects of oestrogen on cognitive skills, evidence is conflicting.  Many 
of the actions of oestrogen suggest it should improve cognition and reduce 
dementia/Alzheimer’s disease (AD) risk or symptoms.  Among these are its effects of 
modulating neural activity that occurs during cognitive processing, increasing cerebral blood 
flow, augmenting glucose transport into the brain, and its influence on several NT systems 
including acetylcholine which may have relevance to memory and attention, monoamine 
neurotransmitters, thought to be important in cognition and mood.  Oestrogenic effects on 
cognition are also implied by performance fluctuations during a woman’s menstrual cycle.  
However, available evidence suggests that oestrogen does NOT have an important effect on 
episodic memory or other cognitive skills, and that serum oestrogen levels at midlife are 
unrelated to memory scores, although two studies did find oestradiol levels to be positively 
related to memory skills.76   
The prevalence of AD increases with age, and is greater in women than men.  Clinical 
evidence to date suggests that beginning HT in the presence of dementia due to AD does 
not improve symptoms or slow progression. In fact, findings from WHIMS raised concerns 
that HT elevates dementia risk within several years of initiation, although the applicability of 
these findings to younger women with short-term usage has been questioned. Observational 
studies with younger women indicate that HT use might reduce AD risk, but  there is no 
evidence that initiating HT after age 63 improves memory or other cognitive abilities.76   
A4.1.4 Glucose metabolism 
 
It has been observed that menopause is associated with significant changes in insulin 
metabolism77  and that the risk of impaired glucose tolerance increases by 6% per year after 
menopause,78  although the impaired fasting glucose and increased serum insulin levels 
may be more related to BMI that menopause.79   Nonetheless, middle-aged women are 
more affected than men and a relationship between sex steroids and insulin sensitivity is 
supported by the increased insulin resistance during pregnancy, the luteal phase of the 
menstrual cycle and in women with high androgen production (PCOS).80  The administration 
of exogenous 17β-oestradiol has been observed in animal studies to play an important role 
in the maintenance of normal insulin sensitivity,  enhancing insulin secretion in islet cells.81 
Additionally, oestrogen-treated women were found to have significantly lower levels of 
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insulin than women who were not taking oestrogen in a comparative study.82  Both 
endogenous and exogenous oestrogens appear to have a modulating effect on insulin 
resistance, although the effects of exogenous oestrogens may be blunted by factors such as 
the first-pass effect of orally administered hormones.  Results from HERS and WHI were 
encouraging in terms of postmenopausal HT for prevention of type 2 diabetes.80 
A4.1.5 Immune function 
 
Oestrogens, androgens and progestins also have important immune regulatory functions.  
The effects of oestrogen on immune function are complex.  For example, oestradiol has 
been found to enhance immunoglobulin G production, down-regulate the thymus and 
enhance or suppress cytokine production in a dose dependent manner. Postmenopausal 
oestrogen replacement therapy has been associated with increased risk for systemic lupus 
erythematosus SLE) and oestrogen-containing oral contraceptives can exacerbate the 
symptoms of SLE.74 
 
It is interesting to note that increased risk of osteoporosis, the metabolic syndrome and 
cardiovascular disease are also adverse sequelae of major depression.83   
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Appendix 5  Monamine transport cycle84,85 
 
The monamine neurotransmitters, noradrenaline, serotonin and dopamine, are quite widely 
distributed in the mammalian brain and are involved in the regulation of mood, cognition, 
locomotion, sleep, appetite arousal, libido, anxiety and aggression.85  Monoamine oxidases 
(MAOs) are the degradative enzymes responsible for the breakdown of these monamine 
neurotransmitters. 
Serotonin and noradrenaline are synthesised via tryptophan hydroxylase and tyrosine 
respectively, and stored in synaptic vesicles.  In response to action potentials, the 
neurotransmitters are released from the synaptic vesicles into the synaptic cleft where they 
exert their effects on various postsynaptic receptors.84  Serotonin can modulate the effect of 
a different type of neurotransmitter on its post synaptic site.  The physiological actions are 
terminated by the transporters which transport the neurotransmitter from the synaptic cleft, 
where it is either further transported into empty storage vesicles, or metabolised by 
monoamine oxidase. 85  
In the case of dopamine, the effects are similarly terminated by the dopamine transporter 
located on neuronal terminals.  However in the prefrontal cortex, the transporter is absent 
and the action of dopamine is terminated by the noradrenaline transporter located on 
noradrenergic terminals.85 
The 5-HT1A auto receptors play an important regulatory role on serotonin neurotransmission 
via a negative feedback mechanism in response to serotonin levels in the synapse.  With 
chronic exposure to increased serotonin levels, these receptors eventually become 
desensitised.84   
 
The noradrenergic system is linked to an array of neurotransmitters that modulate the stress 
response.  These include serotonin, the opioids, GABA, corticotrophin-releasing factor, 
dopamine and glutamate.85 
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Appendix 6  DSM Definitions 
 
A6.1 Dysthymic disorder (DSM-IV p380)86 
 
Dysthymic disorder is a form of chronic low-grade depression that is characterised by 
depressed mood for at least 2 years and the presence of two or more of the following 
symptoms:  
• Chronic low-grade depression or depressed mood for at least 2 years, for most of the 
day, more days than not  
• AND two symptoms from the following:  
• poor appetite or overeating, 
• insomnia or hypersomnia,  
• low energy or fatigue, 
• low self-esteem,  
• poor concentration or difficulty making decisions,  
• feelings of hopelessness 
A6.2 Major Depressive Disorder 
 
According to the Diagnostic and Statistical Manual of Mental Disorders-IV (pp356 & 411),86 
at least five of the following symptoms have been present during the same 2-week period, 
nearly every day, and represent a change from previous functioning.  At least one of the 
symptoms must be either (1) depressed mood or (2) loss of interest or pleasure:  
• Depressed mood most of the day, nearly every day, as indicated by self or others  
• Markedly diminished interest or pleasure in all, or almost all, activities  
• Significant weight loss or weight gain (5 %/mo.) or loss/gain in appetite nearly every 
day.  
• Insomnia or hypersomnia nearly every day  
• Psychomotor agitation or retardation nearly every day (as noted by others).  
• Fatigue or loss of energy nearly every day  
• Feelings of worthlessness or excessive or inappropriate guilt nearly every day  
• Diminished ability to think or concentrate or indecisiveness nearly every day  
• Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a 
suicide attempt or a specific plan for committing suicide.  
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The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning  
Symptoms are not better accounted for by a Mixed Episode, Mood Disorder Due to a 
General Medical Condition, a Substance-Induced Mood Disorder, or Bereavement (normal 
reaction to the death of a loved one)  
Symptoms are not better accounted for by a Psychotic Disorder (e.g., Schizo-affective 
Disorder).  
A6.3 Minor Depression/depressive spectrum disorder  
 
Persistence of depressive mood symptoms for at least 2 weeks but does not meet criteria 
for dysthymic disorder or major depressive disorder.87 
A6.4 Generalised Anxiety Disorder (GAD) 
 
Diagnosis requires excessive anxiety and worry (apprehensive expectation) occurring more 
days than not for at least 6 months and at least six GAD symptoms from DSM-IV (pp429 & 
476)86 
• Restlessness or feeling keyed up or on edge 
• Being easily fatigued 
• Difficulty concentrating or mind going blank 
• Irritability 
• Muscle tension 
• Sleep disturbance (difficulty falling or staying asleep or restless unsatisfying sleep) 
365 
APPENDICES 
 
 
Appendix 7 Hormone Therapy Preparations Available in Australia 
 
 
TABLE A7  EXAMPLES OF HORMONE THERAPY PREPARATIONS AVAILABLE IN AUSTRALIA88 
Regimen Type  Product Administration 
Oestrogen only Piperazine oestrone sulfate 
 
Genoral 
Ogen 
Oral 
Oral 
 Oestradiol 
 
Zumenon 
Oestadiol implants 
Oral   
Subcutaneous 
 Oestradiol gel Sandrena Transdermal 
 Oestradiol cream (WA only) Natragen Transdermal 
 Oestradiol patches 
 
Climara,  
Dermestril 
Estraderm 
Femtran 
Menorest 
Transdermal 
Transdermal 
Transdermal 
Transdermal 
Transdermal 
 Oestradiol hemihydrate 
 
Estrofem 
Aerodiol 
Oral  
Intranasal 
 Oestradiol valerate Progynova Oral 
 Oestriol (+ vaginal tablet, pessaries and 
cream) 
Vagifem 
Ovestin 
 
Vaginal,  
Vaginal & 
Transdermal 
 Conjugated equine oestrogens Premarin Oral 
Progestogens Medroxyprogesterone acetate 
 
 
Medroxyhexal 
Provera 
Ralovera 
Oral 
Oral 
Oral 
 Dydrogesterone Duphaston Oral 
 Norethisterone acetate Primolut N Oral 
 Cyproterone acetate Androcur Oral 
Oestradiol/norethisterone acetate 
 
 
Kliogest1 
Kilovance1 
Trisequens2 
Oral 
Oral 
Oral 
Oestradiol/norethisterone acetate patches 
 
Estalis Sequi2 
Estalis continuous1 
Estracombi2 
Transdermal 
Transdermal 
Transdermal 
Oestradiol/dydrogesterone Femoston2 Oral 
Oestradiol valerate/cyproterone acetate Climen 28 2  
Climen3 
Oral 
Oral 
Combined 
Oestrogen/ 
Progestin 
Conjugated oestrogens/ 
medroxyprogesterone acetate 
Premia,2 
Premia continuous1 
Provelle 281 
Oral 
Oral 
Oral 
 Levonorgesterel  Mirena Intrauterine 
Tibolone Metabolises to compounds with oestrogenic, 
progesterogenic and androgenic effects 
Livial Oral 
Testosterone Testosterone Cream (WA only) Andro-feme) Transdermal 
      1  continuous combined regimen (oestrogen and progestin daily,  with no hormone-free interval.    This 
confers avoidance of cyclical bleeding.  
2  continuous-cyclic regimen (oestrogen daily, progestin 10-14 days) 
      3  cyclic regimen (oestrogen 11 days, oestrogen plus progestin 10 days, 7 therapy-free days during which 
planned bleeding occurs). 
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The principal oestrogen before menopause is 17β oestradiol, which is converted to oestrone 
in the liver and other tissues by 17β oestradiol dehydrogenase.  Oestrone is further 
metabolised in the liver to oestrone sulphate, which constitutes the circulating oestrogen in 
highest concentration.  Oestrone provides a reservoir for oestradiol production.89 
 
Oestradiol is the most stimulating to breast tissue (causing cell division) and oestriol the 
least.  Unlike oestrone, oestriol does not convert to oestradiol.  While oestriol does offer 
significant bioactivity, it binds fleetingly to oestrogen receptors and is metabolised rapidly.  
Only 10-20% remains in circulation, and it is estimated to be only 1/10 to 1/100 as potent as 
oestradiol.  In addition, its affinity for oestrogen receptors compared with oestradiol is only 
14% for α and 21% for β-sites.  Nonetheless, it appears to have the same ability to stimulate 
endometrial proliferation as the stronger oestrogens, despite its weaker activity at some 
tissue sites.89 
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Appendix 8 Benefits and Limitations of Different Routes of Administration 
 
 
The non-oral routes of administration confer several advantages: i) the lower dose required, 
as it by-passes the first hepatic passage, results in fewer side-effects; ii) it is less likely to 
increase sex-hormone binding globulin (SHBG) which also binds other sex steroids such as 
testosterone; and iii) the high levels of circulating sulphate produced by oral oestrogen 
preparations are avoided.  Oestrogen-sensitive tissues such as breast and endometrial 
tissue have a high capacity to convert oestrone sulphate to oestradiol, possibly contributing 
to the greater concentrations of oestrone and oestradiol in breast tissue than in serum.88  
 
However, results from studies of transdermal progestins vary.  One RCT reported a 
significant reduction in vasomotor symptoms, but no effect on bone density with 20 mg 
progesterone for one year in conjunction with daily multiple vitamins and 1,200 mg 
calcium.90  However, a more recent study failed to detect an improvement in vasomotor 
symptoms (hot flashes), mood characteristics, or sexual feelings with the equivalent of 32 
mg progesterone daily over a period of three months.91   
 
Vaginal bleeding was reported by eight of the 43 women treated with the progesterone 
cream in the first study.   An additional limitation of this route of administration is that is does 
not appear to confer the same protection of the endometrium offered by oral progestins in 
HT due to the insufficient serum concentrations.45,92-94  
 
368 
APPENDICES 
 
 
Appendix 9 Side-effects of Provera® and Premarin®  
 
TABLE A9  OTHER SIDE-EFFECTS OF INDIVIDUAL INTERVENTIONS: PROVERA & PREMARIN 
Provera® (Progesterone) 
hypersensitivity reactions, thromboembolic disease, CNS disturbances eg nervousness, insomnia, fatigue, 
depression, dizziness, headaches, tremor, PMS-like depression, dermatological- urticaria, pruritis, rash, acne, 
hirsuitism, alopecia and sweating; GUT: irregular uterine bleeding, spotting and amenorrhoea; GIT- nausea; 
breast tenderness, galactorrhoea; cervix – changes in excretions and secretions; other – Cushings syndrome, 
weight gain, hyperpyrexia, moderate elevation of blood pressure,  increases in white blood cell count and 
platelet counts. 
Premarin® (conjugated oestrogen)  
Increased risk of gall-bladder disease & breast cancer, endometrial cancer, vaginal bleeding, mastodynia, fluid 
retention -a problem in asthma, epilepsy, renal or cardiac dysfunction, migraine, increased blood pressure 
sometimes noticed, hypercalcaemia, renal insufficiency   
GUT:  breakthrough bleeding 
GIT nausea and vomiting, etc,  dermatological, ocular (intolerance to contact lenses, weight changes, oedema, 
changes to libido, aggravates porphyria, beast enlargement or secretion. 
 
 
Appendix 10 Foods Sources of Phytoestrogens 
TABLE A10   CLASSIFICATION AND FOOD SOURCES OF PHYTOESTROGENS                            
Isoflavones                  Lignans                  Coumestans 
Soybean 
products 
Legumes Whole grains Fruits, 
Vegetables, 
Seeds 
Bean sprouts 
Tofu 
Soy meal 
Soy grits 
Soy flour 
Soy milk 
Soybeans 
Lentils 
Beans 
Chickpeas 
Wheat 
Wheat germ 
Barley 
Hops 
Rye  
Oats 
Rice 
Brans 
 
Apple               
Pear                
Cherry              
Carrot 
Fennel 
Onion 
Garlic 
Sunflower seed 
Linseed 
Vegetable oils 
(including linseed, 
olive) 
Alfalfa 
Soybeans 
Clovers  
Adapted from: Murkies AL, Wilcox G, Davis SR. Phytoestrogens. J Clin Endocrinol Metab 
1998,83:297-303.95 
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Appendix 11 Vitex agnus-castus (Chaste-tree/berry) in the Treatment of 
Menopause-related Complaints 
 
M. Diana van Die, BA, Dip Herb Med,1 Henry G. Burger, MD, FRACP,2 Helena J. Teede, 
MBBS, PHD, FRACP,3 Kerry M. Bone, BSc, Dip Phyt, FNIMH, FNHAA4  
1. Royal Melbourne Institute of Technology University, Bundoora, Victoria, Australia; 2. Prince 
Henry’s Institute of Medical Research, Clayton, Victoria, Australia ; 3. Jean Hailes Foundation; 
Monash Institute of Health Services Research, Monash University, Clayton, Victoria, Australia. 
4. MediHerb, Warwick, Queensland, Australia; University of New England, Armidale, New South 
Wales, Australia. 
 
Abstract 
 
The origin of the current practice of administering Vitex agnus-castus in menopause-related 
complaints is uncertain, but appears to be relatively recent.  Here we review the evidence for 
this application of Vitex based on evidence from pharmacological studies and clinical 
research.  The mechanisms of potential relevance in the context of menopause are explored 
with reference to the current understanding of the endocrinology and neuroendocrinology of 
menopause and associated symptoms.  We conclude that, while evidence from rigorous 
randomised controlled trials is lacking for the individual herb in this context, emerging 
pharmacological evidence supports a role for Vitex agnus-castus in the alleviation of 
menopausal symptoms and suggests that further investigation may be appropriate. 
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Introduction 
 
The practice of administering Vitex agnus-castus (Chaste-tree/berry or Monk’s pepper, 
family Verbenaceae) in the treatment of menopause-related complaints appears to be of 
relatively recent origin.  In current Anglo-American and European phytotherapeutic practice, 
Vitex fruit is most widely used for female reproductive problems, finding an application in 
conditions such as pre-menstrual syndrome, anovulatory cycles, infertility and 
hyperprolactinaemia, among others.1,2 It is said to have a normalising action on the 
menstrual cycle.1,2  References to its value for ‘diseases of the uterus’ appear as far back as 
the  works of Hippocrates in 4th century BC and Dioscorides in AD77.3  Gerard, one of the 
great Renaissance herbalists, recommended it for inflammation of the uterus and as an 
emmenagogue to promote menstruation.4   
 
The earliest overt reference in the literature to the application of Vitex in menopause-related 
complaints, however, does not appear until the 20th century.  A 1972 publication of a 
collective report on the clinical experience of five practitioners with Agnolyt® (a patent 
medicine extracted from dried Vitex fruit) reported on its efficacy for menopausal bleeding 
and menopausal complaints.5   Its use in this context appears to have now become relatively 
popular in the Anglo-American tradition.6-9 A practitioner survey of 276 UK herbalists 
reported that 86.3% prescribed it for the treatment of perimenopausal complaints, including 
hot flushes.10  It is also used in clinical practice to assist with withdrawal from Hormone 
Therapy (HT).1,7,10  The fruit is a common ingredient of phytotherapeutic formulations for 
menopause-related complaints in several Western countries (Table 1, Appendix 1).11-14  
While evidence for Vitex  as a sole agent in this context is lacking from RCTs, emerging 
pharmacological evidence, relating to its dopaminergic activity,15-17 affinity for opioid 
receptors18,19 and enhancement of melatonin secretion,20 supports a role for Vitex agnus-
castus in the alleviation of menopausal symptoms.  This paper reviews the clinical and 
pharmacological evidence supporting this practice, and possible rationale for such an 
application. 
 
Inconsistency of Definitions used in reference to Menopause 
 
It is possible that the practice of administering Vitex for menopausal complaints is confined 
to those experienced during the perimenopause, rather than postmenopause.   
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Fluctuating or increased oestradiol secretion characterises the perimenopause21,22  (formerly 
‘climacteric’, the period immediately prior to menopause up to the first year after the final 
menstrual period.22)   Thus, the postulated benefits of Vitex in conditions where unopposed 
oestrogen plays a role1 may be of relevance here.   However, it is often unclear from the 
literature which menopausal phases, and which specific complaints1,6-9 are referred to, due 
to the inconsistencies in the use of terminology relating to the menopausal stages.  For 
example, some studies reviewed here12-14,23  have adopted the recommended definition of 
natural menopause as having occurred after 12 consecutive months of amenorrhoea for 
which there is no other obvious pathological or physiological cause.22  However, some 
others have taken 6 months of amenorrhoea as denoting entry to the postmenopause,11 or 
neglected to define it at all.10,24    Similarly, late perimenopause is commonly defined as 
menses within the preceding 12 months but not the preceding 3 months, in conjunction with 
the co-existence of symptoms,25-27 after excluding other causes where there is a history of 
previous menstrual irregularity.27  However, the Herbal Alternatives for Menopause (HALT) 
study more than one skipped menses within the previous 12 months to denote late 
perimenopause.12    
 
Menopausal Symptoms 
 
Symptom experience varies throughout the transition and between individuals.  It is during 
the perimenopause that most symptoms are reported.28  These can be due to oestrogen 
excess (breast tenderness, menorrhagia, migraine, nausea, shorter cycle length)21,29,30 or 
deficiency (vasomotor symptoms,31 breast tenderness and vaginal dryness.32,33) and often 
fluctuate, reflecting the underlying hormonal instability during these years.30  Dysfunctional 
uterine bleeding is maximal during the menopausal transition due to persistent unopposed 
oestrogen;34,35 low progesterone is associated with failure of the secretory phase in 
anovulatory cycles.27   Rates of psychological distress are also found to peak during the 
perimenopause.36-39  Anecdotal reports suggest that premenstrual syndrome (PMS)-like 
symptoms may be more prevalent at this time, or at least less well-tolerated than 
previously.40  The incidence of hot flushes increases throughout the transition32 with a peak 
generally at the time of the menopause36 and in postmenopausal women. 
 
Hot flushes occurring during the night have been associated with sleep disturbances.41-45  
However, some evidence suggests that not all of the nocturnal flushes result in waking 
episodes or arousals.41   Conversely, other studies have found that not all of the waking 
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episodes are associated with flushing,43,44  suggesting this may not be the only factor 
responsible for disturbed sleep. Other proposed causes of sleep disturbances include an 
age-related decrease in total brain serotonin, one of the main regulators of circadian sleep-
wake cycles,46 an age-related decrease in slow-wave sleep and GH secretion47,48 and 
depression.49 
 
Endocrine changes associated with Menopause 
 
Before discussing the pharmacological mechanisms of Vitex that may be of potential 
relevance to the treatment of menopause-related symptoms, it will be useful to outline the 
current understanding of the endocrinology of menopause and the aetiology of its 
associated symptoms.  
 
The endocrinology of menopause has not yet been fully elucidated, and is complicated by 
the irregular cycles that characterise the menopause transition; these include normal length 
ovulatory and anovulatory cycles, and elongated ovulatory cycles,50 without any orderly 
progression from one type to another. 
 
The previously-held belief that the perimenopause is characterised by a gradual decline in 
oestrogen levels with rising follicle-stimulating hormone (FSH) 51 has been challenged by 
current research indicating that serum oestradiol (or urinary oestrogen excretion) actually 
increases slowly with increasing age,34,52-56 and declines only from about 2 years prior to 
final menses.57  Research on the inhibins has helped to clarify the underlying 
mechanism.58  The main action of the inhibins (ovarian dimeric glycoproteins that regulate 
gonadotropin release during the menstrual cycle) is to inhibit synthesis and secretion of 
FSH.  The falling inhibin levels (especially INH-B), resulting from the declining antral follicle 
count as women age,59 allows the gradual rise in FSH, which drives increased oestradiol 
secretion.56,58,60  This may lead to accelerated follicle development and occasions of multiple 
follicles developing at once, and hence give rise, on occasion, to markedly raised oestradiol 
concentrations in perimenopausal women.21,34,52 Lower than normal levels of oestradiol have 
been found in late-perimenopausal women who had experienced 3 months’ amenorrhoea60 
and in late-perimenopausal women during anovulatory cycles, 61 and in cycles with an 
elongated ‘lag period’ between the menstrual phase and the onset of the follicular phase.62  
There is evidence of reduced hypothalamic–pituitary sensitivity to oestrogen feedback in 
perimenopausal women.29,63,64 
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Oestrogens modify synthesis, release and metabolism of many neurotransmitters   
such as noradrenaline, dopamine, acetylcholine, serotonin and melatonin, and 
neuropeptides including  β-endorphin, which modulate the activity of hypothalamic centres 
and the limbic system.65  Fluctuating levels of sex steroids, particularly oestrogen, result in 
altered function of the hypothalamus and limbic system, and thereby the regulation of mood, 
psychological well- being,66,67 thermoregulation and vasomotor stability,68 and many  other 
functions. 
 
Melatonin levels decrease significantly with age; similarly the time during which melatonin 
remains elevated at night decreases with age.69  An association between the quality of sleep 
and the amount of melatonin secreted has been noted, especially in the elderly. 70   
 
Studies in women during the perimenopause reveal that the decline in melatonin precedes 
FSH  increase during menopause.71  Whether this decline in melatonin secretion contributes 
to the development of menopause or its symptoms has not been established.72 
 
The Vasomotor Symptoms of Hot Flushes and Night Sweats 
 
The term ‘hot flushes’ is used here to include night sweats.  The aetiology of hot flushes is 
currently believed to involve a central noradrenergic mechanism.  In symptomatic women, 
narrowing of the hypothalamic thermoneutral zone has been observed,73 which is at least 
partly due to elevated brain noradrenaline levels.74  Central noradrenergic activity is, in turn, 
modulated by ovarian steroids.75   Within the reduced thermoneutral zone, small elevations 
in core body temperatures that precede most hot flushes are thought to constitute the 
triggering mechanism for hot flushes.73   
 
The central noradrenergic instability associated with hot flushes could be due to the 
reduction of endogenous opioid activity76,77  that results from declining oestrogen levels, as 
hypothalamic opioidergic activity normally has an inhibitory effect on noradrenergic neurons in 
the brainstem.  Casper and Yen45 proposed that successful therapies for hot flushes may 
exert their effects by increasing endogenous opioid peptide activity with consequent inhibition 
of noradrenergic activity below the threshold needed to activate heat loss.  
 
374 
APPENDICES 
 
 
Dopamine has recently been found to be an important thermoregulatory neurotransmitter, 
with D2 receptors involved principally with the maintenance of body temperature in 
euthermia.78 Earlier research had observed the dopamine agonist bromocriptine to increase 
the activity of the endogenous opioid system on the thermoregulation mechanisms that 
regulate body temperature in postmenopausal women79 and to be effective in alleviating hot 
flushes. 80   
 
Oestrogen withdrawal in menopausal women also results in dramatically lowered blood 
serotonin levels.81,82  Low blood oestrogen levels are correlated with upregulation of certain 
serotonin receptors (5-HT2A) in the hypothalamus83 that are believed to be involved in 
thermogenesis.  
 
Mood changes 
 
Findings have been inconsistent regarding an association between depressed mood and 
hormone levels.84-89 However, several effects of oestrogens are of potential relevance to 
menopause-related mood changes (Table 2, Appendix 2). Those of interest in the context of 
Vitex agnus-castus are as follows: 
i. Oestrogen potentiates the activity of opiate-containing neurons90 and increases the 
synthesis and release of β-endorphin. 91  
ii. Oestrogen directly modulates dopaminergic activity,92 increases dopamine release in 
the hypothalamus87 and increases dopamine transmission and D2 receptors.93  
iii. In postmenopausal women, the activity of the dopaminergic system was found to be 
significantly lower than in premenopausal women, but was significantly increased by 
HT administration, with a concomitant significant decrease in psychological 
symptoms.94  
iv. Fluctuating ovarian hormones destabilise circadian rhythms during the perimenopause, 
and may contribute to the development of mood disorders in predisposed women.95  
 
Perimenopausal Premenstrual Syndrome (PMS)-like symptoms  
 
It has also been hypothesised that some symptoms attributed to the menopause-transition 
such as mood changes are more likely to be related to PMS, given that they improve after 
cessation of menstruation.96   The PMS-like symptoms experienced during the 
perimenopause may differ in their aetiology from PMS during normal reproductive years, 
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due to increasing infrequency of ovulatory cycles as the perimenopause progresses.  
According to current understanding, ovulation is a prerequisite for PMS, which is believed to 
result from sensitivity in predisposed individuals to normal hormonal fluctuation during the 
late luteal phase.97,98  It is possible that these PMS-like symptoms in the perimenopause may 
similarly represent an increased sensitivity to normal fluctuations in ovarian 
hormones.29,63,64,99  Alternatively, oestrogen excess has been suggested as a possible cause 
for these symptoms in late perimenopausal women100  Other factors potentially implicated in 
the aetiology of PMS include changes in circadian rhythms, found to be similar to those 
occurring in anxiety and mood disorders, with aberrant timing of the secretion of melatonin, 
cortisol and prolactin.96  
 
Pharmacological Actions of Vitex with potential relevance to Menopause  
 
Phytochemically, Vitex has been shown to contain essential oil, flavonoids, iridoid glycosides 
and dopaminergic compounds belonging to the diterpenes.  Mild D2 receptor agonistic 
properties have been demonstrated,  resulting in inhibition of latent hyperprolactinaemia, 
(the non-physiologically stimulated prolactin release often manifest during the time of 
decreasing progesterone and oestradiol levels, that is frequently also accompanied by an 
insufficient function of the corpus luteum).15-17  Vitex has demonstrated activity as an agonist 
at the mu, and potentially the kappa, opioid receptor.18,19  It has also been found to effect a 
dose-dependent increase in melatonin secretion.20  These actions of Vitex may be of 
relevance to the aetiology of menopausal symptoms and are elaborated below.  Findings 
from recent cell culture experiments indicate that Vitex extracts may contain phytoestrogens; 
the most active of which has been identified as the flavonoid, apigenin.101  However, the 
compounds identified are only weakly oestrogenic, not unique to this herb, and present in 
relatively low levels compared to other herbal and dietary sources. We therefore suggest 
that this finding does not contribute to our understanding of the true mechanism of the action 
of Vitex.   
 
Latent hyperprolactinaemia 
Hyperprolactinaemia results in inhibition of secretion of gonadotropin releasing hormone 
(GnRH) and decreased secretion of luteinising hormone (LH) and FSH.  In the ovary, this 
results in inhibition of progesterone secretion by the granulosa-lutein cells of the corpus 
luteum.102  Premenstrual symptoms, particularly mastodynia, are often accompanied by 
latent hyperprolactinemia,103,104 which can be stimulated by stressful situations.15,105  
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The above may have potential relevance to menopause-related symptoms in several ways: 
i) in light of the suggestion that many of the menopausal symptoms may represent an 
exacerbation of pre-menstrual symptoms, targeting premenstrual latent hyperprolactinemia 
may also be appropriate during the perimenopause; ii) the dopaminergic effects of Vitex may 
be of relevance to alleviating hot flushes, as did the dopamine agonist, bromocriptine.80  
Dopamine has been found to affect thermoregulation, possibly via activation/stimulation of 
the endogenous opioid system.  The effects of Vitex on opioid receptors may also be of 
relevance in this context;  iii) because lower activity of the dopaminergic system is 
associated with psychological symptoms,94 the dopaminergic properties of Vitex may also 
prove beneficial in the amelioration of the emotional symptoms of menopause.   
 
Affinity for opioid receptors 
An action on mu, and potentially kappa, opioid receptors may also be of relevance to the 
use of Vitex for menopause-related symptoms such as flushes and mood symptoms.  
In 2000, Meier and colleagues suggested additional pharmacological actions for Vitex 
agnus-castus via opioid receptors based on in vitro  research.18  They reported a relatively 
potent inhibition for opioid (mu and kappa subtypes) receptor-binding with extracts of Vitex, 
that was most pronounced in lipophilic fractions.  Additionally, binding to delta opioid 
receptors was found to be inhibited mainly by an aqueous fraction of Vitex.  In vitro 
research, with high levels of direct exposure of test cells to the herbal extract, is of uncertain 
relevance to oral dosing of herbs in humans due to the pharmacokinetic factors that affect 
bioavailability of the phytochemicals with oral administration.  However, it was subsequently 
also demonstrated in human and animal models that Vitex acted as an agonist at the mu-
opioid receptor.19 Extracts with and without fatty acids removed showed significant affinities 
to the mu-opioid receptor.   
 
These findings support the beneficial action of Vitex in PMS, as endorphins are known to 
decrease in the late luteal phase106,107 and are found to be associated with symptoms such 
as mood disorders, migraines and fluid retention.108,109 However, they are also of potential 
relevance to its reputed value in treating menopausal symptoms. The reduction of 
endogenous opioid activity may be responsible, at least in part, for the central noradrenergic 
instability associated with hot flushes.76,77  Increasing endogenous opioid peptide activity may 
effect a reduction in hot flushes via inhibition of noradrenergic activity below the threshold 
needed to activate heat loss.45  In an oestrogen-deficient environment, it is possible that mood 
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enhancement may be effected by stimulating the activity of opiate-containing neurons90 and 
thereby increasing the synthesis and release of β-endorphin.91   
 
Melatonin 
The effect of Vitex on melatonin secretion is also of potential relevance to symptoms 
experienced in relation to menopause.  A dose-dependent increase in melatonin secretion, 
especially during the night, was found after administration of Vitex extracts 120 mg and 480 
mg per day (dried herb equivalent 0.6 g and 2.4 g) in an open placebo-controlled trial.  Total 
melatonin output was approximately 60% higher than in the placebo group.20  This has 
obvious potential relevance to menopause-related sleep disturbances.  However, data from 
a recent case report demonstrated that melatonin was able to delay the characteristic 
endocrine parameters associated with menopause onset.110  While further studies are 
needed to confirm this finding, it is extremely interesting in view of the possible role of 
declining melatonin secretion (that precedes FSH increase71)  in the development of 
menopause and its symptoms,72  and the effect of Vitex on melatonin secretion, which may 
be part of the rationale for using it in menopause.   
 
Clinical Studies with Vitex for Menopausal Symptoms 
 
Despite its apparent popularity with UK herbalists, and its use as a component of 
menopause formulations, Vitex as a sole agent does not appear to have been tested in oral 
dosage form in this context in clinical trials.   The data bases searched were PubMed and 
Embase.  Search term used were combinations of Vitex, chaste or agnus with *menopaus*, 
climacteric, flush, flash, vasomotor or *menstrua*. 
 
The steam distilled essential oil of the fruit and leaves have been investigated in two 
studies23,24 that reported benefits for menopausal symptoms.  The first study, with 23 
women, reported improvements following use of the oil of the leaf or fruit, with the majority of 
‘major improvements’ related to the the leaf oil.24  Symptoms clusters for which 
improvements were reported were mood, vasomotor, urogenital, sleep and dysfunctional 
uterine bleeding, and to a lesser extent, cognitive and sexual.  Interestingly, several women 
reported reinstatement of regular menstruation after 3 -1 0 months of amenorrhoea, and one 
after 6 years without a period.  However, this study contained several weaknesses, including 
the use of different extracts and variable doses, different routes of administration 
(transdermal, inhalation, oral), lack of a standardised rating scale and failure to exclude 
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other concomitant treatments such as HT, herbs and acupuncture.  The subsequent study 
with 52 peri- or postmenopausal women aged 38 to 73 used a 1.5% solution of the essential 
oil of Vitex aerial parts in a base cream or lotion.23 Participants applied 2.5 ml of the cream 
dermally, once daily, 5–7 days per week for 3 months.  Overall, 33% reported major 
improvement and 36% reported mild to moderate improvement in troublesome symptoms, 
with greatest improvement observed in the emotional symptoms, (16 responses), hot 
flushes/night sweats (15), and moderation of menstruation (12).  However, these results 
need to be interpreted with caution due to the lack of a control group.  The findings from 
aromatherapy studies utilising the essential oil are of uncertain relevance to the 
administration of fruit extracts in oral dosage forms. 
 
Three randomised controlled trials (RCTs)11-13 and one pilot study14 on multi-component 
formulations containing Vitex for the treatment of menopausal symptoms have been 
reported in the literature.  A small sub-population analysis of PMS-like symptoms in 
perimenopausal women with the combination of Vitex and Hypericum perforatum has also 
been conducted.111  Results of these studies have been inconsistent.    
 
Vitex agnus-castus was one component of a menopause herbal formulation, Phyto-Female 
Complex, found to be significantly superior to placebo in a RCT on menopausal hot flushes 
and night sweats in 50 healthy peri- and postmenopausal women, aged 44-65 years.11  In 
the 35 who completed the study, a 73% decrease in the number of hot flushes was 
observed at the end of the 3-month treatment period in the active treatment (n = 19) 
compared with 38% in the placebo group (n = 16), p = 0.026, and the number of night 
sweats was reduced by 69% and 29% respectively, p  = 0.027.   A significant benefit was 
also observed in terms of sleep quality. The other herbs in the formulation were Cimicifuga 
racemosa (black cohosh) root extract, 100 mg (2.5 mg triterpene glycosides, 2.5%); Silybum 
marianum (St Mary’s thistle/milk thistle) herb extract, 75 mg (60 mg silymarin, 80%); 
Angelica sinensis (dong quai) root extract, 75 mg (7.5 mg ligustilides, 1%); Trifolium 
pratense (red clover) flower extract, 50 mg (4 mg isoflavone, 8%); and Panax quinquefolium 
(American ginseng) root extract, 50 mg (12.5 mg ginsenosides, 25%). The dose of Vitex 
agnus-castus fruit extract (2.5 mg vitexin, 5%) was 50 mg.  Tablets were administered twice 
daily. The multicomponent make-up of this combination does not permit conclusions about 
the contributions of individual herbs.  However, a significant contributor to the effect is likely 
to have been Cimicifuga racemosa (black cohosh), for which efficacy in menopause-related 
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symptoms is supported by evidence from RCTs and randomised comparison group trials.112-
115 In view of the small sample size at the end of the treatment phase, these results are 
encouraging, although not adding specifically to the evidence for Vitex in this context.   
The Herbal Alternatives for Menopause (HALT) study investigated 3 different herbal 
regimens compared with HT and placebo over a period of 12 months.12  Three hundred and 
fifty-one peri- or postmenopausal women with 2 or more vasomotor symptoms per day were 
assigned to one of 5 groups: 1) black cohosh 160 mg daily; 2) multibotanical with black 
cohosh, 200 mg daily, and 9 other ingredients including Vitex agnus-castus; 3) 
multibotanical plus dietary soy counseling (that is, advice from a clinical dietician and 
literature to include 2 soy food servings per day in their diet, equivalent to 12 to 20 g of soy 
protein); 4) conjugated equine estrogen, 0.625 mg daily, with or without 
medroxyprogesterone acetate, 2.5 mg daily; 5) placebo.  The multibotanical contained the 
following daily doses: Cimicifuga racemosa (black cohosh), 200 mg; Medicago sativa 
(alfalfa), 400 mg; boron, 4 mg; Vitex agnus-castus (chaste tree), 200 mg; Angelica sinensis 
(dong quai), 400 mg; Chamaelirium luteum (false unicorn), 200 mg; Glycyrrhiza glabra 
(licorice), 200 mg; Avena sativa (oats), 400 mg; Punica granatum (pomegranate), 400 mg; 
Eleutherococcus senticosus (Siberian ginseng, standardized constituents 0.8% 
eleutherosides E and B), 400 mg.  On the endpoints of the Wilkund vasomotor subscale, 
frequency and intensity of hot flushes and night sweats, no significant difference was found 
between any of the herbal interventions and placebo at any of the 3-monthly time points 
measured, with one exception.  At 12 months, placebo significantly outperformed the 
multibotanical-plus-soy counseling intervention for symptom intensity (p = 0.016).  The 
average difference over all the time points between herbal interventions and placebo was 
less than 0.55 vasomotor symptoms per day, compared with - 4.06 for HT compared to 
placebo. (For the multibotanical, no significant differences were found between the study 
group and placebo at 3 months, p = 0.45, 6 months, p = 0.18, or 12 months, p = 0.88).  
While the sample size and duration of this study are definite strengths, a major limitation is 
the recruitment of women with mild symptoms.  It is recommended by the U.S. Food and 
Drug Administration (FDA) guidelines that seven moderate to severe hot flushes per day, or 
50 to 60 per week, be the minimum requirement for menopause studies, with specific 
definitions of severity.116 
 
A 16-week RCT, conducted by the authors,111 on a combination of Hypericum perforatum 
(St. John’s wort) and Vitex agnus-castus with 100 late-perimenopausal and postmenopausal 
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women found no significant effect for the herbal combination over placebo on vasomotor 
symptoms,  p = 0·42; Greene Climacteric scores, p = 0.13; or  depressed mood, p = 0·42.  
However, both arms showed significant improvements on all outcome measures of 
vasomotor symptoms, (p < 0·001 and p < 0·01 for placebo and study groups respectively), 
depressed mood and overall menopausal symptoms measured on the Greene Climacteric 
scale, (p < 0·001 for both groups).  Substantial placebo effects were observed for all the 
endpoints: 43% for flushing and night sweats, 41% for depression measured on the 
Hamilton Depression Inventory and 41% for Greene Climacteric scores.  The daily dosages 
were consistent with clinical use and other RCTs on these herbs.  No conclusions can be 
drawn regarding the effectiveness of Vitex agnus-castus in isolation, as individual arms were 
not included.  However, a negative interaction between the two herbs is unlikely based on 
the known pharmacological mechanisms. 
 
A pilot study of a combination botanical containing15 herbs in 8 women suggested a 
potential benefit of a combination botanical for improving moderate menopausal symptoms 
in women.14  The herbs were administered in 550 mg capsules, 2 capsules taken twice daily, 
providing a total of 2200 mg of herbs per day.  However, given the large number of herbs in 
the formulation (Cimicifuga racemosa - black cohosh root, Viburnum opulus - cramp bark, 
Mitchella repens - squaw vine, Valeriana officinalis - valerian root , Polygonatum multiflorum 
- King Solomon seed , Taraxacum officinalis - dandelion root, Vitex agnus-castus - chaste 
tree berry, Rosmarinus officinalis -  rosemary leaves, Nigella sativa - black seed, Eupatorium 
purpureum - queen of the meadow , Epimedium grandiflorum - epimedium leaf, Ligusticum 
chuanxiong - chuanxiong rhizome, Schisandra chinensis -schisandra berry,  Mentha piperita 
- peppermint leaves, Rubus idaeus - raspberry leaves), the dose of each individual herb was 
quite low, ranging from 80mg to 300mg per day.  The dose of Vitex was 140 mg per day, or 
6% of the total. In addition, the administration of a multi-component preparation means that 
it is not possible to draw conclusions about the individual contribution of Vitex agnus-castus.  
The lack of a placebo group is a major limitation, as placebo effects with vasomotor 
symptoms in menopause studies are substantial, with 51% being the average for studies of 
HT according to a meta-analysis published in 2004,117 and generally in the range of 30 to 
41% in RCTs of medicinal herbs.11,13,118-120 From baseline to 3 months, a 42% decrease was 
observed in daily hot flushes, p = 0.0003, and Kupperman Index total symptoms score 
decreased by 24%, (p = 0.0028).   Due to substantial placebo effects found in studies of 
vasomotor symptoms, it is possible that the 42% reduction in vasomotor symptoms 
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observed in this study would not be significant over placebo.  The small sample size in this 
study also suggests this result should be interpreted with caution.   
 
As mentioned above, studies of multi-component formulations do not contribute to the 
knowledge about the individual component herbs.  Herbs are chemically complex, and may 
contain in excess of a hundred different plant chemicals, often with synergistic actions.  
While studies of multi-component formulations may reflect clinical practice, the numerous 
potential interactions between the chemical components they contain, makes if impossible to 
extrapolate findings of their effects to any of the individual herbs or chemical components.   
 
Clinical Trials on Premenstrual Syndrome (PMS) and PMS-like symptoms 
  
It is possible that the practice of using Vitex agnus-castus for menopausal symptoms refers 
to its benefits for PMS-like symptoms reported by some women during the perimenopause.   
Vitex has been shown in placebo-controlled,121 comparator122,123 and observational 
studies124-126 to be effective in alleviating symptoms of PMS, which may well be relevant in 
this context. 
 
A small study of PMS-like symptoms by the authors has shown that these improve in late-
perimenopausal women with a combination of Vitex agnus-castus (extract equivalent to dry 
fruit 1,000mg per day) and Hypericum perforatum (extract equivalent to 5,400 mg dry herb 
flowering top standardised to contain hypericins 2,970 mcg, 27 mg hyperforin and 54 mg 
flavonoid glycosides).111  Improvements were observed for total PMS scores and scores on 
all the sub-clusters of anxiety (PMS-A), depression (PMS-D), cravings (PMS-C) and 
hydration (PMS-H) on Abrahams’ Menstrual Symptoms Questionnaire.  The herbal 
combination was significantly superior to placebo for total PMS, PMS-D and PMS-C.   
Limited conclusions can be drawn regarding the individual contributions of the herbs, which 
were administered in combination.  An impact of Hypericum on the depression sub-cluster 
can be inferred from its established efficacy in the context of mild to moderate depression.127 
However, the findings are also consistent with those of previous research on Vitex for PMS 
in premenopausal women.121-126 
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Directions for future research 
  
Although Vitex is currently used clinically and promoted as being effective in the 
management of menopause-related complaints, appropriate evidence to confirm its efficacy 
in this arena is lacking.  While administering herbal formulations reflects clinical practice, 
RCTs of formulations do not permit the effects of the herb as a sole agent to be evaluated.  
Such evidence from rigorous scientific RCTs is needed to clarify the efficacy and safety of 
Vitex in this context.  Because of the substantial response observed in the placebo group in 
menopause trials, probably largely attributable to the natural history of the symptoms under 
investigation, large sample sizes are required to ensure adequate power, and a control 
group is essential in future studies.  Findings from uncontrolled studies must be interpreted 
with caution for the same reasons.  In accordance with the recommendations of bodies such 
as the FDA,116 women with adequate symptom severity should be recruited to clinical trials. 
The findings reported for the PMS-like symptoms, while encouraging, were from a very small 
sample, and need to be replicated in a larger RCT dedicated to study of these symptoms. 
 
Conclusions 
 
The origins of the practice of administering Vitex in menopause are unclear, but it appears to 
be widespread among some groups of herbal practitioners.  While several recent studies 
have suggested a benefit for multi-component formulations containing Vitex in the treatment 
of menopausal symptoms, evidence from rigorous randomised controlled trials is lacking to 
support the use of the individual herb in this context.  Recent evidence from pharmacological 
studies points to possible mechanisms that could account for beneficial effects in some of 
the symptoms of menopause, as well as possibly influencing its onset.  As the endocrinology 
and neuroendocrinology of menopause and its symptoms have not yet been fully elucidated, 
firm conclusions cannot be drawn.  However, in view of current understanding, the emerging 
pharmacological evidence supports a role for Vitex agnus-castus in the management of 
menopause-related symptoms.  In particular, further research may be appropriate into its 
possible role in alleviating the PMS-like symptoms associated with the perimenopause.   
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Manuscript Appendix 1 Herbal Menopause Formulations 
 
TABLE 1  HERBAL MENOPAUSE FORMULATIONS CONTAINING VITEX AGNUS-CASTUS ON THE 
MARKET 
Manufacturer Product 
Forces of Nature  
Fusion Health 
Gaia Herbs  
Herb Farm 
Herbs of Gold   
Nature’s Alternatives 
Naturopathica 
Nature’s Sunshine 
Neways 
NutraLife  
Oona 
Oriental Botanicals  
Planetary Formulas  
Pretorius  
SuperHerb, Netanya 
Totally Natural Products 
Menopause Ease (Essential oil blend – transdermal)  
Menopause  
Supreme Vitex/Alfalfa - A Menopausal Corrective Formula  
Healthy Menopause Tonic (Pulsatilla + Vitex Comp)  
Menopause Night Relief  
Vitex / Black Cohosh Plus: Women’s Menopause Herb Tonic MenoEze 
Forte;  MenoEze Day Night formula; MenoThin 
Menopause support  
Wild yam and chaste tree cream  
MenoLife  
Herbal Supplement for Menopause, with Black Cohosh & Vitex  
Femaren  
MenoChange Cimicifuga-Vitex Compound  
EstroTrim :Menopause Weight Control  
Phyto-Female Complex 
Estro Balance plus Vitex: Menopause Relief 
 
 
Manuscript Appendix 2 Hormones and Menopause-related Mood Changes 
 
TABLE 2  OTHER PROPOSED ROLES FOR HORMONES IN THE AETIOLOGY OF MENOPAUSE-RELATED 
MOOD CHANGES 
• increased variability of oestradiol,128 follicle-stimulating hormone, and luteinising hormone88  
• the rate of change of hormone secretion and levels129-30 
• changes to oestrogen levels influencing neuropeptides and neurotransmitters (cholinergic, 
catecholaminergic and serotonergic130) in the  limbic system and hypothalamus.65 
• periods of elevated oestrogens, or excess relative to serum progesterone during the 
perimenopause. Oestrogens are potentially anxiogenic in excess, while 
progesterone/allopreganolone has a potent anxiolytic effect.131  
• a pre-existing sensitivity in some individuals to the change in the gonadal hormones and resultant 
decreases in neural transmitters38  such as noradrenaline.132  
• in women previously reporting a history of premenstrual syndrome, perimenopausal depression 
could represent the elimination of follicular phase-related symptom remissions, and the development 
of a more persistent pattern of dysphoria.99    
• Oestrogen has reciprocal interactions with CNS growth factors.  Brain-derived neurotropic factor 
(BDNF) levels may be of potential importance in the aetiology and treatment of depression during 
the perimenopause.133 
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Appendix 12 Hypericum in Major Depression 
 
 
As mentioned in the body of the text, most studies on St John’s wort have been conducted 
on major depression (Table 13.1).  Some studies have included a range of depressive 
disorders.96,97  Rarely, only the minimum HAM-D score for inclusion is reported,98 which 
does not enable one to determine whether the study focused on major depression. This 
must be established with reference to some of the key items on the scale.  [The defining 
characteristics of major depression and other depressive disorders can be found in 
Appendix 6.] 
A12.1.1   Hypericum compared with standard antidepressants and placebo in Major 
depression 
 
In terms of the trials comparing Hypericum extracts with standard antidepressants, most are 
restricted to patients with major depression 96,99-106 and the results have largely been 
positive.  When compared to the SSRI fluoxetine in major depression, H. perforatum has 
been found to be at least equivalent in efficacy, but superior in terms of overall incidence of 
side-effects.99,100,103 Compared to 75mg twice daily of the tricyclic antidepressant 
imipramine, Hypericum extract at the dose of 250 mg twice daily for 6 weeks was found to 
be therapeutically equivalent for mild to moderate major depression, but better tolerated.106  
Tolerability of H. perforatum extract was significantly better than older antidepressants and 
slightly better than SSRIs.99,102,107 
A12.1.2   Hypericum compared with standard antidepressants and placebo in Major 
depression 
 
Drug comparison studies that included an additional placebo arm are limited in number and 
have produced conflicting results.  As mentioned previously, the Hypericum Depression Trial 
Study group108 compared St John’s wort with the SSRI sertraline and placebo, and in 340 
patients with major depression (HAMD-17 score of 20+) and reported no effect for  St John’s 
wort Lichtwer Pharma LI160 extract of H. perforatum administered to at a dose of 900 mg 
per day, increasing to 1,200 or 1,500 or 1,800 mg/day as required.  However, no effect over 
placebo was reported for the SSRI either.  In contrast,  Phillip and co-workers102 found 
Hypericum   to be more effective than placebo and at least as effective as 100mg 
imipramine daily in the treatment of moderate major depression in 263 patients with a mean 
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baseline HAMD-17 score of 22.6.   The average dose of H. perforatum STEI 300 
administered was 350mg, three times daily.102  Both RCTs were of 8 weeks duration. 
A12.1.3   Hypericum compared with Placebo in Major Depression 
 
As mentioned in the body of the text, placebo-controlled RCTs conducted on St John’s wort 
for major depression have generally been favourable.109-112  In addition to those already 
discussed, several RCTs with the extract WS 5572 in mild to moderate major depression 
have observed significant effects over placebo over 6 weeks duration.  These include 
studies by Lecrubier and colleagues111 with 375 participants, and WS 5572 at a dose of 
900mg/day, consistent with the 1996 study by Kalb and co-workers110 on 72 patients.  
Kasper and colleagues subsequently trialled the same extract  in 332 patients and found it to 
be superior to placebo at two different doses, 600mg/day and 1,200 mg/day.109  Further 
details of these studies can be found in Table 13.1. 
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Appendix 13 Recruitment 
 
Participants were sourced through 
• 45 newspaper articles/advertisements 
• 3 advertisements in professional journals/special interest group newsletters 
• 16 talks at Universities, Colleges of Natural medicine, Women’s groups 
• 2 radio interviews  
• fliers in waiting rooms of doctors/allied health professionals’ clinics, health food shops, 
The Jean Hailes Foundation, Women’s Health information centre  
• posters at university campuses and colleges of natural medicine 
• websites at RMIT and The Jean Hailes Foundation.  
 
The numbers of enrolled participants recruited from each source is outlined in table A13.1 
below. 
TABLE A13.1  RECRUITS DERIVED FROM EACH SOURCE 
Source 
 
Number 
recruited 
Source 
 
Number 
recruited 
Age newspaper 
Herald-Sun newspaper 
Radio interview ABC 774 
Colleague in Sydney 
RMIT global email 
Word of mouth 
 
Other local papers: 
• Geelong Advertiser (6) 
• Emerald Hill Times (2) 
• Balwyn (1) 
• Cobram Courier (1) 
• Daylesford Advocat (1) 
• Melbourne Times (1) 
• Whittlelsea Star (1) 
• Unspecified (2) 
 
Zest magazine   
MX  
15 
11 
  7 
  7 
  8 
  6 
 
15 
 
 
 
 
 
 
 
 
 
  3 
  1 
Leader newspapers 
• Monash (3) 
• Progress (5) 
• Stonnington (3) 
• Diamond Valley (2) 
• Preston (2) 
• Whitehorse (2) 
• Bayside (1) 
• Bayswater (1) 
• Chelsea (1) 
• Mornington (1) 
• Mt Waverly (1) 
• Mulgrave (1) 
• Whittelsea (1) 
 
Fliers 
Talk 
Unknown 
24 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 2 
 1 
 3 
 
 
Additional sources of information and enquiries that did not result in any recruits are shown 
in table A13.2. 
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TABLE A13.2  ADDITIONAL SOURCES OF ENQUIRIES YIELDING NO PARTICIPANTS 
Source Source 
Other Local Papers: 
• Alexandria & Eildon Standard 
• Bendigo Advertiser 
• Euroa Gazette 
• Melbourne Weekly 
• Moreland Community News 
• Mt Waverley Gazette 
• Portland local paper 
• Unspecified Queensland newspaper 
 
Special Interest Groups: 
• Life newsletter 
• NHAA journal 
• ATMS journal 
 
Leader Newspapers: 
• Brunswick- Moreland 
• Dandenong  
• Darebin 
• Keysborough 
• Knox 
• Maroondah  
• Northcote 
• Port Phillip 
• Prospect 
• Richmond 
• Yarra 
 
Radio Interview: 
3GG radio 
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Appendix 14 MEDICAL PRACTITIONER CLEARANCE FORM 
 
RMIT UNIVERSITY School of Health Sciences 
Complementary Medicine 
 
Project Title: The effect of a Herbal Combination on Menopausal Symptomatology 
 
Names of Investigators: 
 
Ms Diana van Die 
BA (Psych), Dip Ed, Dip Herb Med 
Investigator 
Telephone:   (03) 9925-7596 
Facsimile:     (03) 9467-2794 
Email:             s9403478@student.rmit.edu.au 
Prof Marc Cohen, Supervisor 
MBBS(Hons), PhD, BMedSci(Hons), FAMAS, 
DipAc 
Telephone:   (03) 9925-7440 
Facsimile:   (03) 9467-2794 
Email:  marc.cohen@rmit.edu.au 
 
Prof Henry Burger, Hon Professorial Fellow, Monash University, AO, FAA, FRCP, FRACP, FCP(SA), 
FRCOG, FRANZCOG 
Emeritus Director, Prince Henry’s Institute of Medical Research 
Telephone:   (03) 9594.3553 
Email:  henry.burger@med.monash.edu.au 
 
Dr Helena Teede, MBBS, FRACP, PhD. Head of Endocrinology & Diabetes, Dandenong Hospital, 
NH&MRC CDA Research Fellow, Dept of Medicine, Monash University 
Telephone: (03) 9554-8022    Email: helenat@bigpond.net.au 
 
 
 
I __________________________________________________ 
 (name of medical practitioner) 
have examined _______________________________________  
   (name of participant) 
 
I have also seen the attached summary of the study and understand that participants may be given 
herbal medicine preparations.   
In my opinion, there is no medical problem present or current medication being taken that suggests 
this woman should not participate.  
 
Medical Practitioner’s Signature: 
 
_____________________________________ 
Qualifications:   ______________________________________ 
Address: ___________________________________________ 
___________________________________________________ 
Telephone:   ___________________________ 
Date:   ____________________________ 
 
If you need further information, please contact Diana van Die as above. 
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Needs blood test to determine if she is post or peri-menopausal. Yes         No   
 
Inclusion criteria include:  Please tick to confirm that these have been performed 
  recent breast examination 
  pap smear within past 2 years 
  measurements of blood pressure & pulse  
  a general physical check up  
 
Exclusion Criteria  Please indicate whether any of these apply 
Women on the following medications will be excluded: 
  HRT or concomitant treatment for menopausal symptoms that cannot  be    discontinued for 
the duration of the trial.  [This includes phyto-oestrogen and Vitamin E supplements.] 
  Oral contraceptives, or injected or sub-dermal 
  Herbal medicine that includes Hypericum or Vitex 
  Anti-depressants: SSRI’s and related drugs (citalopram, fluoxetine, fluvoxamine,  
paroxetine, sertraline, nefazodon 
  anxiolytics or hypnotics (psychotropic medication) 
   Digoxin 
   Clonidine 
  HIV medication (including protease inhibitors & non-nucleoside reverse transcriptase  
inhibitors) 
  Anti-coagulant medication such as Warfarin, Phenprocoumon 
  Theophylline 
  Immune-suppressant medication: eg Cyclosporin/tacrolimus 
  Triptans (sumatriptan, naratriptan, rizatriptan, zolmitriptan) 
  Anti-convulsant medication: carbamazepine, phenobarbitone, phenytoin 
  Dopamine receptor antagonists (Largactil, Modecate, Clozapine, Haloperidol)  
  Steroids (eg Cortisone, Prednisolone)           
Also excluded are women with the following: Please indicate if any of these apply  
  medically or surgically induced menopause  
  spasmodic dysmenorrhoea not associated with PMS 
  undiagnosed vaginal bleeding (in post-menopausal women) 
  known photosensitivity 
  known intolerance to Hypericum or Vitex 
  history of epilepsy or seizures 
  pre-existing cancer 
  renal or liver disease 
  major heart disease 
  diabetes mellitus requiring treatment 
  uncontrolled hypertension 
  bipolar disorder 
  severe depression  
  current major psychiatric disorder, history of mania 
  substance abuse 
  pregnancy or attempting to conceive 
 
To the best of my knowledge, none of the above exclusion criteria applies to me. 
 
______________________________________  __________________________ 
  (signature)       (date) 
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Appendix 15  Interviewees 
 
Participants were interviewed at Clinicare Medical Centre, North Fitzroy (134), RMIT city 
campus psychology clinic (40), RMIT Bundoora psychology clinic (16) and a number of rural 
participants were interviewed by telephone (17).   Of the 207 interviewed, 148 were eligible.  
However, 26 of those failed to meet run-in requirements and 19 declined consent.  The 
remaining 103 were randomised.   Reasons given for lack of consent or ineligibility can be 
seen in tables A15.1 and A15.2.  
TABLE A15.1  REASONS FOR INELIGIBILITY AMONG WOMEN INTERVIEWED 
Failed to meet inclusion criteria: 
• Greene score < 20 
• Age > 60 
• No ovaries 
• Not 3 months’ amenorrhoea 
• Insufficient vasomotor symptoms 
Exclusion criteria: 
• Concomitant contraindicated medication 
• Participating in another trial 
Co-morbidity: 
• Severe depression (2) 
• Half a kidney (1) 
• Excess alcohol consumption (1) 
• BMI 53 (1) 
• Flushing pattern atypical of menopause (difficult to quantify) (1) 
Did not complete Run-in requirements: 
• Flushing symptoms abated during run-in to less than 5 per 24 hours 
• Failed to get Medical clearance from GP 
• Started HRT during run-in 
                                                                                                         Total 
 
44 
1 
1 
2 
3 
 
1 
1 
6 
 
 
 
 
 
 
21 
  2 
  3 
85 
 
TABLE A15.2  REASONS FOR LACK OF CONSENT AMONG WOMEN INTERVIEWED 
• Lifestyle too stressful/busy to permit compliance with procedures 
• Counting flushes too depressing 
• Undisclosed 
• Lost to follow-up 
• Unwilling to have pap smear (required within past 2 years) 
• Symptoms too severe  
• Fear of herbs 
• Decided to recommence OTC supplements 
                                                                                                         Total 
  7 
  1 
  5 
  2 
  1 
  1 
  1 
  1 
19 
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Appendix 16 Procedure for Telephone Screening  
 
(Takes 10 minutes) 
 
• Thank caller for enquiry 
• Enquire about her source of Information about trial? 
• Enquire whether she has already read brochure? 
• Explain Objectives of research:  2 herbs (St John’s wort and Chaste tree), 2 groups of 
symptoms (flushing and psychological) , 2 sub-groups (late-peri and post menopause) 
• “We are looking for women aged 40-60 with flushing/or both types of symptoms, who 
still have at least 1 ovary and naturally menopausal (not brought on by surgery, 
chemotherapy or radiotherapy); not pregnant or attempting to conceive and not currently 
in another trial.” 
Exclusion criteria  
Include, for example, other medication for symptoms:  HRT, OCP, anti-depressant or 
anti-anxiety medication; phytoestrogens, Vitamin E for flushing; Vitex of Hypericum unless 
willing to go off for trial period. 
• Intolerance of Vitex or Hypericum; photosensitivity 
 
“Shall I go on?” 
 
• Herbs- give information about known effects. 
• “You will be asked to take tablets twice daily for 16 weeks and keep daily and weekly 
diaries (5 -10 mins max).  Follow-up 8 weeks later. 
• Explain ‘Placebo controlled’.  Placebo group will be offered treatment free of charge for 3 
months at end of trial if found to be effective 
• Chance of ADR’s => Doctor in charge of monitoring. 
 
Contraindicated with herbs are:  
• HIV mdx or immune-suppressant mdx;  
• Digoxin;  
• anti-coagulant medication such as Warfarin, Phenprocoumon;  
• Theophylline for asthma 
• Triptans (migraine medication) 
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• Medication for epilepsy or seizures 
• Dopamine receptor antagonists (Largactil, Modecate, Clozapine, Haloperidol)   
• Steroids (eg Cortisone, Prednisolone)  
 
Also excluded are women with  
• A history of epilepsy or seizures 
• current cancer, renal or liver disease, diabetes mellitus requiring treatment, uncontrolled 
hypertension 
• bipolar disorder, major psychiatric disorder, history of mania 
• substance abuse 
 
“Shall I continue, or are you excluded?” 
 
 If still eligible and interested,  
• get details to send Plain Language Statement  
• arrange interview place and time.  
• ask them to bring list of known medications.   
• Get phone number to confirm appointment.   
• Ask to bring PLS and any questions. 
 
“Any questions?” 
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Appendix 17 Respondents 
 
 
Of the 761 respondents, 8 calls could not be returned, 546 were excluded at telephone 
screening and the remaining 207 were interviewed.  Reasons for exclusion are contained in 
table17. 
TABLE A17   REASONS FOR INELIGIBILITY AMONG WOMEN SCREENED BY TELEPHONE 
Did not meet inclusion criteria: 
• Insufficient vasomotor symptoms 
• Not 3 months’ amenorrhoea 
• No ovaries 
• Outside acceptable age range  
• Interstate 
• Male 
• Only vasomotor symptoms 
 
Exclusion criteria: 
• Concomitant contraindicated medication 
                 For menopausal symptoms  101  (HRT 58; Natural 43) 
                 For other medical conditions  29 
• Co-morbidity (inadmissible medical condition) 
• Participating in another trial 
 
Other: 
• Fear of side-effects 
• Unwillingness to risk allocation to placebo group 
• Personal situation incompatible: stressful/ traumatic/ busy 
• Undisclosed 
• Failed to appear for Interview 
• Discouraged by naturopathic practitioner 
• Wanted Chinese herbs 
• Trial quota already reached 
• Only seeking information 
 
160 
  64 
  18 
    8 
  45 
    2 
    1 
298 
 
130 
     
 
  23 
    4 
455 
 
    6 
  12 
  19 
  34 
  15  
    1 
    1 
    1 
    2 
546 
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Appendix 18 PLAIN LANGUAGE STATEMENT 
 
 
School of Health Sciences (Complementary Medicine) 
Project Title: The effects of a Herbal Combination on Menopausal Symptomatology 
About the Study 
 
The aim of this study is to test a combination of two commonly used herbs in the treatment of 
menopausal symptoms in 40-60 year old women.  It is estimated that at least 84% of women 
experience one or more menopausal symptoms with 40% to 45% rating their symptom(s) as 
problematic.  Typical symptoms include depressed mood, anxiety and nervousness, mood swings, 
irritability, memory and concentration difficulties, fatigue, sleep disturbances, night sweats, hot 
flushes, sweating, dizziness, migraine, palpitations, vaginal dryness, bladder dysfunction, decreased 
libido and dry skin as well as changes to the regularity and flow of menstrual cycles. 
 
The objective of this study is to investigate the effectiveness of a herbal treatment in providing relief 
from menopausal symptoms, especially mood changes and hot flushes.  
 
The study is being undertaken by Diana van Die in the School of Health Sciences (Complementary 
Medicine), RMIT as part of a Higher Degree.  The supervisor for the study is Professor Marc Cohen.  
RMIT has in place public liability insurance in connection with this research.  The herbal tablets to be 
used in the trial have been prepared by MediHerb Pty Ltd, a major manufacturer of practitioner herbal 
products in Australia.  The study is being funded by RMIT.   
 
About the Treatment: St. John’s wort and Chaste tree 
 
St. John’s wort (Hypericum perforatum) is probably best known nowadays for the relief of depression 
and much research has shown it to be as effective as anti-depressant medication for the treatment of 
mild to moderate depression.  Traditionally, however, it was used specifically for the treatment of 
menopausal symptoms to relieve anxiety, irritability, nervous tension and insomnia.  A recent 
research study found it effective in reducing the psychological symptoms of menopause as well as 
hot flushes. 
 
Chaste tree (Vitex agnus castus), also traditionally used in menopause, is still widely used by medical 
herbalists today for this.  Most research, however, has been on its effectiveness in relieving the 
symptoms of pre-menstrual syndrome, which are commonly experienced in the years leading up to 
menopause (peri-menopausal years).    
 
The combination of these two herbs is commonly prescribed in clinical herbal practice, although no 
reports of clinical trials on this specific combination were found.  In the current study, these herbs will 
be given in tablet form.  The St. John’s wort tablets contain Hypericum extract equivalent to 1.8g dry 
fruit each, standardised to contain hypericin 0.99mg each; the Vitex tablets contain extract equivalent 
to 500mg dry fruit each.  If this combination is found to be effective in reducing menopausal 
symptoms, it may offer an important alternative to HRT.  
401 
APPENDICES 
 
402 
 
Safety and Side-effects 
 
As with any form of medication, there is a chance of side effects occurring.  Both herbs are on the List 
of approved substances by the Therapeutic Goods Administration in Australia and are readily 
available over-the counter.  They are suitable for long-term use when used within the recommended 
dosage range.  
 
Mild side effects have been found with St. John’s wort, although these are rare (2.4%-4.1%). 
Recorded adverse events occurring in a small minority of people include minor gastro-intestinal 
irritations (0.6%), slight nausea, rash (0.5%), fatigue (0.4%), restlessness (0.3%) and photosensitivity. 
Photosensitivity may occur with prolonged exposure to full sun or artificial UVA radiation (sunlamps, 
solariums). You are therefore advised to avoid using solariums while on this trial, and to avoid 
exposing your skin to the sun without sun block.  
Less common are dizziness, headaches, sleep disturbances, paraesthesia (numbness and tingling) 
(3 cases) and palpitations.  
 
 There have been no reports of serious adverse effects with Chaste tree.  In a few cases 
(approximately 5%), its use has been associated with headaches, gastrointestinal complaints, nausea 
and acne.  There has been one report each of abscesses, bleeding between periods and nettle rash. 
 
Should any information become available that may affect your willingness to continue participating in 
the trial, you will be notified as soon as possible. 
Adverse reactions 
 
If an adverse reaction does occur while you are participating in this study, we advise that these steps 
be taken: 
• Temporarily discontinue the tablets 
• Contact Professor Marc Cohen or Diana van Die 
• Dr Helena Teede will speak with you and advise you how to proceed.     
What you will have to do 
 
An initial interview will be conducted to assess your eligibility for the study.  You will be asked about 
you current health status, current menopausal symptoms and their severity, current medication, 
including natural supplements, and past medical history.   It is important that you provide this 
information as fully and accurately as possible to avoid putting yourself at risk as both herbs are 
contraindicated in certain medical conditions and both are known to interact with certain drugs. 
Anyone with drug or alcohol addictions will not be eligible to participate.  If you are eligible for the 
study, you will be asked to sign a consent form, given to you at the initial interview. 
 
You will then be randomly allocated to one of two groups: the placebo group or the treatment group.  
There will be weekly questionnaires to fill out (which should take no more than 5 - 15 minutes), and 
you will be required to take three tablets on rising and two tablets later in the day.  There is no 
guarantee that you will derive any alleviation of menopausal symptoms from participation in this 
study.   However, at the end of the trial, those participants in the placebo group will be offered the 
treatment for a standard treatment period of 3 months if it is found to be effective. 
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If you become pregnant during the trial, you must notify the investigators immediately.  Your 
participation in the trial will cease.  Your participation on the trial must also cease if you commence 
taking any of the following drugs: Digoxin, HIV medication, Warfarin, Phenprocoumon, 
antidepressants, oral contraceptives, Theophylline, Cyclosporin, immune-suppressant medication, 
Triptans (migraine medication such as Imigran) or dopamine receptor antagonists.  You must notify 
the investigators immediately if you are prescribed any of the above medication. 
 
Summary of Treatment Program: 
You will be required to continue the treatment for 16 weeks.  However, the total period of your 
participation will be 20 weeks with a follow-up questionnaire at week 32. 
Weeks 1 –2 
Baseline 
General physical check-up by GP; diet & health questionnaire, menopausal symptoms scale, 
depression scale & quality of life scale.  Daily flushing record is to be kept during run-in. 
Weeks 3 –18 
Treatment 
Menopausal symptoms scale, depression scale and lifestyle diary are required to be 
completed monthly.  A flushing diary is to be completed daily. A menstrual symptoms diary 
will be completed every 4 weeks where relevant. 
Weeks 18-20 
Post-treatment 
Dietary questionnaire & Quality of Life scale to be completed in week 18. 
 
3 months after 
treatment 
Follow-up 
Menopausal symptoms scale, flushing count, depression and lifestyle questionnaire are 
required to be completed. 
Telephone contact will be made to determine your current symptoms and discuss any 
issues that may have arisen since your involvement with the study. 
 
Confidentiality 
All data such as questionnaires collected from the research will be kept confidential and secured in a 
locked filing cabinet in the School of Health Sciences (Complementary Medicine) at RMIT.  No 
identifying information will be included in data; only participant code numbers will be used.  Only the 
investigators will have access to confidential information.  Your participation in this study is voluntary 
and you may withdraw from the trial at any time.  If you have any further enquiries about this study, 
please feel free to contact us at any time. 
Diana van Die, Investigator, BA (Psych), Dip Ed, Dip Herb Med 
Telephone:  (03) 9925-7596   Facsimile: (03) 9467-2794 
Email:   s9403478@student.rmit.edu.au 
Prof Marc Cohen, Supervisor, MBBS(Hons), PhD, BmedSci (Hons), FAMAS, DipAc 
Telephone:    (03) 9925-7440   Facsimile:   (03) 9467-2794 
Email:   marc.cohen@rmit.edu.au 
 
Prof Henry Burger, Supervisor, Hon Professorial Fellow, Monash University; Emeritus Director, Prince 
Henry’s Institute of Medical Research; AO;FAA;RCP;FRACP;FCP(SA);FRCOG;FRANZCOG 
Dr Helena Teede, Supervisor, MBBS, FRACP, PhD. Head of Endocrinology & Diabetes, Dandenong 
Hospital, NH&MRC CDA Research Fellow, Dept of Medicine, Monash University 
Assoc Prof Kerry Bone, Consultant, Founder and Director of Research & Development, MediHerb, 
Associate Professor of University of New England  
Any complaints about your participation in this project may be directed to the Secretary, RMIT Human 
Research Ethics Committee, University Secretariat, RMIT, GPO Box 2476V, Melbourne, 3001.  Telephone 
(03) 9925 1745.  Details of the complaints procedure are also available from the above address. 
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Appendix 19 Initial Interview Consent Form 
 
 
RMIT University School of Health Sciences 
Complementary Medicine 
Initial Interview Consent Form 
Project Title:  The Effects of a Herbal Combination on  
Menopausal Symptomatology 
 
 
Names of Investigators: 
Diana van Die (Investigator)   Professor Marc Cohen (Supervisor) 
Tel:  (03) 9925 7596    Tel:  (03) 9925 7440 
Email:  s9403478@student.rmit.edu.au Email: marc.cohen@rmit.edu.au 
 
 
 
I agree to take part in the initial interview for the above study. 
 
I understand that I will be asked to provide personal information.  I am aware that this 
interview is for the purpose of establishing whether or not I am eligible to participate in the 
above study, and that I may not be invited to participate. 
 
I have been informed that all information I provide during this interview will be treated as 
confidential.  It will be safeguarded by code and only disclosed in a de-identified form. 
 
I am aware that I may withdraw from this interview at any time.  
 
 
 
Participant’s Consent: 
 
Name:   _________________________________ Date: __________________ 
   (Participant) 
 
Name:   _________________________________ Date: __________________ 
       (Witness to signature) 
 
Name:   _________________________________ Date: __________________ 
       (Consented by) 
 
Any complaints about your participation in this project may be directed to the Secretary, RMIT Human 
Research Ethics Committee, University Secretariat, RMIT, GPO Box 2476V, Melbourne, 3001.  
Telephone (03) 9925 1745.  Details of the complaints procedure are also available from the above 
address. 
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Appendix 20 Screening and Recruitment Forms 
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Appendix 21 Drug Accountability Form  
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Appendix 22 Sample Questionnaire booklet 
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Appendix 23 Informed consent Form 
 
RMIT HUMAN RESEARCH ETHICS COMMITTEE 
Prescribed Consent Form For Persons Participating In Research Projects Involving Tests and/or 
Medical Procedures 
 
SCHOOL OF HEALTH SCIENCES 
AREA COMPLEMENTARY MEDICINE 
Name of participant:  
Project Title: The effects of a Herbal Combination on Menopausal  
 Symptomatology 
Name(s) of investigators:    (1) Diana van Die Phone: 9925 7596 
(2) Professor Marc Cohen Phone: 9925 7440 
 
 
1.           I have received a statement explaining the procedures involved in this project. 
 
2.        I consent to participate in the above project, the particulars of which - including details of procedures –  
              have been explained to me. 
 
3.       I authorise the investigator or his or her assistant to use with me the tests or procedures referred to in 1  
              above. 
 
4.       I acknowledge that: 
 
(a)   The possible effects of the tests or procedures have been explained to me to my satisfaction. 
(b)   I have been informed that I am free to withdraw from the project at any time and to withdraw any  
          unprocessed data previously supplied (unless follow-up is needed for safety). 
(c)   The project is for the purpose of research.  It may not be of direct benefit to me. 
(d)   The privacy of the personal information I provide will be safeguarded and only disclosed where I  
          have consented to the disclosure or as required by law. 
(e)   The security of the research data is assured during and after completion of the study.  The data  
         collected during the study may be published, and a report of the project outcomes will be  
         provided to RMIT University.   Any information which will identify me will not be used. 
 
Participant’s Consent 
 
 
Name:  Date:  
(Participant) 
Name:  Date:  
 
(Witness to signature) 
Name:  Date:  
 
(Consented by) 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
 
 Any complaints about your participation in this project may be directed to the Secretary, RMIT Human Research Ethics Committee, 
University Secretariat, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 1745.   
Details of the complaints procedure are available from the above address. 
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Appendix 24 Case report forms 
 
 
The following appendix contains Case Report Forms completed for each participant 
throughout the trial. 
 
These include  
• Follow-up forms for contact at the end of weeks 1,4, 8,12 and 16 
• hospitalisation form 
• Follow-up record at 8 weeks post completion 
• study termination record form. 
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Appendix 25 Suspected Adverse Events Report Form  
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Appendix 26 Thin Layer Chromatography (TLC) assessment to check 
veracity of code 
 
“Tablets were crushed and extracted using ultrasound 91 tab/5mL methanol.  Samples were 
transferred to disposable glass tubes, centrifuged and transferred again to small plastic 
effendorf tubes and centrifuged again using the microfuge.  Samples were then suitable for 
application using the Camag semi-automatic spotter.    
 
A luteolin-7glycoside standard was prepared.   Two Mediherb liquid samples , St John’s 
Wort (Batch no 125178) and Chaste tree (Batch no124324) were also spotted onto plate.  
The plate was the standard Merck TLC silica gel 60 F354 plate used for in-house TLC 
analysis at Mediherb. 
 
Samples were spotted left to right on plate as detailed in table below and shown in the 
photograph below.    
Chromatogram development was by using the solvent mix as outlined in the Camag 
application note for Chaste tree flavonoids. 
(THF-Toluene-Formic Acid-Water / 16:8:2:1 ).  
Visualisation was by derivatisation using natural product reagent/PEG. 
 
FIGURE A26  TLC FINGERPRINTS FOR ST JOHN’S WORT AND CHASTE TREE SAMPLES 
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TABLE A26   RESULTS OF VISUAL AND TLC ASSESSMENT WITH RETURNED TABLETS 
 
 
Position # 
 
Sample 
 
Herb identity in 
sample 
Prior Visual 
Assessment 
result 
Do the 
Different 
Analyses 
Match 
1 Luteolin-7-gly - - - 
2 M/H SJW Liquid - - - 
3 M/H  
Chaste tree 
Liquid 
- - - 
4 11A Placebo Placebo Match 
5 11B Placebo Placebo Match 
6 38A SJW  SJW Match 
7 72A SJW SJW Match 
8 92A SJW SJW Match 
9 92B Chaste Tree Chaste Tree Match 
10 99A Placebo Placebo Match 
11 99B Placebo Placebo Match 
12 101A SJW SJW Match 
13 103A SJW SJW Match 
14 103B Chaste tree Chaste Tree Match 
15 67B Placebo Placebo Match 
16 M/H  
Chaste tree 
Liquid 
- - - 
17 M/H SJW Liquid - - - 
18 Luteolin-7-gly - - - 
 
 
Comments and Observations: 
 
“The match of both the visual and TLC results to each other and also to the information 
supplied in the email confirms there is no mix-up of tablets for the ones analysed here.  As 
noted in the visual assessment report analysis of several of the requested tablet samples 
was not possible since none were returned for those particular numbers.”
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Appendix 27 Unadjusted flushing scores  
 
TABLE A27  UNADJUSTED MEAN DAILY WEIGHTED FLUSHING SCORES BY STUDY WEEK    
 
Hot Flushes
Dependent Variable: average daily weighted score
16.35 14.13 12.23 11.95 11.52 10.84 9.97 10.67 10.55 9.94 9.82 9.96 10.03 9.21 9.28 9.13 9.32
1.33 1.34 1.35 1.35 1.35 1.34 1.31 1.42 1.37 1.38 1.38 1.40 1.40 1.38 1.38 1.38 1.38
13.75 11.49 9.57 9.29 8.87 8.21 7.40 7.89 7.86 7.23 7.10 7.21 7.29 6.50 6.56 6.42 6.60
18.96 16.76 14.89 14.61 14.18 13.47 12.55 13.44 13.24 12.66 12.53 12.70 12.78 11.93 11.99 11.85 12.03
16.53 14.45 13.30 12.90 12.13 11.58 10.77 10.89 9.82 11.13 10.90 10.94 10.91 10.88 11.29 11.73 10.86
1.34 1.37 1.40 1.40 1.40 1.35 1.34 1.42 1.38 1.37 1.37 1.37 1.37 1.37 1.37 1.37 1.37
13.90 11.77 10.56 10.15 9.39 8.92 8.14 8.11 7.10 8.44 8.21 8.25 8.23 8.20 8.61 9.04 8.17
19.16 17.14 16.04 15.64 14.88 14.24 13.40 13.67 12.53 13.81 13.58 13.63 13.60 13.57 13.98 14.41 13.55
Mean
Std. Error
95% Confidenc
Interval
Mean
Std. Error
95% Confidenc
Interval
subject group
placebo
active treatme
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
PHASE
 
 
Generated using Linear Mixed model analysis
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Appendix 28 Greene Climacteric Subscale scores  
 
TABLE A28 GREENE CLIMACTERIC SUBSCALE SCORES (INCLUDING FOLLOW-UP)  
Mean (SE)  95% Confidence Intervals, Lower bound and Upper bound 
Subscale       Phase 
Group 
 baseline Week 4 Week  8 Week 12 Week 16 Follow-up 
Psychological placebo mean 11·48 8·63* 7·95** 7·47** 6·73** 7·88** 
subscale1  Std error 0·71 0·73 0·74 0·75 0·75 0·75 
  95% - 10·07 7·19 6·50 6·00 5·27 6·41 
  CI 12·89 10·06 9·41 8·94 8·20 9·35 
 active mean 11·73 9·51* 8·42** 8·37** 8·50** 8·29** 
  Std error 0·72 0·75 0·74 0·74 0·74 0·76 
  95% - 10·33 8·04 6·96 6·92 7·05 6·81 
  CI 13·15 10·98 9·88 9·83 9·96 9·78 
Anxiety placebo mean 6·36 4·67* 4·53** 4·28** 3·71** 4·14** 
subscale1  Std error 0·40 0·41 0·41 0·42 0·42 0·42 
  95% - 5·58 3·87 3·72 3·46 2·90 3·33 
  CI 7·15 5·47 5·33 5·09 4·53 4·96 
 active mean 6·33 5·14* 4·57** 4·43** 4·61† 4·49** 
  Std error 0·40 0·42 0·41 0·41 0·41 0·42 
  95% - 5·56 4·32 3·76 3·63 3·80 3·67 
  CI 7·12 5·95 5·38 5·24 5·41 5·32 
Depression placebo mean 5·12 3·96* 3·38** 3·20** 3·02** 3·68** 
subscale  Std error 0·36 0·37 0·37 0·38 0·38 0·39 
  95% - 4·39 3·24 2·63 2·44 2·26 2·93 
  CI 5·85 4·70 4·12 3·96 3·78 4·43 
 active mean 5·40 4·37* 3·85** 3·94** 3·89** 3·80** 
  Std error 0·37 0·39 0·38 0·38 0·38 0·39 
  95% - 4·67 3·61 3·10 3·18 3·14 3·04 
  CI 6·13 5·13 4·60 4·69 4·45 4·56 
Somatic placebo mean 4·94 3·21** 3·06** 2·74** 2·83** 3·30* 
subscale  Std error 0·35 0·36 0·36 0·37 0·37 0·36 
  95% - 4·25 2·51 2·36 2·02 2·11 2·59 
  CI 5·63 3·91 3·76 3·46 3·54 4·01 
 active mean 4·64 3·76* 2·89** 3·21** 3·13** 3·41** 
  Std error 0·35 0·36 0·36 0·36 0·36 0·37 
  95% - 3·95 3·05 2·19 2·50 2·42 2·70 
  CI 5·33 4·48 3·60 3·92 3·84 4·13 
Vasomotor placebo mean 4·28 3·29** 2·98** 2·74** 2·59** 3·09** 
subscale  Std error 0·21 0·22 0·22 0·22 0·22 0·22 
  95% - 3·86 2·87 2·56 2·31 2·15 2·66 
  CI 4·70 3·72 3·40 3·17 3·02 3·51 
 active mean 3·92 3·20* 2·79** 2·83** 2·83** 2·70** 
  Std error 0·21 0·22 0·22 0·22 0·22 0·22 
  95% - 3·50 2·76 2·36 2·40 2·40 2·26 
  CI 4·34 3·63 3·22 3·26 3·26 3·13 
Sexual placebo mean 1·72 1·33* 1·40 1·20* 1·15** 1·34 
subscale  Std error 0·14 0·15 0·15 0·15 0·15 0·15 
  95% - 1·44 1·05 1·11 0·90 0·86 1·05 
  CI 2·00 1·62 1·68 1·49 1·44 1·63 
 active mean 1·74 1·52 1·49 1·53 1·49 1·46 
  Std error 0·14 0·15 0·15 0·15 0·15 0·15 
  95% - 1·62 1·23 1·20 1·24 1·20 1·16 
  CI 2·02 1·81 1·78 1·82 1·78 1·75 
1.  Covariates appear in the model: baseline phytoestrogen intake  
*significant from baseline at p < 0.05 ** significant from baseline at p < 0.01 
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Appendix 29   Total adverse events 
 
TABLE A29    
Total adverse events during trial by subject grouping
Count
6[1] 13[7] 19
1 3[1] 4
5 5[2] 10
1[1] 1 2
1 1
2 2
1 1
6[1] 6
3 3
18[3] 23[5] 41
3 2 5
2[1] 2[1] 4
1[1] 4[3] 5
3[1] 3
2[1] 1 3
1 1
2 2
1 1[1] 2
4[1] 7[2] 11
1 2 3
3[1] 4 7
1 1
14[4] 13[3] 27
10 4[2] 14
3[2] 3
1 2 3
1 2 3
2 2
2[1] 2
11[1] 3 14
5 2 7
1 1 2
1 1
3[1] 3
107 110 217
MS pains, strains +
UTI
accidents, injuries,
allergy
anxiety*
breast tenderness*
breathlessness
cardiovascular
cold sore*
cold/flu
constipation*
cyst
dental complaints
depression
dizziness*
dry eyes
dysmenorrhoea*
fatigue
headache*
migraine*
nausea*
nosebleed
other GI complaints*
other RTI
other infection
palpitations*
paraesthesia*
period
reproductive
skin complaints*
stomach
upset/cramp*
vomiting
weakness
weight gain
Total
placebo
active
treatment
subject group
Total
 denotes nubmer of cases rated as severe[]. 
 
Adverse events reported in previous trials of Hypericum or Vitex are indicted with an 
asterisk. 
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Appendix 30 PMS-subscale Scores 
 
TABLE A30.1  SIGNIFICANCE LEVELS FROM PAIRED SAMPLES T-TESTS BETWEEN BASELINE AND 
ALL DATA COLLECTION POINTS FOR ACTIVE TREATMENT GROUP 
 
         Week 
Cluster  
Week 4 
p-value 
Week  8 
p-value 
Week 12 
p-value 
Week 16 
p-value 
PMS-Total 0.007 0.003 0.006 0.000 
PMS-A 0.02 0.04 0.04 0.003 
PMS-C 0.04 0.03 0.12 0.01 
PMS-D 0.03 0.01 0.006 0.001 
PMS-H 0.22 0.08 0.07 0.002 
 
 
 
TABLE A30.2   MEAN DIFFERENCES FROM BASELINE TO WEEK 16 FOR PLACEBO AND ACTIVE 
ARMS 
 Placebo n= 6 Active  n =8 
 Mean Diff (SE) 95% CIs p-value Mean Diff (SE) 95% CIs p-value 
Total PMS 6.83(5.30) -3.88, 17.54 0.205 15.25(4.59) 5.98,24.53 0.002 
PMS-A 3.00(1.49) 0.008,6.01 0.051 3.50(1.29) 0.90,6.11 0.010 
PMS-C 0.33(1.75) -3.21, 3.87 0.850 3.25(1.52) 0.18, 6.32 0.038 
PMS-D 1.83 (1.58) -1.37,5.03 0.254 5.63 (1.37) 2.85,8.40 0.000 
PMS-H 1.67(1.65) -1.66,5.00 0.318 2.88(1.43) -.008,5.76 0.051 
Mean (SE) 
Calculated using last observation carried forward and mixed model analysis. 
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